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Chaperonins have classically been thought of as intracellular molecules involved
in the correct folding of proteins. Their expression is upregulated during times of
stress such as heat (hence their common nomenclature as heat shock proteins
[HSP]), anoxia, hypoglycaemia and reactive oxygen species [1]. These are condi-
tions found in infected tissues or in tissues with chronic inflammation such as the
rheumatoid synovium. In their intracellular location they protect the cell from
apoptotic death due to stress. Increasingly chaperonins have been recognised to
subserve extracellular functions for which they have received the name ‘chaper-
okines’ since they bind to specific receptors on the cell surface and activate cells
of the innate immune system to secrete inflammatory cytokines, chemokines and
small molecular weight mediators such as prostaglandins [2]. Indeed, an early
event in inflammation is cell stress/necrosis leading to the release of HSP60 and
HSP70 that binds via a CD14-mediated mechanism to Toll-like receptors 2 and 4
[2] as part of the ‘danger’ signal [3]. The secretion of tumour necrosis factor
alpha, IL-1, IL-12 and other chemokines prepares the environment for a TH1
adaptive immune response. It is now recognised that some chaperonins, such as
BiP and HSP27, may activate the innate immune system to secrete anti-inflamma-
tory cytokines, such as IL-10 [4,5] that may skew the adaptive immune response
to TH2. Recent work by our group has shown that BiP can not only prevent but
also treat ongoing collagen-induced arthritis in DBA/1 mice [6], suggesting that
chaperonins may down modulate ongoing TH1 responses. Thus, it may be possi-
ble to suppress rheumatoid inflammation by administration of appropriate chaper-
onins such as BiP. Finally, chaperonins may be important system regulators
determining the outcome between TH1 and Th2 immune responses.
References
1. Pockley AG: Heat shock proteins as regulators of the immune response.
Lancet 2003, 362:469-476.
2. Asea A: Chaperokine-induced signal transduction pathways. Exerc
Immunol Rev 2003, 9:25-33.
3. Matzinger P: The danger model: a renewed sense of self. Science 2002,
296:301-305.
4. De AK, Kodys KM, Yeh BS, Miller-Graziano C: Exaggerated human
monocyte IL-10 concomitant to minimal TNF-alpha induction by heat-
shock protein 27 (Hsp27) suggests Hsp27 is primarily an antiinflam-
matory stimulus. J Immunol 2000, 165:3951-3958.
5. Corrigall VM, Bodman-Smith MD, Brunst M, Cornell H, Panayi GS: Inhibi-
tion of antigen-presenting cell function and stimulation of human
peripheral blood mononuclear cells to express an antiinflammatory
cytokine profile by the stress protein BiP: relevance to the treatment of
inflammatory arthritis. Arthritis Rheum 2004, 50:1164-1171.
6. Panayi G, Brownlie R, Corrigall V, Bodman-Smith M, Thompson S:
Immunotherapy of collagen induced arthritis with the stress protein
BiP. FASEB J 2004, 18(suppl S):A1174.
Acknowledgements GSP and VCC are shareholders in Immune Regulation Ltd
that is investigating the potential of BiP as an immunotherapeutic agent for the
treatment of rheumatoid arthritis.
S3
Autoimmune diabetes: mechanisms
A Cooke
University of Cambridge, UK
Arthritis Res Ther 2005, 7(Suppl 1):S3 (DOI 10.1186/ar1508)
Type 1 diabetes is an autoimmune disease that is increasing dramatically in inci-
dence in the developed world. Explanations for this increase in incidence include
viral precipitation of disease and the so-called ‘hygiene hypothesis’.
In Type 1 diabetes the insulin-producing beta cells of the pancreas are selectively
destroyed by the immune system. Type 1 diabetes is generally recognised as a T-
cell-mediated autoimmune disease with the autoantibody response to islet anti-
gens serving as markers of ongoing beta cell destruction.
Studies in spontaneous animal models of this human condition suggest that it is a
Th1-mediated autoimmune disease with an involvement of both CD8+ T cells and
macrophages in pathology. There are multiple ways in which the beta cell could
be destroyed including a Class I restricted killing by CD8+ T cells, proinflamma-
tory cytokine-mediated cell death and death induced by Fas/FasL interactions.
At the time of clinical diagnosis it is possible that the patient will have destroyed 70%
of their beta cell mass and exogenous insulin is required to maintain glucose home-
ostasis. There is currently much interest in the development of tolerogenic strategies
to inhibit and halt beta destruction. This coupled with strategies to facilitate the
replacement of the destroyed beta cells would constitute a cure for this disease.
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Human autoimmune diseases are characterized by chronic, non-remitting inflamma-
tion. In the early phase of chronic arthritis auto-reactive T cells initiate a cascade of
events that leads to chronic inflammation. Following the initial phase of the disease,
other cells such as macrophages and monocytes mainly mediate the ongoing non-
specific inflammation. At this later stage, auto reactive T cells presumably do not
play an important role in sustaining the chronic inflammation. Mechanisms underly-
ing the perpetuation of this cascade of non-specific inflammation are still poorly
understood. As a consequence, treatment of the disease until now has been mainly
focused on non-specific suppression of inflammation. In patients with chronic arthri-
tis, such juvenile idiopathic arthritis (JIA) and rheumatoid arthritis (RA) blockade of
the tumour necrosis factor alpha pathway has proven to be a very potent treatment
option. On the other hand, such treatment is costly and fails to induce a long-lasting
remission of the disease. As a consequence long-term treatment with immune sup-
pressive agents is necessary, which increases not only the costs of the treatment
but also harbours considerable risk for long-term side effects. Thus, the need for
additive and/or alternative strategies is growing. Ideally such alternative treatment
should be safe, not expensive and specifically modulate cells that are responsible
for the inflammation and/or counter-regulation. Lately, a lot of attention has focused
on the role of regulatory T cells for the control of autoimmunity. There are currently
two well-characterized types of regulatory T cells, Tr1 cells and CD4+CD25+ T reg-
ulatory cells. The CD4+CD25+ T regulatory cells are a heterogeneous group of
cells identified by the expression of CD25 and the transcription factor foxP3. We
recently showed that these so-called naturally occurring T regulatory cells and regu-
latory T cells with specificity towards heat shock proteins may play a role in deter-
mining disease outcome in JIA [1,2]. Following autologous stem cell transplantation
for arthritis T regulatory cell function is restored coinciding with a remission of the
arthritis (de Kleer et al., submitted). Moreover, oral treatment with a peptide
(dnaJP1), derived from heat shock protein dnaJ, restored T regulatory cells in
peripheral blood mononuclear cells from patients with RA [3].
Thus, due to insufficient numbers of regulatory T cells, feedback mechanisms fail,
resulting in an unrestrained proinflammatory immune response and severe tissue
damage in RA and JIA. A lack of a counter-regulatory mechanism based by regu-
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latory T cells is at least in part responsible for the perpetuation of inflammation
[4]. Heat shock proteins may be instrumental in restoring the immunological
balance and thus contribute to a long-lasting disease remission.
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We have developed new tools that allow detection of peptide–MHC II presentation
to naïve CD4+ T cells in vivo. These tools were used to track early events in the
immune response to a subcutaneously injected antigen. Following such an injection,
antigen is quickly carried via lymphatic vessels into the draining lymph nodes, and
down through thin collagen-based conduits that run through the T-cell-rich area.
Langerhans cells and dermal dendritic cells near the conduits acquired antigen, pro-
duced peptide–MHC II complexes, and were the first cells to stimulate naïve antigen-
specific CD4+ T cells. About 18 hours after antigen injection, dermal dendritic cells
migrated from the injection site and arrived in the lymph nodes displaying a large
number of peptide–MHC II complexes. Elimination of these cells truncated CD25
expression by antigen-specific CD4+ T cells and ablated the development of cell-
mediated immunity. Injection of antigen with the adjuvant lipopolysaccharide allowed
blood-derived myeloid and lymphoid dendritic cells to produce peptide–MHC II com-
plexes. Antigen-specific, but not non-specific, B cells acquired antigen and produced
peptide–MHC II complexes by 6 hours. These B cells migrated from random posi-
tions in the follicles to the border with the T-cell area, and interacted stably there with
peptide–MHC II-specific CD4+ T cells by about 36 hours. These results demon-
strate the antigen-specific CD4+ T cells interact with a variety of antigen-presenting
cell types during the primary immune response.
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Until very recently the field of genetics of musculoskeletal diseases had few suc-
cesses to report, all essentially limited to monogenic conditions or candidate
gene findings mostly of strongly associated genes lying within the MHC.
Amongst these success stories have been important contributions to our under-
standing of conditions such as rheumatoid arthritis and ankylosing spondylitis.
However the field stalled on the identification of the polygenes that contribute the
majority of the genetic risk in a wide variety of common musculoskeletal diseases.
This has led to considerable criticism of the field, with many observers, often criti-
cal of the financial costs of this research, arguing that hypothesis-free genetic
approaches are fatally flawed and wasteful.
Over the past 5 years, however, an increasing run of genes have been identified
using a variety of approaches for conditions including rheumatoid arthritis, anky-
losing spondylitis, chondrocalcinosis and osteoporosis. The successful methods
that have been applied will be discussed along with illustrations of how these
findings have impacted on our understanding of disease pathogenesis.
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Our research is dedicated to the molecular analysis of autoimmune diseases with
a strong focus on rheumatoid arthritis (RA). In order to detect disease-relevant
processes and biomarkers in patients suffering from RA, we searched for con-
spicuous differences in the abundance of soluble proteins between synovial
fluids (SF) and plasmas of patients. Detailed analysis of two-dimensional gel elec-
trophoresis-separated protein spots by means of MALDI-MS and MALDI-QIT-
ToF-MSn sequencing [1,2] revealed that the haptoglobin α-chain is present in
both body fluids in at least four variants. This result suggests that specific post-
translational modification processes occur in SF that could be playing an impor-
tant role in the inflammatory degradation process of the joint.
We therefore analyzed pannus tissue from RA patients and compared the
obtained protein pattern with that from tissues derived from patients with
osteoarthritis (OA) first by RNA microarray-analysis (Affymetrix) [3,4]. Our com-
bined approach started with screening the human genome for protease genes.
There are 590 proteases encoded by the human genome, 397 of which are
found on the Affymetrix chips, represented by 687 unique probe sets. In addition,
from the 159 protease inhibitors in the genome, 106 are presented on the chips
by 164 unique probe sets. Interestingly, only approximately 330 protease probe
sets and approximately 70 inhibitor probe sets yielded in so-called ‘present calls’.
A comparison of the RNA abundances between RA and OA showed that approx-
imately 40 protease and 16 inhibitor gene products could be identified as differ-
entially expressed. One of them was Cathepsin B, which was found
approximately twofold more expressed in the pannus (RA) than in synovial tissue
(OA) at the RNA level. Parallel proteomics investigations showed over 800
protein spots in the gels from tissue materials. Approximately 250 of the protein
spots were analyzed by mass spectrometry, resulting in the identification of
approximately 180 unique proteins. Among the identified proteins 12 belonged to
the group of proteases. Again, Cathepsin B was found significantly upregulated.
In addition, the small calcium binding protein S100A9 (MRP14) was identified as a
discriminatory marker protein in SF by global proteomic analysis [5,6]. These results
were confirmed by ELISA and it was found that plasma levels of the S100A8/A9 hete-
rocomplex are correlating well with levels in SF; hence determination of plasma levels
is applicable for distinguishing RA patients from patients with other inflammatory joint
diseases as well as from OA patients and from controls. Initial studies on RA samples
indicate that plasma levels of the S100A8/A9 heterocomplex might become a useful
marker in monitoring anti-tumor necrosis factor alpha therapy responses.
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Cartilage is a highly organised tissue where the arrangement of collagen and pro-
teoglycan and minor components is carefully controlled. The chondrocytes main-
tain a precise balance between anabolic and catabolic processes that maintains
this extracellular matrix. Proteoglycan removal is rapid and reversible while colla-
gen removal is slower but, once removed, is difficult to replace. Our main
research focus is to discover the mechanism of collagen turnover and we study
the members of the matrix metalloproteinase (MMP) family that specifically cleave
type II collagen to give characteristic one-quarter and three-quarter fragments;
MMP-1, MMP-8, MMP-13 and also MMP-2 and MMP-14 cleave in this way.
Oncostatin M (OSM) is a member of the IL-6 family that synergises with IL-1 to
induce cartilage proteoglycan and collagen degradation in a cartilage explant
culture system [1]. A significant finding is the synergistic induction of the collage-
nase, MMP-1, which occurs via interplay between the JAK/STAT, AP-1 and MAPK
pathways. Other collagenases such as MMP-8 and MMP-13 are also upregulated
along with MMP-14 and MMP-3. This latter enzyme can activate the collagenases,
and an important feature of OSM may be its ability to promote the activation of
enzymes that initiate activation cascades that lead to the production of active col-
lagenases. OSM can also exacerbate the effects of other important proinflamma-
tory mediators such as tumour necrosis factor alpha (TNF-α) and IL-17.
Molecular and cellular studies aim to discover the mechanism of action that leads
to synergy. Affymetrix microarrays show that a specific cohort of genes are upreg-
ulated by these cytokine mixtures including MMPs, ADAMs (A disintegrin and
metalloproteinases), activators, cell surface proteins and cytokines. Two-dimen-
sional gel electrophoresis and proteomic analysis confirm that many of the corre-
sponding proteins are made by chondrocytes after stimulation. Purification of
specific proteins from conditioned culture medium has been undertaken to try
and determine the enzymes responsible for collagen turnover.
In order to assess the effects of these cytokine combinations in vivo, we have
injected OSM in combination with either IL-1 or TNF-α intra-articularly into murine
knee joints using recombinant adenovirus. Engineered adenoviruses were adminis-
tered for only 7 days, after which time joints were fixed, decalcified and sectioned.
Histological analyses indicated marked synovial hyperplasia and inflammatory cell
infiltration for IL-1, TNF-α and OSM treated joints but not in controls (joints treated
with an ‘empty’ adenovirus). The inflammation was more pronounced for both OSM
+ IL-1 and OSM + TNF-α combinations with evidence of extensive cartilage and
bone destruction. Significant loss of both proteoglycan and collagen was also seen
for these combinations, and an increased expression of MMPs with decreased tissue
inhibitors of metalloproteinases was found in both articular cartilage and synovium.
The effects of these combinations were significantly greater than those seen with any
of the cytokines alone. Cytokine combinations also upregulated RANK/RANKL, and
increased the number of TRAP-positive cells showing an increase in osteoclast for-
mation and bone damage. Taken together, these data confirm that, in vivo, OSM can
significantly exacerbate the effects of both IL-1 and TNF-α resulting in inflammation
and tissue destruction characteristic of that seen in rheumatoid arthritis.
These studies provide further evidence to implicate the upregulation of collage-
nases as a key factor in the destruction of collagen that occurs in joint pathology,
and suggests that OSM is a potent mediator when found in the joint with other
proinflammatory cytokines.
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Degradation of cartilage matrix, which mainly consists of collagen fibrils and aggre-
can, seriously impairs the function of joints. The primary cause of this process is ele-
vated proteolytic enzymes. Collagen fibrils are degraded by a group of matrix
metalloproteinases (MMPs) including collagenases (MMP-1, MMP-8 and MMP-13),
gelatinase A (MMP-2) and MT1-MMP (MMP-14). Aggrecan is degraded by MMPs
and ‘aggrecanases’ belonging to the ADAMTS family. Inhibitors of these metallopro-
teinases are considered as potential therapeutic agents to protect cartilage degrada-
tion, and many active site-directed inhibitors with a zinc-chelating moiety have been
developed. Unfortunately, those compounds have serious side effects possibly due
to lack of selectivity [1]. In the hope of developing new types of inhibitors we have
been investigating the mechanisms of action of collagenases and aggrecanases.
Collagenases are unique as they can degrade triple helical interstitial collagens into
three-quarter and one-quarter fragments, a crucial step for collagenolysis in the
tissue. Typical collagenases consist of a catalytic domain and a hemopexin domain
that are connected by a linker peptide. Both domains are essential for collagenolysis.
The three-dimensional structure of a prototypic collagenase, collagenase 1 (MMP-1),
however, indicated that the active site of the enzyme is too narrow to accommodate
triple-helical collagen. We have recently shown that collagenase locally unwinds
triple helical collagen before it hydrolyses the peptide bonds [2]. Based on a series
of mutagenesis mutagenesis we predict that the collagen binding site is created by
both the catalytic and the hemopexin domains. This potential collagen binding
groove is partially blocked by the prodomain in the zymogen of MMP-1 (proMMP-1),
explaining its inability to bind to collagen unless it is activated. Overall proMMP-1 has
a ‘closed’ configuration in contrast to the ‘open’ configuration of the active MMP-1.
The exact mechanism of how collagenase unwinds collagen is under investigation.
Another key collagenase is MT1-MMP. It is highly expressed in rheumatoid syn-
ovial lining cells invading into the cartilage. Overexpression of recombinant MT1-
MMP in COS7 cells in vitro degrade reconstituted type I collagen films. This
reaction requires dimerisation of the enzyme on the cell surface through the
hemopexin domains. When dimerisation of MT1-MMP is prevented by overex-
pression of the membrane-anchored MT1-MMP hemopexin domain, the col-
lagenolytic activity was blocked, but not its general photolytic activity.
Among 19 ADAMTSs in humans, six have been shown to have aggrecanase activity.
Their non-catalytic domains include one disintegrin, one or more thrombospondin,
one cysteine-rich and one spacer domain. Full-length ADAMTS-4 (aggrecanase 1) is
active on aggrecan only, but when the C-terminal spacer domain is deleted it
expresses broader proteolytic activity and digests fibronectin, fibromodulin, decorin
and biglycan, as well as maintaining aggrecanase activity [3]. Further deletion of the
cysteine-rich and thrombospondin domains greatly reduces both activities [3].
These studies suggest that activities of collagenases and aggrecanases will be
attenuated by inhibitors or antibodies that interact directly with their non-catalytic
ancillary domains (exosite/allosteric inhibitors). Such molecules will be attractive
for therapy as they will be highly selective because they are based on the unique
mechanism of each proteinase.
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Rheumatoid arthritis (RA) represents an excellent model for gaining insights into the
adverse effects of inflammatory arthritis on skeletal remodeling. Bone erosions at the
margins of diarthrodial joints represent the radiographic hallmark of RA. Histopatho-
logic examination of the bone–pannus interface in patients with RA reveals the pres-
ence of a heterogeneous population of cells lining the bone surface, including
multinucleated cells expressing the full phenotypic repertoire of osteoclasts, the cells
that mediate bone resorption in physiologic remodeling. Further evidence implicating
osteoclasts in the pathogenesis of marginal joint erosions is derived from animal
models of inflammatory arthritis in which animals lacking the capacity to form osteo-
clasts fail to develop joint erosions. Studies have shown that the RA synovial tissue
contains abundant osteoclast precursors and that the RA synovium is a rich source
of factors with potent osteoclast differentiation and activation activity. Particular
attention has focused on receptor activator of NF-κB ligand (RANKL), a member of
the tumor necrosis factor ligand family, because of the requirement of this factor for
osteoclastogenesis. RANKL is expressed by synovial fibroblasts and activated T cells
in RA synovial tissues and in several different animal models of inflammatory arthritis,
treatment with osteoprotegerin (the soluble receptor that inhibits RANKL activity)
results in marked suppression of focal bone erosions. In addition, mice possessing
the null mutation for RANKL are protected from focal bone destruction in the serum
transfer model of inflammatory arthritis. An additional observation in patients with
active RA is the absence of radiographic evidence of bone repair. This finding sug-
gests that the processes that regulate coupling of bone resorption and formation
under physiologic conditions have been disrupted and that the enhanced focal bone
Available online http://arthritis-research.com/supplements/7/S1S4
resorption is not matched by a compensatory increase in bone formation. In addition
to the disordered focal bone remodeling associated with the synovial lesion, patients
with RA also exhibit evidence of generalized axial and appendicular bone loss at sites
that are distant from inflamed joints. Assessment of biochemical markers of bone
turnover indicates that there is a generalized increase in bone resorption, and that
there is a correlation between disease activity and the rate of systemic bone resorp-
tion. It is likely that this generalized skeletal bone loss is mediated by synovial
cytokines with osteoclastogenic activity that enter the circulation and act as
‘endocrine’ factors to adversely affect systemic bone remodeling. Recent studies
indicate that agents, such as the bisphosphonates, that target osteoclast-mediated
bone resorption have the capacity to reduce not only generalized bone osteoporosis
but also may have efficacy in retarding the progression of focal joint erosions.
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Bone diseases are a common cause of morbidity and mortality in developed coun-
tries, and genetic factors play an important role in the pathogenesis of these dis-
eases. The most common form of bone disease is osteoporosis, which is
characterized by reduced bone mineral density (BMD) and an increased risk of frac-
ture. Environmental factors such as diet and exercise influence BMD but genetic
factors play a predominant role, accounting for up to 85% of the variation in peak
BMD. Several candidate genes have been identified that regulate BMD and suscep-
tibility to fracture, including bone morphogenic protein 2, collagen type I alpha 1, the
vitamin D receptor, the estrogen receptor and lipoprotein receptor related protein 5
(LRP5). Paget’s disease of the bone (PDB) is characterised by focal abnormalities of
increased bone turnover. Mutations in several genes have been identified as causes
of PDB and related syndromes including receptor activator of NF-κB (RANK), osteo-
protegerin, sequestosome 1 and valosin containing protein. All of these genes play a
role in the RANK signalling pathway, which is essential for osteoclast activation. Rare
bone diseases such as osteopetrosis and hereditary osteoscleroses are also caused
by mutations in genes that affect bone cell function. Osteopetrosis is characterised
by increased BMD, and failure of osteoclastic bone resorption due to mutations in
genes that encode proteins that are essential for osteoclast activity like the chloride
pump and proton pump, or mutations in genes like cathepsin K, which breakdown
bone matrix. Although the bones are dense, fractures are common in osteopetrosis
because of reduced bone quality. Osteosclerosis occurs because of mutations in
genes that increase osteoblast activity, including SOST, transforming growth factor
beta and LRP5. Osteosclerotic patients also have increased BMD but fractures are
rare, because bone quality is normal. From a clinical standpoint, advances in knowl-
edge about the genetic basis of bone disease offers the prospect of developing new
markers for assessing fracture risk and the identification of new molecular targets
that will form the basis for the design of new treatments.
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One of the most important but as yet unanswered questions in inflammation
research is not why chronic inflammation occurs but why it does not resolve.
Current models of inflammation stress the role of antigen-specific lymphocyte
responses and attempt to address the causative agent. However, recent studies
have begun to challenge the primacy of the lymphocyte and have begun to focus
on an extended immune system in which stromal cells, such as macrophages and
fibroblasts, play a role in the persistence of the inflammatory lesion.
In this lecture I will illustrate how fibroblasts play an important role in regulating the
switch from acute resolving to chronic persistent inflammation associated with the
pathology of diseases such as rheumatoid arthritis [1]. In chronic inflammation the
normal physiological process of the death and emigration of unwanted inflammatory
effector cells becomes disordered leading to accumulation of leucocytes [2–4]
within lymphoid aggregates that resemble those seen in lymphoid tissue [5]. I will
describe how fibroblasts from the rheumatoid joint provide survival and retention
signals for leucocytes leading to their inappropriate and persistent accumulation
within inflamed tissue [6]. Our work suggests that targeting the stromal microenvi-
ronment is likely to be an important strategy for future anti-inflammatory therapies.
References
1. Buckley CD, Pilling D, Lord JM, Akbar AN, Scheel-Toellner D, Salmon M:
Fibroblasts regulate the switch from acute resolving to chronic persis-
tent inflammation. Trends Immunol 2001, 22:199-204.
2. Salmon M, Scheel-Toellner D, Huissoon AP, Pilling D, Shamsadeen N,
Hyde H, D’Angeac AD, Bacon PA, Emery P, Akbar AN: Inhibition of T cell
apoptosis in the rheumatoid synovium. J Clin Invest 1997, 99:439-446.
3. Buckley CD, Amft N, Bradfield PF, Pilling D, Ross E, Arenzana-Seisdedos
F, Amara A, Curnow SJ, Lord JM, Scheel-Toellner D, Salmon M: Persistent
induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial
T cells contributes to their accumulation within the rheumatoid syn-
ovium. J Immunol 2000, 165:3423-3429.
4. Buckley CD: Why do leucocytes accumulate within chronically inflamed
joints? Rheumatology 2003, 42:1433-1444.
5. Amft N, Curnow SJ, Scheel-Toellner D, Devadas A, Oates J, Crocker J,
Hamburger J, Ainsworth J, Mathews J, Salmon M, et al.: Ectopic expres-
sion of the B cell attracting chemokine BCA-1 (CXCL13) on endothelial
cells and within lymphoid follicles contributes to the establishment of
germinal center-like structures in Sjögren’s Syndrome. Arthritis Rheum
2001, 44:2633-2641.
6. Parsonage G, Falciani F, Burman A, Filer A, Ross E, Bofill M, Martin S,
Salmon M, Buckley CD: Global gene expression profiles in fibroblasts
from synovial, skin and lymphoid tissue reveals distinct cytokine and
chemokine expression patterns. Thromb Haemost 2003, 90:688-697.
S15
Regulating apoptosis in fibroblasts
T Pap1, A Cinski2, A Drynda2, A Wille2, A Baier2, S Gay3, I Meinecke4
1Division of Molecular Medicine of Musculoskeletal Tissue, University Hospital,
Munster, Germany; 2Division of Experimental Rheumatology, University Hospital
Magdeburg, Germany; 3Center of Experimental Rheumatology, Department of
Rheumatology, University Hospital, Zurich, Switzerland; 4Department of Traumatology,
Hand and Reconstructive Surgery, University Hospital, Munster, Germany
Arthritis Res Ther 2005, 7(Suppl 1):S15 (DOI 10.1186/ar1515)
Apoptosis constitutes a highly selective way of eliminating aged and injured cells
and is a key mechanism for the balanced growth and regeneration of tissues. In
addition to genotoxic stress and the withdrawal of growth factors, apoptosis can
be induced by death receptors. Such receptors trigger apoptosis through an
approximately 90 amino acid death domain. Prominent and best-characterized
members of the death domain receptor family are Fas (CD-95/Apo-1) and the
p55 TNF receptor (TNFRI). Alterations in receptor-mediated apoptosis may result
in changes of tissue homeostasis and have been found in a variety of malignan-
cies as well as in the inflamed and hyperplastic synovium in rheumatoid arthritis.
Accumulating evidence suggests that the activation of rheumatoid arthritis syn-
ovial fibroblasts (RASF) is associated with alterations in apoptosis, especially at
sites of invasion into cartilage and bone. Specifically, it has been demonstrated
that RASF are less susceptible to Fas-induced cell death than osteoarthritis syn-
ovial fibroblasts but show higher expression levels of Fas.
Recent studies have shown that both cytokine-dependent and cytokine-indepen-
dent mechanisms contribute to the resistance of RASF against Fas-induced
apoptosis. Thus, tumor necrosis factor alpha (TNF-α) — a major inflammatory
cytokine in the rheumatoid synovium — fails to induce apoptosis in RASF, but
reduces the susceptibility of these cells to Fas-mediated cell death through the
induction of the transcription factor NF-κB. Providing a link between altered
apoptosis and cartilage destruction, we have shown that overexpression of TIMP-3
through gene transfer not only reduces the invasiveness of RASF but also modu-
lates the apoptosis-inhibiting effects of TNF-α. RASF overexpressing TIMP-3 are
sensitized strongly to Fas/CD95-mediated cell death by TNF-α, and gene transfer
of TIMP-3 inhibits the TNF-α-induced activation of NF-κB. While these effects of
TNF-α on apoptosis can be found in different fibroblasts, several anti-apoptotic
molecules have been demonstrated to be upregulated specifically in RASF.
In this context, we have investigated the role of the small ubiquitin-like modifier
SUMO-1 in the regulation of apoptosis. We found that increased levels of
SUMO-1 in RASF but not in osteoarthritis synovial fibroblasts were associated
with a reduced susceptibility of RASF to Fas-induced apoptosis. Using small inter-
fering (si)RNA to knock-down the expression of SUMO-1 as well as retroviral gene
transfer of SUMO-1, we could establish a functional relationship between the
expression of SUMO-1 and the resistance of RASF against apoptosis. Moreover, it
was demonstrated by gene transfer of the nuclear SUMO-protease SENP1 that,
rather than by interacting directly with the Fas-associated death domain, SUMO-1
inhibits apoptosis through recruiting pro-apoptotic molecules such as DAXX into
nuclear PML bodies, where they cannot exert their pro-apoptotic effects.
Taken together, there is growing evidence that in activated fibroblasts, such as in
RASF, there is a close association between anti-apoptotic and destructive path-
ways. In addition to cytokine-dependent inflammatory mechanisms, the intrinsic
upregulation of anti-apoptotic molecules contributes to the resistance of RASF
against apoptosis. Post-translational modification of nuclear proteins through
SUMO-1 appears to constitute an important mechanism of apoptosis regulation.
Therefore, the inhibition of molecules that confer the resistance of RASF to apop-
tosis constitutes a most interesting therapeutic target.
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Rheumatoid arthritis (RA) is an immune-mediated disease with synovial inflamma-
tion and invasion of the extracellular matrix. While adaptive immunity plays a key
role in the pathogenesis of RA, the contribution of innate immune responses has
been increasingly appreciated in recent years. Toll-like receptors (TLRs) and
cytokines in the rheumatoid synovium can activate signal transduction pathways
that induce proinflammatory genes and perpetuate synovitis. Understanding
these signaling mechanisms helps us understand the pathogenesis of disease
and identify novel therapeutic targets.
Among the signaling pathways that are potentially involved in inflammation, the
IKK-related kinase, inducible IKK (IKKi or IKKε), appears to play a key role in
innate immune responses in the joint and modulates synovial inflammatory
responses. This kinase, along with a second IKK-related kinase TANK binding
kinase 1 (TBK1), was originally identified as a NF-κB activating enzyme that
phosphorylates IkB. It is now clear, however, that this represents only one of
several substrates for this family. For instance, IKKi also phosphorylates interferon
regulatory factor (IRF) and coordinates the activation of IRF and NF-κB after TLR
ligation. IKKi may also link the NF-κB and CCAAT enhancer binding protein
(C/EBP) pathways in lipopolysaccharide-stimulated cells. The novel roles for IKKi
suggests that it contributes to the signaling pathways involved in synovial inflam-
mation. Moreover, IKKi appears to play a key role in the establishment of an ‘anti-
viral state’ through the activation of IRF3 and c-Jun with subsequent production
of interferon beta (IFN-β) and other genes involved in host defense.
We previously demonstrated that IKKi is constitutively expressed in RA synovial
tissue and fibroblast-like synoviocytes (FLS), and that the gene can be induced
by cytokine stimulation. More recent studies now show that functional activity of
IKKi in cultured synoviocytes is rapidly increased by exposure to proinflammatory
cytokines and TLR agonists. We have also shown that IRF3 is activated in RA
synovium, which represents an early step in the IKKi-mediated expression of anti-
viral genes like IFN-β. Additional preliminary data with human FLS suggest that
the IKKi pathway can activate other signaling cascades, such as c-Jun, which play
a role in assembly of the interferon ehanceosome to increase IFN-β expression.
Using FLS from IKKi knockout mice, we have shown that IKKi can act as a key
link between TLR/cytokine receptor ligation and expression of cytokines and
matrix metalloproteinases. IKKi might serve in an alternative signaling pathway for
activation of innate immunity in RA and establishing an anti-viral state in the syn-
ovium, especially through the activation of IRF3-driven and c-Jun-driven genes.
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Objective NF-κB is a key regulator of synovial inflammation. In the initiation phase
of rheumatoid arthritis (RA) dendritic cells and T cells are likely to be important,
whereas in established arthritis other cells play a key role as well. We investigated
the relative effect of upstream NF-κB inhibition specifically in T cells versus non-cell
type specific NF-κB inhibition in different stages of rat adjuvant arthritis (AA), using
either the T-cell specific PKC-theta inhibitory factor (PIF) peptides or non-cell type
specific IKK-beta blocking NEMO binding domain (NBD) peptides. The effects of
the NBD peptide on human RA synovial tissue in culture were also evaluated.
Methods AA was induced in Lewis rats by intradermal injection of heat-killed
mycobacteria. Rats develop clinical signs of arthritis 10–12 days after immuniza-
tion. PIF or NBD peptides (150 µg) were administered either intraperitoneally or
intra-articularly into the ankle joint at different time-points. The course and severity
of arthritis was monitored using water-displacement plethysmometry. On day 21
rats were sacrificed and tissue specimens were collected for routine histology
and X-rays of the ankle joints. Human RA synovial tissue was collected by
arthroscopy and cultured ex vivo ± NBD (100 µM). Tumor necrosis factor alpha
induced IL-6 production was measured in the supernatant after 7 days by ELISA.
Results Intra-articular injection of the T-cell specific PKC-theta inhibitor PIF on
days 10 and 12 did not result in amelioration of arthritis nor reduced bone
erosion. However, intraperitoneal injection of PIF on days –1, 1 and 3 resulted in
reduced T-cell proliferation on day 5 in response to TCR triggering (50%;
P = 0.03) or cognate antigen (PPD) (30%; P = 0.05). Furthermore, this resulted
in a slightly reduced severity of arthritis (area under the curve 18.47 versus
22.86; P = not significant) and radiological damage (erosion score 4 versus 6;
P = not significant). Non-cell type specific NF-κB blockade by the NBD peptide
resulted, however, in significantly reduced severity of arthritis (P < 0.0001) and
radiological damage (P = 0.04) when injected intra-articularly on days 10 and 12.
In addition, proinflammatory cytokine expression was significantly lower in syn-
ovial tissue of NBD-treated rats. Incubation of human RA synovial tissue with
NBD peptides resulted in 33% inhibition of tumor necrosis factor alpha induced
IL-6 production in the supernatant (P < 0.01).
Conclusions Specific NF-κB blockade using a small molecule inhibitor of IKK
beta has anti-inflammatory effects in AA and human RA synovial tissue. Inhibition
of PKC-theta has clear effects on T-cell proliferation when administered around
the induction of arthritis, but very limited effects on the clinical course of arthritis,
suggesting that NF-κB activity in other cell types contributes significantly to the
inflammatory response. These results indicate that IKK-beta-targeted NF-κB
blockade is superior to T-cell specific PKC-theta inhibition in established arthritis.
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The aim of our study was to evaluate antibodies against ‘specific liver’ antigens in
selected sera from patients with positive ‘AMA like’ and unidentified (UD) Hep2
cytoplasmic immunofluorescence (ctp IIF).
Sera of 75 inpatients and outpatients from the Department of Rheumatology,
Ljubljana met the inclusion criteria: 36 with AMA-like and 39 with UD pattern. All
sera were also negative for anti-M2 and/or antibodies against pyruvat dehydroge-
nase complex as well as negative to other defined ctp IIF patterns according to
European Consensus Finding Study: lysosomal-like, Golgi-like, vimentin-like and
actin-like. The majority of patients fulfilled the criteria for connective tissue dis-
eases and rheumatoid arthritis.
Antibodies against intracellular antigens were screened by IIF on HEp2 cells
(Immunoconcepts, Sacramento, CA, USA). Antibodies against LKM1, SLA, LC1
and Sp100 were performed by line immunoassay (Imtec, Berlin, Germany).
There was no difference in AMA-like and UD ctp IIF concerning antibodies
against ‘specific liver’ antigens. A surprisingly high prevalence of positive anti-
LKM1 was found in sera regardless of the IIF pattern (Table 1).
Table 1
Antibodies against ‘liver specific’ antigens in sera with AMA-like and
UD ctp IIF
n Sp100 LKM1 SLA LC1
AMA-like 42 4 19 (45%) 0 1
Unidentified 33 4 14 (42%) 2 0
All 75 8 (11%) 33 (44%) 2 (3%) 1 (1%)
Anti-LKM1 has been considered as one of the markers for autoimmune hepatitis
type II characterised by fulminant onset and high inflammatory activity according
to Imtec data. None of our patients with positive anti-LKM1 had any serious
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hepatic involvement, therefore they had not been histopathologically evaluated.
Only few of them exhibited minor deviations in liver enzymes (less than 1 × upper
normal limit). There was slightly lower prevalence of connective tissue disease
patients found among UD ctp IIF (Table 2).
Table 2
Antibodies against ‘liver specific’ antigens in sera with AMA-like and
UD ctp IIF
Patients n (%) Sp100 LKM1 SLA LC1
AMA (n = 42)
Connective tissue 
diseases 25/42(60%) 3 8 0 1
Rheumatoid arthritis 6/42 (14%) 0 5 0 0
Other 11/42 (26%) 1 6 0 0
Unidentified (n = 33)
Connective tissue 
diseases 15/33 (46%) 3 6 2 0
Rheumatoid arthritis 6/33 (18%) 0 2 0 0
Other 12/33 (36%) 1 6 0 0
An UD ctp IIF pattern is a frequent laboratory finding but it seems not to be of
much help to rheumatologists. A search for antibodies against ‘specific liver’ anti-
gens seems not to be justified for delineation of hepatic involvement in patients
with rheumatic diseases. According to the literature in patients with autoimmune
hepatitis the meaning of these antibodies is different.
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Background Tissue hypoxia in inflammation induces the upregulation of a gene
program associated with angiogenesis, glycolysis and adaptation to pH via the
hypoxia-inducible transcription factors (HIFs). In this study we investigate the rela-
tionship between synovial tissue oxygen levels in inflammatory arthritis and tissue
expression of HIF-1α and vascular endothelial growth factor (VEGF).
Methods Novel silver microelectrode technology was used to measure synovial
tissue oxygen levels under direct vision during arthroscopy in six patients with
inflammatory arthritis of the knee. A sterile silver needle electrode comprising a
teflon-insulated silver wire was embedded in a 19 G hypodermic needle of 10 cm
length and introduced to the intra-articular space via a medial suprapatellar
approach such that the electrode tip could be directly visualised by the arthro-
scope introduced from a standard lateral infrapatellar approach. The voltage
applied was adjusted to give a diffusion-limited current for the reduction of
oxygen. Synovial biopsies were taken under direct vision from exactly the point at
which tissue oxygen levels were measured and snap-frozen immediately. HIF-1α,
HIF-2α and VEGF were detected by immunohistochemistry in fixed synovial
biopsy sections and the immunopositive area fraction was determined by quanti-
tative digital image analysis.
Results  The mean and standard deviation for oxygen tension in the synovial
tissue of the joints sampled was 15.4 ± 9.6 mmHg, range 24.4 mmHg. The mean
and standard deviation for immunopositive area fraction for HIF-1α was
0.64 ± 0.39% and for HIF-2α was 4.9 ± 6.7%. HIF-1α and HIF-2α staining were
detected predominantly in the synovial lining layer. There was a significant,
inverse relationship between synovial tissue oxygen measurement in vivo and
tissue expression of HIF-1 (Pearson r = –0.86, P = 0.03) and similarly between
synovial tissue oxygen and tissue expression of VEGF (Pearson r = –0.89,
P = 0.02). There was a positive, highly significant correlation between synovial
expression of HIF-1α and VEGF (Pearson r = 0.97, P = 0.0005).
Conclusions  In this study we directly demonstrate that intra-articular pO2 is
markedly reduced in inflammatory arthritis. Furthermore, in the same patients, syn-
ovial tissue oxygen tensions are inversely proportional to HIF-1α and VEGF
expression, suggesting that this environment contributes to the perpetuation of
inflammation and associated tissue destruction.
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Background and objectives Rheumatoid arthritis is an autoreactive disease in
which activated T cells play an important role orchestrating the autoimmune
responses giving rise to the inflammatory cascade responsible for joint inflamma-
tion and bone destruction. The CD28/B7 costimulatory pathway is critical for full
T-cell activation, and modulating this pathway has been shown to inhibit T-cell
activation leading to inhibition of these immune responses. Abatacept modulates
T-cell activation by interfering with the engagement of CD80/86 with CD28.
Abatacept has been shown to provide significant improvement in the signs and
symptoms of rheumatoid arthritis in a phase II trial. Here, we examine the effect
abatacept administration has on disease induction, anti-collagen antibody pro-
duction and bone destruction in a rat model of collagen-induced arthritis.
Methods Female DA rats were immunized subcutaneously on day 0 with 300 µg
bovine type II collagen in incomplete Freund’s adjuvant at the base of the tail.
Immunized rats were administered either 1 mg/kg abatacept or a control human
IgG IP on days –1, 0, 2, 4, 6, 8 and 10. Disease progression was monitored by
measuring the paw volume in milliliters with a plethysmometer. Both hind paws
were measured and the change in volume from baseline measurements (day 0)
were recorded. At the conclusion of the study (day 27) serum samples were col-
lected from each animal for measurement of collagen-specific antibodies by
ELISA as well as serum cytokine measurements. Legs from the rats were
removed and placed in formalin and prepared for histological analysis as well as
analysis of bone morphology by micro-CT.
Results By day 16 of the study, significant paw swelling was observed in the
IgG-treated control animals and continued to increase throughout the study until
reaching a plateau (~ 3–3.5 ml) on day 21. Administration of abatacept abro-
gated paw swelling throughout the course of the study. The IgG-treated rats
reached 100% incidence while no incidence was observed in the abatacept-
treated group. Serum anti-collagen antibody levels correlated well with the paw
swelling data where abatacept administration resulted in 90% inhibition of colla-
gen-specific antibodies. We also found that abatacept decreased the expression
of many of the circulating cytokines and chemokines that were upregulated in dis-
eased animals. The micro-CT data revealed that abatacept treatment protects the
bone from destruction as the knees and ankles of these rats appear to be normal.
Conclusion Abatacept, a selective co-stimulation modulator, significantly inhib-
ited the onset and progression of disease in a rat collagen-induced arthritis
model. In these studies, paw swelling, collagen-specific antibodies and bone
destruction were all inhibited by the treatment.
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Background The transcription factor T-bet is a critical regulator of Th1 effector
function. Animals deficient in T-bet are protected from a variety of inflammatory
diseases, including systemic lupus erythematosus and inflammatory arthritis. An
essential function of Th1 cells is the ability to traffic appropriately to sites of
inflammation, which is largely dependent on the expression of specific selectin
ligands and chemokine receptors. We therefore hypothesised that T-bet would
modulate lymphocyte trafficking in vitro and in vivo by direct regulation of both
selectin binding and chemokine function.
Methods Balb/c mice deficient in, or transgenic for, T-bet had been generated
previously. T-bet–/– × DO11.10 TCR and T-bet–/– × IFN–/– mice were generated
by backcrossing for >10 generations. CD4+ T cells were generated from primary
lymph nodes from all these mice by positive selection and stimulation with appro-
priate antigen. Functional analysis used the following four methods: adoptive
transfer into WT Balb/c mice, which were then injected with OVA, cells were har-
vested from the spleen, lymph node and peritoneum; selectin binding, interac-
tions with immoblised P-selectin and E-selectin under conditions of laminar flow
were examined in a parallel plate flow chamber; expression of selectin ligands,
using flow cytometry, real-time PCR and 35S incorporation; and chemokine
receptor expression and function, using flow cytometry, real-time PCR, transwell
chemotaxis and endothelial binding under flow conditions.
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Results Selective migration of T-bet–/– CD4+ T cells in a Th1-dependent model
of peritoneal inflammation was completely abrogated. Further investigation
revealed that this effect was due to a 50% reduction in binding to P-selectin but
not E-selectin under in vitro flow conditions and that this was as a result of
impaired tyrosine sulfation of PSGL-1. In addition, mRNA and surface expression
of CXCR3, but not CCR5, was reduced and this was associated with a reduction
in both transwell chemotaxis and binding to endothelial cells. Retroviral transfer
experiments of T-bet cDNA into T-bet–/– and T-bet–/– × IFN–/– cells demonstrated
that these effects were independent of interferon.
Conclusions  These data establish that T-bet imprints a specific migratory
program onto developing CD4+ cells via control of PSGL-1 sulfation (and thus
P-selectin binding) and CXCR3 expression and function. Furthermore, as
E-selectin and CCR5 binding are unimpaired, this reveals a level of control on
trafficking of Th1 lymphocytes not recognised by previous paradigms.
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Background It has been suggested that rheumatoid arthritis (RA) is initiated or
perpetuated by CD4 T cells activated by presentation of joint antigens by sus-
ceptible MHC class II molecules including HLA-DR4 and DR1. A number of can-
didate antigens have been investigated including cartilage-derived type II
collagen and aggrecan. Immunisation of susceptible strains of mice with aggre-
can, including BALB/c (H-2d), induces autoimmune arthritis, providing an animal
model of human RA [1]. Immunisation with peptides predicted to bind to HLA-
DR4 also induces T-cell responses in HLA-DR4 transgenic mice [2]. The auto-
immune T-cell response focuses on only a few epitopes within restricted regions
of aggrecan such as the G1 globular domain, for reasons that are poorly under-
stood. One explanation is a failure of self-tolerance due to poor presentation of
these aggrecan epitopes in the thymus, and presentation of the same epitopes in
joints following release and processing of the normally sequestered aggrecan
induced by early inflammatory events. T-cell responses have also been observed
in RA patients mapping epitopes within the G1 domain.
Aim To characterise aggrecan-specific T-cell hybridomas from BALB/c (H-2d)
and DR1 transgenic mice to investigate the mechanisms of antigen presentation
of arthritogenic CD4 T-cell epitopes of aggrecan.
Methods Aggrecan-specific T-cell hybridomas were generated from spleen cells of
BALB/c and DRB1*0101-transgenic mouse-MHC class II knockout (DR1-tg) mice
immunised with deglycosylated bovine aggrecan. Synthetic peptides of three known
arthritogenic H-2d-restricted epitopes (amino acids 68–82, 84–103 and 169–189)
and three DR1-restricted epitopes known to be recognised by RA patients (amino
acids 148–165, 201–213 and 292–311) from the G1 domain of bovine aggrecan
were used to define the specificity of T-cell hybridomas. Cultured bone marrow
macrophages were treated with deglycosylated bovine aggrecan or synthetic pep-
tides and used as antigen-presenting cells. T-cell hybridoma responses were mea-
sured by proliferation of CTLL-2 indicator cells to T-cell hybridoma supernatants in
the presence of tritiated thymidine and expressed as counts per minute.
Results The specificity of most aggrecan-specific T-cell hybridomas mapped to
the aggrecan G1 domain using synthetic peptides representing known H-2d-
restricted or DR1-restricted CD4 T-cell epitopes. However, most cloned (and
recloned) T-cell hybridomas recognised two of the H-2d-restricted epitopes
(84–103 and 169–189) as well as two of the DR1-restricted epitopes (148–165
and 292–311). The same synthetic peptides were not recognised by H-2d-
restricted and DR1-restricted T-cell hybridomas of unrelated specificities and
were not mitogenic for spleen cells from BALB/c or DR1-tg mice. None of the
T-cell hybridomas recognised aggrecan epitopes 68–-82 or 201–213.
Conclusion  We are investigating this unexpected pattern of cross-reactivity
between a number of known arthritogenic epitopes of aggrecan using lymph
node T-cell responses of peptide-immunised BALB/c and DR1-tg mice. In addi-
tion we are investigating the mechanisms of antigen presentation of these epi-
topes, which may shed light on why this particular region of aggrecan is antigenic
for autoreactive T cells.
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Background Tendon disease is often the first presentation of rheumatoid arthritis
(RA). Tenosynovial proliferation results in scarring and adhesion formation.
Synovial invasion into tendons occurs in 50% of cases and is associated with
multiple tendon ruptures and a poorer prognosis. Recent work on diseased joints
suggests that hypoxia may play a key role in synovial invasion. We hypothesised
that hypoxia promotes and maintains the inflammatory response in RA teno-
synovium via neovascularisation.
Objectives To measure oxygen tension (pO2) within the synovium of rheumatoid
tendons and joints in vivo. To study markers of hypoxia and neovascularisation in
invasive and non-invasive tendon synovium by immunohistochemistry. To investi-
gate the effects of hypoxia on in vitro cultures of invasive and non-invasive
tenosynovium.
Methods Patients undergoing elective hand surgery for RA were recruited into
the study. In vivo oxygen tension measurements were taken intra-operatively
using an established microelectrode technique. Readings were taken from
tendon and joint synovium. Diseased tissue was harvested from areas of oxygen
sampling for immunohistochemical analysis of CD31 expression.
Tissue was also harvested from invasive and non-invasive tenosynovium. Joint
tissue was used as a control. Serial sections of tissue were stained for the pro-
angiogenic factor vascular endothelial growth factor (VEGF) and the hypoxia-
regulated transcription factor hypoxia inducible factor (HIF)-2α.
Separate tissue from these three areas of interest was enzymatically digested and
cultured in hypoxic (1% oxygen) and normoxic (21% oxygen) conditions. Super-
natants were harvested at 24 hours and analysed for expression of key inflamma-
tory cytokines by ELISA.
Results We observed profound hypoxia in the synovium of RA tendons and joints
in vivo despite immunohistochemical evidence of markedly increased vascularity,
measured as expression of CD31. Immunohistochemical analysis revealed
twofold greater VEGF expression in tenosynovium (P < 0.05), compared with
joint synovium from the same patient. Levels of HIF-2α were found to be similar in
tendon and joint synovium.
One of the consequences of synovial hypoxia could be the modulation of inflam-
matory and angiogenic cytokines. We found that hypoxia upregulated in vitro
expression of pro-angiogenic cytokine VEGF in both joint and tenosynovial cul-
tures (P < 0.05) by an average of 128%, and in parallel increased levels of the
pro-inflammatory cytokine tumour necrosis factor alpha by an average of 105%.
In contrast, hypoxia downregulated expression of monocyte chemoattractant
protein-1 (P < 0.05) by an average of 44%.
Conclusions Hypoxia is a feature of rheumatoid tenosynovitis. Key cytokines are
regulated by hypoxia in this disease process. HIF-2α may represent the link
between hypoxia and VEGF-driven angiogenesis in rheumatoid tendon disease.
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Objective Adenovirus 5 (Ad5) receptors other than Cocksackie-ad receptor have
not been well explored in rheumatoid arthritis (RA) human fibroblast-like synovio-
cytes (FLS). Defining these receptors may enable development of improved Ad5
vectors to specific synovial targets. As Cocksackie-ad receptor is absent in RA
FLS, we investigated the efficacy and receptor usage of fibre-modified Ad5
vectors for gene delivery in vitro and ex vivo.
Methods Short fibre modified vectors with seven fibre repeats (Ad5GFP-R7-
knob, Ad5GFP-R7-RGD) were compared with wild-type (WT) 22 repeats
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(Ad5GFP-FiWT) and GFP expression measured in RA human FLS and a syn-
ovium explant model. Integrin expression was determined by flow cytometry.
Receptor usage was examined by competition binding assays with viral penton
base (PB) WT, RGD and LDV-mutant peptides, and antibodies against PB and
integrins. Viral neutralization by synovial fluid was examined.
Results Ad5GFP-R7-knob gene transduction was 25-fold higher than Ad5GFP-
R7-RGD and 40-fold to 50-fold higher than Ad5GFP-FiWT in FLS. Ad5GFP-R7-
knob gene transduction was reduced with PB, RGD and LDV, and antibodies
against PB and αv, αvβ3, αvβ5, and β1 integrins. Ad5GFP-R7-knob transduction
was increased by tumour necrosis factor and IL-1, remained 30-fold to 40-fold
higher than Ad5GFP-FiWT in the presence of synovial fluid and preferentially
transduced synovium explant outgrowth/tissue.
Conclusion Ad5GFP-R7-knob has broadened viral tropism superior to RGD-
modified and WT vectors, mediated by integrin-binding RGD and non-RGD
motifs in viral PB capsomers in RA FLS. Ad5 short fibre modifications utilize
tropism of the native PB to optimise integrin usage as both attachment and endo-
cytotic receptors. This may be a useful strategy of enhancing gene delivery in RA,
reducing vector dose and induction of inflammation and toxicity.
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Background and objective Elevated expression of laminins (LN) and integrins in
the synovial membrane of rheumatoid arthritis (RA) versus osteoarthritis patients
has been reported but metabolic effects of attachment of synovial fibroblasts (SF)
to LN are not well studied. We therefore investigated gene expression patterns in
SF upon attachment to LN1 (EHS laminin) in comparison with LN10.
Methods Expression of IL-1α, IL-1β, IL-6, IL-8, IL-16, IL-18 as well as matrix met-
alloproteinase (MMP)-1 and MMP-3 were investigated in RA SF (n = 6) or
osteoarthritis SF (n =7) in primary or early passage cultures. Fibroblasts were
seeded onto LN1-coated vessels (BD BioCoat®) for 24–72 hours and cells
attached to cell culture vessels served as controls in all experiments. In addition,
cells were activated with cytokines and growth factors such as transforming
growth factor beta (TGF-β). After activation, transcript amounts of individual
genes were enumerated by quantitative RT-PCR. A recombinant cytokine stan-
dard and GAPDH RT-PCR served as controls in each sample. Expression of the
α1, β1 and γ1 chains of LN1 laminin by SF was investigated by quantitative RT-
PCR and immunocytochemistry. The secretion of MMPs was enumerated by
ELISA in SF supernatants.
Results Growth of SF on LN1-coated surfaces without additional stimuli induced
a significant IL-8 mRNA response (3.1-fold, ± 1.24, P  ≤ 0.001) and lower
responses for IL-1β, IL-16, IL-1α, IL-18 and IL-6. MMP-1 mRNA was upregulated
2.3-fold (± 0.79, P ≤ 0.001), and MMP-3 mRNA only 1.5-fold. Upon incubated of
SF on LN10, cytokine and MMP expressions were not changed. Addition of TGF-β
(10 ng/ml, 24 hours) to SF attached to tissue culture vessels showed a different
induction profile. Here IL-6, IL-1β, IL-1α, IL-8, IL-16 and MMP-1 mRNAs were
induced to some degree, IL-18 mRNA was reduced whereas MMP-3 mRNA was
induced (3.15-fold, ± 0.7, P ≤ 0.04), when compared with controls. Next combina-
tions of activation by TGF-β and laminin signaling were investigated. For cytokine
expressions no additive effects of combining these signals were seen and MMP-1
mRNA was induced to some extent (threefold, ± 1.76). In contrast, MMP-3 mRNA
was induced more that 10-fold (12.8 ± 8.7, P ≤ 0.025) and MMP-3 secretion was
elevated almost 20-fold (19.67 ± 6.9, P ≤ 0.06). In SF, mRNAs encoding α1, β1
and γ1 laminin — which encode the proteins for LN1 — were detected by quantita-
tive RT-PCR and transcript amounts encoding the α1 and β1 chains of LN1 were
higher than mRNA encoding the LN1 γ1 chain. Using an anti-EHS serum, LN1
was detected on SF by immunocytochemistry. However, using monoclonal anti-
bodies to laminin α1 or γ1 proteins, staining signals were very weak.
Conclusions Attachment to LN1-laminin in the presence of TGF-β induces ele-
vated MMP-3 expression in SF. However, an autocrine stimulation of MMP-3
expression by SF via TGF-β and LN1 seems rather unlikely, as LN1 is not
expressed in high amounts in the adult synovial membrane. Still, activation of SF
by LN1 may serve as a model for activation of fibroblasts by extracellular matrix
compounds in the presence of growth factors or cytokines, and both pathways
contribute to the aggressive invasive growth of SF in the course of RA.
P10
Peptide mimetics of anti-dsDNA idiotypes as a tool for
lupus-specific IVIG preparation: specificity and efficacy in
the treatment of experimental systemic lupus
erythematosus
M Blank1, I Nur2, R Meidler2, L Bar2, L Slutzki1, Y Shoenfeld1
1The Center for Autoimmune Diseases, Department of Medicine ‘B’, Sheba Medical
Center, Tel-Hashomer, Israel; 2OMRIX Biopharmaceuticls Inc., Nes-Ziona, Israel
Arthritis Res Ther 2005, 7(Suppl 1):P10 (DOI 10.1186/ar1531)
Background Since the idiotypic network is an important mechanism for control-
ling the immune repertoire, we tested anti-idiotypic modulation employing con-
centrated specific natural polyclonal anti-dsDNA anti-idiotypic antibodies
obtained from a commercial IVIG in the treatment of experimental systemic lupus
erythematosus (SLE).
Aim To address the specificity and efficacy of affinity purified IVIG, affinity purified
on peptide mimetics of anti-dsDNA idiotypes, in vitro and in vivo, as treatment for
experimental lupus.
Materials and methods Specific natural polyclonal anti-dsDNA anti-idiotypic
antibodies were affinity purified from IVIG (OMRIX Biopharmaceuticls Inc., Nes-
Ziona, Israel) on an anti-dsDNA-Sepharose column constructed with anti-dsDNA
idiotypes affinity purified from 55 patients with SLE. This compound improved the
clinical manifestations of NZBXWXF1 mice in 200 times lower concentration
than IVIG. This lupus-specific IVIG was introduced to a peptide phage display
library (C-7mer-C). The identified synthetic peptides (idiotype mimetics) were
synthesized and used to replace the human anti-dsDNA idiotypes column. IVIG
affinity purified on the synthetic peptides columns were determined as peptide-
specific IVIG (psIVIG). The psIVIG compound was tested for specificity by ELISA
and competition assays.
Results Each psIVIG inhibited the binding of anti-dsDNA antibodies from 12
lupus patients, to dsDNA, differentially by 15% up to 46% or as a mix up to
87–94%. Naïve mice immunized with a branched peptide composed of the syn-
thetic mimetics of anti-dsDNA idiotypes induced the generation of elevated titers
of anti-dsDNA. The anti-dsDNA generation was inhibited in the branced peptide
immunized mice, following treatment with psIVIG. A cocktail of psIVIG was intro-
duced to NZBxWxF1. The following clinical parameters were improved in the
NZBxWxF1 psIVIG subjected mice: circulating anti-dsDNA antibodies, leukope-
nia, proteinuria and immunoglobulin deposits in the kidneys.
Conclusion We introduce herein an IVIG subfraction, specific for anti-dsDNA
treatment for lupus patients, and discuss its efficacy and beneficial effect in sup-
pression of humoral and clinical signs of SLE versus regular IVIG.
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Background Impaired clearance of apoptotic cellular debris by macrophages
was recently suggested as a mechanism leading to the systemic pathogenesis of
systemic lupus erythematosus patients. Serum Amyloid P component (SAP) is a
plasma protein that binds apoptotic cells and macrophages.
Objective To investigate the ability of SAP protein and its synthetic peptide
derivates to enhance the clearance of apoptotic cells by macrophages in vitro.
Methods Macrophages were isolated from peripheral blood cells of 30 healthy
donors and the purity was confirmed by FACS analysis using CD14-PE. Apopto-
sis was induced in Jurkat cells using anti-Fas antibodies and confirmed by stain-
ing with a caspACE™ FITC-VAD-FMK. The apoptotic cells were introduced to
macrophages in the presence/absence of SAP protein and SAP synthetic
peptide derivatives. Clearance of labeled apoptotic cells by macrophages, in
vitro, was detected by FACS and analyzed under fluorescence microscope.
Results In the presence of SAP, the clearance of apoptotic cells increased twice
(index 2.03) compared with the control (index 1). In the presence of SAP derivate
synthetic peptide (marked as peptide 26), an increase of 53% (index 1.53) was
detected. A D-form of the SAP synthetic derivate peptide was used as a negative
control and gave a clearance index of only 1.1 in comparison with the control. A
significant correlation was found between the concentration of SAP protein and
SAP synthetic peptide derivates and the clearance index.
Conclusion Herein we show the role of SAP and SAP-derived synthetic peptides
in accelerating clearance of apoptotic cells by macrophages in vitro. Our results
may pave the way for future development of SAP-derived synthetic peptides for
apoptotic cell clearance improvement in systemic lupus erythematosus patients.
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Objectives Heart valve lesions and central nervous system (CNS) involvement
are among the most common manifestations of antiphospholipid syndrome
(APS). We evaluated possible inter-relations between these manifestations in a
large group of APS patients.
Methods Two hundred and eighty-four APS patients were retrospectively evalu-
ated, 159 of whom had primary APS (PAPS). Cardiac–CNS associations were
determined for the entire study population, and for subgroups of patients with
PAPS or APS secondary to systemic lupus erythematosus (SLE).
Results Significant associations where found between cardiac vegetations and
epilepsy (P  < 0.02), and between cardiac valves thickening or dysfunction and
migraine (P = 0.002). Borderline association was found between valvular vegeta-
tions and migraine (P = 0.09). Subanalyses revealed that patients with PAPS had
significant associations between cardiac valve pathology and both epilepsy and
migraine, while patients with APS secondary to SLE presented no such associations.
Conclusions Our study points to potentially different biological behaviors in PAPS
than in APS secondary to SLE. According to our results, the presence of cardiac
valves pathology may be a risk factor for several CNS involvements in PAPS.
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Objective Ribosomal P is located in the cytoplasm. The detection of antibodies is
to the 60 kda fraction. Anti-ribosomal P antibodies are highly specific for systemic
lupus erythematosus (SLE), and are detected at a 15–20% frequency according
to the literature. Elevated anti-ribosomal P titers correlate with disease activity
and are specifically associated with neuropsychiatric disease such as psy-
chosis/depression. and coexist with anti-dsDNA antibodies. The aim of our study
was to evaluate the frequency of anti-ribosomal P antibody titers and the correla-
tion with manifestations in SLE patients.
Methods Sera samples from 174 individuals were evaluated for titers of anti-
ribosomal P antibodies: 77 samples from SLE patients, 22 patients with
antiphospholipid syndrome (APS), 20 patients with familial Mediterranean fever,
12 patients with infections, and 43 healthy controls. Anti-ribosomal P antibody
titers were tested by ELISA. Manifestations of SLE at the time of serum sampling
were determined by the SLEDAI score.
Results Six SLE patients (11%) harbored elevated anti-ribosomal P antibody
titers. Five SLE patients were females, mean age 44.3 years (range, 18–73 years
old), and the mean SLEDAI mean score was 7 (range, 3–10) indicating moderate
disease. Elevated titers of anti-dsDNA were detected in 50% of SLE patients
with elevated anti-ribosomal P antibodies. One patient had secondary APS. One
patient with elevated titers of anti-ribosomal had renal disease and psychosis.
Three patients had a rash, while none of the patients had arthritis or leukopenia.
Anti-ribosomal P titers were not elevated in patients with primary APS, familial
Mediterranean fever, infections, or in healthy controls.
Conclusion The prevalence of elevated titers of anti-ribosomal P antibodies was
restricted to SLE patients. No correlation with a specific manifestation was found.
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Background Post-translational modification of human type II collagen (hCII) in
the form of hydroxylation of Pro and Lys residues and glycosylation of some
hydroxylated Lys residues has been shown to correlate with hCII arthritogenicity
in susceptible strains of mice [1,2]. At the epitope level, O-linked glycosylation of
Lys264 located within the arthritogenic region hCII259–273 has been implicated in
the creation of neoepitopes recognized by arthritogenic T cells [3]. Macrophages
and to lesser extent primed B cells have been implicated in processing hCII for
presentation of hCII259–273 epitope to specific T cells [4,5], whereas Langerhans
dendritic cells are unable to process CII [6]. Macrophages may thus play a pivotal
role in activation of autoreactive T cells during collagen-induced arthritis.
However, no information is available on the mechanisms of antigen processing of
the glycosylated arthritogenic epitope, although it is likely to be crucial for an
understanding of the activation of autoimmune T cells in rheumatoid arthritis.
Objective We investigated the mechanisms of intracellular processing of hCII for
presentation of the glycosylated epitope hCII259–273  to CD4 T cells in
macrophages from HLA-DR1-transgenic mice.
Methods HLA-DRB*0101 C57BL/6J0-0 transgenic mice (designated HLA-DR1-
tg) were developed by backcrossing HLA-DRB*0101+Aq+ mice onto a MHC
class II-deficient background. T-cell hybridomas specific for the glycosylated and
non-glycosylated hCII259–273 epitope were developed to study antigen presenta-
tion of the glycosylated epitope by bone marrow macrophages used as antigen-
presenting cells. Subcellular fractions of macrophages were used as a source of
enzyme activity to digest hCII at pH 4.5 in the presence and absence of enzyme
inhibitors to localize stages of hCII degradation to particular endosomal/lyso-
somal compartments and to identify the families of enzymes involved.
Results HLA-DR1-tg mice lacking mouse MHC class II were susceptible to colla-
gen-induced arthritis. Macrophages from DR1-tg mice processed intact hCII for
presentation of the glycosylated epitope hCII259–274 to T-cell hybridomas. T-cell
hybridomas specific for the glycosylated peptide did not cross-react with the non-
glycosylated peptide. Intracellular processing of hCII for presentation of the glycosy-
lated epitope was prevented by inhibitors of serine-proteases, cysteine-proteases,
aspartic-proteases and metallo-proteinases or agents that raise endosomal pH,
suggesting a requirement for extensive lysosomal processing. Lysosome-enriched
subcellular fractions of macrophages were identified as the main organelles
involved in processing and presentation of the glycosylated epitope from hCII, as
these compartments contained: proteolytic enzymes of the serine-proteinase and
cysteine-proteinase families that could generate the glycosylated hCII epitope; the
glycosylated hCII epitope itself generated by intracellular processing of hCII;
peptide-receptive HLA-DR1 molecules; and complexes of HLA-DR1 molecules with
the glycosylated and non-glycosylated hCII259–274 epitopes.
Conclusion We showed stringent conditions for intracellular lysosomal process-
ing of hCII for presentation of the arthritogenic glycosylated epitope by HLA-DR1
molecules to CD4 T cells, which may explain the lack of tolerance to glycosylated
collagen and induction of arthritis in HLA-DR1-tg mice.
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Background Accelerated atherosclerosis accounts for the increased mortality
seen in patients with established rheumatoid arthritis (RA). Recent research has
Available online http://arthritis-research.com/supplements/7/S1S10
shown that RA is associated with an increase in the carotid intimal medial thick-
ness (IMT). To date, there is no prospective study in RA that examines this ques-
tion and none that includes an inflammatory disease control.
Objectives To evaluate prospectively the burden of inflammation in a cohort of
patients with early inflammatory arthritis, including RA and psoriatic arthritis
(PsA). To correlate inflammatory burden with IMT in this cohort and to compare
with normal age-matched control subjects.
Methods RA and PsA patients with disease duration of more than 5 years were
selected from the early arthritis clinic database for further study. Controls without
inflammatory conditions were recruited from the general clinic. Men older than
40 years and women older than 50 years were excluded. Patients with known
predisposing risks for ischaemic heart disease were also excluded. At the time of
clinical assessment blood samples were collected for erythrocyte sedimentation
rate (ESR) and C-reactive protein (CRP) together with fasting lipid samples, and
carotid artery ultrasound was performed at the same time. The mean IMT was
then calculated by averaging the values at three points, 1 cm above, at, and 1 cm
below the area of maximal IMT for each carotid artery.
Results To date, 61 patients (29 RA, 26 PsA and six control subjects) have been
reviewed. Twenty-one (72%) of the RA patients compared with 11 (42%) of the
PsA patients had an increased IMT (normal IMT <0.5 cm). Mean ± standard devi-
ation IMT values in the RA cohort (0.6 ± 0.14) and in the PsA cohort (0.5 ± 0.15)
were significantly greater than controls (P = 0.003, P = 0.03, respectively). IMT
values in the RA cohort were greater than in PsA (P = 0.017). There was a signif-
icant correlation between IMT and age in the RA cohort. However, mean age in
the three groups was not different and no correlation between IMT and age was
seen in either the PsA or the control group. The area under the curve (AUC) ESR
correlated with the AUC CRP in the group as a whole and in both RA and PsA
separately. No correlation was found between the AUC for ESR or CRP and IMT
in the different subgroups or in patients with an increased IMT.
Conclusions Patients with inflammatory arthritis (RA > PsA) are at a greater risk
of developing atherosclerosis compared with control subjects. No correlation has
been found to date between IMT values and the burden of inflammation as mea-
sured by ESR and CRP over time. Some additional mechanism of accelerated
atherosclerosis in inflammation, yet to be determined, may well apply. The results
are preliminary and recruitment with additional analysis is ongoing.
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The intimal lining of synovial tissue consists of fibroblast-like synoviocytes (type A
synoviocytes) and macrophages (type B synoviocytes). These cells are able to
interact through the CD97/CD55 receptor ligand system. The CD97 receptor is
a heterodimer receptor composed of an alpha and a beta subunit. The
CD97alpha subunit may exist as three isoforms due to alternative spliced tran-
scripts, each having a different affinity for CD55.
When comparing synovium of rheumatoid arthritis (RA) patients with synovium of
patients with osteoarthritis (OA), no increase in the level of total of CD97alpha or
in the level of CD97beta transcripts was found. However, in RA synovium a rela-
tive increased expression of CD97 transcripts encoding isoforms with an
increased affinity for CD55 (CD97alpha2 and CD97alpha3 mRNA) was detected.
A difference in CD97 splice variants between RA and OA tissues could not be
attributed to differences in composition of cells as in both tissues the majority of
CD97+ cells were CD14+ macrophages/monocytes — 93% in RA and 94% in
OA, respectively.
These data indicate that during inflammation CD97 splicing is regulated, and we
propose that this is likely to affect trafficking and functioning of CD97-positive
leukocytes.
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Background Rheumatoid arthritis (RA) is a chronic, inflammatory disease with a
number of phenotypic and functional T-cell defects. We previously demonstrated
abnormal differentiation and hyperproliferation of RA patient T cells [1], in relation
with inflammation and associated with reduced thymic activity as measured by
T-cell recepter excision circle (TREC) content. However, it is still not clear
whether these dysfunctions are a primary feature of RA or only secondary to
inflammation. Therefore we analysed RA patients in clinical remission in whom
systemic inflammation was controlled.
Methods Patients were defined as ‘in remission’ when they had controlled
disease, with no change of activity for at least 6 months, C-reactive protein below
15, no swollen or tender joints and on stable treatment (with or without therapy).
Measurements of TREC content in CD4+ T cells was by real-time PCR. IL-7
quantification was by ELISA. Proliferation assay in response to mitogen, IL-2,
TCR stimulation or recall antigen.
Results The TREC content of CD4+ T cells in these patients was heterogeneous
(n = 35). However, two groups of patients could be defined: group 1 (TREC
rich), similar to healthy controls (n = 17); group 2 (TREC poor), close to active
disease (n = 19). No conventional clinical parameter such as age, sex, disease
duration, remission duration, treatment, clinical scores or rheumatoid factor could
explain this difference. However, age at disease onset was significantly distrib-
uted between these two groups (P = 0.021) and correlated with a familial mater-
nal history of RA. IL-7 is essential to thymic T-cell development and to T-cell
activation in the periphery. We found large variations in IL-7 circulating levels
between RA patients in remission (n = 57). There was a positive correlation
between the circulating levels of IL-7 and the TREC content (r = 0.701,
P < 0.0001), suggesting that recovery of thymic activity was limited by the avail-
ability of IL-7. We investigated T-cell responses to mitogen, antigen, recall
antigen and IL-2 in patients with high and low levels of circulating IL-7 (n = 5 for
each group). Low levels of IL-7 were associated with hyporesponsiveness to all
stimuli, which could be overcome by adding IL-7 to the cultures. In contrast, high
levels of IL-7 were associated with optimal responses to all stimuli including recall
antigen and were not greatly ameliorated by supplementing IL-7.
Conclusion RA patients in clinical remission are clearly separated in two groups,
according to their ability to express IL-7 and the associated consequences on
thymic activity and T-cell responses. This ability was dependent on the age of the
patients at disease onset. This was only associated with a maternal family history
of RA and suggests that genetic anticipation may be involved.
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Background Rheumatoid arthritis (RA) exact pathogenesis remains uncertain,
although autoimmune processes appear to play a role, and RA is often referred to
as a Th1-driven disease. However, it is well known that RA patients have a
reduced capacity to produce IL-2 and interferon gamma (IFN-γ). IL-7 is an impor-
tant cytokine during early events leading naïve T cells towards Th1 polarisation.
We have associated low levels of circulating IL-7 with reduced thymyc T-cell
development and T-cell functions in the periphery. The origin of IL-7 in the circula-
tion is not clear and stromal cells in the bone marrow, liver, gut and lymph nodes
are potential production sources. The only cytokines known to regulate the
expression of IL-7 in different tissues are IFN-γ (bone marrow), transforming
growth factor beta (TGF-β) (skin) and both IL-1 and tumour necrosis factor alpha
(TNF-α) (synovium). We therefore investigated the relationship between levels of
circulating IL-7, a Th1 (IFN-γ) and a Th2 (TGF-β) cytokine, a proinflammatory
cytokine (TNF-α) and two transcription factors essential for T-cell polarisation
(T-bet and GATA3).
Methods Patients ‘in remission’ were defined as having controlled disease, with
no change of activity for at least 6 months, C-reactive protein below 15, no
swollen or tender joints and on stable treatment (with or without therapy). A
cohort of these patients was selected on the basis of their high and low levels of
circulating IL-7. RA patients with active, early, disease-modifying anti-rheumatic
drug (DMARD) naive disease were also recruited. Circulating levels of cytokines
were measured by ELISA and the expression of T-bet and GATA3 by real-time
PCR on mRNA extracted from peripheral blood mononuclear cells.
Results We selected 10 patients with either low or high levels of circulating IL-7.
Levels of IFN-γ, TGF-β and TNF-α were measured. High levels of IL-7 were signif-
icantly associated with higher levels of IFN-γ (P = 0.04) and a tendency for lower
levels of TGF-β but no difference was found for TNF-α. Furthermore, there was a
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direct correlation between levels of IL-7 and IFN-γ (R = 0.650, P = 0.005). It is
established that a high ratio of expression between T-bet and GATA3 defined a
tendency towards Th1 polarisation. T-bet levels of expression were significantly
higher in patients with high IL-7 (P < 0.0001) and we found a positive correlation
between the two (R = 0.600, P = 0.011). Similar results and correlation were
found using the ratio of T-bet to GATA3 expression (P < 0.0001 and R = 0.700,
P = 0.002). These results were confirmed in a cohort of 10 patients with active,
early, DMARD naïve disease.
Conclusion These results confirm that Th1 polarisation is impaired in RA. In addi-
tion, they suggest that either the Th1 cytokines regulate the levels of circulating
IL-7 or that the transcription factors regulating Th1 polarisation also regulate the
expression of IL-7. Further studies on the mode of regulation for IL-7 expression
in the circulation are necessary to understand how this cytokine may participate
to the pathogenesis of RA.
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Background We have previously reported on the abnormal expression of the dif-
ferent members of the Jagged/Notch signalling pathway in early rheumatoid arthri-
tis (RA) patients. HES1 and Deltex are two major signalling molecules resulting
from the transduction of notch signals. We have shown that signalling through the
Jagged/Notch pathway is involved in the development of an anergic phenotype in
a T-cell clone model in vitro. We have also used this model to establish a Notch
signalling signature characterising a T-cell suppression reaction. We analysed the
Notch signature of effecter CD4+T cells and CD4+CD25high regulatory T cells in
RA patients and compared it with healthy controls.
Methods The HA1.7 CD4+T-cell clone develops an anergic phenotype associ-
ated with high CD25 expression when stimulated with its cognate peptide in the
absence of co-stimulation. These cells were used in a suppression assay of fresh
HA1.7 (CD25low) cells, activated by anti-CD3/CD28 antibodies in proliferation
assays. Real-time PCR for the quantification of gene expression was undertaken.
CD4+CD25– T cells and CD4+CD25high regulatory T cells were sorted using flow
cytometry from 50 ml blood from five RA patients with early, disease-modifying
anti-rheumatic drug naive disease and seven healthy controls. Gene expression
was quantified by real-time PCR.
Results During a suppression reaction of fresh HA1.7 cells (CD25low) by anergic
HA1.7 expressing high levels of CD25, the expression of HES1 was induced;
however, Deltex was inhibited. This signature is unique and differs from either an
activation (downregulation of both) or an anergy signalling signature (upregula-
tion of both). Results from a similar quantification in RA patients, suggest that
CD4+CD25high T cells in RA have the signature of anergic cells with high levels of
both HES1 and Deltex, whereas control regulatory cells display a signature com-
parable with previously published data (low HES1, high Deltex) [1]. Preliminary
results in RA patients, pre and post TNF-blockade, suggest that the response to
therapy is associated with a normalisation of the Notch signature post treatment
to resemble the signature of control activated regulatory T cells (upregulated
HES1 and downregulated Deltex).
Conclusions CD4+CD25high regulatory T cells in RA appear anergic and may
therefore not be able to suppress an undesirable auto-immune reaction very early in
the RA disease process. Altogether, our results on the abnormal baseline expres-
sion of Jagged/Notch molecules and these atypical signalling signatures suggest
that the Jagged/Notch pathway may be involved in the pathogenesis of RA.
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Introduction Antibodies to citrullinated proteins are the most specific serological
marker for rheumatoid arthritis (RA). They are associated with severity of disease
and may occur years before clinical manifestations. It is unclear whether antibod-
ies to citrullinated proteins react with any citrullinated protein or whether there are
specific citrullinated proteins driving the autoimmune response. In this study we
use the HL60 cell line as a substrate for identifying autoantigens in myelomono-
cytic cells, the major cell type present in the rheumatoid joint.
Method Citrullinated autoantigens were sought by immunoblotting with a screen-
ing panel of four RA and one healthy control sera, using lysates of HL60 cells,
untreated or differentiated to monocytes or granulocytes. Each lysate was incu-
bated with or without peptidyl arginine deiminase in vitro. Reactive bands were
identified using two-dimensional gel electropheresis and MALDI TOF microse-
quencing. IgG antibodies to purified α-enolase, incubated with or without pep-
tidyl arginine deiminase, were detected by immunoblotting with 53 RA and 40
healthy control serum samples. Immunohistochemistry of synovial sections and
immunoblotting of lysed synoviocytes was performed using anti-α-enolase anti-
body diluted to 1:400. Macrophages stimulated with lipopolysaccharide or
tumour necrosis factor were derived from primary monocytes, differentiated with
monocyte colony-stimulating factor.
Results By immunoblotting, a band of 47 kDa in the deiminated lysates of HL60s
differentiated to monocytes and granulocytes reacted selectively with the four RA
sera (Fig. 1, sera A–D), but not with the control serum. It was identified as citrulli-
nated α-enolase by microsequencing and confirmed by immunoblotting of two-
dimensional subcellular fractions with an anti-α-enolase antibody and RA sera. In a
larger panel of sera, 24 (46%) of the RA samples reacted with citrullinated α-
enolase, of which seven also reacted with the uncitrullinated form. Six (15%)
normal sera reacted with both forms. α-Enolase was demonstrated in the subsyn-
ovium and vascular endothelial cells in all synovial membrane biopsies. This was
confirmed by immunoblotting where a protein in RA synoviocyte lysates, co-migrat-
ing with purified α-enolase, reacted with anti-α-enolase antibody. Stimulation of
macrophages with lipopolysaccharide or tumour necrosis factor upregulated and
induced secretion of α enolase. Secretion was inhibited with monensin.
Conclusions In this study, nearly one-half of the RA sera reacted with citrulli-
nated  α-enolase. This is a high frequency given the relative insensitivity of
immunoblotting. We suggest that using a more refined ELISA-based assay, both
diagnostic sensitivity and specificity will increase. The finding of antibody,
together with abundant expression of antigen in the joint (which is amplified with
inflammatory stimuli) makes citrullinated α-enolase a candidate autoantigen for
driving the chronic immune response in RA.
Acknowledgment This work was supported by the Arthritis Research Campaign (arc).
P21
Abatacept (CTLA4-Ig) modulates human T-cell proliferation
and cytokine production but does not affect
lipopolysaccharide-induced tumor necrosis factor alpha
production by monocytes
PM Davis, SG Nadler, KA Rouleau, SJ Suchard
Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey, USA
Arthritis Res Ther 2005, 7(Suppl 1):P21 (DOI 10.1186/ar1542)
Background and objectives Activated T cells play a central role in the inflammatory
cascade leading to the joint inflammation and destruction characteristic of rheuma-
toid arthritis (RA). The cytokines secreted by activated T cells are thought to both ini-
tiate and propagate the immunologically driven inflammation associated with RA.
Abatacept, the first of a new class of agents for the treatment of RA that selectively
modulates the co-stimulatory signal required for full T-cell activation, was evaluated
for its ability to regulate human T-cell proliferation and cytokine production in vitro.
The effect of abatacept on lipopolysaccharide (LPS)-induced tumor necrosis
factor alpha (TNF-α) from monocytes was evaluated to distinguish the impact of
this agent on innate versus adaptive, antigen-specific immune responses.
Methods T cells were isolated from normal healthy human volunteers. The effect
of abatacept on antigen-dependent T-cell activation was evaluated using either
an irradiated human B-cell line (PM-LCL) as the antigen-presenting cells (APCs)
for a primary mixed lymphocyte reaction (MLR), or autologous E-PBMCs as APCs
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Figure 1
Reactivity of rheumatoid arthritis and healthy serum with non-citrullinated/
citrullinated lysates of HL60 monocytes. PAD, peptidyl arginine deiminase.S12
for a recall response to tetanus toxin (TT). Cytokines were measured at various
times post activation, with proliferation determined on day 5. Monocytes were iso-
lated by elutriation, challenged with LPS and TNF-α levels measured at 6 hours.
Chi L6 was included as a non-specific fusion protein control.
Results  Abatacept significantly downmodulated T-cell proliferation, in both
primary and recall responses, at concentrations between 0.3 and 100 µg/ml, with
maximal inhibition (~60–80%) observed at ~3–10 µg/ml. These concentrations
are below the abatacept trough plasma levels observed in patients receiving a
clinically effective dose [1]. Under conditions of maximal inhibition of proliferation,
and similar to trough plasma levels in patients (30 µg/ml), abatacept also inhib-
ited IL-2, TNF-α and interferon gamma secretion in both primary and TT-depen-
dent recall responses. However, the extent, kinetics and rank order of cytokine
inhibition by abatacept was somewhat different between primary and recall
responses. In contrast, abatacept did not inhibit LPS-induced TNF-α production
in primary human monocytes, demonstrating that its action is restricted to
antigen-dependent T-cell responses.
Conclusion Abatacept, a selective co-stimulation modulator, significantly inhib-
ited the activation (as measured by cytokine production) and proliferation of
human T cells in the context of a primary MLR or TT-dependent memory
response. This inhibition occurred at concentrations below the serum Cmin levels
observed in patients receiving a clinically effective dose of abatacept [1]
(10 mg/kg monthly), consistent with suppression of T-cell activation in vivo. There
was no effect of abatacept on LPS-stimulated TNF-α production in monocytes
indicating that this agent may largely preserve innate immune responses.
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Objective NF-κB is highly activated in synovium of RA patients, and can induce
transcription of proinflammatory cytokines, adhesion molecules, and inducible
nitric oxide, among others. Phosphorylation of the inhibitor of κB (IκB) proteins is
an important step in NF-κB/Rel activation and is regulated by IκB kinase (IKK). The
IKK complex consists of at least three subunits, including IKKα and IKKβ (also
called IKK1 and IKK2) and the regulatory subunit IKKγ. In an initial study in Lewis
rats with adjuvant arthritis (AA) adenoviral dominant-negative IKK2 (Ad.IKK2dn)
significantly ameliorated the severity of disease as evidenced by decreased paw
swelling compared with Ad.GFP-treated rats [1]. However, adenoviral vectors are
known to be very immunogenic, compromising stable long-term expression of the
transgene. Adeno-associated virus (AAV) is considered the most promising vector
for gene therapy in RA. In a comparative serotype study we found that direct injec-
tion of AAV5 into the ankle joints of rats with AA resulted in the highest synovial
transduction, with good expression of the transgene at the protein level until the
end of the study, followed by AAV2. In the present study we investigated the effect
of inhibiting NF-κB in AA in rats using AAV-mediated intra-articular gene therapy.
For this purpose we used the following vectors: AAV5 containing the IKK2dn gene
(AAV5.IKK2dn) or AAV2 containing the IκBα-supressor gene (AAV2.IκBα SR).
Methods AAV5.IKK2dn (2.5 × 1010vp), AAV2.IκBα SR (2.5 × 1010vp) or AAV5/
AAV2.GFP were injected into the right ankle joints of rats with AA on day 11 after
adjuvant immunization. Subsequently, the effect of both genes on paw swelling
was measured by water displacement plethysmometry. Animals were sacrificed
2 weeks after intra-articular injection and joints were collected for analysis. Bone
degradation was examined using X-rays of the ankle joints and histology was per-
formed to assess synovial inflammation and joint damage.
Results In the rats treated with IKK2dn, significantly reduced paw swelling was
observed (P < 0.05, AAV5.dnIKK2 versus AAV5.GFP). No significant effect was
found on cartilage and bone destruction. Intra-articular treatment of the rats with
AAV2.IκBα SR only showed a marginal effect on the clinical course of arthritis.
Conclusion We demonstrate that AAV5-mediated IKK2dn gene transfer to the syn-
ovium reduces the severity of inflammation in AA rats, when the treatment was
started after the onset of disease. In contrast, injection of AAV2.IκBα SR had a poor
clinical effect on paw swelling in rats with AA. This could either be due to the dissimi-
larities in the mechanisms that these genes use to inhibit NF-κB activation (IKK2
versus IκBα) or to the use of different AAV serotypes as vector (AAV5 versus AAV2).
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Background Collagenous repeat containing sequence of 26 kDa protein
(CORS-26) is a recently discovered novel member of the TNF/C1q/adiponectin
superfamily. CORS-26 has been detected in chondrocytes and osteoblasts, but
its functional properties are largely unknown. As CORS-26 shows structural
analogies to adiponectin, which has been shown to exert proinflammatory and
destructive properties in arthritic synovium, the goal of the present study was to
examine the expression and regulation of CORS-26 in adipocyte differentiation.
Methods Gene expression of 3T3-L1-preadipocyte cultures were examined on
the protein and mRNA level by real-time PCR, Western blot, electrophoretic
mobility shift assay and luciferase-reporter gene assay.
Results CORS-26 showed numerous homologies to adiponectin such as a C-
terminal globular domain and a N-terminal collagen domain. CORS-26 mRNA
expression could not be detected in preadipocytes and in early adipocytes after
48 hours of culture. After 4–9 days of adipocyte differentiation, however, upregu-
lation of CORS-26 mRNA and protein could be detected. CORS-26 promoter
activity and RNA expression could be stimulated by troglitazone and fenofibrate
but not by 15-deoxy-prostaglandin J2. In addition, PPARγ, but not PPARα, binds
specifically to a promoter response element at position –641/–596.
Conclusions CORS-26 appears to be a novel adiponectin with strong homolo-
gies to the other members of the C1q/TNF/adiponectin superfamily, which
includes its functional properties that may be as proinflammatory in the arthritic
joint as those of adiponectin.
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Background  Several studies have linked human endogenous retroviruses
(HERVs) with autoimmune disease. We have previously demonstrated that the
full-length polymorphic HERV-K113 provirus prevalence is increased in both Sjö-
gren’s syndrome (15.6%) and multiple sclerosis (11.9%) compared with the
normal UK population (4%). Recent studies have shown that exogenous viral
RNA can activate dendritic cells via the TLR7/8-mediated pathway. In this study
we investigate the possibility that HERV-K113 RNA sequences are capable of
activating both dendritic cells and macrophages. We examine the production of
cytokines by both cell types in response to a series of different HERV-K113 RNA
species to identify any differences in the profile produced.
Methods A clone of the full-length HERV-K113 provirus was digested with restric-
tion enzymes to generate different length fragments of the 5′-LTR and gag gene for
in vitro transcription, producing single-stranded RNA species. The RNA was
treated to remove any residual protein, DNA, lipopolysaccharide or other contami-
nants. After quantitation, the RNA was complexed with Lipofectamine 2000 (Invitro-
gen, Paisley, UK) or left uncomplexed before being used to treat cells. Cytokines
levels in the cell supernatants were measured by ELISA. Dendritic cells were
assayed for tumour necrosis factor (TNF), IL-6 and IP-10, while macrophages were
assayed for TNF, IL-6, IL-8 and IL-10. Controls used were un-complexed RNA, poly-
U synthetic RNA, and the chemical activator of TLR 7 and 8, Resiquimod (R-848).
Results  Stimulation with R-848 produced TNF, IL-6, IL-8 and IL-10 from
macrophages and TNF, IL-6 and IP-10 from dendritic cells (Table 1). Uncom-
plexed RNA did not stimulate cytokine production in any cell type demonstrating
a lack of lipopolysacharide or other contaminant activation of cells. Stimulation of
dendritic cells with each of the three complexed RNA species resulted in the pro-
duction of IL-6, TNF and IP-10 (Table 1). Stimulation of macrophages only pro-
duced TNF. Although low levels of IL-6 were detected, there was no increase
over control cells (Table 1). Neither IL-8 nor IL-10 was produced in macrophages
in response to any of the RNA species. All three RNA species were more active
than a poly-U synthetic RNA control.
Conclusions The data demonstrate that RNA from HERVs is capable of inducing
cytokine release by both macrophages and dendritic cells. The pattern of cytokine
expression differs between the two cell types and may reflect different activation
pathways in each case. This work demonstrates a possible mechanism of action for
HERV induction of an inflammatory response leading to an autoimmune disease.
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Table 1
Cytokine release in response to one species of HERV-K113 RNA from
different cells
Tumor 
necrosis 
factor IL-6 IP-10 
(ng/ml) (ng/ml) (ng/ml)
Macrophage and K113 RNA 5.46 0.234 Not done
Macrophage and R848 (positive control) 5.78 15.56 Not done
Macrophage and control RNA (negative control) 0.04 0.0 Not done
Dendritic cell and K113 RNA 4.45 3.75 5.2
Dendritic cell and R848 (positive control) 6.49 13.57 5.12
Dendritic cell and control RNA (negative control) 0.095 0.458 0.824
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Background Anti-tumour necrosis factor alpha (anti-TNF-α) treatment could
induce the onset of new autoantibodies [1,2] or clinical features of other autoim-
mune diseases than rheumatoid arthritis (RA) [2].
Aim To analyse the efficacy and safety of anti-TNF-α treatment in six patients
affected by RA with anti-Ro/SSA antibodies and to evaluate the clinical and labo-
ratory changes during the treatment.
Patients and methods Antinuclear antibodies (IFI on HEp-2 cells), anti-dsDNA
(Farr assay), anticardiolipin (aCL, ELISA) and anti-ENA (CIE) were evaluated
before the treatment and every 6–12 months. Anti-Ro/SSA antibodies were con-
firmed by ELISA, using recombinant 52 and 60 kDa Ro proteins (Pharmacia).
Results Six patients had anti-Ro/SSA antibodies before anti-TNFα treatment.
Anti-Ro/SSA was detected in four sera using both CIE and ELISA, while two sera
showed anti-60 kDa Ro antibodies only by ELISA. Six patients (mean age,
58 years; standard deviation [SD], 9.8) were affected by long-acting RA (mean
duration, 7 years; range, 5–22 years), not responding to common disease-modi-
fying anti-rheumatic drugs (mean, 5 disease-modifying anti-rheumatic drugs; SD,
2.3). All the patients were treated for a mean of 31 months (SD, 20.4 months),
four subjects with Infliximab and two with Etanercept. Before the treatment the
patients showed active arthritis with a mean of 25.3 tender joints (SD, 2.16),
17.3 swollen joints (SD, 8.6) and Disease Activity Score (DAS) of 5.5 (SD, 1.04);
after 6, 12, 18, and 24 months all the patients showed a rapid and sustained
improvement with reduction of DAS value (see Table 1).
All the patients were affected by Sjögren syndrome (SS), associated to RA, clinically
stable during the treatment. One subject was also affected by primary biliary cirrho-
sis, which remained clinically and histologically stable. Three patients developed anti-
dsDNA at low titre after 6 months and a fourth after 12 months of treatment. Only
one patient developed skin lesions after 6 months of Infliximab, clinically and histolog-
ically similar to subacute cutaneous lupus with IgM deposits at basal membrane. No
patients developed aCL, while the titre of anti-Ro antibodies by ELISA was stable
during the treatment. One subject, affected by RA and HCV hepatitis, stopped the
etanercept treatment due to severe increase of hepatic enzymes.
Table 1
Clinical response to anti-tumour necrosis factor alpha treatment in
patients with rheumatoid arthritis and anti-Ro/SSA antibodies
Mean Disease Activity Score 44 P
At onset 5.56
6th month 3.38 0.006
12th month 3.41 0.03
18th month 3.33 0.01
24th month 2.88 0.006
Conclusions Anti-TNF treatment in RA-SS patients with anti-Ro/SSA showed a
good and sustained efficacy until the 24th month. Four patients (66.7%) showed
anti-dsDNA after 6–12 months, while only one developed subacute cutaneous
lupus-like symptoms. No other autoantibodies nor an increase of the anti-Ro titre
were observed.
References
1. Charles PJ, Smeenk RJ, DeJong J, Feldmann M, Maini RN: Assessment of
autoantibodies to double-stranded DNA induced in rheumatoid arthri-
tis patients following treatment with infliximab, a monoclonal antibody
to tumor necrosis factor alpha: findings in open-label and randomized
placebo-controlled trials. Arthritis Rheum 2000, 43:2383-2390.
2. Cush JJ: Unusual toxicities with TNF inhibition: heart failure and drug-
induced lupus. Clin Exp Rheumatol 2004, 22(Suppl 35):S141-S147.
P26
Ha-Ras/ERK1-2 pathway is responsible for oxygen species
generation in scleroderma fibroblasts
S Svegliati1, MM Luchetti1, P Paroncini1, A DiCarlo1, F Bevilacqua1, 
N Campelli1, E Avvedimento2, A Gabrielli1
1Istituto di Clinica Medica Generale, Ematologia ed Immunologia Clinica,
Università Politecnica delle Marche, Ancona, Italy; 2Dipartimento di Biologia e
Patologia cellulare e Molecolare, Università Federico II, Napoli, Italy
Arthritis Res Ther 2005, 7(Suppl 1):P26 (DOI 10.1186/ar1547)
Background Reactive oxygen species (ROS) are involved in scleroderma (SSc)
fibroblast activation, proliferation and type I collagen gene expression [1]. In order
to understand the signal trasduction pathway involved in ROS generation by SSc
fibroblasts, we have assessed the role of Ha-Ras and Ki-Ras proteins and that of
their downstream effectors.
Materials and methods Intracellular ROS were evaluated with 2′,7′-dichlorofluo-
rescein diacetate (DCHF-DA 10 µM). For Ha-Ras and Ki-Ras protein expression
whole cell lysates were immunoprecipitated with specific antibodies and sub-
jected to SDS-PAGE or cells were fixed in paraformaldehyde (4%) and observed
by confocal microscopy. SSc skin fibroblasts were transiently transfected with
the dominant negative form of Ha-Ras (H17Ras) or with the empty vector using
the Effectene Trasfection reagents (BioRad).
Results Quiescent SSc fibroblasts contain an altered ratio between the two Ras
isoforms showing a selective increase of the mass and the activity of Ha-Ras
protein when compared with normal controls. Moreover ERK1-2 are constitutively
phosphorilated in quiescent SSc fibroblasts. Inhibition of either Ras, ERK1-2,
ROS with specific inhibitor or trasfecting with the negative Ras variant reverse
this phenotype back to normal and reduce collagen overproduction by SSc cells.
Conclusions These results suggest that ROS production in SSc fibroblasts is
linked and ultimately dependent on increased Ha-Ras signalling via ERK1-2. These
events are responsible for the characteristic cellular phenotype of scleroderma
fibroblasts and explain some of the clinical features of the disease. Moreover, these
data provide evidence for the use of Ras inhibitors in the treatment of the disease.
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Objective To assess spinal inflammation by magnetic resonance imaging (MRI)
before and after treatment with the tumor necrosis factor (TNF) receptor fusion
protein etanercept compared with placebo.
Methods MRI examinations of the lower thoracic and lumbar spine of 40 patients
with active ankylosing spondylitis (AS) were performed as part of the recently
published randomized controlled trial at four different timepoints: baseline (BL),
after 12 weeks (FU1), 24 weeks (FU2) and 48 weeks (FU3). Nineteen patients
received etanercept twice weekly, 2 × 25 mg subcutaneously, for 1 year and 21
patients received placebo for 6 months (until FU2) before switching to etaner-
cept. The patients’ (mean age 39.7 years, 75% male, 89% HLA-B27-positive)
mean disease duration was 13 years. MRI examinations included T1-weighted
sequences before (T1) and after application of gadolinium-diethylenetriamine-
pentaacetic-acid (T1/Gd-DTPA) and T2-weighted fat-saturated (T2-FS)
sequences. MRI examinations were scored by a modified ASspiMRI score using
predefined vertebral units as a basis.
Available online http://arthritis-research.com/supplements/7/S1S14
Results After 12 weeks, spinal inflammation (T2-FS) regressed by 54% (1.33
mean scoring points per vertebral units at BL and 0.61 at FU1, P = 0.002) in the
etanercept group, but worsened by 13% in the placebo group (0.94 at BL and
1.06 at TP1, respectively; P  < 0.05). After switching to etanercept, placebo
patients improved similarly. T1/Gd-DTPA MRI sequences performed equally well.
About 60% of all active lesions at BL were detected in the thoracic spine. There
were no significant changes in the chronicity score.
Conclusions  Treatment with etanercept of patients with active AS results in
regression of spinal inflammation as assessed by spinal MRI. Inclusion of the tho-
racic spine in MRI examinations of AS patients may be of particular importance.
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Objectives The tumor necrosis factor alpha (TNF-α) receptor fusion protein etaner-
cept has proven short-term efficacy in patients with active ankylosing spondylitis
(AS). The results of continuous treatment with etanercept over 1 year were reported
previously. Here we report the experience with the second year of follow-up.
Methods Overall, 23 out of 30 AS patients (77%) who had participated in the initial
placebo-controlled phase of the trial were included in this 2-year extension, where
patients with active disease were treated with etanercept (2 × 25 mg subcuta-
neously twice a week). Disease-modifying anti-rheumatic drugs and steroids were
not allowed. The clinical response was assessed by standard assessment tools for
disease activity (Bath AS Disease Activity Index [BASDAI]), function (Bath AS
Functional Index) and mobility (Bath AS Metrology Index). The primary outcome of
this trial was efficacy on disease activity after 2 years of continuous treatment with
etanercept in AS patients, compared with patient status at baseline (BL).
Results Of the 30 initial patients, 21 (70%) completed year 2. At week 102, 54%
of the patients had maintained a 50% improvement of BASDAI, and 9/21 (43%)
were in a state of partial remission according to the ASAS criteria. The mean
BASDAI score remained stable (2.6 ± 2.2 at week 54 and 2.7 ± 2.4 at week 102)
in the second study year. Similarly, all other clinical parameters showed no change
during year 2 with significant improvement compared with BL. Two patients experi-
enced serious adverse events leading to discontinuation of therapy.
Conclusions This study confirms the efficacy and safety of etanercept in the
therapy of patients with active AS without simultaneous administration of disease-
modifying anti-rheumatic drugs or steroids over 2 years of continuous treatment.
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Objective Infliximab, a monoclonal antibody against tumor necrosis factor alpha
(TNF-α), is approved in Europe for the treatment of patients with active ankylos-
ing spondylitis (AS) who have responded inadequately to conventional therapy.
This report provides analyses from a 3-year extension study, as a follow-up to
both the 1-year and 2-year open label extensions of the original 3-month random-
ized controlled trial of infliximab in patients with AS.
Methods Of the 49 patients with AS who completed the second year of the
study, 46 continued treatment with infliximab 5 mg/kg every 6 weeks through
week 156. The Bath AS Disease Activity Index (BASDAI), the Bath AS Functional
Index, the Bath AS Metrology Index, patient’s and physician’s global assessment,
quality of life (Short Form-36), C-reactive protein, and erythrocyte sedimentation
rate were assessed throughout the study period.
Results The improvement of signs and symptoms observed in the majority of the
patients during the first and second year was sustained throughout the third year
of the study. Forty-three patients (62% of the 69 patients enrolled at baseline and
93% of the patients who started the third year) completed week 156. A BASDAI
50% improvement was achieved by 28 of 43 patients (65%) at week 156. The
scores for other efficacy assessments were similar to the values observed at
weeks 54 and 102. Median C-reactive protein levels remained low (1.5 mg/l at
week 156). There were no relevant side effects and no discontinuation because
of drug-related adverse events during the third year of the study.
Conclusions Patients with AS receiving infliximab for 3 years showed durable
clinical response without loss of efficacy. Long-term infliximab treatment was well
tolerated by patients in this study.
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Objective To analyze the clinical response and the time to relapse after with-
drawal of continuous long-term infliximab therapy in patients with ankylosing
spondylitis (AS).
Methods After 3 years of infliximab therapy, all AS patients (n = 42) discontinued
treatment (TP1) and were visited regularly in order to assess the time to relapse
(TP2) for 1 year. Relapse was defined as an increase to a Bath AS Disease Activ-
ity Index (BASDAI) value and physician’s global assessment >4 according to the
ASAS recommendations.
Results After 52 weeks, 41 of the 42 patients (97.6%) had to be reinfused
because of relapse. The mean change of the BASDAI between TP1 and TP2 was
3.6 ± 1.7, and for the physician’s global assessment was 4.4 ± 1.8 (both
P < 0.001). The mean time to relapse was 17.5 weeks (± 7.9 weeks, range
7–45 weeks). Ten patients (24%) showed a relapse within 12 weeks and 38
patients (90.5%) within 36 weeks. After 52 weeks, only one patient had remained
in ongoing remission without anti-tumor necrosis factor therapy. Patients who
were in partial remission and those with normal C-reactive protein levels at base-
line had longer mean time to relapse after discontinuation. Retreatment with inflix-
imab was safe and resulted in clinical improvement similar to the state before
withdrawal in all patients.
Conclusions Discontinuation of long-term therapy with infliximab led to relapse of
disease activity in all but one patient after different time periods. Remission and
low C-reactive protein levels at the time of withdrawal were associated with
longer flare free periods. Retreatment with infliximab was safe and efficacious.
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Background Anti-tumor necrosis factor therapy is clinically efficacious in patients
with active ankylosing spondylitis (AS) and leads to improvement of spinal inflam-
mation, as assessed by magnetic resonance imaging. It is unclear whether anti-
tumor necrosis factor therapy has influence on chronic spinal changes in AS.
Objective To analyze the effect of infliximab on the radiographic course of AS
over 2 years.
Methods Complete sets of lateral radiographs of the cervical and the lumbar
spine were available from 82 patients from two sources: 41 patients (group 1)
had been treated with infliximab (5 mg/kg/6 weeks) as part of a recent random-
ized controlled trial, and 41 patients (group 2) were part of the early German AS
cohort (GESPIC), without controlled interventions. Radiographs were performed
at baseline and after 2 years and were scored by the modified SASSS.
Results Patients in the infliximab group were older, had a longer disease duration
and more radiographic damage at baseline. The mean modified SASSS change
was 0.4 (± 2.7) and 0.7 (± 3.4) for group 1 and group 2, respectively (P = not
significant). Radiographic damage at baseline was a predictor for more radi-
ographic progression. Patients with baseline damage who were treated with
infliximab showed a trend for less radiographic progression. There were no corre-
lations between clinical parameters and radiographic progression.
Conclusions  AS patients treated with infliximab showed somewhat less radi-
ographic progression after 2 years. Patients with prevalent radiographic damage
are prone to develop more damage over time. Infliximab may decelerate radi-
ographic progression in such patients. Larger studies are needed to prove that
anti-tumor necrosis factor therapy inhibits structural damage.
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Objective In earlier studies we found that FcγRI determines chondrocyte death
and matrix metalloproteinase (MMP)-mediated cartilage destruction during inter-
feron gamma (IFN-γ)-regulated immune complex (IC)-mediated arthritis [1]. As
binding of ICs to FcγRI leads to oxygen radical production, we now investigate
the contribution of oxygen radicals to induction of both parameters of cartilage
destruction using P47phox knockout mice. These mice have a defect in NADPH-
oxidase activation and fail to produce oxygen radicals.
Methods IFN-γ was expressed in knee joints of P47phox–/– and their wildtype
(WT) controls by local injection of adenoviral IFN-γ construct. One day thereafter,
a passive IC-mediated arthritis was induced. Chondrocyte death and MMP-medi-
ated cartilage destruction were measured in various layers of the knee joint using
histology of total knee joints. Neoepitopes induced by MMPs were detected
using immunolocalisation and anti-VDIPEN antibodies. Synovium was isolated
and mRNA levels (MMPs/ tissue inhibitors of metalloproteinases [TIMPs]) were
determined using quantitative RT-PCR.
Results High levels of IFN-γ were found 1 day after injection of the IFN-γ adenovi-
ral construct in knee joints of P47–/– and WT controls, and resulted in a high and
comparable upregulation of FcγRI up to day 7 in both groups. Induction of IC-
mediated arthritis in IFN-γ-treated knee joints resulted in prominent but compara-
ble joint inflammation both at day 3 and day 7. At day 7, macrophages formed the
dominant cell type. When compared with WT controls, RNA levels of MMP-3 and
MMP-13, which are crucial in cartilage destruction within this model, were ele-
vated in inflamed synovia of P47phox–/– whereas TIMP-3, a crucial inhibitor of
MMP-3, was completely absent. Nevertheless, MMP-mediated cartilage destruc-
tion was significantly lower in P47phox–/– at day 7 (between 30–60%). Moreover
chondrocyte death that was evident in arthritic WT controls (20–60% at day 3
and 30–80% at day 7) was completely blocked in P47phox–/–.
Conclusion During IFN-γ-regulated IC-mediated arthritis, oxygen radicals, which
are strongly induced after FcγRI stimulation, determine chondrocyte death and
largely mediate MMP-mediated cartilage destruction.
Reference
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Objective In systemic sclerosis (SSc), characterised by microvascular changes
leading to ischemia and impaired angiogenesis, the lack of an angiogenic response
to hypoxia may be due to inappropriate synthesis of angiogenic and angiostatic
factors. Tissue kallikrein (t-kallikrein) is a potent angiogenic agent regulating the
kallikrein kinin system with kallistatin as its natural inhibitor. T-allikrein is synthesised
by endothelial and vascular smooth muscle cells as well as inflammatory cells.
Aim To evaluate, in SSc patients: t-kallikrein and kallistatin levels and their corre-
lation with clinical features and parameters of microvascular involvement; and
t-kallikrein expression in the skin of SSc patients.
Methods Serum levels of t-kallikrein and kallistatin (ELISA) were assayed in 43
SSc patients, also evaluated for subsets (dSSc, 11 patients; lSSc, 32 patients),
clinical and immunological features and microvascular involvement (ulcers,
teleangiectasias, nailfold videocapillaroscopy). Expression of t-kallikrein (immuno-
histochemistry) was evaluated in biopsies taken from the involved skin of the
forearm of six SSc patients (two lSSc and four dSSc) and six controls.
Results Circulating levels of t-kallikrein were higher in SSc patients than in controls
(n = 35) (P < 0.001). No differences in t-kallikrein were detected between lSSc
and dSSc. T-kallikrein levels were higher in patients with early (five patients) and
active (31 patients) capillaroscopic patterns than in those with a late pattern (seven
patients) (P = 0.019 and 0.023). Patients with giant capillaries and capillary micro-
hemorrhages (35 patients) had higher t-kallikrein levels than patients with architec-
tural derangement (8 patients) (P = 0.04). Neither differences in kallistatin levels
were detected between SSc patients and controls nor between lSSc and dSSc. In
control skin samples, t-kallicrein immunoreactivity was shown in endothelial and
smooth muscle cells and pericytes of microvessels. In lSSc skin, immunoreaction
for t-kallicrein was found in microvascular endothelial cells and in perivascular
inflammatory infiltrates present in the papillary dermis near to the dermo-epidermal
junction. In dSSc skin, the few remaining vessels showed no immunoreactivity for
t-kallicrein, except for the vessels near sweat glands and nerves.
Conclusions Our findings indicate that both t-kallikrein levels and t-kallikrein skin
expression are related to typical SSc microvascular changes as assayed by nail-
fold videocapillaroscopy and by immunohistochemistry of skin biopsies.
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Background  For functional annotation, similarity-based approaches [1] do not
take into account all the information from comparative and evolutionary biology.
They do not differentiate between orthologs and paralogs among homologs and,
furthermore, the closest BLAST is often not the nearest neighbour [2]. Phyloge-
netic approaches taking into account duplication and speciation events are neces-
sary to solve these problems. But they do not blend any data from transcriptional
behaviour. Nevertheless, orthologs can have very similar ‘molecular function’ but
undergo a different ‘macroscopic function’ because of a transcriptional shift.
Growing data for gene expression profiling are available in various databases
concerning normal or pathological tissues (Expressed Sequence Tags [ESTs]
from NR, TIGR, GeneNote, Gepis, etc.). Some works recently examined the cor-
relation between evolution (duplication and speciation) of genes and expression
divergence within and between species [3,4], and some examine the expression
profile between orthologous genes in sequenced species [5].
Methods We performed a phylogenetic analysis of a protein family, using EST
databases. This allowed us to enlarge the dataset of species containing
homologs and consequently to improve the reconstruction of the genes’ evolu-
tionary history. We then extracted all the transcriptional data contained in EST
databases, to decipher the gene expression pattern. Because gene annotation is
currently labour intensive, we used a locally developed platform dedicated to phy-
logenetic annotation (named FIGENIX) [6]. We validated this approach on a
family of genes possibly implied in rheumatoid arthritis; the peptidyl arginine
deiminase (PADI) genes.
Results  We show here a phylogenetic annotation with an enlarged dataset
including EST contigs and expression data. It allowed us to integrate more func-
tional data for analysis of a set of genes and permits us to give a transcriptional
footprint of the gene. Our analysis showed that the PADI-2 paralog group have
kept the ancestral molecular function coupled with a probable ancestral expres-
sion profile. These classified data permitted us to perform an updated footprint of
the transcriptional data for each paralog group from this protein family.
Conclusion We believe this method announces a new way to annotate unchar-
acterized ESTs. More than classical phylogeny, it allows highlighting of the tran-
scriptional shift between paralogs, and is thus a good tool to improve annotation.
It showed that functional shift can occur in differential tissue expression rather
than in biochemical function of the protein.
This method of analysis is at its beginning and has to be extended to all kinds of
expression database, including databases where expression data are normalized
such as UniGene. In the future it cannot be ignored in annotating new unknown
ESTs, underlined by DNA microarray assays for example.
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Background Toll-like receptors (TLRs) have a crucial role in early host defence
against invading pathogens. They recognize specific molecular patterns that are
present in microbial and viral components, whereas several endogenous mole-
cules seem to be placed among their expanding group of ligands. The CD91
receptor (low-density lipoprotein receptor-related protein [LRP1] or alpha 2-
macroglobulin receptor [A2MR]) is a multifunctional receptor that recognizes
hsp-chaperoned peptides, which are processed and presented by the MHC
class I and MHC class II molecules. So far, there is an increasing evidence that
the receptors of innate immunity also play an important role in acquired immunity.
Objective The objective of our study was to evaluate the expression of TLRs and
CD91 in minor salivary gland (MSG) biopsy tissues and non-neoplastic salivary
gland epithelial cell lines obtained from patients with primary Sjogren’s syndrome
(pSS).
Methods At the mRNA level, the expression of TLR2, TLR4, TLR7, TLR9 and
CD91 was examined in a non-neoplastic salivary gland epithelial cell line from a
patient with pSS by means of RT-PCR. Protein expression of TLR2, TLR4 and
CD91 was studied by immunohistochemistry in MSG biopsy tissues from 12
patients with pSS and nine control patients with non-specific sialadenitis.
Results  RT-PCR analysis revealed transcriptional activation of TLR2, TLR4,
TLR7, TLR9 and CD91 genes in the epithelial cell line of pSS patient. In MSG
biopsy tissues, abundant expression of CD91 was observed in ductal cells of
both pSS and control tissues, but also in the focal lymphocytic infiltrates of pSS
patients. TLR2 and TLR4 protein expression was localized in single, scattered
cells, both in pSS patients and, to a lesser extent, in control patients, showing a
distinct staining pattern.
Conclusion The presence of CD91 and TLRs in the immunopathologic lesion of
Sjogren’s syndrome provides preliminary evidence, suggesting their possible role
in innate immune responses within the lesion.
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Background The molecular basis for the strong association of HLA-B27 with
ankylosing spondylitis (AS) has not been elucidated. A number of B27 alleles
including B*2704 and B*2705 are associated with increased susceptibility to
AS; in contrast, the alleles B*2706 and B*2709 are not associated with AS.
These alleles differ in amino acid regions that have been shown to influence the
interaction with tapasin, an accessory molecule that plays a critical role in incor-
porating HLA class I into the peptide loading complex (PLC). Our aim was to
determine whether B27 subtypes differ in their association with the PLC.
Methods The .221 line that is negative for HLA class I alleles A, B and C was trans-
fected with B*2704, 05, 06 and 09 expression constructs, and stable long-term
transfectants with equivalent HLA-B27 expression were selected. The PLC was
immunoprecipitated using the anti-TAP antibody 148.3 (provided by R Tampe) and
magnetic anti-immunoglobulin microbeads. Non-specific binding of HLA class I was
determined by immunoprecipitation with an isotype control mAb. Following reduc-
ing SDS-PAGE and western blotting of the eluted proteins, the co-precipitation of
HLA-B27 was detected by probing the immunoblots with the anti-HLA class I mAb,
HC10, followed by HRP-linked secondary antibodies and visualized using electro-
chemiluminescence. Detection of TAP and tapasin was achieved by stripping
bound mAbs and reprobing the immunoblots with RING4C (provided by P Cress-
well) or ‘Giles’ (provided by T Elliott) polyclonal antisera, respectively.
Results Only HLA-B*2704, 05 and 09 were found to be readily detectable above
background on the immunoblot; suggesting that they were co-precipitated by the
anti TAP mAb and therefore incorporated into the PLC. Despite expressing equiv-
alent quantities of HLA class I heavy chain to the other B27 subypes, HLA-
B*2706 was unique in that it was not detectable above background levels. The
inability to detect B*2706 was not due to different efficiencies in immunoprecipi-
tation of the PLC since equivalent quantities of TAP and tapasin were immuno-
precipitated from the cell lysates of all B27 subtypes.
Conclusions We have shown that B*2706 differs from the other B27 subtypes
in that it cannot be detected within the PLC. B*2706 differs from B*2704 at
amino acid positions 114 and 116, and we suggest that these amino acid differ-
ences confer the PLC independence of this allele. PLC independence may play a
role in contributing protection from arthritis by a number of potential mechanisms
such as conferring an inability to bind an athritogenic peptide that is only effi-
ciently bound in the context of the PLC. Alternatively, lack of association with the
PLC could also modify an event downstream of peptide loading that may protect
from disease susceptibility.
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The class of immune response against autoantigens could profoundly influence
the onset and/or outcome of autoimmune diseases. Until now, there is only
limited information on the antigen-specific balance between proinflammatory and
regulatory responses in humans. Here we analyzed the natural immune response
against a candidate autoantigen in rheumatoid arthritis, Human Cartilage gp-39
(HC gp-39).
Peripheral blood mononuclear cells from healthy individuals reacted against HC
gp-39 with the production of IL-10, but not interferon gamma (Fig. 1). Ex vivo
assays indicated that the naturally occurring HC gp-39-specific immune
response in bulk is powerful enough to suppress antigen-specific recall
responses, demonstrating that, rather than being unresponsive, the HC gp-39-
directed immune response in healthy individuals shows a strong bias towards a
regulatory phenotype. Moreover, CD4+ T-cell lines directed against HC gp-39
expressed CD25, GITR and Foxp3 molecules and were capable of suppressing
antigen-specific T-cell responses. Cell–cell contact was required for this sup-
pression. As opposed to healthy individuals, the HC gp-39-directed immune
response in 50% of patients with rheumatoid arthritis exhibits polarization
towards a proinflammatory Th1 phenotype and is significantly less powerful in
suppressing antigen-specific recall responses.
Together these findings indicate that the presence of HC gp-39-specific immune
responses in healthy individuals may have an inhibitory effect on inflammatory
responses in areas where HC gp-39 is present. Furthermore, these data indicate
that the class of HC gp-39-directed immune response in RA patients has shifted
from an anti-inflammatory towards a proinflammatory phenotype.
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Figure 1
Human Cartilage gp-39 (HC gp-39)-specific immune reactivity in healthy donors.
(a) Peripheral blood mononuclear cells from healthy donors (n = 31) react
against HC gp-39 by production of IL-10 but not interferon gamma (IFN-γ). (b)
‘Control’ recall antigen-induced responses are dominated by IFN-γ production.S17
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Background Chronic inflammatory disease is characterised by predilection for
certain sites, the molecular basis of which remains obscure. We investigated the
role that fibroblasts play in governing the survival (persistence) as well as the type
of infiltrate (predominantly neutrophil versus lymphocyte) using a leucocyte–
fibroblast co-culture model. We used matched synovial, bone marrow and skin
fibroblasts to test the hypothesis that a fibroblast-derived, stromal area post code
identifies microenvironments that can support differential leucocyte accumulation.
Methods Matched synovial (SFb), bone marrow (BMFb) and dermal fibroblast
(DFb) lines were established from eight patients satisfying ACR criteria for
rheumatoid arthritis undergoing total hip or knee arthroplasty. Activated peripheral
blood CD4 T cells prepared by negative depletion and neutrophils prepared by
density gradient centrifugation were co-cultured with fibroblasts. Survival, apop-
tosis and proliferation were assessed using total cell counts and active caspase
3 staining (T cells) or DiOC6 staining (neutrophils).
Results Site-specific survival of CD4 T cells was observed in all eight sets of
matched samples: at 3 days, DFb maintained better T-cell survival than culture in
medium alone (40 ± 1.2% (mean ± standard error) compared with 25.4 ± 1.4%
(P < 0.05)). However, both SFb and BMFb maintained even better T-cell survival
compared with DFb: 58.8 ± 1.2% (P  < 0.001 versus DFb) and 51.4 ± 2%
(P < 0.05 versus DFb). Fibroblast pre-activation with a wide range of proinflam-
matory signals had no effect on differential survival. T-cell survival was partially
reconstituted by medium from T cell:fibroblast co-cultures and reduced by 50%
in the presence of transwells suggesting that T cell:fibroblast interactions are
necessary for increased survival. Unlike the case for T cells, resting fibroblasts did
not affect neutrophil survival. However pre-treatment of all fibroblasts with tumour
necrosis factor alpha significantly increased neutrophil survival: SFb
51.2 ± 6.1%, BMFb 51.1 ± 5.5%, DFb 50.6 ± 4.7%, versus control 16.2 ± 3.3%,
P < 0.001. Fibroblast conditioned media reconstituted the survival effect, indicat-
ing that a soluble survival factor(s) as opposed to cell–cell contact mechanism is
involved in neutrophil survival.
Conclusions Fibroblasts differentially regulate leucocyte subset survival in both a
site-dependent and activation-dependent manner. Our results provide an alterna-
tive explanation for site-specific differences in the pattern of T-cell and neutrophil
accumulation in different chronic inflammatory diseases.
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Background DBA/1 mice are susceptible to collagen-induced arthritis and to
low-grade spontaneous inflammatory arthritis in elderly males. CD4+CD25+
T cells have been implicated in the suppression of arthritis in the susceptible
DBA/1 strain [1,2] and in patients with rheumatoid arthritis [3]. We have studied
the function of the CD4+CD25+ T-cell subset in DBA/1 and arthritis-non-suscep-
tible C57Bl/6 male mice.
Methods The frequencies of CD4+CD25+ T cells were assessed in lymph nodes
and the spleen of DBA/1 and C57Bl/6 mice by FACS analysis. Spleens were
harvested from adult male DBA/1 and BALB/c mice. CD4+CD25+ and
CD4+CD25– T cells were purified using Miltenyi reagents and a VarioMACS.
Proliferation assays in response to either Concanavalin A (1 µg/ml) or soluble
anti-CD3 (0.1–10 µg/ml) were performed using 5e4 CD4+CD25– cells with 1e5
irradiated adherent splenocytes as antigen-presenting cells. Co-culture of
CD4+CD25+ and CD4+CD25– T cells in a 1:1 ratio was used to assess suppres-
sion. Cytokines (IL-2, interferon gamma, IL-4, IL-10, tumour necrosis factor alpha,
IL-6, IL-17, IL-15) were measured in the tissue culture supernatant after 36 hours
incubation. Proliferation was measured by [3H]-thymidine incorporation. Suppres-
sion ratios (SRs) were calculated as follows: SR = (response from
CD25+:CD25– T-cell coculture) / (response from CD25– T cells alone). SRs in
DBA/1 and C57Bl/6 mice were compared using Student’s t test.
Results The frequency of CD4+CD25+ T cells was comparable in the spleen and
lymph nodes of DBA/1 and C57Bl/6 mice. SRs were higher (i.e. less suppression)
in proliferation assays from DBA/1 mice compared with C57Bl/6 mice, which were
stimulated with anti-CD3 (P = 0.03). DBA/1 cultures were generally associated
with higher cytokine levels. Cytokine SRs were higher (i.e. less suppression) for
DBA/1 compared with C57Bl/6 cultures for IL-6 and IL-17. SRs were lower (i.e.
more suppression) for DBA/1 compared with C57Bl/6 cultures for IL-4 and IL-10.
Conclusions The arthritis-susceptible DBA/1 mouse strain appears to have a func-
tional defect in the CD4+ CD25+ T-cell compartment. IL-4 and IL-10 are efficiently
suppressed by CD4+CD25+ T cells. Suppression of IL-6 and IL-17 appears to be
defective. This may partly explain the susceptibility of DBA/1 mice to erosive arthritis.
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Heme oxygenase 1 (HO-1) plays an important role in vascular disease, transplan-
tation and inflammation. In animal models of acute and chronic inflammation,
induction of HO-1 has anti-inflammatory and cytoprotective properties. Since
inflammation is an important trigger of osteoclastogenesis, we hypothesized that
HO-1 might play a role in osteoclastogenesis.
When HO-1 was induced by hemin in vitro, a significant dose-dependent inhibitory
effect on osteoclastogenesis was observed. Hemin primarily inhibited differentiation
of mononuclear osteoclast precusors to osteoclasts. These effects were based on
a downregulation of the expression of c-fms and RANK, the receptors for mono-
cyte-colony stimulating factor and RANKL, whereas MAP kinase, NF-κB or Akt sig-
nalling were not affected. In vivo, HO-1 induction prevented endotoxin-induced
calvarial bone resorption. Furthermore, assessment of synovial tissue from rheuma-
toid arthritis (RA) patients showed expression of HO-1 in monocytes and fibro-
blasts, whereas osteoclasts were rarely HO-1 positive. To further assess the role of
HO-1 activity in RA patients, we correlated the presence of local bone erosions
with serum bilirubin levels. We observed significant higher bilirubin levels in non-
erosive than in erosive RA patients. Thus, an increase of HO-1 expression is anti-
osteoclastogenic in vitro and might protect from increased bone resorption in vivo.
Acknowledgement This study was supported by the START price of the Aus-
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Background T-cell receptor (TCR)-induced IL-2 expression is suppressed at the
level of mRNA and protein following chronic culture of T cells with tumour necro-
sis factor (TNF) at picomolar concentrations, an effect that is reversible upon
removal of TNF. This TCR hyporesponsiveness is reminiscent of that of T cells
recovered from inflamed sites such as the rheumatoid synovium. We have found
that, although chronic TNF attenuates TCRζ expression and TCR-proximal sig-
nalling, IL-2 expression is suppressed regardless of whether cells are stimulated
via the TCR, or with phorbol ester and calcium ionophore to activate the MAPK
and NFAT pathways directly. Suppression therefore occurs independently of
TCR-proximal effects of TNF [1,2].
Objectives We are studying the mechanisms by which chronic TNF suppresses
T-cell responses in the CD4+ mouse T-cell hybridoma clone, 11A2. We have
compared the stability of induced IL-2 mRNA, and the regulation of transcription
factors important for IL-2 gene expression, in control and TNF-treated cells; and
we have recently begun to study effects of chronic TNF on chromatin remodelling
across the IL-2 proximal promoter (pIL-2), which precedes initiation of transcrip-
tion, using the chromatin accessibility real-time PCR (CHART-PCR) assay [3].
Methods Cells were grown in the presence or absence of 2.5 ng/ml murine TNF
for 8 days. Washed cells were stimulated with either plate-bound anti-CD3ε, or
phorbol 12-myristate 13-acetate (PMA) and ionomycin, for 4 hours.
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mRNA stability assay Actinomycin D was added and cells harvested over a
further 4-hour time-course. Total RNA was extracted and probed for IL-2 mRNA
by ribonuclease protection assay.
Transcription factor regulation Whole cell lysates were probed for NF-κB and IκB
family proteins by immunoblot.
Chromatin remodelling Nuclei were isolated and subjected to limited nuclease
digestion. DNA was extracted and quantitative analysis of target sequences
within pIL-2 carried out by real-time PCR. An increase in the threshold cycle (CT)
of a target sequence PCR product from activated cells was indicative of stimula-
tion-induced chromatin remodelling.
Results IL-2 mRNA induced via TCR was unstable (t1/2 < 30 min), whereas PMA
and ionomycin stabilised IL-2 mRNA strongly (t1/2 > 2 hours). However, the initial
rate of decay was similar in control and TNF-treated cells, suggesting that reduced
expression in TNF-treated cells was not due to decreased stability of IL-2 mRNA.
c-Rel, IκBβ and IκBε were regulated differently in control and TNF-treated cells:
expression of IκBε was comparatively enhanced, while that of c-Rel and IκBβ was
attenuated in TNF-treated cells. These altered responses may affect the ability of
TNF-treated cells to remodel pIL-2 productively through NFκB consensus binding
upon cell stimulation [4]. This hypothesis is now being tested by CHART-PCR.
Conclusions Chronic culture of murine T cells in TNF does not alter the stability
of IL-2 mRNA induced via TCR, or by PMA and ionomycin, in those cells.
However, altered regulation of NF-κB expression and activity in TNF-treated cells
may contribute to poor inducibility of IL-2 through effects on stimulus-induced
changes in chromatin conformation across pIL-2.
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Objective Rheumatoid arthritis (RA) is characterized by inflammation of synovial
joints and degradation of these joints. Fibroblast-like synoviocytes (FLS) are
thought to play a role, because they can invade normal human cartilage in SCID
mice [1] and matrigel in vitro [2]. This study was undertaken to investigate the
association of these in vitro characteristics with the disease characteristics in
patients with RA.
Methods Synovial tissue samples of 72 RA and 50 osteoarthritis patients were
obtained; from seven patients with RA, samples of different joints were collected.
The FLS invasiveness in Matrigel matrix was studied; the intra-individual and inter-
individual differences were compared. The radiological scores of the X-rays of the
hands and feet of the patients with the FLS that exhibit the most extreme differ-
ences in in vitro ingrowth (most invasive and least invasive FLS) were determined
with the Sharp–van der Heijde method to determine the relationship between in
vitro invasion data and clinical data.
Results FLS from patients with RA are more invasive than FLS from patients with
osteoarthritis (P < 0.001). The intra-individual variation in FLS invasion was much
less than the inter-individual variation (P = 0.028; mean difference ± standard
deviation, 1204 ± 926 and 3476 ± 2367 for intra-individual and inter-individual
variation, respectively), showing that the level of FLS invasion is a patient charac-
teristic. The mean Sharp score of X-rays of the hands and feet divided by the
disease duration was 4.7 ± 3.2 units per year of disease duration (n = 9) for the
patients with the least invasive disease, which was much lower as compared with
22.3 ± 9.4 units per year of disease duration (n = 8) for the patients with the
most invasive disease (P < 0.001).
Conclusion The ex vivo behaviour of FLS is a patient characteristic given the
small intra-individual variation, and is highly correlated with the rate of joint
destruction in patients with RA. This suggests that the ex vivo invasive behaviour
of FLS from patients with RA is of relevance for the rate of joint destruction in
patients with RA.
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Background Despite the accumulation of evidence that CD4+CD25high regulatory
T cells play an important role in the prevention of autoimmune disease, little is
known about how they are regulated in vivo. There are thought to be at least two
mechanisms for the generation of regulatory T cells: naturally occurring
CD4+CD25high regulatory T cells derive from the thymus, and peripherally-induced
regulatory cells arise under tolerogenic conditions. Recently, cytokine activation
requirements for CD4+CD25high regulatory T-cell function were associated with
IL-7, as well as IL-2 and IL-4. We examined a cohort of patients with rheumatoid
arthritis whose disease was well controlled, and where we had previously shown
that heterogeneous circulating levels of IL-7 positively correlated with thymic activ-
ity, to investigate the role of IL-7 on the function of CD4+CD25high T cells.
Methods Peripheral blood samples were taken from patients with rheumatoid
arthritis whose disease was well controlled. Serum IL-7 levels were measured by
ELISA. Quantification of the CD4+CD25high T-cell subset was performed using
flow cytometry. Thymic activity was evaluated by real-time PCR quantification of
T-cell receptor excision circles in CD4+ T cells. Thymidine incorporation assays
were used to assess the response of CD4+CD25high T cells to IL-7 stimulation,
and also their ability to suppress the proliferation of CD4+CD25– T cells in
response to phytohaemagglutinin in co-culture.
Results Circulating levels of IL-7 positively correlated with the frequency of circu-
lating CD4+CD25high T cells (n = 47, R = 0.647, P < 0.0001). This appeared to
result from an increased production of these cells by the thymus. High levels of
circulating IL-7 in vivo were associated with increased suppressor functions of
CD4+CD25high T cells in vitro (n = 5, mean 79% suppression by cells from
patients with high IL-7 levels, and 39% suppression by cells from patients with
low IL-7 levels). In patients with low circulating IL-7 levels, adding exogenous IL-7
to co-cultures appeared to increase suppression.
Conclusions Our data suggest that IL-7 has a role in regulating CD4+CD25high
T-cell number and function. Circulating IL-7 levels are low in active rheumatoid
arthritis, and this may be a contributory factor to the reduced size and suppressor
function of the CD4+CD25high regulatory T-cell population in this disease.
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The European Consensus Finding Study Group on Autoantibodies is currently
formed by 43 European laboratories involved in the field of serological diagnos-
tics in rheumatic diseases. The aim of this group is to work towards achieving
common consensus in this field: a laboratory result should be the same, wherever
the result is obtained.
The Steering Committee of the Consensus Finding Study Group tested 24 can-
didate sera that had been contributed by the participating laboratories. Ten sera
were selected for the annual serum round. This year, special emphasis was put
on anti-DNA antibody testing. For this purpose four sera were included that con-
tained different specificities of anti-DNA (Table 1). The remaining six sera were
positive for a variety of autoantibodies (Table 1).
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Table 1
Summary of results for 10 distributed sera
Serum Detected antibodies Comments
1 dsDNA Only Crithidia luciliae positive
2 SS-A 52 kDa + 60 kDa, SS-B Good consensus
3 SS-A 52 kDa, SCL-70 SS-A 60 kDa only found by minority
4 PR-3 ANCA Very few incorrect results
5 SS-B SS-A found by ELISA, 
counterimmunoelectrophoresis and 
immunoblot mostly negative
6 U1-snRNP, A and C protein 70K negative, good consensus
7 Centromere (CENP-B) Good consensus
8 ssDNA Perfect consensus
9 dsDNA No consensus
10 dsDNA Good consensus
For the first time, a dedicated computer program was used to allow more easy
data entry and statistical analysis. Next to the 10 sera, a CD-ROM containing 20
HEp-2 cell staining patterns was dispatched to the participating laboratories. The
CD-ROM also contained the spreadsheets to be filled in by the participants.
Results were returned by 38 out of 43 participating laboratories. The data were dis-
cussed at a satellite meeting during the 24th European Workshop on Rheumatology
Research in Berlin and were published on the website of the Sanquin Blood Supply
Foundation in Amsterdam (via a link distributed to the participants). In depth analysis
of individual results compared with the consensus were sent to the participants.
In general, the participants reached a high degree of consensus for most of the
samples. The results for anti-DNA were very promising. A perfect consensus was
reached for the absence of dsDNA antibodies in an anti-ssDNA specific serum
(serum 8). The absence of false positive results showed that assays measuring
anti-dsDNA antibodies have been improved such as to exclude detection of anti-
ssDNA. Serum 9 was obtained from a rheumatoid arthritis patient who had been
treated with anti-tumour necrosis factor alpha (Infliximab) and developed anti-
dsDNA antibodies, yet showed no clinical signs of systemic lupus erythematosus.
Using different assays, divergent results were obtained. Most laboratories found
anti-dsDNA antibodies by the indirect immunofluorescence technique (substrate
Crithidia luciliae), whereas anti-dsDNA ELISAs were negative. For this sample
most (commercial) Farr assays showed positive reactions. Detailed analysis of
the serum in Amsterdam showed the presence of low avidity IgM and IgG anti-
bodies to dsDNA. In order to understand the cause of the discrepancies the influ-
ence of choice of assay will be studied in more detail. Divergent results,
depending on the method for detection, were also found for antibodies to SS-A.
Obviously, ELISA-based techniques were more sensitive. Unfortunately, most
ELISAs do not distinguish between anti-SS-A 52 and anti-SS-A 60 antibodies.
The clinical relevance of the lower limit of detection has to be established in the
future. We will include a more detailed method analysis in the next rounds.
There was general agreement among the participating laboratories that these Con-
sensus Rounds should be continued, including the HEp-2 cell pattern recognition
CD-ROM effort. It was decided to focus next round on anti-phospholipid antibodies.
For information about the study group please contact Ruud Smeenk
(r.smeenk@sanquin.nl).
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Background  Autoantibodies directed against citrullinated proteins (e.g. anti-
CCP) can be detected in rheumatoid arthritis (RA) patients with very high speci-
ficity. The antibodies are present already years before the first clinical symptoms
and their presence predicts the development of erosive disease. Citrullinated pro-
teins, the target of anti-CCP antibodies, are formed by post-translational deimina-
tion of arginine residues, catalyzed by peptidylarginine deiminase enzymes
(PADs). PAD enzymes are expressed by cells present in the inflamed joints of RA
patients. These data are the basis of our hypothesis that protein citrullination by
PAD is intimately involved in the development of RA.
Objective To investigate the effect of PAD4 overexpression in synovium of naive
mice and in mouse models of arthritis.
Methods An adenoviral delivery tool for local expression of mouse PAD4 was
successfully constructed. Using this adenoviral construct, PAD4 overexpression
was effectuated in cells present in the synovial cavity after intraarticular injection.
Effects of PAD4 overexpression in mice with or without co-induction of arthritis
(streptococcal cell wall arthritis) were investigated using routine scoring of
arthritic features (e.g. swelling) and histology. The presence of citrulline-specific
antibodies was measured by ELISA using a synthetic citrullinated peptide
(CCP1) and a noncitrullinated control peptide.
Results In all naive mice (C57/Bl6, n = 12) we were able to effectively overex-
press PAD4 in the synovial tissue, lasting at least 1 week. This overexpression
resulted in the generation of citrullinated proteins in vivo. In mice receiving a
control adenovirus no citrullinated proteins were observed. The overexpression
did not induce inflammation. Similar experiments in streptococcal cell wall
(SCW)-induced mice (C57/Bl6 + SCW, n = 8) showed a prolonged expression
of citrullinated proteins when the knees were preloaded with PAD4 (compared
with control adenovirus-treated SCW mice, n = 8), but this did not affect the level
of inflammation or tissue damage. Overexpression of PAD4 did not lead to the
production of citrulline-specific autoantibodies in these mice.
Conclusion Adenoviral expression constructs can successfully be used to intro-
duce PAD enzymes in mouse synovium. Overexpression of PAD4 results in the
production of synovial citrullinated proteins, but did not cause additional inflam-
mation in mice nor did it cause an immune response to citrullinated proteins.
Generating anti-CCP-positive mice will be crucial in studying the effect of
specific immune complexes on arthritic phenomena in mouse models of arthritis.
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Background In the early 1990s, we used the monoclonal antibody alemtuzumab
(MabCampath, Schering AG, Berlin, Germany) to treat patients with refractory
rheumatoid arthritis. This treatment provided temporary relief of symptoms but
was associated with long-term lymphopenia, particularly of T lymphocytes [1].
We continue to follow these patients to exclude any adverse effects of their long-
term lymphopenia.
Objective The objective of the current study was to compare 10-year mortality in
this patient cohort with mortality in a control patient cohort.
Methods Fifty-three rheumatoid arthritis patients that received alemtuzumab
(median dose, 172 mg; range, 1–420 mg) between 1991 and 1994 (cases) were
monitored via the Office for National Statistics Central Registry, to ensure notifica-
tion of death. A retrospective, matched-cohort study of mortality was performed
with 102 control subjects selected from the European League Against Rheumatism
database. This database comprises patients with rheumatic disorders who have
received immunosuppressive drugs, usually cyclophosphamide or azathioprine.
Results Median (range) duration of follow-up was 10.29 (1.27–12.15) years for
cases and 10.35 (1.18–12.14) years for controls. There were 20 deaths among
the cases compared with 37 among the controls. This provided a mortality rate of
0.045 deaths per person per year for the cases and 0.041 deaths per person per
year for the controls. The mortality rate ratio was 1.10 (95% confidence interval,
0.61–1.95). There was no significant difference in survival between the two
groups (P = 0.73, log-rank test). Figure 1 illustrates Kaplan–Meier survival plots
for cases and controls. The causes of death in the cases reflected those
expected in a hospital-based rheumatoid arthritis cohort. Median time (range)
from treatment to death for cases was 5.9 (1.3–11.7) years. Mortality did not
differ according to total dose of alemtuzumab or the number of courses received.
Conclusions Despite long-term lymphopenia, there was no excess mortality in
recipients of alemtuzumab at a median follow-up of 10.3 years from treatment.
Reference
1. Isaacs JD, Greer S, Sharma S, Symmons D, Smith M, Johnston J, Wald-
mann H, Hale G, Hazleman BL: Morbidity and mortality in rheumatoid
arthritis patients with prolonged and profound therapy-induced lym-
phopenia. Arthritis Rheum 2001, 44:1998-2008.
Acknowledgements This work was supported by Ilex Oncology, Inc. and the
Arthritis Research Campaign
Available online http://arthritis-research.com/supplements/7/S1S20
P47
The persistence of abnormal T-cell differentiation patterns
predicts relapse in rheumatoid arthritis patients with
controlled disease
A Brown1, F Ponchel1, J Isaacs2, P Emery1
1University of Leeds, UK; 2University of Newcastle, UK
Arthritis Res Ther 2005, 7(Suppl 1):P47 (DOI 10.1186/ar1568)
Background We previously demonstrated abnormal T-cell differentiation in
rheumatoid arthritis (RA) and hyperproliferation of T cells in relation with inflamma-
tion. However, it is still not clear whether these T-cell dysfunctions are a primary
feature of RA or are only secondary to inflammation. We therefore analysed RA
patients in clinical remission in whom systemic inflammation was controlled.
Methods  Patients were defined as in remission when they had controlled
disease, with no change of activity for at least 6 months, C-reactive protein below
15, no swollen or tender joints and on stable treatment. Relapse was defined as a
change in disease activity sustained for at least 3 months, requiring or not a
change in treatment. Flow cytometry was used to assess T-cell differentiation
pattern in controls (n = 23), active RA (n = 28) and remission (n = 34). CD4+ T-
cell proliferation assay in response to mitogen, IL-2, and antibody stimulation in
eight paired blood samples for active and remission disease. Statistical analysis
was used to seek clinical and laboratory correlate to differentiation abnormalities.
Results The abnormal differentiation patterns observed in active disease were main-
tained in remission. The first inflammation-associated subset was persistent. The
second atypical subset was never observed in health, poorly represented in active
disease but largely accumulated in remission. The hypreproliferation associated with
the first subset was lost in remission and was therefore driven by inflammation. The
second atypical subset was associated with profound hyporesponsiveness in both
active and remission disease. Relapse occurred in 13 out of 32 patients within
12 months of follow-up. Relapse was associated with a higher frequency of the
inflammation-related cells (P = 0.017). We proceeded to a complete analysis of
factors that could predict relapse. Only rheumatoid factor positivity (P = 0.033) and
possibly having nodules (P = 0.079) were associated with relapse. Using a regres-
sion analysis revealed that the frequency of inflammation related cells was highly sig-
nificant in predicting relapse, being correct in 78% of cases (P = 0.025). Neither the
presence of rheumatoid factor or nodule improved this model.
Conclusions These results suggest that the hyper-reactivity of the inflammatory
subset is associated with disease activity; however, its persistence in the absence
of inflammation suggests a primary defect possibly in activation-induced cell death.
The second subset appear fairly inactive, but more work is necessary to fully char-
acterise these cells. Its complete absence in health and accumulation in disease
remission also suggests a primary defect in T-cell differentiation pathways in RA.
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Objectives Despite indirect evidence suggesting that low oxygen levels might
occur in the rheumatoid arthritis (RA) synovium, direct proof of the presence of
hypoxia in the arthritic synovium as well as the relevance of low oxygen levels for
joint destruction is lacking. The aim of this study was to analyse the distribution of
hypoxia in arthritic joints and to evaluate the molecular effects of the hypoxic envi-
ronment on the phenotype of RA synovial fibroblasts (SF).
Methods The hypoxia marker EF-5 was applied in mice with the collagen-induced
arthritis (CIA). Expression profile analysis with hypoxic and normoxic SF was per-
formed using subtractive hybridization and microarray. The expression of the
inhibitor of differentiation-2 (Id-2), CD68 (macrophage marker) and prolyl hydrox-
ylase (fibroblast marker) was evaluated by immunohistochemistry on synovial
tissues from RA, osteoarthritis patients and CIA mice. To evaluate the function of
Id-2 in SF, cells were transfected with the pcDNA3.1 containing cDNA for Id-2 or
Id-2-specific siRNA or mock controls. The expression of Id-2 and genes regulated
by Id-2 in transfected SF was evaluated by SYBR Green real-time PCR and
western blot. SF stably transfected with Id-2 were cocultured with bone marrow
cells in a transwell system. The expression of the receptor activator of NF-κB
ligand (RANKL) and osteoprotegerin were measured by real-time PCR. The
development of osteoclasts was evaluated by visualization of the activity of tar-
trate-resistant acid phosphatase.
Results Using the hypoxia marker EF-5 we found that in mice with CIA, synovial
cells invading bone and cartilage are exposed to reduced oxygen levels. Expres-
sion profile studies identified Id-2 as being upregulated under low oxygen condi-
tions. In addition, IL-1beta stimulation increased the expression of Id-2 in these
cells. Histological studies of RA synovium and CIA synovium showed strong
expression of Id-2 in SF at sites of synovial invasion into bone. Overproduction of
Id-2 in SF by stable transfection triggered the expression of several genes pro-
moting osteoclastogenesis, including BMP-2, PTHrP, Wnt5a and vascular
endothelial growth factor. Conversely, the suppression of endogenous Id-2 led to
the downregulation of the expression of these molecules. Consistent with these
findings coculture of Id-2 transfected SF with bone marrow cells increased the
expression of the osteoclast differentiation factor RANKL, and decreased the
expression of the osteoclast inhibitory factor osteoprotegerin in bone marrow
stromal cells, which was followed by an increase in the number of osteoclasts.
Conclusion Taken together, our data provide evidence that hypoxia is present at
sites of synovial invasion in RA and that Id-2 induced by hypoxia contributes at
these sites to joint destruction by promoting SF-dependent osteoclastogenesis.
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Introduction EMR2 is a member of the EGF-TM7 family closely related to CD97.
Chondroitin sulphates have recently been identified as ligands for EMR2 and
CD97. Chondroitin sulphates have been implicated in the pathogenesis of
rheumatoid arthritis (RA). The objective of this study is to determine the expression
of EMR2 and the distribution of EMR2 and CD97 ligands in RA synovial tissue.
Methods Synovial tissue samples were obtained by arthroscopy from patients
with RA (n = 19), inflammatory osteoarthritis (n = 13), and reactive arthritis
(n = 13). Immunohistologic staining was performed with EMR2 mAb and stained
synovial tissue sections were analysed by digital image analysis. Co-expression of
EMR2 with lineage and activation markers was determined by double immuno-
fluorescence microscopy. To evaluate the expression of EMR2 and CD97 ligands
in RA synovium, binding assays using fluorescent beads loaded with EMR2-Fc or
CD97-Fc constructs were performed.
Results EMR2 expression in the synovial sublining was significantly higher in RA
compared with disease controls. Most EMR2-positive cells were macrophages
and dendritic cells, expressing co-stimulatory molecules and tumour necrosis
factor alpha. Dermatan sulphate was shown to be the ligand of the largest
isoform of EMR2 and CD97 in rheumatoid synovium. In addition, the smaller
isoforms of CD97, but not EMR2, bound CD55 on fibroblast-like synoviocytes.
Conclusion The EGF-TM7 receptor EMR2 and CD97 are abundantly expressed
on myeloid cells in synovial tissue of RA patients where they encounter their
ligands dermatan sulphate and CD55. These interactions might facilitate the
retention of activated macrophages in the synovium.
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Background Defensins are small positively charged peptides (29–47 amino acids)
that are highly conserved among species and play a role in host defense against
bacteria and viruses. There are two categories of defensins: A-defensins are
secreted from human neutrophils, and B-defensins are produced from the epithelial
cells. Each peptide contains six cystein amino acid residues, connected with disul-
fide bonds. The physicochemical properties of defensins are similar with the proper-
ties of another molecule, B2-glycoprotein I (B2-GPI), the major target of the
autoantibodies found in the sera of patients with antiphospholipid syndrome (APS).
Objective  We investigated whether sera from patients with APS as well as
primary Sjogren Syndrome (pSS), systemic lupus erythematosus (SLE), and
rheumatoid arthritis (RA) contain autoantibodies that react with defensins.
Methods We synthesized the linear peptides NH2-ACYCRIPACIAGERRYGTCIYQ-
GRLWAFCC-OH and NH2-GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKC-
CKKP-OH, corresponding to the amino acid sequences of the mature forms of A1
(defA1) and B2 (defB2) defensins, respectively. These peptides were oxidized, in
order for the disulfide bonds of the native molecules to be created, and subse-
quently were lyophilized. The peptides were dissolved in water and they were
tested in ELISA experiments against sera from patients with APS (n = 24), pSS
(n = 24), SLE (n = 16), and RA (n = 8). Additionally, sera from normal individuals
were tested. Homologous inhibition experiments were performed in order to
examine the specificity of the immune response against defensins.
Results None from the tested sera reacted against the defA1. Sera from patients
with systemic autoimmune diseases contained autoantibodies to defB2 as
follows: 21% of patients with APS and 25%, 31%, and 12% of the sera from the
patients with pSS, SLE, and RA, respectively, gave a positive reaction against the
same peptide. None of the normal sera reacted with the peptides at all. In the
inhibition experiments the defB2 peptide, when it was used as soluble inhibitor,
inhibited the binding of the antibodies at the plate-bound defB2 by 64%.
Discussion  Defensins are components of the innate immunity and share
common physicochemical properties with the B2-GPI molecule. A rather small
proportion of sera from patients with systemic autoimmune diseases contain anti-
bodies that react specifically with the defB2 peptide. The presence of these
autoantibodies is not disease specific and their pathogenic significance, if any,
remains to be elucidated.
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Background Mesenchymal stem cells (MSCs) are bone-marrow-derived progeni-
tor cells, widely investigated for their potential of differentiation towards multiple
lineages, such as osteocytes and chondrocytes. Recently, we and others showed
that MSCs exhibit immunosuppressive properties inducing in vivo tolerance of T
lymphocytes towards allogeneic cells. Moreover, these cells can be easily geneti-
cally modified to express ectopic molecules, such as anti-inflammatory cytokines.
Objective Here, we investigated whether naïve and IL-10-expressing MSCs
could display an inhibitory effect towards self-reactive T lymphocytes in vitro and
have a biological effect in the murine model of collagen-induced arthritis (CIA).
Methods We used the murine C3H10T1/2 cell line (C3 MSCs) in the CIA
murine model of RA. We injected various doses of MSC at immunization or at
boost and evaluated the clinical and immunological parameters. Immunosuppres-
sive properties of MSC were determined in vitro in mixed lymphocyte reactions.
Results We evaluated the potential immunosuppressive role of MSCs in the CIA
model and showed that MSCs did not display any benefit whatever the day of cell
injection (day 0 or day 21) and the numbers of MSCs (106 or 4 × 106). Both clin-
ical and immunological analysis argued for the accentuation of the Th1 helper
response. Using luciferase-expressing MSCs, we were unable to detect labeled
cells in the articular environment of the knee, suggesting that worsening of the
symptoms was unlikely due to the homing of MSCs in the joints. Experiments in
vitro showed that addition of tumor necrosis factor alpha was sufficient to reverse
the immunosuppressive effect of MSCs on T-cell proliferation and this observa-
tion was associated with an increase of IL-6 secretion.
Conclusion Here, we demonstrated that the immunosuppressive properties of
MSCs did not provide any clinical benefit in CIA. Our data suggest that environ-
mental parameters, in particular inflammation, may influence the immunosuppres-
sive properties of MSCs.
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Background Rheumatoid arthritis is characterized by an intermittent course of the
disease with alternate periods of remission and relapse. T cells, and in particular
the T-cell cytokine IL-17, are expected to be involved in this flare-up of arthritis.
Objective To study the role of T-cell IL-17 in flare-up of experimental arthritis.
Methods Antigen-induced arthritis was induced in C57Bl/6 mice by immunizing
and boosting with mBSA/ complete Freund’s adjuvant, and subsequent intra-
articular injection of 60 µg mBSA. At week 4 of arthritis, 2 µg mBSA was injected
into the arthritic joint to induce a flare-up of the smouldering inflammation. To
study the role of IL-17 in this flare-up, neutralizing rabbit-anti-mouse-IL-17 anti-
bodies (or control antibodies) were injected 2 hours prior to antigen rechallenge.
Results Quantitative PCR at various time points after arthritis induction showed
that IL-17 mRNA expression was already upregulated at day 1, increased even
more at day 2 and day 7, and clearly diminished at day 21. After antigen rechal-
lenge, IL-17 mRNA expression rapidly increased, peaking at 4 hours with a 250-
fold upregulation compared with naive mice.
Neutralizing IL-17 significantly prevented joint swelling, as measured by 99mTc
uptake at day 1 (Fig. 1a). Arthritic knee joints were isolated at day 4, and histo-
logical analysis showed significantly suppressed joint inflammation (Fig. 1b) and
cartilage proteoglycan depletion in the anti-IL-17-treated group.
Blocking IL-17 also clearly protected arthritic mice against bone erosions
(Fig. 1c). Cathepsin K staining showed reduced osteoclast-like activity, and quan-
titative PCR showed reduced RANKL mRNA expression in the anti-IL-17-treated
group. The degree of bone erosions strongly correlated with the severity of joint
inflammation, suggesting that neutralizing IL-17 reduces bone erosion by sup-
pressing joint inflammation.
Interestingly, mice treated with anti-IL-17 antibodies showed reduced protein
levels of IL-1β, tumor necrosis factor alpha, and the cytokine-induced neutrophil
chemoattractant KC, suggesting that IL-17 acts as an upstream mediator in
destructive joint inflammation during flare-up of experimental arthritis.
Available online http://arthritis-research.com/supplements/7/S1S22
Conclusion These data indicate IL-17 to be an important upstream proinflammatory
cytokine driving joint pathology during flare-up of experimental arthritis and suggest
therapeutic benefit of neutralizing IL-17 during relapses of rheumatoid arthritis.
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Background Toll-like receptors (TLRs), a family of pathogen recognition recep-
tors, represent an important component of the innate immune system that also
contributes to the development of acquired immunity. TLR9 expressed in the
cytoplasm of several cell types including B cells, and recognize and are activated
by unmethylated CpG-rich, pathogen-derived DNA sequences. This CpG stimu-
lation triggers B-cell proliferation and promotes Th1 response. Moreover, DNA
containing CpG-rich motifs, acting as polyclonal stimuli, participates in the main-
tenance of serological memory by human memory B cells. Recent data indicate
that bone marrow in rheumatoid arthritis (RA) patients may actively participate in
the pathogenesis of RA as a secondary lymphoid organ via overproduction of
proinflammatory cytokines and a site of effective antigen presentation.
Objective To test the hypothesis that RA bone-marrow-derived B cells express
functional TLR9.
Methods Bone marrow mononuclear cells (BMMC) were isolated from RA bone
marrow samples obtained during joint replacement surgery. The expression of
TLR9 protein on B lymphocytes, gated as CD19-positive cells in BMMC prepara-
tion, was assessed by intracellular staining and flow cytometric analysis. BMMC
were stimulated in vitro with agonistic (CpG-ODN) or control (GpC-ODN)
oligodeoxynucleotides (15–30 µg/ml). In blocking experiments chloroquine
(2–3 µg/ml) was added to the culture 50 min before stimuli. The expression of
activation markers CD86 and CD54 on B lymphocytes (CD19+) were analyzed
after 48 and 72 hours in culture using flow cytometry. Ki-67 and CFSE staining
(flow cytometry) was applied to evaluate B-cell proliferation after 72 and
120 hours of culture with oligodeoxynucleotides. The concentrations of oligo-
deoxynucleotides and chloroquine used in experiments were not toxic to BMMC
as judged by colorimetric lactate dehydrogenase assay. The presence of bacter-
ial DNA in bone marrow plasma and BMMC was evaluated by DNA extraction
and PCR amplification. Primers used for PCR recognize highly conserved regions
of the eubacterial 16S-ribosomal RNA gene.
Results  RA bone-marrow-derived B lymphocytes express TLR9 protein that
could be detected via intracellular staining and flow cytometric analysis. Impor-
tantly, these TLR9 are functional. CpG-ODN, but not control GpC-ODN, in a
dose-dependent manner enhanced the expression of activation markers (CD86
and CD54) on B cells in BMMC cultured in vitro. The specificity of CpG-ODN
triggered expression of CD86 was confirmed in experiments where cells cultured
in the presence of chloroquine, a known inhibitor of TLR9-triggered signal tran-
duction, failed to respond to CpG-ODN. Moreover, CpG-ODN triggers bone
marrow B-cell proliferation in vitro, as judged by enhanced expression of prolifer-
ation marker Ki-67 and a diminished level of CFSE dye. Interestingly, our prelimi-
nary data indicate the presence of bacterial DNA in several samples of bone
marrow tissues isolated from RA patients. We could amplify DNA encoding bac-
terial 16S-ribosomal RNA in one bone marrow plasma and three BMMC out of
total five analyzed samples.
Conclusions Our results indicate that CpG oligodeoxynucleotides, the potent
agonists of TLR9, modulate the activity of B cells from bone marrow of RA
patients via induction of costimulatory and adhesion molecules (CD86, CD54)
expression, and via cell proliferation. Thus, our data suggest that bone marrow of
RA patients may represent an important secondary lymphoid organ that actively
participates in the pathogenesis of RA.
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Background Previously we have described the stress protein BiP as a putative
autoantigen in RA [1]. The administration of BiP intravenously (i.v.) prior to induc-
tion of collagen-induced arthritis (CIA) resulted in almost complete amelioration
of disease [1]. Our studies now indicate that BiP has several immunomodulatory
actions including the skewing of T-cell differentiation towards Th2 [2].
Aim This study focused on the therapy of CIA and investigated subcutaneous
administration of BiP in comparison with intravenous administration and whether
adoptive transfer of BiP-treated cells could successfully inhibit the onset of
disease. Finally, IL-4 knockout mice were used to determine the importance of the
T cell in the therapeutic role of BiP
Methods CIA was induced in DBA-1 mice by injection of bovine collagen type II
(CII) in complete Freund’s adjuvant followed by a booster injection in incomplete
Freund’s adjuvant at day 21. At the first appearance of swollen joints, the mice
were injected subcutaneously (s.c.) with BiP, a control protein, BSA or vehicle
control (PBS). Disease progression was followed by measurement of swollen
joints. At termination, splenocytes and draining lymph node cells were removed
and T-cell cytokine secretion was assessed. Mixed spleens and lymph nodes
from groups of DBA-1 mice that had been immunized s.c. with BiP or BSA
(200 µg), or i.v. with BiP or BSA (10 µg), were collected 12 days after immuniza-
tion. Cell cultures (2.5 × 106 cells/ml) were set up with 20 µg of the respective
protein (BiP or BSA) for 5 days. Cells were then washed and injected intraperi-
toneally into DBA/1 mice (20 × 106 cells/mouse) that had received the first CII
immunization 24 days previously. DR1+/+ IL-4 knockout mice, (n = 20) developed
by backcrossing C57Bl/6 IL4–/– mice to DR1+/+ mice, were immunized with CII,
and on day 24 after immunization were given 10 µg BiP i.v. Wild-type HLA-
DR1+/+ transgenic mice (n = 20/group) were administered 10 µg BiP or PBS i.v.
Results Administration i.v. or s.c. of BiP significantly reduced (P < 0.05) the inci-
dence and severity of CIA when given at the onset of disease. A lower incidence
of arthritis was also recorded from groups of mice treated with BiP s.c. and i.v.
(37.5% and 64%, respectively) as compared with 100% recorded from the
control group by day 70. T cells removed from mice that had been treated with
BiP via both routes were shown to secrete IL-4 in response to in vitro BiP stimu-
lation. In response to CII, results indicated upregulation of IL-5 and IL-10 produc-
tion from BiP-treated groups compared with the arthritic control group. In the
adoptive transfer studies the mice receiving subcutaneous BiP-primed cells had a
significant suppression of arthritis by day 48, and by day 66 in those receiving
intravenous BiP-primed cells, compared with mice that had received BSA-primed
T cells (P < 0.05). When the IL-4–/– mice were scored for disease severity the
IL-4–/– mice treated with BiP were no different from wild-type mice treated with
PBS whereas wild-type mice treated with BiP had a significant suppression of
arthritis (P ≤ 0.05, Students test).
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Figure 1
(a) Joint swelling, (b) inflammation,
and (c) bone erosion in arthritic mice
before (background) and after flare-up
of experimental arthritis, treated with
anti-IL-17 antibodies or control
antibodies. * P < 0.01, ** P < 0.005
versus control-treated group. R/L ratio,
ratio between the mouse right
inflamed knee joint (R) and left
uninflamed knee joint (L).S23
Conclusion These findings suggest that treatment of CIA with BiP is mediated at
least in part by induction of IL-4-dependent regulatory T cells.
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Background High-dose chemotherapy (HDC) and stem cell transplantation
(SCT) is an experimental treatment option for patients with refractory rheumatoid
arthritis (RA). The re-infusion of stem cells with a possible intrisic cell defect may
be the cause for disease relapse despite increased sensitivity to disease-modify-
ing anti-rheumatic drugs (DMARDs). This can be avoided by a syngeneic trans-
plantation with healthy stem cells from an identical sibling.
Objectives We treated a 44-year-old woman, who had seropositive, erosive RA,
with HDC and syngeneic SCT from her healthy identical twin sister. The patient
had undergone multiple joint operations and had become refractory to conven-
tional DMARDs, etanercept and infliximab.
Methods Outcome measures were DAS 28, rheumatoid factor titer (IgM), need
for DMARD therapy and synovial inflammation for which tissue was obtained at
baseline, 2, 3 and 6 months through knee arthroscopy. Stem cells from the donor
were mobilized with filgrastim and collected by leukapheresis on day –1 and 0.
HDC consisted of cyclophosphamide (total dose 13.4 g intravenously) combined
with 1 mg/kg prednisone. On day 0 an unmanipulated graft containing 182 × 109
leukocytes, containing 769 × 106 CD34+ cells, was administered.
Results Before conditioning, infliximab, methotrexate and prednisone were dis-
continued, which resulted in a disease flare (Fig. 1). The treatment was well toler-
ated and the patient was discharged on day 14 without joint complaints. After
1 month disease activity flared accompanied by an acute phase response.
Despite maintenance therapy with 10 mg prednisone and re-institution of
methotrexate up to 22.5 mg/week she had continued active disease up to 1 year
after SCT (Fig. 1). Synovial biopsies at all timepoints showed a marked infiltration
with neutrophils and plasmacells, even 2 months after HDC. Immunohistological
staining showed infiltration of activated T cells (CD38+), B cells (CD19+) and
plasma cells (CD138+)
Discussion HDC and syngeneic SCT did not result in remission of RA. The per-
sistence of RF, anti-CCP (IgG) and plasma cells in the synovial tissue suggests
host plasma cells were not eradicated by cyclophosphamide, nor replaced by
donor plasma cells (rheumatoid factor and anti-CCP negative).
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Background Idiopathic inflammatory myopathies, myositis, are characterized by
infiltrates of T lymphocytes and macrophages in muscle tissue. Some patients
with myositis are very resistant to immunosuppressive treatment. Thus new thera-
pies are urgently required. An increased knowledge of the key molecular mecha-
nisms in myositis would be important for development of new targeted therapies
for these patients. IL-18 is a pleiotropic cytokine with proinflammatory and
immunoregulatory effects. It has been shown to play an important pathogenic role
in various autoimmune disorders (e.g. rheumatoid arthritis and Sjögrens syn-
drome). Whether IL-18 has a role in disease mechanism in myositis is not known.
Objective To study the expression of IL-18 in muscle tissue of patients with idio-
pathic inflammatory myopathies.
Methods Thirteen treatment-resistant patients, six polymyositis, four dermato-
myositis, one juveline dermatomyositis, and two inclusion body myositis with signs
of active muscle inflammation, were included in our study. Muscle biopsies were
investigated by immunhistochemistry using monoclonal antibodies against IL-18.
Results Intracellular IL-18 expression was detected in all patients with polymyosi-
tis, dermatomyositis and inclusion body myositis. The IL-18 expression was pre-
dominantly localized to inflammatory cells, in large infiltrates and scattered in
tissue, in endothelial cells of capillaries (11/13), in fibroblast-like cells and smooth
muscle cells.
Conclusion This is the first study to demonstrate IL-18 expression at the protein
level in muscle tissue from patients with idiopathic inflammatory myopathies. This
was a consistent finding in mononuclear inflammatory cells in all three subsets of
patients with treatment-resistant disease. These results suggest that IL-18 could
have a role in the immunopathogenesis of myositis.
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Background An understanding of the mechanisms involved in cartilage degrada-
tion that occur in rheumatoid arthritis and osteoarthritis is essential for the devel-
opment of treatments to block disease progression. Culturing chondrocytes to
synthesize a cartilage matrix would ideally provide a cartilage matrix of consistent
composition that would reproducibly respond to different stimuli. When cultured
in monolayers, chondrocytes convert to a fibroblastic morphology and gradually
lose their native phenotype, no longer able to synthesize type II collagen and
aggrecan. However, when chondrocytes are cultured at a high density in the
presence of growth factors, the chondrocytes regain their native phenotype and
native round morphology [1].
Objective To optimise the culture conditions for chondrocyte micromass synthe-
sis of matrix components, and to evaluate the response of the culture to cytokine
stimulation by measuring the degradation of matrix components.
Methods Chondrocytes extracted from bovine nasal cartilage were passaged
several times to produce substantial cell stocks. Harvested cells were resus-
pended at 2 × 107 cells/ml and seeded in the centre of each well of a 48-well
plate (20 µl/well). Cultures were maintained in a serum-free medium with or
without ITS (insulin, transferrin and selenium), ascorbic acid, and transforming
Available online http://arthritis-research.com/supplements/7/S1
Figure 1S24
growth factor beta 1 (TGFβ1) for 14–21 days. Histological analysis of the micro-
mass cultures examined the presence of proteoglycans and type II collagen. The
effects of cytokine stimulation with IL-1, oncostatin M (OSM), and the combina-
tion of both cytokines on matrix degradation were tested by analysing proteo-
glycan and collagen release. Collagenase activity was measured by bioassay.
Results Both ITS and ascorbic acid were necessary for maximum collagen incor-
poration into micromass cultures. Collagen and proteoglycan incorporation
increased with increasing TGFβ1 concentration and increasing culture duration,
maximum incorporation detected when TGFβ1 was used at 30 ng/ml and cultures
were maintained for 21 days. Histology showed that both proteoglycans and type
II collagen were present throughout the chondrocyte micromass matrix. When
micromass cultures were stimulated with IL-1, OSM and IL-1/OSM for 14 days,
proteoglycan release was greater compared with control, but there was no differ-
ence for collagen release (see Fig. 1). Active collagenase levels were negligible,
although high levels of pro-collagenase were detected.
Conclusion The chondrocyte micromass cultures synthesized a matrix that con-
tained proteoglycan and type II collagen. The micromass culture may serve as a
good model for studying proteoglycan but not collagen degradation.
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Background  We have earlier shown that polyethylene glycol (PEG)-precipitated
immune complexes (IC) from systemic lupus erythematosus (SLE) patients can induce
IL-10 and IL-6 production from peripheral blood mononuclear cells. SLE is associated
with IC-induced classical complement activation. Autoantibodies together with
autoantigens released from apoptotic cells partly explain the IC formation. We there-
fore wanted to investigate how complement activation and levels of autoantibodies
correlate to the amount of circulating IC and IC-induced cytokine production.
Others have previously shown an inverse correlation between IL-10 and IL-12 in
SLE and we have shown that the degree of complement activation affects IC-
induced IL-10 and IL-12 in different ways. A second aim was to investigate the
effect of SLE IC on the production of IL-10 and IL-12.
Methods In total 195 SLE samples were investigated. Levels of autoantibodies
(anti-nuclear antibodies, anti-DNA, SSA, SSB, RNP and Sm) were known for
116/195 samples. In a first study we investigated 19 patients with paired serum
samples obtained at different occasions and mostly showing activation of the
classical complement pathway. Here we primarily wanted to evaluate the effect of
disease activity on IC-induced cytokine production. In a second study 78
samples with normal classical complement function and known autoantibody
status were studied. Samples were PEG-precipitated and 10% PEG precipitates
were added to serum-free cultures of normal peripheral blood mononuclear cells,
and the levels of IL-10, IL-6 and IL-12p40 were measured in the supernatants
after 20 hours. Classical complement pathway function, levels of C3, C3d and
circulating IC were measured in all samples.
Results In paired analysis, increased complement activation (lowered classical
function and raised C3d/C3 ratios) was associated with increased IL-10 produc-
tion (P = 0.046). For IL-6 there was a parallel but non-significant trend.
Decreased C3 levels were also associated with increased IL-12 production
(P = 0.03). When investigating these complement-activating sera in cross-
section we found increased IL-10 levels in ENA+ (P = 0.03) and DNA+ samples
(P = 0.046) compared with ENA– and DNA– samples with the largest impact of
anti-SSA/SSB (P = 0.02). The same pattern was found for IL-6.
In sera with normal complement levels there was no association between anti-
body status and IL-10 production, but IL-12 levels were increased in ENA+ cul-
tures (P = 0.01) and linked to anti-SSA/SSB (P  < 0.0001). There was no
association to anti-DNA.
Circulating IC in serum and PEG IC-induced IL-10 production correlated in
samples from active SLE (r = 0.55, P = 0.003), and we therefore used circulating
IC as a surrogate marker for IC-induced IL-10 production in statistical evaluation
of all sera with known antibody status. In analysis of variance with circulating IC
as the dependent variable we found a strong interaction between decreased
complement function and the occurrence of ENA, especially anti-SSA (comple-
ment  P  < 0.0001, anti-SSA P = 0.0001, interaction P = 0.002). Anti-DNA
showed no association.
Conclusion We have found a link between classical complement activation,
levels of circulating IC and induction of the cytokines IL-10, IL-6 and IL-12 with
strong interaction between complement activation and presence of autoantibod-
ies, notably anti-SSA. We hypothesize that, in quiescent SLE, autoantibodies cir-
culate in monomeric form. In active SLE apoptotic cells release SSA forming IC
with circulating anti-SSA, with subsequent induction of cytokines like IL-10.
PEG-precipitated SLE IC induce the production of IL-10 and IL-12 with parallel
patterns depending on complement and autoantibodies. Inverse regulation of
IL-10 and IL-12 in SLE therefore does not seem to depend on SLE-specific IC.
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Introduction Current guidelines on the use of anti-tumour necrosis factor alpha
(anti-TNF-α) therapies in rheumatoid arthritis (RA) recommend a 3-month trial of
the drug before a clinical assessment of treatment efficacy can be made. The
serum level of the type II collagen propeptide CPII correlates with type II collagen
synthesis, and is elevated in RA. The collagen cleavage neo-epitope C2C is spe-
cific for the destruction of type II collagen by the collagenases MMP-1, MMP-8
and MMP-13. Previously we have shown that the ratio of C2C/CPII is increased
in osteoarthritis and correlates with cartilage destruction. The current pilot study
assessed the utility of serum measurement of C2C and CPII in predicting early
response to treatment with anti-TNF-α therapy in a group of 20 RA patients.
Method Twenty patients were assessed before commencement of either inflix-
imab (n = 5) or etanercept (n = 15) therapy, and at 1-month and 3-month time-
points after therapy was commenced. Measurements of 28 swollen and tender
joint counts for DAS28 score, erythrocyte sedimentation rate (ESR) and C-reac-
tive protein (CRP) were taken at the time of each assessment. Additional serum
was collected for measurement of CPII and C2C by ELISA. The change in serum
levels of ESR, CRP, C2C, CPII and a ratio of C2C/CPII between 0 and 1 month
was calculated, and then correlated with clinical outcomes at 3 months to assess
their predictive value, using the Spearman Rank Correlation Coefficient.
Results The median DAS28 score fell from 6.20 to 3.74 following 3 months of
treatment (P = 0.0004, Wilcoxon Sign Rank Test). The change in C2C/CPII at
1 month of therapy was more closely associated with the change in swollen joint
count at 3 months (P = 0.16) than either CRP (P = 0.62) or ESR (P = 0.24). The
change in C2C/CPII at 1 month was more closely associated with tender joint
count at 3 months (P = 0.19) than either the ESR (P = 0.59) or CRP (P = 0.52).
One-month changes in C2C and CPII when used individually were not predictive
of swollen joint count at 3 months (P = 0.55 and P = 0.74, respectively) or
tender joint count at 3 months (P = 0.4 and P = 0.8, respectively).
Conclusion The ratio of C2C/CPII appears to offer a better method of predicting
early response to biological therapy than the standard acute phase markers CRP
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Figure 1
The effect on proteoglycan and collagen release when bovine nasal chondrocyte
micromass cultured for 14 days in serum-free medium supplemented with
25 ng/ml transforming growth factor beta 1 and then stimulated for 14 days with
IL-1 (1 ng/ml), oncostatin M (OSM) (10 ng/ml) and IL-1/OSM combination
(1/10 ng/ml). A significant difference with control was identified by Student’s t
test, *** P < 0.005.S25
and ESR. Measurement of the C2C/CPII ratio may more closely reflect cartilage
changes in RA through measurement of both the synthesis and destruction of
type II collagen. A further trial with larger patient numbers is required to fully
assess the utility of this measure in predicting outcome to therapeutic intervention
in the treatment of RA.
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Introduction Oncostatin M (OSM), an IL-6 type cytokine, is raised in the rheuma-
toid arthritis (RA) joint and correlates with markers of inflammation and cartilage
destruction. This study explores the mechanistic role of OSM in cell adhesion,
angiogenesis and matrix degradation.
Methods Microvascular endothelial cells (EC), primary RA synovial fibroblasts
(SFC), synovial explant culture and RASFC/normal cartilage co-cultures were stim-
ulated with OSM (20 ng/ml) ± IL-1 (5 ng/ml). Cell proliferation, cell adhesion mole-
cules expression, tubule formation, cell migration and matrix degradation were
assessed by proliferation, flow cytometry, matrigel angiogenesis and ELISA assays.
Results OSM stimulated EC/RASFC (basal = 0.9/0.56 to 1.56/1.94; P < 0.05,
day 4) alone but demonstrated a synergistic effect in the presence of IL-1
(P < 0.01). OSM and IL-1 increased intercellular adhesion molecule expression,
with no effect on vascular cell adhesion molecule or platelet endothelial cell adhe-
sion molecule. OSM had an additive effect with IL-1 on intercellular adhesion mol-
ecule expression (P < 0.05). OSM increased EC tubule formation (basal =
20 ± 1.5 to 47 ± 3.7; mean ± standard error, P < 0.01), and increased EC migra-
tion (basal = 1.265 ± 0.115 to 1.67 ± 0.187; P < 0.05). OSM synergistically
increased TIMP-1 production in EC, SFC and synovial explants in the presence of
IL-1, with no effect on αvβ3 or urokinase (-type plasminogen activator) receptor
expression. OSM and IL-1 stimulated MMP-1 and MMP-13 expression in carti-
lage and SFC alone (P < 0.05) but had a significant threefold synergistic induc-
tion when cultured together (P  < 0.01). Cartilage sections stained with
safranin-O demonstrated almost complete depletion of proteoglycan expression
in RASFC/cartilage co-cultures following 4 weeks incubation with IL-1/OSM.
This was reflected in the supernatants where IL-1 and OSM together synergisti-
cally increased GAG release from a basal level of 3.5–9.1 (µg GAG/mg cartilage
weight) compared with either IL-1 or OSM alone.
Conclusion OSM plays a critical role in RASFC activation and cartilage invasion,
also promoting angiogenesis. Its ability to act synergistically with other proinflam-
matory cytokines such as IL-1 further supports a key role for OSM in RA.
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Background Tumor necrosis factor alpha (TNF-α) is found at high concentra-
tions in the rheumatoid joint and induces upregulation of synovial fibroblast IL-15,
a cytokine known to induce fibroblast proliferation through an autocrine loop. The
mechanism of action of low-dose oral methotrexate (MTX) is not well understood.
By inhibiting AICAR transformylase, MTX has been described to induce the extra-
cellular release of the potent anti-inflammatory autacoid adenosine.
Objective To test the effect of MTX on TNF-α-induced synovial fibroblast IL-15
expression and proliferation.
Methods Synovial fibroblasts (Sfib) isolated from surgical specimens of rheuma-
toid arthritis (RA) patients (n = 10) were cultured in six-well plates. Sfib were
stimulated with 10 ng/ml TNF-α and pretreated for 2 hours with medium or MTX
at varying doses (0, 0.01, 0.1, 1, 10 µM) in the presence or absence of adeno-
sine deaminase, DPCPX (adenosine A1 receptor antagonist) or DMPX (adeno-
sine A2 receptor antagonist). Surface and intracellular IL-15 protein were
determined by immunofluorescence and flow cytometry. IL-15 mRNA was mea-
sured by real-time quantitative RT-PCR in a LightCycler instrument (Roche). Sfib
proliferation was evaluated using the alamar blue bioassay.
Results TNF-α induced an upregulation of intracellular and surface IL-15 protein
expression and of IL-15 mRNA, together with an increased Sfib proliferation rate.
Sfib proliferation was significantly inhibited by a neutralizing anti-IL15 monoclonal
antibody but not by an isotype control antibody. In the presence of MTX, TNF-α-
induced IL-15 upregulation and Sfib proliferation were reduced by 40–65% in a
dose-dependent manner. Adenosine deaminase reversed the effects of MTX as
did addition of DMPX but not DPCPX 1 hour prior to MTX.
Conclusion MTX interferes with TNF-α-induced synovial fibroblast IL-15 upregu-
lation and proliferation. This effect seems to be mediated through adenosine
release and adenosine A2 receptor engagement. This may be a mechanism by
which MTX controls the aggressive behavior of synovial fibroblasts in RA.
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Rheumatoid arthritis (RA), a chronic inflammatory joint disease, develops in
patients expressing particular HLA-DR alleles. RA patients’ sera contain antibod-
ies to a post-translationally modified form of fibrin on which arginyl residues are
transformed in citrullins.
We tested whether HLA-DR alleles influence the production of anti-citrullinated
fibrin antibodies in RA patient sera and whether the replacement of arginyl residues
by citrullyl residues on fibrin peptides could modify their binding to RA-associated
HLA-DR molecules and their recognition by T cells in RA patients and controls.
We found that RA-associated HLA-DR alleles are also associated with presence of
anti-citrullinated fibrin antibodies in RA patient sera. Multiple peptides from the alpha
and beta chain of fibrin are capable to bind many HLA-DR alleles. RA-associated
HLA-DR alleles are good fibrin peptide binders. However, citrullination does not influ-
ence fibrin peptide binding to HLA-DR or fibrin peptide recognition by T cells.
Finally, peripheral blood T cells that recognize native or citrullinated fibrin
peptides are common in RA patients and very uncommon in normal controls.
These results suggest that citrullination of fibrin has nothing to do with peptide/
HLA-DR/T cell interaction and is merely involved in the definition of B-cell epitopes.
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Introduction Recent data indicate that bone marrow plays an important role not
only as a primary lymphoid organ responsible for haemopoiesis, but also as a sec-
ondary lymphoid organ with capability of antigen presentation exceeding that of
lymph nodes. Although in chronic inflammatory/immune disease, like rheumatoid
arthritis (RA), bone marrow participates in the initiation and/or perpetuation of the
disease, there is little information about the real number of lymphocyte subpopu-
lations in the bone marrow of these patients and how they can be modulated by
T-cell growth factors. IL-15 acting through IL-15 receptors (including high-affinity
IL-15R alpha chain) is a key cytokine influencing the development of natural killer
cells in bone marrow, and proliferation and maintenance of the memory CD3+ cell
pool. However, there is no information about the levels of IL-15 in bone marrow.
Objectives To compare the real cell numbers within lymphocyte subsets in bone
marrow isolated from RA and osteoarthritis (OA) patients. To measure the levels
of soluble IL-15 and surface-expressed IL-15R alpha in bone marrow plasma and
cells, respectively. To analyze the presence of memory and actively proliferating
T cells in the bone marrow.
Available online http://arthritis-research.com/supplements/7/S1S26
Methods Bone marrow samples, obtained from RA and OA patients (mean age
53.1 ± 10.6 years and 54.3 ± 13.6 years, respectively) undergoing joint replace-
ment surgery, were diluted four times in heparinized PBS. Bone marrow plasma
samples were obtained by centrifugation and levels of IL-15 were measured
using specific ELISA. The real number of lymphocytes stained for CD3+ and
CD19+ were counted in the presence of TruCount beads using flow cytometry.
Surface-expressed IL-15R was done on cells separated by gradient centrifuga-
tion, acid wash of surface-bound IL-15 and flow cytometric analysis. Surface
expression of CD45RO was evaluated by flow cytometry. Cell proliferation was
measured by intracellular expression of Ki-67.
Results There were twice as many T (CD3+) cells in RA in comparison with OA
bone marrow (6.1 ± 2.8 versus 3.2 ± 1.6 cells × 106/ml bone marrow,
P = 0.008). In contrast, only 42% of B (CD19+) cells present in OA were present
in RA bone marrow (2.0 ± 0.9 versus 0.85 ± 0.3 cells × 106/ml bone marrow,
P = 0.02). Interestingly, both CD3+CD4+ and CD3+CD8+ cells obtained from RA
patients expressed a significantly higher level of CD45RO (P = 0.002 and
P = 0.001, respectively), measured as the mean fluorescence intensity, than in
OA. In addition, there was a tendency (although not statistically significant,
P = 0.08) for a higher percentage of CD3+CD8+CD45RO+ cells in bone marrow
from RA patients in comparison with OA patients (38.7% versus 28.1%). Inter-
estingly, lymphocytes isolated from RA patients expressed a significantly higher
level of surface IL-15R alpha chain (P = 0.01), indicating their activation status.
Cells isolated from RA bone marrow bound significantly more Ki-67 than cells
isolated from OA bone marrow, indicating that RA cells proliferated more vigor-
ously There were elevated levels of IL-15 in bone marrow plasma from RA in com-
parison with OA patients (1304.5 ± 956.3 pg/ml and 760 ± 238.7 pg/ml,
respectively, P = 0.01).
Conclusion Lymphocytes obtained from RA patients expressed higher levels of
IL-15R alpha and proliferated more rapidly than lymphocytes obtained from OA
patients. It is likely that locally overproduced IL-15 is responsible for the elevated
number of T cells in RA bone marrow. Higher density of CD45RO+ memory
marker expressed on T cells from RA patients further supports the role of IL-15 as
a known growth factor for memory T cells. A significantly lower B-cell number in
RA than in OA suggests that these cells actively emigrate from RA bone marrow
to peripheral blood and affected joints. Distinct subpopulations of mature lympho-
cytes present in bone marrow from RA and OA patients indicate that the bone
marrow acts as a secondary lymphoid organ that actively contributes to the
pathogenesis of RA.
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Tumor necrosis factor alpha-related apoptosis inducing ligand (TRAIL) is a pro-
apoptotic factor that can also induce cell proliferation. The role of TRAIL in
rheumatoid arthritis (RA) is still unclear. Previously, we reported that TRAIL
induces RA fibroblast-like synoviocyte (FLS) proliferation. We now investigate the
intracellular mechanisms involved in TRAIL-induced cell proliferation. Therefore,
we tested the effect of TRAIL on signaling pathways including MAP kinases (p38
and ERK1/2) and PI3 kinase/Akt, known to control cell proliferation. For all these
experiments, the concentration of TRAIL used to stimulate cell was 0.5 nM.
TRAIL induced p38 MAP kinase but with a lower intensity in comparison with
tumor necrosis factor alpha (TNF-α) (n = 3). TRAIL also induced ERK1/2 and Akt
phosphorylation in RA FLS in a time-dependent manner, showing maximum acti-
vation between 5 and 10 min by western blot (n = 3). This kinetic and intensity of
ERK and Akt activation were similar to positive control TNF-α (n = 3). The tran-
scription factor NF-κB plays a major role in cell survival and is activated by MAP
kinases and Akt. When NF-κB is activated, it translocates from the cytoplasm to
the nucleus. We examined NF-κB translocation into the nucleus of RA FLS fol-
lowing TRAIL stimulation using immunofluorescence. RA FLS treated with TRAIL
did not induce a nuclear uptake of NF-κB (n = 3). The percentages of RA FLS-
positive NF-κB translocation was increased from 4.3 ± 0.9% to 8.9 ± 2.3% when
stimulated with TRAIL. For the positive control IL-1β, this percentage increased to
97.9 ± 1.1%. This result was confirmed by western blot. To determine the impli-
cation of MAP kinases, and PI3 kinase/Akt in TRAIL-induced proliferation, we
therefore tested different specific signaling inhibitors including PI3 kinase
inhibitor LY294002, ERK1/2 inhibitor PD98059, and p38 inhibitor SB203580.
RA FLS were pretreated with the specific inhibitors at different concentrations or
Me2SO vehicle control for 1 hour and were then stimulated with TRAIL. Prolifera-
tion was assessed according to the level of incorporated tritiated thymidine. ERK
1/2 inhibitor PD98059 and p38 inhibitor SB203580 significantly downregulated
TRAIL-induced proliferation in a dose-dependent manner (n  = 3). PI3 kinase
inhibitor LY294002 almost completely blocked proliferation promoted by TRAIL.
These results highlight the main role of Akt in TRAIL-mediated proliferation.
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Introduction IL-18 is a member of the IL-1 family of proteins that exerts proinflamma-
tory effects and is a pivotal cytokine for the development of T-cell-mediated immune
responses. IL-18 can promote both the Th1 and Th2 pathways. Recent studies indi-
cated IL-18 as an important stimulator of chronic inflammation in human diseases
such as rheumatoid arthritis, Crohn’s disease and several allergic disorders.
Objective To investigate the aggravating effect of local IL-18 overexpression on
both joint inflammation and joint destruction in murine collagen-induced arthritis.
Methods: Collagen-induced arthritis was induced in DBA-1 mice by intradermal
injection of 100 µg bovine type II collagen in FCA. At day 21 the mice were
boosted with 100 µg type II collagen. IL-18 gene transfer was performed on day
22 by intra-articular injection of 1 × 107 pfu AdmIL-18. As control we injected
1×1 0 7 pfu Ad5del70.3 Histopathology was examined at days 5 and 12 after
AdIL-18 injection. Bone destruction was investigated using X-ray analysis. In
addition, both systemic and local cytokine levels were determined in sera and
patellae washouts, using a multiplex bead array (Luminex Technology). Osteopro-
tegerin levels were examined by ELISA.
Results Here we report that overexpression of IL-18 in knee joints of collagen
type II primed DBA-1 mice resulted in aggravation of joint inflammation.
Enhanced influx of proinflammatory cells, predominantly polymorphonuclear cells,
was seen already at day 5 in both synovial tissue and the joint cavity. At day 12
extremely severe joint inflammation was seen in the AdIL-18 injected knee joint,
whereas the Ad5del70.3-injected or saline-injected mice showed modest joint
inflammation. Of high interest, although severe joint inflammation developed after
IL-18 gene transfer, no signs of joint destruction were noted at day 12 after IL-18
overexpression. Histopathological and X-ray analysis revealed that both cartilage
and bone destruction were completely prevented after intra-articular IL-18 expo-
sure during collagen-induced arthritis. In addition, we found that local overexpres-
sion of IL-18 resulted in elevated levels for IL-4 in both serum (29 ± 14 versus
4 ± 3 pg/ml) and in synovial tissue washouts (1240 ± 220 versus 24 ± 7 pg/ml)
when compared with Ad5del70.3. Remarkably high levels of osteoprotegerin
were found in synovial tissue washouts at day 12 after IL-18 gene transfer com-
pared with Ad5del70.3 vector (1570 ± 270 versus 210 ± 20 pg/ml). Moreover,
local IL-10 levels were strongly enhanced whereas IL-1β levels were significantly
reduced after IL-18 gene transfer.
Conclusion The present study clearly demonstrated that local IL-18 overexpres-
sion accelerates joint inflammation, but prevents development of severe cartilage
and bone destruction. High levels of both IL-4 and osteoprotegerin indicate
establishment of a non-destructive type 2 inflammation. These data suggest that
IL-18 may have a dual role in chronic destructive arthritis and that therapies
based on local IL-18 blockade might be inadequate in rheumatoid arthritis.
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Objective The molecular pathogenesis of rheumatoid arthritis (RA) is still poorly
understood. Given the heterogeneity in gene expression patterns and cellular dis-
tribution between RA synovial tissue, we determined whether this variability is
also reflected at the level of fibroblast-like synoviocytes (FLS) cultured from those
synovial tissues.
Methods Gene expression profiles in FLS from 19 RA synovial tissues were ana-
lyzed using cDNA microarrays and hierarchical cluster analysis. To validate the
subclassification, we performed prediction analysis and principal component
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analysis. Genes that differed significantly in expression between FLS cultures
were selected using statistical analysis of microarrays. Real-time PCR was per-
formed to validate microarray data. Immunostaining was applied to study the
expression of the genes of interest in FLS and synovial tissues.
Results Hierarchical clustering identified two main groups of FLS characterized
by distinctive gene expression profiles. FLS from high inflammatory synovial
tissues revealed increased expression of a transforming growth factor beta/
Activin A inducible gene program that is characteristic of myofibroblasts, a cell
type that is considered to be involved in wound healing, whereas increased
growth factor (IGF2/IGFBP5) production appears to constitute a characteristic
feature of FLS derived of low inflammatory synovial tissues. The molecular feature
that defines the myofibroblast-like phenotype is reflected as an
increased proportion of myofibroblast-like cells in the heterogeneous FLS popula-
tion. Myofibroblast-like cells are also found upon immunohistochemical analysis of
synovial tissue.
Conclusion  The data support the notion that heterogeneity between synovial
tissues is reflected in FLS as a stable trait, and provide evidence for a possible
link between FLS behavior and the inflammatory status of RA synovium.
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Backround Both gene and protein expression of IL-1 are highly upregulated in
skin and synovium of patients with psoriatic arthritis (PsA) and psoriasis. IL-1 is
known to play a key role in keratinocyte activation, matrix metalloproteinase
upregulation, differentiation of osteoblast precursors into mature osteoblasts,
angiogenesis and the development of erosive disease. Thus, the purpose of the
study is to assess the effects of IL-1 inhibition on the clinical features of psoriasis
and PsA disease activity, on synovial and cutaneous immunohistology and on
magnetic resonance imaging (MRI) features of an affected knee joint.
Methods To date, eight PsA patients (six male and two female, average age
41 years [22–61 years]) with active skin and joint disease have been enrolled for
treatment over 12 weeks with 100 mg anakinra daily by subcutaneous injection.
Physical examination, patient and physician global assessment of disease activity
(on a scale of 0–3), tender and swollen joint scores, erythrocyte sedimentation
rate, C-reactive protein and PASI scores were performed at all visits. Plain X-rays
of hands, wrists, knees and feet were performed at baseline. A biopsy of a psori-
atic plaque, multiple arthroscopic synovial biopsies and a MRI scan of an inflamed
knee joint were performed at baseline and week 12. HAQ scores, patient assess-
ment of disease activity and pain using visual analogue scales were obtained at
weeks 0 and 12. PsA-QoL were calculated at weeks 0 and 12. The primary end-
point was the proportion of patients who met the Psoriatic Arthritis Response Cri-
teria (PsARC) at 12 weeks.
Results Seven patients completed the study. One male patient was non-compli-
ant with the study protocol and susbsequently withdrew before completion of the
study. Baseline physical examination revealed psoriasis and active synovitis in all
patients. Three of the seven patients (43%) met the PsARC at week 12. Mean
HAQ scores improved from 1.23 (0.75–1.9) to 0.96 (0.25–1.6), while mean PsA-
QoL scores changed from 22/46 (9–41) to 20/46 (5–40). Other relevant data
are presented in Table 1.
Conclusion This ongoing study has shown anakinra to be of modest benefit in
patients with PsA. Further patient recruitment, MRI assessment and immunohisto-
chemical analysis of tissue samples is ongoing.
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To provide insight into the mechanisms whereby sustained tumour necrosis
factor (TNF) stimulation promotes chronic inflammatory responses, we have
examined TNF-R signalling pathways in murine T-cell hybridomas. Prolonged TNF
signalling attenuates p55 TNF-R (TNF-RI)-induced JNK activation through mecha-
nisms that are NF-κB dependent and that target receptor proximal pathways,
since arsenite-induced JNK activation is preserved. In contrast, phosphorylation
and degradation of IkB alpha, combined with nuclear translocation and gel shift
assays, demonstrate that prolonged TNF stimulation promotes chronic NF-κB
activation. However, acute and chronic TNF signals are qualitatively distinct. In
chronic TNF-treated T cells degradation of IkB alpha and nuclear translocation of
RelA (p65) are not as pronounced as that in cells following acute stimulation,
while translocation of NF-κB1 (p50) is enhanced. Gel shift assays demonstrate
consistent differences in the binding of Rel family proteins to DNA, since acute
TNF stimulation induces formation of a dominant DNA binding complex compris-
ing p65:p50 heterodimers (complex I), while the binding capacity of a second
complex (complex II), which may include p50:p50 homodimers, is increased in
nuclear extracts of chronic TNF-stimulated cells. Preliminary data indicate that
chronic but not acute TNF stimulation also induces RelB nuclear translocation
and DNA binding. A direct comparison of gene expression profiles in control,
acute and chronic TNF-stimulated T cells suggests that differences in TNF-R sig-
nalling translate to distinct gene fingerprints. By interrogation of extended frag-
ments of genomic sequence from 66 TNF-induced genes, we have mapped the
DNA binding consensus sequence sites for different transcription factors. For the
classical NF-κB DNA binding motif GGGRNNYYCC our analysis revealed multi-
ple kB ‘hits’ in 55/66 TNF-induced genes. Variation in kB motifs was observed
across gene clusters. Our results have uncovered differences between acute and
chronic TNF signals that may arise through variation in signal input, specific
requirements for Rel family dimers, divergence in kB consensus sequences and
differences in affinities of protein-DNA binding.
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Background Rheumatoid arthritis (RA) is a chronic autoimmune disease that is
characterized by inflammation of the synovial joints, which leads to joint destruc-
tion. Dendritic cells (DC) are specialized antigen presenting cells, which are acti-
vated by ‘pathogen associated molecular patterns’ via toll-like receptors (TLRs).
TLR3 and TLR7 are important in the recognition of viral RNA, whereas TLR2 and
TLR4 are involved in the recognition of bacterial components and host-derived
molecules, including heat shock proteins, fibronectin, hyaluronic acid. TLR and
DC are critical in the regulation of immune responses.
Aim To determine the expression of TLR2, TLR3, TLR4 and TLR7 in synovial biop-
sies and to evaluate the potential differences in DC maturation and cytokine produc-
tion upon TLR-mediated triggering of cells from RA patients and healthy controls.
Available online http://arthritis-research.com/supplements/7/S1
Table 1 (abstract P68)
Patient Physician  Patient 
assessment assessment  Tender  Swollen  assessment  Patient 
of disease  of disease  joint  joint  of disease  assessment  Erythrocyte 
activity activity score  score activity of  pain  PASI  sedimentation  C-reactive 
(0–3) (0–3) (0–78) (0–76) on VAS on VAS score rate protein
Baseline 2.14 (1–3) 2.28 (1–3) 24 (11–38) 20 (7–29) 61 (27–85) 61 (21–90) 5.21% (1–11) 27 (3–78) 33 (4–70)
Week 12 1.7 (1–3) 1.7 (1–3) 16 (12–21) 11 (5–25) 43 (12–70) 46 (20–71) 4.5% (0–8) 18 (2–46) 13 (4–29)S28
Methods The presence of TLR2, TLR3, TLR4 and TLR7 in synovial tissue, from
RA patients, osteoarthritis patients and healthy controls was studied with
immunohistochemistry techniques. Furthermore, monocyte-derived dendritic cells
from RA patients and healthy controls were cultured for 6 days and subsequently
stimulated via specific TLR pathways; TLR2 (pam3cys), TLR3 (poly(IC)), TLR4
(LPS) and TLR7 (R848). We determined the expression of cell surface markers
(CD14, CD80, CD83, CD86, MHCI and MHCII) by flow cytometry and tumour
necrosis factor alpha, IL-6, IL-10 and IL-12 production was measured by multiplex
cytokine bead arrays.
Results TLR2, TLR3, TLR4 and TLR7 expression was markedly increased in syn-
ovial tissue from RA patients, compared with synovial tissue from osteoarthritis
patients and healthy controls. After stimulation via specific TLR pathways, flow
cytometry showed a clear DC maturation upon stimulation via all TLR pathways
without any difference between RA cells and cells from healthy controls.
However, cytokine production by DC from RA and controls was clearly different.
RA DC produced increased levels of the proinflammatory cytokines tumour
necrosis factor alpha and IL-6 upon stimulation of TLR2 or TLR4. In contrast,
such differences were not noted after TLR3 and TLR7 stimulation. Triggering of
TLR3 and TLR7 pathways resulted in increased production of IL-12, which was
equal between RA and control DC. Intriguingly, simultaneous stimulation of
TLR3/4, TLR3/7 and TLR4/7 pathways resulted in a marked synergy with respect
to the production of proinflammatory mediators.
Conclusion These results point out that despite a comparable DC phenotype,
RA cells produce higher cytokine levels upon stimulation of TLR2 and TLR4 com-
pared with healthy controls. The combination of specific TLR stimulations
resulted in a distinguished synergy in cytokine production. Here, we postulate the
hypothesis that the persistence of viral material in synovial tissue triggers the
TLR3 and TLR7 pathways, which subsequently results in inflammation and
release of endogenous ligands, resulting in TLR4 stimulation that leads to a
vicious circle of synovial inflammation.
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Background Monocytes and macrophages are abundant in rheumatoid synovial
tissue and play a major role in the pathogenesis of rheumatoid arthritis (RA) by
secreting proinflammatory cytokines such as tumour necrosis factor alpha (TNF-α).
An innovative approach is based on the regulation of mRNA stability and degrada-
tion, which constitute a critical step in the control of gene expression rather than
neutralization of the downstream protein. Stability and degradation of TNF-α mRNA
are regulated by cis-acting sequences as AU-rich elements (AREs). Tristetraprolin
(TTP), a class of Cys-Cys-Cys-His (CCCH) zinc finger proteins, was identified as
the critical TNF-α ARE-binding protein. Importantly, TTP knockout mice develop
inflammatory arthritis, dermatitis and myeloid hyperplasia, prevented by anti-TNF-α
antibodies. A recent study suggested that a low TTP/TNF-α RNA expression ratio
could indicate failure of RA patients to produce adequate amounts of TTP in
response to increased TNF-α production. Our aim is to investigate the therapeutic
potential of gene expression of ARE-binding elements for anti-TNF-α therapies.
Methods We used the THP1 human monocyte cell line known for a high
lipopolysaccharide (LPS)-induced TNF-α secretion. An expression vector con-
taining TTP gene driven by the CMV promoter was constructed. TTP expression
was evaluated by western blot following transfection by electroporation
(320 mV). The secretion of TNF-α by THP1 was assessed by ELISA before and
after TTP transfection (1 µg/106 cells), following LPS stimulation (50 ng/ml).
Results A significant decrease in TNF-α expression was observed in the TTP-
transfected THP1 cells, compared with a GFP mock control. This suppression
increased over time and last at least 48 hours after LPS stimulation (23% at
3 hours and 37% at 24 hours).
Conclusion These preliminary results support an important role of TTP in regulat-
ing TNF-α in monocytes and might be the new target for gene delivery in an anti-
TNF-α strategy in RA. In vivo evaluation of this strategy in experimental models of
RA will be tested.
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Background Patients with recurring or persisting inflammatory arthritis of the knee
despite anti-rheumatic therapies are frequently treated with intra-articular steroid
injections. Lavage of a rheumatic joint may also be benificial by removing synovial
debris and proinflammatory substances from the joint. Only uncontrolled studies
have been performed so far and none of these has studied local synovial features.
Objectives To compare the therapeutic effect of three local interventions:
arthroscopic lavage with steroid application (AL + st), arthroscopic lavage with
placebo (AL + pl) and needle biopsie with steroids (NB + st, as a representative
of joint injection). To study synovial tissue biopsies for predictive factors for the
response to local therapy.
MethodsArthroscopic lavage with 1 l saline was performed under local anaesthe-
sia using 2 trocharts. At the end of the procedure 80 mg methylprednisolone or
placebo was instilled. Needle biopsy was performed under local anaesthesia with
1 trochart and instillation of 80 mg methylprednisolone. In all patients synovial
tissue specimens were obtained and histologically analyzed. Kaplan–Meier
curves were constructed depicting the time until recurrence of arthritis. Cumula-
tive incidences of recurrence were used to calculate relative risks (RRs) between
treatment groups.
Results Seventy-eight patients were equally randomized over the three interven-
tions. AL + st was the best therapy with a median time untill recurrence of 0.58
years, followed by NB + st (0.23 years) and AL + pl (0.08 years) (Fig. 1) The RR
for recurrence compared with AL + st was 2.0 for NB + st (P = 0.03) and 4.7 for
AL + pl (P < 0.001). Synovial tissue analysis showed a relation between infiltrating
lymphocytes and outcome of AL + st; RR = 2.7 (P = 0.01) in patients with less
infiltrating lymphocytes. The opposite was found for fibrosis; RR = 2.9 (P = 0.03)
in patients with more fibrosis.
Conclusion Joint lavage preceding steroid injection had a marked effect on time
until recurrence when compared with joint lavage or steroid injection alone. The
clinical effect was correlated with the presence of a lymphocytic infiltrate and the
absence of fibrosis.
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Objective Mesenchymal stem cells (MSC) are progenitor cells of mesodermal lin-
eages that are present in different tissues such as the fat pads and the bone
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Figure 1
Kaplan–Meier curves for the time until recurrence of arthritis.S29
marrow (BM) but also in the cartilage and the synovial membrane (SM). The aim
of this study was to better characterize BM-derived and SM-derived MSC and
discriminate between the two tissue sources.
Methods BM-MSC and SM-MSC were compared for the expression of cell surface
markers and induction of MHC class I and class II molecules by interferon (IFN)-α2,
IFN-β and IFN-γ. Functional characterization was assessed through their differentia-
tion potential towards chondrocytes and osteoblasts using quantitative RT-PCR, and
their immunosuppressive properties by mixed lymphocyte reaction and indoleamine
2,3-dioxygenase activity. Using macroarray technology, the expression of 268 genes
was monitored in four samples from BM-derived and SM-derived MSC.
Results BM-derived and SM-derived MSC were shown to express CD44, CD73,
CD90 and CD105 in the same range and to respond to IFN stimulation. We
showed that IFN-β, IFN-α2 and IFN-γ are able to stimulate the expression of MHC
class I and class II molecules on the MSC surface from both origins. Using quan-
titative analysis, we demonstrated similar differentiation capacities (osteogenesis
and chondrogenesis induction) for BM-derived or SM-derived MSC. Moreover,
our data are the first to show the same immunosuppressive features in mixed lym-
phocyte reaction (>90% of T-cell proliferation inhibition) and similar expression of
indoleamine 2,3-dioxygenase in BM-derived and SM-derived MSC. Nevertheless,
the macroarray analysis shows a statistically significant discrimination between
SM-derived and BM-derived MSC, in particular inflammatory cytokine as IL6 and
IL8 were upregulated in synoviocytes compared with BM-MSC. Validation in
terms of expression of specific proteins is being undertaken.
Conclusion Altogether, the data indicate that BM-MSC and SM-MSC shared
multiple phenotypic and functional properties. However, the genomic signature
permits one to discriminate the MSC originating from the two different tissues.
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The increasing recognition that angiotensin II (Ang II) has proinflammatory roles
suggests it may therefore contribute to chronic inflammatory conditions such as
rheumatoid arthritis (RA), but this requires investigation. Walsh and colleagues
demonstrated the presence and upregulation of AT1 receptors [1] and
angiotensin-converting enzyme [2] in the synovium of RA patients. The aim of this
study was to elucidate the role of Ang II in rat knee joint pathophysiology and to
investigate the anti-inflammatory potential of AT1 receptor antagonist losartan in
models of arthritis. The second phase of this study was to determine the mecha-
nism of any anti-inflammatory action of losartan. In vivo losartan has been reported
to undergo hepatic first-pass metabolism [3], yielding two metabolites, EXP-3174
(the active metabolite) and EXP-3179. The latter is structurally similar to the non-
selective cyclooxygenase inhibitor indomethacin. Since the anti-inflammatory
benefit of cyclooxygenase inhibitors is well documented, we aimed to determine
whether any anti-inflammatory benefit associated with losartan was attributable to
AT1 receptor antagonism or inhibitory action on the prostanoid system.
In vivo experiments  Experimental arthritis was induced under anaesthesia
(halothane/O2/N2O) by intra-articular and peri-articular injection of Freund’s com-
plete adjuvant in adult male Wistar rats (350 ± 20 g body weight, mean ± SEM,
n = 6). Knee joint swelling was measured using callipers and expressed as the
percentage change from pre-induction values. The anti-inflammatory potential of
losartan (Merck & Co., USA) was tested both prophylactically and therapeutically.
Prophylactically, losartan (15 mg/kg; subcutaneous) was given 1 hour prior to
induction of inflammation and every 48 hours thereafter. Therapeutically, 12 days
after the induction of inflammation, losartan (15 mg/kg; subcutaneous) treatment
was started and dosing continued every 48 hours. The mechanism of action of
losartan was investigated using EXP 3174 (Merck & Co.), given prophylactically
(15 mg/kg; subcutaneous, maintenance every 48 hours) 1 hour prior to induction
of inflammation (Freund’s complete adjuvant).
In vitro experiments U937 human monocytes at a logarithmic phase of growth
were harvested and adjusted to 106 cells/ml in the presence of 10 nM phorbol 12-
myristate 13-acetate for 3 days to differentiate into adherent macrophages. Cells
were then quiesced for 24 hours before experiments commenced. Cells were then
stimulated with lipopolysaccharide (50 ng/ml) incubated in the presence of medium
(control), Ang II (10–9 mol) or losartan (10–9 mol to 10–6 mol). Supernatants were
collected and tumour necrosis factor alpha (TNF-α) levels measured by ELISA.
Prophylactic administration of losartan resulted in a significant reduction in knee
joint swelling over 14 days (two-way analysis of variance [ANOVA], P < 0.00001;
n = 6). Therapeutic losartan treatment reduced established knee joint swelling
compared with vehicle control (two-way ANOVA, P < 0.00001; n = 7). Prophy-
lactic administration of EXP-3174 also resulted in a reduced percentage increase
in knee joint diameter, again found to be significant (two-way ANOVA,
P < 0.00001; n = 6–8). Losartan inhibited TNF-α production from U937 cells in
a dose-dependent manner (cf. LPS-treated cells; n = 3).
The anti-inflammatory benefit of both prophylactic and therapeutic losartan treat-
ment suggests both an important role for Ang II in arthritis, and a novel therapeu-
tic application for AT1 receptor antagonists. This anti-inflammatory action may be
due to inhibition of TNF-α release from macrophages.
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The generation of tumour necrosis factor alpha (TNF-α) in the rheumatoid syn-
ovium is widely perceived as pivotal to disease pathogenesis in rheumatoid arthri-
tis (RA). While TNF-α production in dispersed synovial cell cultures is
T-cell-dependent [1] there is little evidence of antigen-dependent T-cell activa-
tion. One explanation for this apparent paradox is the well-documented ability of
appropriately activated T cells to drive production of TNF-α from macrophages
through a cell contact-dependent, antigen-independent mechanism [2]. Despite
some promising leads (e.g. CD69 [3]), the identities of the relevant stimulating T-
cell surface ligands, and the macrophage signalling pathways engaged following
cell contact remain obscure. Our approach has been to develop new proteomic
techniques to address these issues in a systematic and unbiased fashion.
We used cell surface biotinylation and solution-phase isoelectric focusing to
extract and resolve plasma membrane proteins from murine T-cell hybridomas
and primary splenocytes prior to identification using liquid chromatography
tandem mass spectrometry (LC MS/MS). Using this method we identified 75
plasma membrane proteins, 13 of which appeared to be regulated following stim-
ulation with phorbol 12-myristate 13-acetate and ionomycin. Six of these putative
changes were verified independently by western blotting or by flow cytometry [4].
To develop protocols to examine macrophage signalling pathways we utilised anti-
phosphotyrosine antibodies to recover tyrosine phosphoproteins from RAW 264.7
cells activated with the tyrosine phosphatase inhibitor, pervanadate. Recovered pro-
teins were eluted using phenyl phosphate, then resolved and identified by solution-
phase isoelectric focusing and LC MS/MS. We identified 113 proteins inducibly
associated with anti-phosphotyrosine immunoprecipitates from distinct subcellular
compartments (cytosol, nucleus and plasma membrane), many of which were
known tyrosine phosphoproteins (e.g. Fyn, Syk, SHIP, SLP76) but also included
several hypothetical proteins, hitherto not documented at the protein level.
We then used this methodology to identify macrophage signalling proteins phos-
phorylated following cell contact with T-cell receptor transgenic splenocytes stim-
ulated for 48 hours with specific (influenza virus hemaglutinin), or non-specific
(ovalbumin), peptide. Proteins recovered in RAW cell phosphotyrosine immuno-
precipitates were analysed by western blotting using antibodies to phosphotyro-
sine or the signalling molecules phospholipase C gamma, Hck, p38 and ERK.
Cell contact with either resting or activated splenocytes induced acute and tran-
sient tyrosine phosphorylation of the src kinase Hck and phospholipase C
gamma. In contrast, sustained activation of the MAP kinases p38 and ERK was
observed only after contact with activated splenocytes.
Application of these methods should shed new light on the molecular bases of
the contact-dependent activation of macrophages by activated T cells and,
thereby, suggest novel targets for therapeutic intervention in RA.
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The molecular events that define early phases of activation and differentiation of
effector T cells have been well characterised. Those events regulating terminal
differentiation and effector function of chronically activated T cells at sites of
inflammation, on the other hand, are less well understood. Using in vitro and in
vivo models, we have explored the effects of the chronic inflammatory process on
T-cell differentiation by investigating how tumour necrosis factor (TNF) regulates
T-cell activation and effector responses. These studies have revealed that TNF-
stimulated T cells resemble those derived from inflamed synovial joints since they
express cell surface activation antigens, but are profoundly hyporesponsive to
TCR engagement. Studies with mouse T cells suggest that this may be explained,
at least in part, by the fact that TNF selectively targets the expression of the TCRζ
chain. Loss of TCRζ expression perturbs the assembly, expression and stability of
the TCR/CD3 complex leading to attenuation of membrane proximal tyrosine
phosphorylation, intracellular calcium mobilisation and the transcription of
cytokine genes upon TCR engagement, when compared with untreated T cells.
We have begun to investigate whether TCRζ expression could be used as a ‘bio-
marker’ for chronically activated, hyporesponsive T cells in human peripheral
blood. Using a FACS-based assay, we have identified subsets of CD3+ T cells
expressing low levels of TCRζ (hereafter termed TCRζdim cells) in the peripheral
blood of healthy donors, as well as patients with inflammatory arthritis. In vitro
studies of peripheral blood lymphocytes from healthy donors define not only
antigen-dependent downmodulation of TCRζ expression, which is transient, but
also more sustained downregulation, which may arise through antigen-indepen-
dent mechanisms. Experiments reveal that, when compared with TCRζbright cells,
the TCRζdim population is enriched for cells expressing effector memory cell
surface markers. While TCRζdim cells are hyporesponsive to TCR engagement,
they retain effector potential, since a significant proportion are capable of produc-
ing TNF-α and interferon gamma upon stimulation with phorbol ester and calcium
ionophore. In contrast, the TCRζbright subset is enriched for IL-10 producers. Fur-
thermore, TCRζdim T cells are capable of activating monocytes through cell
contact-dependent mechanisms. Together these data suggested that TCRζdim
T cells may represent a subset of circulating effector memory cells in vivo.
Finally, we observed that TCRζdim T cells are enriched in inflamed joints of
patients with inflammatory synovitis. Treatment of rheumatoid arthritis patients
with anti-TNF (infliximab, 3 mg/kg) leads to significant accumulation of TCRζdim
T cells in peripheral blood of a subset of patients. Indeed, the extent of accumula-
tion at 14 weeks after starting treatment predicts the DAS28 clinical response at
30 weeks. We propose that sustained downregulation of the TCRζ chain defines
a checkpoint where intracellular signals driving T-cell differentiation and effector
responses switch from antigen mode to inflammation mode, where effector func-
tion may be largely antigen independent. As such this cell subset may represent a
valid therapeutic cellular target.
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In rheumatoid arthritis, leukocytes are recruited from the blood by vascular
endothelial cells (EC) and accumulate in stromal tissue forming ectopic leukocyte
aggregates that contribute to soft tissue remodelling and bone destruction. The
signals that regulate the process of chronic leukocyte recruitment into the dis-
eased joint are poorly defined; however, it is probable that cells of the tissue
stroma that have undergone a disease-specific transition in phenotype contribute
to inflammation by the inappropriate production of proinflammatory cytokines and
chemokines [1,2]. Here we have used a novel co-culture model [3] to monitor the
role of stromal cells in regulating the quality and quantity of leucocytes that enter
the synovium. We tested the hypothesis that fibroblasts from the rheumatoid joint,
but not fibroblasts from normal tissue (skin), have the ability to drive inflammation
by activating EC and promoting the recruitment of neutrophils.
EC were established in co-cultured with fibroblasts from the synovium (SF) or
skin (DF) of RA patients on the opposite sides of porous transwell membranes.
After 24 hours of EC conditioning, co-cultures were incorporated into a parallel
plate leukocyte adhesion assay and the ability of EC to recruit flowing neutrophils
determined. Neutrophils adhered efficiently to EC co-cultured with 5 × 105 SF
(88 ± 12/mm2/106 cells perfused) but not to EC cocultured with DF
(12 ± 9/mm2/106 cells perfused). Anti-P-selectin and anti-E-selectin antibodies
markedly decreased neutrophil adhesion, and an anti-CD18 antibody (the β2 inte-
grin) abolished neutrophil recruitment. The antibody blockade of the neutrophil
chemokine receptor CXCR2 but not CXCR1 also abolished neutrophil recruit-
ment. Supernatants collected from cocultures of EC/SF, but not from SF cultured
alone, activated EC to support neutrophil adhesion, indicating the presence of a
soluble activating factor(s) generated exclusively in co-culture. EC/SF co-culture
supernatants also contained a high concentration of IL-6 (2925.2 ± 521.2 pg/ml),
and both IL-6 levels and neutrophil adhesion were reduced in a dose-dependent
manner by the inclusion of hydrocortisone in the co-culture medium. An anti-IL-6
antibody also abolished neutrophil adhesion.
We propose that in the rheumatoid synovium, a previously unsuspected process
of cross-talk involving IL-6 signalling occurs between synovial fibroblasts and vas-
cular EC resulting in the upregulation of adhesion molecules and chemokines that
support neutrophil recruitment. The observation that neutrophil adhesion in this
coculture system can be inhibited by anti-IL-6 neutralising antibodies or hydrocor-
tisone suggests that this novel in vitro model of the synovium faithfully mimics
important in vivo processes involved in leukocyte accumulation within the syn-
ovium. It also suggests that this new model can act as a useful screen for new
anti-inflammatory therapies in rheumatoid arthritis.
References
1. Buckley CD, Filer A, Haworth O, Parsonage G, Salmon M: Defining a role
for fibroblasts in the persistence of chronic inflammatory joint disease.
Ann Rheum Dis 2004, 63(Suppl 2):ii92-ii95.
2. Parsonage G, Falciani F, Burman A, Filer A, Ross E, Bofill M, Martin S,
Salmon M, Buckley CD: Global gene expression profiles in fibroblasts
from synovial, skin and lymphoid tissue reveals distinct cytokine and
chemokine expression patterns. Thromb Haemost 2003,90:688-697.
3. Rainger GE, Stone P, Morland CM, Nash GB: A novel system for investi-
gating the ability of smooth muscle cells and fibroblasts to regulate
adhesion of flowing leukocytes to endothelial cells. J Immunol Methods
2001, 255:73-82.
P78
Impaired early B-cell tolerance in patients with rheumatoid
arthritis
J Samuels1, Y-S Ng1, D Paget1, E Meffre1,2
1Laboratory of Biochemistry and Molecular Immunology, Hospital for Special Surgery,
New York, USA; 2Weill Medical College of Cornell University, New York, USA
Arthritis Res Ther 2005, 7(Suppl 1):P78 (DOI 10.1186/ar1599)
Purpose Autoantibody production is a characteristic of most autoimmune dis-
eases including rheumatoid arthritis (RA), but the stage of B-cell development at
which B-cell tolerance is broken remains unknown. We previously established in
healthy donors that most autoreactive developing B cells were removed either in
the bone marrow or in the periphery, revealing two B-cell tolerance checkpoints.
We aimed to determine whether the autoreactive B cells in RA evade one or both
of these checkpoints. In addition, analysis of the antibody repertoires in RA might
lead to potential insights about the mechanisms that may explain loss of B-cell
tolerance.
Methods We obtained peripheral blood from four patients with clinically and sero-
logically documented active RA, who had not yet received steroids, disease-modify-
ing anti-rheumatic drugs or biologic therapy, or who had been off such regimens for
at least 4 months. After isolating their peripheral B cells, we sorted, cloned and
expressed in vitro antibodies from single new emigrant (CD19+CD10+IgM+CD27–)
and mature naive (CD19+CD10–IgM+CD27–) B cells. In total, we examined by
ELISA the specificity of 232 recombinant antibodies.
Results The antibody sequences in two of the patients showed a significant
increase in the proportion of 11 amino-acid long CDR3s in IgK chains (previously
described in RA synovium and blood), while the other two patients demonstrated
an increase in Jκ1 usage along with a shift towards more downstream Vκ seg-
ments. This skewed IgK repertoire suggests that receptor editing, one of the
mechanisms that ensures B-cell tolerance, is defective in those two patients.
Despite the different antibody sequence patterns of our RA patients, all four
patients showed significantly increased proportions of polyreactive antibodies in
the new emigrant compartment (23.1% versus 8.2% in controls, P = 0.0094),
autoreactive antibodies in the mature naïve compartment (45.3% versus 20.4%
in controls, P = 0.0001), and anti-CCP antibodies in both compartments (13.8%
versus 0% in controls, P = 0.019). This demonstrates that autoreactive B cells in
RA patients fail to be removed at both checkpoints of early B-cell tolerance.
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Conclusions RA patients exhibit defective central and peripheral B-cell tolerance,
which may favor the development of autoimmunity. We have also identified two dis-
tinct groups of RA patients based on their antibody sequences that suggest diver-
gent mechanisms within the RA population — yet lead to a common phenotype.
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Introduction Chlamydia trachomatis (CT) is a clinically important pathogen. In
2–5% of cases, infection results in the development of reactive arthritis. We have
previously shown that human dendritic cells (DC) can be readily infected with live
CT following in vitro exposure [1]. Infected DC efficiently process chlamydia and
present chlamydial antigens to both CD4+ [1] and CD8+ T cells [1,2]. Infected
DC also produce a number of cytokines including IL-12 and tumour necrosis
factor alpha but not IL-10 [1]. The production of IL-12 following infection gives
DC the ability to stimulate Th1 responses to chlamydia. Here we have investi-
gated production of another two cytokines from the IL-12 family — IL-23 and IL-27 —
by DC infected with live CT. The results were compared with those obtained fol-
lowing DC activation with other inflammatory stimuli.
IL-23 is a heterodimer composed of p19 and p40 subunits, where the p40
subunit is shared between IL-23 and IL-12. IL-27 is a heterodimer composed of
p28 and Epstein–Barr virus-induced protein 3 (EBI3) subunits. The main function
of both of these cytokines is to stimulate interferon gamma (IFN-γ) production in
T cells. However, whereas IL-27 activity primarily affects naïve T cells, IL-23 stim-
ulates both primed and memory cells.
Methods  DC were generated in vitro from CD14+ monocytes purified from
peripheral blood mononuclear cells. After 7 days of culture in the presence of
GM-CSF and IL-4, DC were fully differentiated. Immature DC, DC activated with
lipopolysaccharide (LPS), IFN-γ, heat-killed CT and infected with live CT were
used for these experiments. Total RNA was purified using the High Pure RNA iso-
lation kit (Roche). IL-23 oligos used were: p19 forward, 5′-tcg-gca-cga-gaa-caa-
ctg-ag-3′; p19 reverse, 5′-tgg-gga-aca-tca-ttt-gta-gtc-t-3′; p40 forward,
5′-att-gag-gtc-atg-gtg-gat-gc-3′; p40 reverse, 5′-att-gct-ggc-att-ttt-gcg-gc-3′. IL-
27 oligos used were: p28 forward, 5′-gcg-gaa-tct-cac-ctg-cca-g-3′; p28 reverse,
5′-cgg-gag-gtt-gaa-tcc-tgc-a-3′; EBI3 forward, 5′-cgt-gcc-ttt-cat-aac-aga-gca-3′;
EBI3 reverse, 5′-gac-gta-gta-cct-ggc-tcg-g-3′. GAPDH was used as control.
PCR settings: 95°C for 3 min followed by 29 cycles of 95°C for 30 sec, 60°C for
30 sec, 72°C for 90 sec. PCR products were resolved on 1.5% agarose gel.
Results We showed that infection of DC with live CT resulted in the upregulation
of message for all four subunits studied (p19, p40, p28, EBI3). The message was
detected at 18 and 24 hours post infection. LPS-activated DC upregulated p28,
p40 and EBI3 but not p19. There was no p19 message at either 18 or 24 hours
post stimulation. The main subunit upregulated following IFN-γ activation was p28
and there was no detectable p19 mRNA at any of the times studied. Interestingly,
there was also no expression of p19 when immature DC were exposed to heat-
killed CT. Exposure of DC to heat-killed CT did, however, upregulate p28, p40
and EBI3. A small amount of EBI3 message was detected in immature DC, but
on none of the other subunits studied.
Conclusion Whereas activation of DC with LPS, IFN-γ and heat-killed CT stimulates
production of IL-27, these stimuli are insufficient to induce p19 upregulation, and in
consequence IL-23 production. However, infection of DC with live CT resulted in the
production of mRNA for both IL-23 and IL-27. This study highlights important differ-
ences in immune responses following exposure to live and heat-killed CT.
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Background and objectives Defective NKT cell function has been linked with
autoimmunity. Both the number of NKT cells and their functional capacity of
releasing interferon gamma (IFN-γ) and IL-4 after TCR ligation are for instance
impaired in NOD mice developing diabetes, in mice developing a model of multi-
ple sclerosis and also in humans with autoimmune diseases. To investigate the
NKT cell role in rheumatoid arthritis, we studied their quantitative and qualitative
profile in collagen-induced arthritis (CIA) DBA/1 susceptible mice, and we tested
whether NKT stimulation with their synthetic ligand alpha-galactosylceramide (α-
GalCer) was therapeutic in CIA.
Methods The number of NKT cells in the liver was determined by flow cytometry
with an anti-TCRαβ or empty or α-GalCer-loaded CD1 tetramer. CIA was
induced by immunization of DBA/1 mice with collagen II (CII) in adjuvant, and
with a boost 21 days later. α-GalCer (4 µg) was administered at the same time of
the first immunization. In one experiment, one group of mice was also treated with
an anti-IL-10 receptor antibody. CII-specific CD4+ cells from lymph node (LN)
response was monitored by immunizing mice with 75 µg CII in adjuvant in hind
paws. Some mice were administered 4 µg α-GalCer in the CII/adjuvant mixture at
the same time. Nine days after immunization, CD4+ cells were purified from LN
and cultured with CII and antigen-presenting cells. Proliferation was measured
after 3 days by measuring BrdU incorporation, and IL-4, IL-10 and IFN-γ levels
were assessed by ELISA in the supernatants.
Results The number of NKT cells among leucocytes in the liver of DBA/1 mice was
comparable to what is generally observed in C57Bl/6 and suggest a normal quanti-
tative profile of NKT cells in DBA/1 mice. In contrast, in vivo NKT cell function was
altered in DBA/1 mice since stimulation with α-GalCer (4 µg intraperitoneally) led
to decreased IL-4 and IFN-γ levels in the serum 2 hours after the injection, as com-
pared with C57Bl/6 mice (693 ± 154 pg/ml versus 1557 ± 137 g/ml IL-4
[P < 0.01] and 2077 ± 378 versus 4005 ± 581 IFN-γ [P < 0.02]). Treatment of
CIA with α-GalCer at day 0 induced a clear-cut diminution of clinical (ANOVA test,
P = 0.0001) and histological scores (1.19 ± 0.14 versus 1.85 ± 0.24, P < 0.05) of
arthritis, as compared with the control group. Importantly, treatment of mice with an
anti-IL-10 receptor abrogated the protective effect of α-GalCer. The α-GalCer-
induced protection was associated with the ability of LN CD4+ cells from CII-immu-
nized and α-GalCer-treated DBA/1 mice to secrete larger amounts of IL-10 upon in
vitro  restimulation with CII, while IL-4 and IFN-γ levels were not affected. CII-
induced proliferation was slightly reduced in LN CD4 cells from CII-immunized and
α-GalCer-treated DBA/1 mice as compared with controls.
Conclusion These findings raise the possibility that NKT stimulation might induce
a shift toward an anti-inflammatory Th2 status and could be used therapeutically
to treat chronic autoimmune arthritis.
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Background Anti-tumour necrosis factor (TNF) therapy with both etanercept and
infliximab decreases radiographic progression of patients with rheumatoid arthri-
tis (RA), while the effect of local corticosteroid injections, a routine adjuvant
therapy in arthritis, on bone metabolism is still debated. Thus, we investigated the
effect of both anti-TNF and local corticosteroid therapy on synovial expression of
osteoprotegerin (OPG) and receptor activator of NF-κB ligand (RANKL).
Methods OPG and RANKL were evaluated by immunohistochemistry in serial
synovial biopsies obtained from 18 RA patients before and after 8 weeks of treat-
ment with etanercept (nine patients) or infliximab (nine patients). Eighteen addi-
tional patients with arthritis that received a local corticosteroid injection were
evaluated before and after 2 weeks of the injection. Biopsies were evaluated by
double-blind semi-quantitative analysis and image analysis. The in vitro effect of
TNF antagonists and corticosteroids (dexametasone) on RANKL/OPG expres-
sion in osteoblasts was evaluated by western blot. Statistical analysis was per-
formed using the Wilcoxon’s signed-rank test followed by Bonferroni correction.
Results OPG was present in all biopsies with a characteristic pattern restricted
mainly to the endothelial cells and few mononuclear cells. RANKL was present
mainly in the T-cell area and to a lesser extent on some endothelial cells, but
absent in other mononuclear cells. Treatment with both infliximab and etanercept
increased synovial OPG expression. Neither infliximab nor etanercept influenced
RANKL expression following 8 weeks of treatment. The RANKL/OPG ratio
decreased following therapy in both groups, the effect being more pronounced in
the responders as compared with non-responders to therapy. Local corticos-
teroid treatment resulted in a similar change of the RANKL/OPG ratio through a
different mechanism, with a significant decrease of the synovial RANKL and no
changes in the OPG expression. In vitro both TNF antagonists and corticos-
teroids mimicked the in vivo effect inducing a decrease in the RANKL/OPG ratio
in TNF-primed osteoblasts.
Available online http://arthritis-research.com/supplements/7/S1S32
Conclusion Therapy with both TNF antagonists and local corticosteroids modu-
lates the RANKL/OPG system, inhibiting bone destruction through distinct mech-
anisms. Thus, association of these two therapies may be beneficial in preventing
bone erosions in RA.
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Background: Rheumatoid arthritis (RA) is an autoimmune disease characterized
by systemic, chronic joint inflammation. In spite of great efforts, the etiology of RA
has not been completely elucidated to date. Toll-like receptors (TLRs) belong to
the family of pattern recognition receptors and are involved in both innate and
adaptive immune responses against microorganisms via recognition of pathogen-
associated molecular patterns. In addition, TLRs have been reported to recognize
several endogenous ligands, which are generated under stress conditions and
cartilage damage. Triggering of TLRs results in the release of various proinflam-
matory cytokines such as IL-1β and tumor necrosis factor alpha. IL-1β is one of
the crucial cytokines in the pathogenesis of RA and is involved in Th1-mediated
processes and cartilage and bone destruction. Therefore, TLRs may potentially
be involved in either initiation or chronicity of arthritis.
Objective To study the contribution of TLR2 and TLR4 in IL-1β-driven joint
inflammation, cartilage destruction and bone erosion.
Methods C57BL/6 wild-type (WT), BL/6 TLR2 knockout (KO), C57BL/10 WT
and BL/10 TLR4 KO mice were intra-articularly injected with 3 × 106 PFU mouse
IL-1β adenoviral vector (AdmIL-1β) or control vector (Ad5del70-3). Inflammatory
cell infiltration, cartilage proteoglycan (PG) depletion and cartilage and bone
destruction were microscopically examined 7 days after virus injection.
Results Prolonged expression of mIL-1β in mice knee joints induced a severe
arthritis in WT animals, exhibiting pathophysiologic changes resembling those in
human RA. High amounts of inflammatory cells, predominantly polymorphonu-
clear cells, were present in the knee joint cavities of both WT and KO mice.
Severe PG depletion, cartilage destruction and bone erosion were observed in
WT mice, which did not differ from those in TLR2-deficient mice. Interestingly, in
TLR4-deficient mice, cartilage PG depletion and destruction were significantly
reduced. TLR4 KO mice showed also a marked reduction in bone erosion com-
pared with WT mice, although this reduction was not significant.
Conclusion These data strongly suggest that TLR4 is involved in IL-1β-driven
pathologic processes. Both cartilage and bone destruction were reduced in
TLR4 KO mice, although joint inflammation was comparable with WT mice. This
indicates the involvement of potential TLR4 ligands, generated by IL-1β-induced
cartilage degradation, in chronic RA. Our data point out that TLR4 may be a novel
therapeutic target in the treatment of RA.
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Background Primary or acquired drug resistance is well recognized as a
common cause of treatment failure of patients with cancer. From a rheumatoid
arthritis (RA) perspective, the issue of resistance to anti-rheumatic drugs (e.g.
disease-modifying anti-rheumatic drugs [DMARDs]) has not received much atten-
tion. A possible mechanism of drug resistance is overexpression of multidrug
resistance (MDR)-related proteins. The objective of this study was to identify
whether various MDR proteins are expressed on macrophages as potential target
cells for DMARDs.
Methods Monocyte-derived macrophages (MDM) were obtained from 15 RA
patients (median age: 56 years, 13 females/two males) and eight healthy controls
(median age: 51 years, four females/four males). Monocytes were isolated from
peripheral blood mononuclear cells and differentiated into macrophages in the
presence of monocyte-colony stimulating factor. Cytospins of MDMs were pre-
pared for immunohistological analysis of the MDR-related proteins: P-glycopro-
tein, multidrug resistance associated protein (MRP) 1, MRP4, MRP5, breast
cancer resistance protein (BCRP) and lung resistance protein (LRP). Staining
intensities were scored as follows: (0), negative; (1), weakly positive; (2), positive;
(3), strongly positive. The total score is depicted as the summation of percentiles
of cells with intensities 0–3.
Results MDMs of healthy controls and of RA patients stained strongly positive for
macrophage markers CD68 and 3A5. Except for MRP4, MDR protein expression
was observed both in MDMs of healthy controls and RA patients. Results are
shown as the median score with ranges (in parentheses) for MDR expression and
a statistical evaluation (Mann–Whitney U test) for differential expression (Table 1).
Table 1
Multidrug resistance (MDR) protein expression in monocyte-derived
macrophages from rheumatoid arthritis patients and healthy controls as
median scores (ranges)
Rheumatoid arthritis 
MDR protein patients (n = 15) Controls (n = 8) P value
BCRP 1.04 (0.51–2.27) 0.63 (0.44–1.45) 0.043
LRP 0.87 (0–2.49) 0.64 (0.1–1.35) 0.876
MRP1 0.36 (0–1.03) 0.25 (0.09–1.01) 0.309
MRP5 0.31 (0–1.04) 0.12 (0.05–0.78) 0.238
P-glycoprotein 0.24 (0–1.05) 0.1 (0.05–1.06) 0.813
MRP4 <0.05 <0.05
Conclusions MDR proteins, known to be involved in conferring drug resistance,
are expressed on macrophages of RA patients. Beyond this, there seems to be a
trend for a higher expression of MDR proteins on MDM from RA patients com-
pared with healthy controls. Further studies are warranted to assess whether
MDR is a clinically relevant issue in daily treatment of RA patients.
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Introduction The folate antagonist methotrexate (MTX) is the ‘anchor-drug’ in the
treatment of patients with rheumatoid arthritis (RA) [1]. The main target of MTX in
intracellular folate metabolism is dihydrofolate reductase (DHFR) but several
other targets have been described (e.g. thymidylate synthase [TS] and 5-amino-
imidazole-4-carboxamide ribonucleotide [AICAR]). At present the exact mecha-
nism of action of MTX in RA still remains elusive [1]. Despite the potent
anti-rheumatic capacity of MTX many patients (at least 50%) become resistant to
MTX during long-lasting therapy. However, little is known about the mechanisms
of resistance against MTX in RA patients [2].
From the field of oncology, where MTX is used against haematological malignan-
cies, new anti-folate drugs were developed to circumvent MTX resistance [3].
These new folate antagonists have the following characteristics: are better trans-
ported through the reduced folate carrier, are retained intracellular more effi-
ciently by polyglutamylation via folylpolyglutamate synthetase, and/or have other
targets in the folate pathway besides DHFR (e.g. TS).
Objective To investigate whether two new-generation anti-folate drugs, PT523
(DHFR-inhibitor) and ZD1694 (TS-inhibitor), have equal or better anti-inflamma-
tory capacity compared with MTX based on their capacity to inhibit tumour necro-
sis factor alpha (TNF-α) production by activated T cells.
Methods Whole blood from 11 RA patients and six healthy volunteers was incu-
bated ex vivo with MTX, PT523, ZD1694 and, as a control, the DMARD sul-
phasalazine (SSZ) after T-cell stimulation with α-CD3/CD28. Inhibition of TNF-α
production was measured after 72 hours by ELISA [4].
The IC-50 values (defined as the drug concentration exerting 50% inhibition of
TNF-α production) are used as a value for the anti-inflammatory capacity of the
drug (Table 1).
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Table 1
Characteristics of drugs and mean IC-50 values (± standard deviation)
Mean IC-50 for 
TNF-α inhibition
Reduced Folylpoly-
folate glutamate  Rheumatoid 
carrier synthetase  arthritis 
affinity affinity  patients  Controls 
Drug Target (cell uptake) (cell retention) (n = 11) (n = 6)
MTX DHFR + + + 78 (77) nM 57 (27) nM
PT523 DHFR + + + – 5.8 (3.2) nM 6,4 (8.3) nM
ZD1694 TS + + + + + + 16 (26) nM 4.8 (3.0) nM
SSZ NF-κB – – 278 (216) µM 191 (29) µM
Results Both PT523 and D1694 turned out to inhibit TNF-α production by activated
T cells much more efficiently than MTX (5–15 times). For comparison, the DMARD
SSZ is effective at much higher concentration (µM range). The inhibition of TNF-α
production by the anti-folate drugs does not seem to be a result of (apoptotic) cell
death of T cells whereas SSZ induces apoptosis of T cells (data not shown).
Conclusion In an ex vivo setting, two novel anti-folate drugs designed to circum-
vent MTX resistance proved to be very effective in inhibiting TNF-α production by
activated T cells from RA patients and healthy volunteers. Future experiments are
designed to evaluate ex vivo anti-folate sensitivity profiles for ‘MTX-responders’
and ‘MTX-non-responders’ to investigate whether these novel generation of
antifolate drugs can be useful in cases of clinical failure on MTX.
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Background In chronic inflammatory diseases, IL-1 is known as an important
proinflammatory cytokine inducing the expression of a variety of genes mediating
the synthesis of several proteins, which can induce both acute and chronic
inflammatory changes. Idiopathic inflammatory myopathies, such as polymyositis
and dermatomyositis, are chronic autoimmune muscle disorders characterised by
proximal muscle weakness and histopathological signs of patchy distribution of
inflammatory cells in the skeletal muscle. Muscle tissue of patients with such
myopathies has been shown to have an increased expression of IL-1α and IL-1β;
however, the expression and pathophysiological role of IL-1 receptors in muscle
tissue from such patients and healthy subjects has not yet been elucidated.
Aim To investigate the expression of IL-1 receptors in muscle tissue from both
patients and healthy subjects and to describe whether IL-1 receptors are differen-
tially expressed in symptomatic and non-symptomatic muscle tissue of patients
with polymyositis and dermatomyositis.
Method Muscle biopsies from eight patients with polymyositis, three patients
with dermatomyositis, and six healthy subjects were included in this study.
Muscle biopsies were taken from two different sites, one from a symptomatic
muscle and another biopsy from a non-symptomatic muscle. IL-1α, IL-1RI, and
IL-1RII expression were investigated by immunohistochemistry. IL-1RI and IL-1RII
were also investigated by confocal microscopy.
Results In patients with polymyositis and dermatomyositis, IL-1α was found to be
expressed in endothelial cells and inflammatory cells, and significantly increased
in symptomatic when compared with non-symptomatic muscle tissue. IL-1α was
not expressed in muscle tissue of healthy subjects. In patients, IL-1RI and IL-1RII
were strongly expressed in inflammatory cells, endothelial cells, in the membrane
of the muscle fiber, as well as in the nucleus of the muscle fiber of patients,
whereas in muscle tissue of healthy subjects only a scattered pattern of IL-1RI
and IL-1RII expression in a few endothelial cells and in a few of nuclei of the
muscle fiber could be observed. The membrane and nuclear expression were
confirmed by double stainings.
Discussion This is the first study to show the expression of IL-1RI and IL-1RII in
the cell nuclei and in the membrane of muscle fibers. Moreover, we have found
some marked differences between symptomatic and non-symptomatic muscle
tissue of patients and healthy subjects indicating a potentially important role of
IL-1 receptors in the pathogenesis of idiopathic inflammatory myopathies.
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Introduction The inflamed joints in rheumatoid arthritis patients are ideally suited
for gene therapy applications to acquire local production of potent anti-inflamma-
tory biologics. The need for precise and absolute targeting as for treating cancer
is not necessary in rheumatoid arthritis. However, the challenge is to obtain long-
term transgene expression. For this purpose we used in this study HIV-based
lentiviruses (LV) for the stable transduction of the murine synovium.
Methods  The coding sequence of murine interleukin-1 receptor antagonist
(IL-1Ra) was inserted into the pRRLcpptpgkmcspreSsin transfer vector (self-
inactivating vector was a gift from D Trono, Geneva, Switzerland) behind the
phosphoglycerate kinase-promoter. Vesicular stomatitis virus G envelope
pseudotyped lentiviruses were produced by cotransfection of 293T-cells [1].
Recombinant lentiviruses were purified and titres were determined using the p24
ELISA (Murex HIV Antigen MAB, Abbott). Lentiviruses encoding for firefly
luciferase (Luc) were used for control. The lentiviruses were injected intra-articu-
larly into the murine knee joint. Synovial explants were taken to measure the
luciferase activity using a luminometer. Mice immunized against bovine collagen-
type II received an intra-articularly injection of lentiviruses 1 day after the antigen
booster but without any visual signs of collagen-induced arthritis.
Results Naïve C57Bl/6 mice were injected with 300 ng (p24 value) of LV-Luc
into the knee joint. The Luc activity in the synovial biopsies increased steadily until
day 7 and remained at this level until the end of the experiment (day 21 after
injection). Next we injected the same amount of LV-mIL-1Ra and LV-Luc into the
right knee joint of collagen-type II immunized mice just before onset of arthritis. At
day 31 after immunization all mice in the LV-IL-1Ra and LV-Luc-treated groups
developed clinical signs of severe arthritis in the paws. However, macroscopic
examination of the injected knees showed a significant reduction in joint inflam-
mation in all mice of the LV-mIL-1Ra group (arbitrary score [0–3] 0.55 ± 0.37) as
compared with the LV-Luc-treated mice (score 1.55 ± 0.53). Microscopic evalua-
tion confirmed the marked reduction in joint inflammation. Furthermore, the joint
that received LV-mIL-1Ra showed a marked reduction in bone destruction
whereas the extent of cartilage destruction was comparable with the LV-Luc-
treated knees during collagen-induced arthritis.
Conclusion We show for the first time that lentiviral-mediated local overexpres-
sion of IL-1Ra had a pronounced effect on the development of collagen-induced
arthritis in that particular knee joint. No protective effect was observed on the ipsi-
lateral or contralateral paws as we have demonstrated previously for IL-1Ra gene
transfer using adenoviral vectors [2,3]. The lentiviral transduction of the synovium
seems feasible and efficacious for treatment of arthritis.
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Background Microsomal prostaglandin E synthase (mPGES)-1 is upregulated in
experimental arthritis and is markedly expressed in synovial tissue from patients
with rheumatoid arthritis (RA), suggesting its important role of in the pathogene-
sis of inflammatory arthritis. However, the effects of current anti-rheumatic thera-
pies on mPGES-1 expression have not been examined.
Objective To study the effects of anti-tumour necrosis factor (TNF) alpha blockers
and glucocorticoids on prostaglandin (PG) E2 biosynthesis and mPGES-1 expres-
sion in synovial fluid mononuclear cells (SFMC) and synovial tissue from RA patients.
Methods Synovial tissues were obtained from 18 RA patients before and after
treatment with TNF-blockers (infliximab and etanercept) and from 16 patients
before and after intra-articular injection of steroids. SFMC were obtained from
eight RA patients. In vitro effects of TNF-blockers and dexamethasone (Dex) on
mPGES-1 expression in SFMC were examined by flow cytometry. PGE2 levels in
culture supernatants were analyzed by enzyme immunoassay. Immunohistological
analysis and double immunofluorescence were performed using antibody against
mPGES-1, cyclooxygenase (COX) and CD163.
Results Treatment of SFMC with TNF-blockers or Dex decreased lipopolysac-
charide-induced mPGES-1 and COX-2 expression in CD14+ monocytes and
PGE2 synthesis in culture supernatants. Double immunofluorescence revealed
that mPGES-1 and COX-2 were co-localized in SFMC and in synovial tissue
cells. Local treatment with steroids significantly reduced the mPGES-1, COX-2
and COX-1 expression in synovial tissue. However, neither mPGES-1 nor COX-2
expression in RA synovial tissues were significantly affected by anti-TNF therapy.
Conclusion In vitro, both TNF-blockers and Dex suppressed mPGES-1 in SFMC.
In RA synovial tissue, local steroids but not TNF-blockade downregulate mPGES-
1. These data provide support to the use of combination of TNF-blockade and
inhibitors of PGE2 production for optimal anti-inflammatory achievement.
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Introduction Mitogen-activated protein kinases (MAPKs) are important effector
enzymes of different molecular signaling cascades with critical roles in inflamma-
tion, in particular in the induction and downstream effects of tumor necrosis
factor (TNF) alpha and IL-1. Inhibition of the MAPK signaling cascades has been
identified as a potential therapeutic target in chronic arthritis. Little is known
about the activation and extent of MAPK signaling in the synovium of patients
with psoriatic arthritis. We studied phosphorylation of the three common MAPKs
(p38, extracellular regulating kinase [ERK] and C-jun-N-terminal kinase [JNK]) in
psoriatic arthritis and the effect of anti-TNF therapy on their activation.
Materials and methods Synovial biopsies were obtained by needle arthroscopy
in nine patients with active psoriatic arthritis in a clinically involved knee before
the initiation of etanercept (Enbrel©; Wyeth Pharmaceuticals, Louvain-la-Neuve,
Belgium). All patients were included in a 6-month open-label clinical trial of 25 mg
etanercept two times a week [1]. Follow-up biopsies were taken in the same knee
after 6 months. Six biopsies were used for histological examination. Frozen sec-
tions were stained with H&E or used for immunofluorescense. Sections were
fixed with acetone and stained with goat-anti-human phosphorylated ERK,
mouse-anti-human phosphorylated p38 or mouse-anti-human phosphorylated
JNK (all from Santa Cruz Technologies, Santa Cruz, USA). Cy2-conjugated
donkey anti-goat or Cy3-conjugated goat anti-mouse antibodies (Jackson
Immunoresearch, West Grove, USA) were used as secondary antibodies. Nega-
tive controls were performed with non-specific IgG. Severity of synovitis was
assessed with a composite score based on a blinded semi-quantitative score
(0–3) of four parameters (lining layer thickness, sublining vascularity, inflamma-
tory cell infiltration and presence of lymphoid aggregates). Activation of MAPKs
was quantified with Image J digital analysis software. The area of fluorescent
staining due to antibody-linked fluorochrome emission was normalized to cell
number based on area of emission by DAPI nuclear staining. For statistical analy-
sis non-parametric Wilcoxon test for paired samples was used.
Results Activated p38 was present in both lining and sublining layers. In the sublining
layer, positive cells were found in inflammatory infiltrates, in perivascular zones and in
the endothelium. Activated ERK was present in the sublining layer only, both in
mononuclear cell infiltrates and perivascularly. Activation of JNK was recognized in
cells of the lining layer, in some sublining cell infiltrates and the endothelium. The com-
posite histological severity score was significantly lower after etanercept treatment
(median score 4 versus 1; P < 0.02). Etanercept therapy resulted in a significant
decrease in ERK (median normalized fluorescent area 0.096 versus 0.04; P < 0.03)
and JNK (median normalized fluorescent area 0.91 versus 0.34; P < 0.03) but not in
p38 activation (median normalized fluorescent area 0.04 versus 0.07; P > 0.07).
Conclusion Different MAPKs are activated in psoriatic arthritis synovium. The
activation pattern suggests distinct roles for specific MAPKs in synovitis. The
activation pattern of p38 and pERK strongly mimics the pattern described in
rheumatoid arthritis [2]. Activation of JNK in the lining layer of rheumatois arthritis
synovium has not been reported. Etanercept therapy had a significant effect on
JNK and ERK but not on p38 activation. These data suggest that other, probably
TNF-independent, signals activate p38 in psoriasis arthritis synovium.
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Background In the inflammatory process preceding erosive arthritis, IL-18 plays an
important role. IL-18 is known to regulate immune responses by stimulating Th1 mat-
uration, and signaling is initiated through formation of a trimericc receptor complex,
consisting out of IL-18 bound to the IL-18Rα and its accessory receptor IL-18Rβ.
Objective The aim of this study was to determine the physiological role of a recently
described soluble form of the IL-18 receptor accessory protein (sIL-18Rβ) in mice.
Methods Mouse sIL-18Rβ (genebank accession number AK053176) was cloned
from murine lung cDNA and used for the generation of an adenoviral vector
(Ad.5IL-18Rβ). Expression analysis of the sIL-18Rβ and its full-length membrane
bound IL-18Rβ in different murine tissue was achieved through endpoint PCR. To
investigate the in vivo mode of action, sIL-18Rβ was systemically overexpressed in
collagen type II-immunized male DBA/1 mice. Systemical overexpression was
achieved through intravenous injection of 3 × 108 pfu Ad5sIL-18Rβ or the control
vector (Ad5Luc) before clinical manifestation of collagen-induced arthritis (CIA). At
1 and 4 days post adenoviral injection, splenocytes were harvested and the
cytokine profile in plasma and splenocyte culture supernatants was determined
Results Short IL-18Rβ mRNA was highly expressed in tissue of lymphoid origin,
and no expression could be observed in immune privileged organs like the testis,
the eye and the brain, suggesting a prominent role in immune regulation. Expres-
sion of sIL-18Rβ was disease regulated in mice suffering from CIA, whereas the
full-length IL-18Rβ was not regulated. Splenocytes of sIL-18Rβ-treated immu-
nized mice produced significantly less interferon gamma and IL-10 compared
with control treated animals. Adenoviral overexpression of the sIL-18Rβ before
clinical manifestation of CIA significantly aggravated arthritis, which was accom-
panied by a reduction of circulating IL-10, interferon gamma and a significant
increased anti-bovine collagen II IgG1.
Conclusion Our results describe the existence of a novel short soluble form of
the membrane IL-18Rβ, which is mainly expressed in lymphoid tissues. This sIL-
18Rβ expression appears regulated during CIA. Furthermore, we show that this
novel soluble IL-18Rβ functions as a putative modulator of IL-18 signaling; aggra-
vating CIA, by modulating T-cell immunity.
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Th lymphocytes are considered to be key players in chronic inflammation. Upon
repeated re-stimulation and differential instruction, they can develop a stable
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memory for the expression of distinct genes coding for cytokines, chemokines,
adhesion molecules, and so on. This functional memory contributes considerably
to the chronicity of inflammation and its eventual refraction to therapy.
Here, we describe the global gene expression profiles of in vitro repeatedly re-
activated murine Th1 and Th2 cells, and compare them with those of naïve and
once activated Th1 and Th2 cells, both before and after re-stimulation (Fig. 1).
Among differentially expressed genes is a novel transcription factor, which down-
modulates NF-κB signalling and is exclusively expressed in repeatedly re-activated
Th1 cells. High expression of this gene can be detected in Th cells isolated from the
site of inflammation of patients suffering from distinct forms of rheumatic diseases
or ulcerative colitis, but not in Th cells isolated from healthy tissue or from blood.
Expression of this gene in Th cells at the site of inflammation highlights the role of
chronic T-cell activation in chronic inflammation and may represent an endoge-
nous mechanism to limit inflammation. Apart from its diagnostic value, this molec-
ular pathway also points to a new therapeutic target.
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Background IL-1α is synthesized as a precursor (preIL-1α), which is processed
into mature IL-1α and a N-terminal propeptide by calpain-like proteases. Besides
its classical effects elicited upon IL-1 receptor binding, preIL-1α exerts intracellular
functions, including the modulation of cell growth and apoptosis. Nuclear translo-
cation of preIL-1α, mediated by the N-terminal propeptide, is required for these
effects. IL-1 receptor antagonist (IL-1Ra) inhibits the classical effects of IL-1 by
preventing the interaction of IL-1 with its receptor. Four different isoforms of IL-1Ra
have been described, of which one is secreted and three others are intracellular
(icIL-1Ra1, icIL-1Ra 2, icIL-1Ra 3). Due to their intracellular localization, icIL-1Ras
cannot interact with cell surface receptors and have been suggested to carry out
specific functions inside cells. The description of nuclear functions for preIL-1α
suggested that icIL1Ra variants might antagonize intracellular effects of preIL-1α.
Objective and methods The aim of this study was to investigate effects of preIL-
1α and icIL-1Ra1 on cell growth using stably transfected SaOS-2 osteosarcoma
cells. IL-1α and IL-1Ra expression was quantified by ELISA and their localization
was examined by immunofluorescence. Cell counts, lactate dehydrogenase activ-
ity and [3H]-thymidine incorporation were used to monitor cell growth.
Results IL-1α expression ranged from 5.3 to 9.4 ng/106 cells in culture super-
natants and from 39.8 to 87.3 ng/106 cells in lysates of preIL-1α transfected
SaOS-2 cells. Immunostaining showed nuclear localization of preIL-1α, which
was not modified by co-transfection of icIL-1Ra1. Expression levels of IL-1Ra
ranged from 53 to 219 ng/106 cells in supernatants and from 1678 to 4414
ng/106 cells in lysates of icIL-1Ra1 transfected cells. IL-1Ra staining was essen-
tially cytoplasmic. Transfection of SaOS-2 cells with preIL-1α significantly
decreased cell growth, as indicated by reduced cell counts and lactate dehydro-
genase activity. PreIL-1α also decreased thymidine incorporation, indicating an
inhibition of cell proliferation. In contrast, addition of exogenous mature IL-1α
(500 pg/ml) had no inhibitory effect on SaOS-2 proliferation, suggesting that the
effect of preIL-1α on cell growth is intracellular. Transfection of SaOS-2 cells
with icIL-1Ra1 alone did not affect cell growth. Moreover, co-expression of icIL-
1Ra1 did not reverse the growth inhibitory effect of preIL-1α. However the induc-
tion of IL-6 secretion, a classical, receptor-mediated effect of preIL-1α, was
inhibited in icIL-1Ra1 co-transfected cells.
Conclusions Expression of preIL-1α decreased the growth of SaOS-2 cells. Co-
transfection of icIL-1Ra1 did not antagonize this effect. These observations
suggest that intracellular effects of preIL-1α are not necessarily susceptible to
inhibition by icIL-1Ra.
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Background Microsomal prostaglandin E synthase (mPGES)-1 catalyzes the forma-
tion of prostaglandin (PG) E2 from cyclooxygenase (COX)-derived PGH2. mPGES-1
is induced by proinflammatory cytokines, such as IL-1β and tumor necrosis factor
alpha, and is linked to conditions with high PGE2 biosynthesis and inflammation. A
recent study has demonstrated enhanced COX-1 and COX-2 expressions in
affected muscle tissues of patients with polymyositis (PM) and dermatomyositis
(DM), suggesting their important role in the pathophysiology of these diseases.
However, expression of mPGES-1 in muscle tissue has not been investigated.
Objective To study the expression of mPGES-1 in muscle tissue of patients with
idiopathic inflammatory myopathies.
Methods Muscle biopsies were obtained from 13 patients with idiopathic inflam-
matory myopathies (six PM, four DM, one juvenile DM, two inclusion body myosi-
tis) and from six healthy subjects. Immunohistochemical analysis was performed
using antibodies against mPGES-1.
Results mPGES-1 staining was detected in all patients with PM, DM and inclusion
body myositis. Specifically strong intracellular staining was observed in inflamma-
tory cells in infiltrates, in endothelial cells of capillaries, in scattered mononuclear
cells and in fibroblast-like cells. In some patients mPGES-1 staining was localized in
smooth muscle cells and endothelial cells of large vessels. In healthy subjects, weak
mPGES-1 staining was detected only in scattered fibroblast-like cells, in a few
mononuclear cells surrounding large vessels and in some capillaries.
Conclusion These results demonstrate the upregulation of mPGES-1 in muscle
tissue of refractory patients with idiopathic inflammatory myopathies compared
with healthy controls, suggesting a role of mPGES-1 in the pathophysiology of
these diseases.
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Background HLA-DRB1 alleles encoding the shared epitope (SE) susceptibility
sequence predispose to rheumatoid arthritis (RA). Having two copies results in
even higher risk. This study analyzes whether the contribution of the second SE
allele to RA risk is identical to that of the first SE allele.
Methods In a meta-analysis of 44 datasets of case–control studies meeting pre-
defined criteria, the odds ratios OR1/0 and OR2/1 are calculated, as an estimate of
the relative risk for RA for individuals having one compared with zero, or two com-
pared with one SE allele; from these, the ratio OR2/1:OR1/0 is calculated.
Results Overall the weighted mean ratio OR2/1:OR1/0 (95% confidence interval)
was 0.90 (0.80–1.01). In the 39 studies in which all patients met the ACR criteria
for RA, the overall ratio OR2/1:OR1/0 is 0.89 (0.78–1.01; see Fig. 1). In a multiple
regression analysis on a group level the ratio OR2/1:OR1/0 was not influenced by
racial origin, the frequency of compound heterozygosity (0401/0404 or
0401/0408), the percentage of female or rheumatoid factor-positive patients,
disease duration or age at disease onset.
Conclusions The contribution of the second SE allele to RA risk does not differ
significantly from that of the first SE allele. This result will help to pool immuno-
genetic data across populations, resulting in a detailed description of the contri-
bution of immunogenetic factors to RA risk.
In addition this finding implies that pathogenetic models for RA that incorporate
the role of HLA should explain the fact that the first and the second SE alleles
increase RA risk equally. Such effects might, for example, be described for
models incorporating presentation of pathogenic antigenic peptides.
Available online http://arthritis-research.com/supplements/7/S1
Figure 1
Hierarchical clustering of differentially expressed genes among doublets of the nine
investigated cell populations (w, weeks in culture; res, 3 hours re-stimulated) using
Affymetrix Mouse Genome 430A 2.0 Arrays and DNA-Chip Analyzer (dChip).S36
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Introduction We recently demonstrated that the proinflammatory and immuno-
regulatory cytokine IL-18 is strongly upregulated in salivary glands (SG) of Sjo-
gren’s syndrome (SS) patients. IL-18 gain or loss of function experiments in
animal models of human diseases have provided evidence of the pathogenic role
of this cytokine in chronic inflammation. However, in SS the pathogenic relevance
of IL-18 in the development of murine autoimmune sialoadenitis has not as yet
been evaluated. Here we describe in vitro experiments in which murine SG
epithelial cells were tested for transfection efficiency with IL-18 and IL-
18BPcAdV gene transfer. In addition, in preparation for in vivo SG modulation of
IL-18 function by AdV-mediated gene transfer, we optimised retrograde SG can-
nulation in mice.
Methods Primary SG ductal epithelial cells (SG-DEC), established from sub-
mandibular glands of C57BL/6 mice using the explant outgrowth technique, as
well as a murine SG-DEC line were used for AdV transfection. A mIL-18AdV from
plasmid IL-18 TG3652 [1] was developed in our laboratory while we used the
same mIL-18BPcAdV construct as previously reported [2]. AdVs encoding for
LacZ or luciferase were used as controls. All AdVs were incubated at 50 MOI.
Efficiency of gene transfer was evaluated through detection of IL-18 and IL-
18BPc protein expression assessed by both immunostaining and western blot.
Beta-galactosidase staining was performed to evaluate efficiency of transfection
of LacZAdV. Feasibility of local delivery of compounds through retrograde cannu-
lation of murine submandibular glands was also tested.
Results High efficiency of transfection of cultured murine SG-DEC was obtained
with both IL-18AdV (Fig. 1) and IL-18BPcAdV (Fig. 2). Western blot confirmed
the presence of protein production detectable as single bands from target-
geneAdV but not control-geneAdV transfected SG-DEC. A time-course study
demonstrated in vitro gene expression up to 3 weeks after transfection. Feasibil-
ity of local SG delivery through retrograde submandibular duct cannulation was
demonstrated by injection of trackable compounds.
Conclusion Here we report for the first time evidence of high and sustained effi-
ciency of IL-18 and IL-18BPc AdV gene transfer in murine SG-DEC. In addition,
we successfully adapted a cannulation technique previously used in bigger
animals for in vivo local delivery of modulatory molecules to murine salivary
glands.
Local delivery of IL-18/IL-18BPc adenoviral vectors in vivo in salivary glands of
NOD mice and other murine models of SS through retrograde submandibular
excretory duct cannulation will provide evidence of a possible pathogenic role of
IL-18 in participating in autoimmune sialoadenitis and will establish a rationale for
using IL-18 blocking agents as therapeutic tools in SS.
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Systemic lupus erythematosus is a severe systemic autoimmune disease charac-
terized by loss of tolerance towards a restricted panel of autoantigens. As a
result, pathogenic autoantibodies against dsDNA or the Sm proteins occur. We
identified the SmD1(83-119) peptide, the C-terminus of the spliceosomal protein
SmD1, as a major B-cell and T-cell autoantigen in human and murine lupus [1–3].
In previous work we could show that intravenous high-dose application of
SmD1(83-119) prolongs survival in NZB/W F1 mice and delays occurrence of
anti-dsDNA autoantibodies [4]. Higher percentages of CD4+ T cells that produce
IL-10 and interferon gamma were detected on restimulation with phorbol 12-
myristate 13-acetate/ionomycin later on in the spleen, indicating involvement of
type 1 regulatory T cell (Tr1 cell)-mediated tolerance [4]. Transfer of splenic
CD90+ T cells from mice treated with high doses of SmD1(83-119) into
untreated mice delayed the occurrence of anti-dsDNA autoantibodies in these
recipients as well [4].
We now performed a SmD1(83-119) specific analysis of the CD4+ T cells after
high-dose application of SmD1(83-119) and detected SmD1(83-119)-reactive
CD4+IL-10+ Tr1 cells in the spleen and in draining lymph nodes after additional
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Figure 1
Ratio OR2/1:OR1/0 (see Methods) with 95% confidence interval of the 44 study
groups and the overall weighted mean.
Figure 1
(a) Expression of murine IL-18 in salivary gland ductal epithelial cells (SG-DEC)
transfected with IL-18AdV but not with LacZAdV (b). (c) Beta-galactosidase
staining confirmed effective transfection of SG-DEC by LacZAdV.
Figure 2
(a) Expression of murine IL-18BPc in salivary gland ductal epithelial cells
transfected with IL-18BPcAdV but not with LucAdV (b) or medium alone (c).S37
immunization with SmD1(83-119). In  vitro experiments showed that Tr1-cell-
mediated suppression of anti-DNA autoantibody production is dependent on the
activity of IL-10 as the addition of neutralizing anti-IL-10 antibodies abrogated this
effect. Furthermore, adoptive transfer of SmD1(83-119) reactive Tr1-cell-contain-
ing lymph node cells delayed the occurrence of anti-DNA autoantibodies in the
recipient mice as well.
We conclude that high-dose application of SmD1(83-119) induces SmD1(83-119)
specific tolerance in NZB/W F1 mice, which is mediated by SmD1(83-119)-
reactive Tr1 cells. These results may open new ways for future autoantigen
specific cell-based therapies in systemic lupus erythematosus.
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Background The proinflammatory cytokine IL-1β has been implicated in the
pathogenesis of a number of the hereditary periodic fever syndromes. One such
syndrome, Muckle–Wells syndrome (MWS), is characterised by the triad of
urticaria, progressive sensorineural deafness and systemic amyloid A amyloido-
sis. Other features include rigors, leucocytosis, raised acute phase reactants and
serum amyloid A levels. A number of case reports have recently emerged involv-
ing treatment with the recombinant human IL-1 receptor antagonist, Anakinra
(Kineret; Amgen, Cambridge, UK) [1–3].
Case report A 59-year-old caucasian female presented with increasingly severe
and intractable disease over a 15-year period. In addition to the above features,
she also exhibited papilloedema and chronic aseptic meningitis. No other family
members were affected. Upon commencing treatment with Anakinra, there was
complete resolution of her inflammatory symptoms within 24–48 hours, and rapid
normalisation of her C-reactive protein and serum amyloid A levels (from
415.0 mg/l to 12.6 mg/l after 4 weeks of therapy). Her intracranial pressure and
CSF white cell counts also returned to normal. Audiometry confirmed a
15–30 decibel improvement in the 250–4000 Hz frequency range in each ear.
No mutations of the responsible gene — NALP3/CIAS1 on chromosome 1q44 —
were demonstrated on her DNA sequencing.
Discussion Our patient is the oldest reported sporadic case of MWS. Heterozy-
gous missense mutations have thus far been reported in only 60% of MWS
patients analysed [4]. The confirmed improvements in hearing, intracranial pres-
sure, and CSF white cell counts seen here with Anakinra lend further support to
the treatment of the autoinflammatory conditions by targeting IL-1. The pathogene-
sis of the sensorineural deafness in MWS is unclear although it is postulated that
expression of mutated NALP3/CIAS1 in cartilage may have a causative role [3].
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Objective The aim of the study was to analyze the cytokine memory of Th cells
derived from systemic lupus erythematosus (SLE) patients and healthy donors
enriched for autoantigen-specific T cells by in vitro stimulation with SmD183-119, a
common autoantigen in SLE.
Method Autoreactive CD3+ T cells derived from 37 SLE patients and 14 healthy
donors were enriched by repetitive ex vivo stimulation of peripheral blood mononu-
clear cells with SmD183-119. For control, peripheral blood mononuclear cells were
stimulated only with IL-2. After two rounds of antigen stimulations, cultures were
stimulated with phorbol 12-myristate 13-acetate/ionomycin for intracellular
cytokine staining. Frequencies of cytokine-expressing T cells were analyzed and,
in SLE patients, compared with disease activities and autoantibody levels.
Results Comparing cultures from SLE patients with those from healthy donors, SLE
patients displayed higher frequencies of tumor necrosis factor alpha-positive T cells
and the frequencies correlated with disease activity. SmD183-119-induced tumor
necrosis factor alpha expression correlated with serum anti-dsDNA antibody levels.
The frequencies of IL-10-expressing T cells were lower in cultures from SLE
patients. Cultures from patients with high frequencies of IL-10+ T cells revealed
low disease activities. SmD183-119-induced increases in IL-10-expressing T cells
were associated with low anti-dsDNA and anti-SmD183-119 antibody levels in
culture supernatants.
Conclusion The enrichment of SmD183-119-reactive T cells by in vitro cultures
showed that cytokine changes specifically occur in lupus patients. The results
give insight into the cytokine memory of autoreactive Th cells and their role in
lupus pathogenesis.
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Background Due to the complex multigenic nature of rheumatoid arthritis (RA)
identification of RA susceptibility and severity genes appears to be more chal-
lenging than originally anticipated. Among many recently reported RA susceptibil-
ity genes, a missense single nucleotide polymorphism in the protein tyrosine
phosphatase PTPN22 appears to be involved in susceptibility to multiple autoim-
mune diseases including diabetes, systemic lupus erythematosus and Graves
disease. Whether this polymorphism is also associated with severity of the phe-
notype in diseased individuals is not known.PTPN22 encodes a hematapoetic
phosphatase also known as Lyp that functions as a negative regulator of T-cell
activation via interaction with the c-Src tyrosine kinase Csk and phosphorylation
of regulatory tyrosines or other Src family kinases, such as Lck and Zap70. The
R620W polymorphism results in substitution of conserved arginine with trypto-
phan in the proximal SHH-3 binding domain of PTPN22, which is necessary for
interaction with Csk. In vitro experiments show that the W620 variant of PTPN22
binds less efficiently to Csk, suggesting T cells expressing this allele may be
hyper-responsive and more prone to autoimmunity.
Objective To investigate the association of R620W polymorphism with RA in a
Dutch Caucasian population and to determine whether this polymorphism associ-
ates with a qualitative phenotype of RA (remission versus progression) or a quan-
titative phenotype (rate of joint damage).
Methods PTPN22 genotyping was performed on DNA from 425 RA and 343
undifferentiated arthritis patients participating in the Leiden Early Arthritis Clinic
and over 200 control individuals, both of Dutch Caucasian origin. Samples were
genotyped using allele-specific kinetic PCR. Disease features were measured as
previously published. X-rays were scored every year.
Results We confirmed association of the R620W allele of PTPN22 polymor-
phism with RA in our Dutch Caucasian population. Minor allele frequencies of
0.07 and 0.12 were found in controls and cases, respectively, with P = 0.008
and an allelic odds ratio of 1.91, 95% confidence interval = 1.18–3.11. Surpris-
ingly PTPN22 appeared to be a susceptibility gene for undifferentiated arthritis
that either progresses or does not progress to RA. PTPN22 status did not influ-
ence the disease persistency, as analyzed in the remission versus non-remission
group, or the disease severity as determined by analysis of joint damage.
Available online http://arthritis-research.com/supplements/7/S1S38
Conclusion: Our results suggest that the R620W allele of PTPN22 increases
susceptibility to RA but does not confer risk to a more severe disease course
either with respect to joint destruction or with respect to disease severity.
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Background Protease-activated receptor-2 (PAR-2) is one of a family of G-
protein coupled transmembrane receptors activated by proteolytic release of a
‘tethered’ ligand. We previously reported this receptor has a pivotal role in
chronic joint inflammation using a PAR-2 ‘knockout’ mouse [1], but the serine
protease responsible for its activation remains uncertain.
Objective We investigated whether β-tryptase has proinflammatory actions in the
mouse knee and specifically whether a tryptase inhibitor can modulate experi-
mentally induced chronic joint inflammation.
Methods Five micrograms of human β-tryptase was injected into the knee joint
cavity of two groups of anaesthetized (Halothane/O2/N2O) mice (30 g): wild-type
(PAR-2+/+) C57BL/6J mice and PAR-2 gene disrupted mice (PAR-2–/–). Joint
swelling was assessed by comparing caliper measurements of knee joint diame-
ter pre-injection and post-injection. Chronic monoarthritis was induced using the
same anaesthetic regime in separate wild-type mice by intra-articular and peri-
articular injection of Freunds complete adjuvant (FCA) (in 5% methycellulose). In
a parallel group of mice, 50 µ g of the tryptase inhibitor 4-amidino phenyl pyruvic
acid (APPA) was co-administered with the FCA/methycellulose emulsion. Joint
diameter was measured over 10 days.
Results Intra-articular injection of β-tryptase resulted in rapid joint swelling in
wild-type mice that was completely abrogated in PAR-2–/– mice (Fig. 1a), sug-
gesting that tryptase-mediated inflammatory actions require functional PAR-2.
Tryptase plays an important role in mediating chronic inflammation as APPA co-
administration substantially inhibited FCA-induced joint swelling (Fig. 1b). The
present study extends our previous finding [1] that PAR-2 plays a key role in
mediating chronic joint inflammation, by demonstrating that tryptase may be a
crucial activating protease required for such PAR-2-mediated actions.
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Background Comparative immunogenetic studies of systemic lupus erythemato-
sus with co-existing Sjogren’s syndrome (SLE-SS), systemic lupus erythemato-
sus without Sjogren’s syndrome (SLE-noSS) and primary Sjogren’s syndrome
(pSS) are lacking.
Objective In the present study, we conducted a thorough evaluation of the geno-
type and haplotype profiles in well-defined subgroups of patients with SLE-SS,
SLE-noSS and pSS, including their association with disease parameters.
Methods HLA-DRB1, HLA-DQA1 and HLA-DQB1 alleles were determined by
PCR and hybridization with sequence-specific oligonucleotide probes in DNA
specimens derived from 23 patients with SLE-SS, 41 patients with SLE-noSS
and 55 patients with pSS (all Caucasians). Patients’ records were retrospectively
evaluated for various clinical and laboratory parameters.
Results  Compared with healthy controls (odds ratios analyses), SLE-SS and
pSS patients displayed a statistically increased frequency of the DRB1*0301-
*1104 heterozygote genotype, whereas SLE-noSS patients had an increased fre-
quency of the genotypes DQA1*0401-*0501, DRB1*0301-*1501 and
DQB1*0201-*0602. Such statistical associations were stronger for genotypes
than single alleles. The analysis of haplotype estimated frequencies (by EM
algorithm) had revealed an increased frequency of the DRB1*0301-DQA1*0501-
DQB1*0201 haplotype, as well as of the extended haplotype DRB1*0301-
DQA1*0501-DQB1*0201/DRB1*1104-DQA1*0501-DQB1*0301 in SLE-SS
and pSS patients. In contrast, SLE-noSS patients had an increased estimated
frequency of the DRB1*1501-DQA1*0102-DQB1*0602 haplotype. In SLE-SS
patients, positive associations of the DQB1*0201 allele with anti-dsDNA (strong)
and of DQA1*0501 with anti-La/SSB (marginal) were observed. In SLE-noSS,
DQB1*0301-*0602 was strongly positively associated with interstitial lung
disease, DQB1*0201-*0602 with central nervous system involvement,
DQA1*0501 with serositis and DRB1*1501 with anti-dsDNA, whereas
DQB1*0301 homozygosity demonstrated a significant protective effect for
glomerulonephritis. In pSS patients, the DRB1*0301-*1104 and DQB1*0201-
*0301 genotypes were strongly positively associated with purpura, DRB1*1104-
*1601 with arthritis, DQB1*0201-*0502 with renal tubular acidosis, DQB1*0301
homozygosity with lymphadenopathy, DQA1*0501 homozygosity with low C4
and DRB1*0301 allele with anti-La/SSB, low C4 and cryoglobulinemia. In these
patients, the extended haplotype DRB1*0301-DQA1*0501-DQB1*0201/
DRB1*1104-DQA1*0501-DQB1*0301 associated strongly with the occurrence
of low C4, anti-La/SSB and purpura.
Conclusions The present study indicates that SLE-SS and the SLE-noSS
patients are immunogenetically dissimilar, whereas there is an apparent close
immunogenetic relationship between SLE-SS and pSS patients. Furthermore, our
data corroborate that the synergistic interactions between distinct pairs of alleles
in the DR or the DQ locus confer higher relative risk for these diseases and for
distinct clinical manifestations than each of these alleles individually. In pSS, the
presence of the extended haplotype DRB1*0301-DQA1*0501-DQB1*0201/
DRB1*1104-DQA1*0501-DQB1*0301 appears to associate with adverse pre-
dictors for lymphoma development.
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Background Phosphorylation-dependent inactivation of FoxO transcription
factors by the proto-oncogene product protein kinase B (PKB) plays a central
role in promoting cellular survival, proliferation, and activation mediated by PI3-
kinase. PI3-kinase-dependent activation of PKB has been observed in rheumatoid
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Figure 1
Progression of joint damage (Sharp–van der Heijde units).
Figure 1
(a) Six hours after intra-articular injection of β-tryptase, knee joint swelling is evident
in wild-type (PAR-2+/+) mice but is virtually absent in PAR-2 gene disrupted (PAR-
2–/–) mice (P < 0.001, n = 4). (b) Knee joint swelling 10 days after Freunds
complete adjuvant (FCA) treatment is significantly inhibited by co-administration of
4-amidino phenyl pyruvic acid (APPA) with FCA (P = 0.014, n = 4).S39
arthritis (RA) synovial tissue, and blocking PKB activation has a protective effect
in animal models of arthritis. However, the molecular mechanisms by which acti-
vation of PKB promotes arthritis have not been elucidated.
Objectives To determine whether FoxO transcription factors (FoxO1, FoxO3a,
and FoxO4) are specifically inactivated in RA synovial tissue, to identify cell types
in RA synovial tissue in which FoxO proteins are inactivated, and to identify
inflammatory stimuli relevant to RA that inactivate FoxO transcription factors in
cultured RA fibroblast-like synoviocytes (FLS) in vitro.
Methods Expression and PKB-dependent phosphorylation of FoxO1, FoxO3a, and
FoxO4 were determined using specific antibodies in immunohistochemical and
computer-assisted quantitative digital analysis of synovial tissue sections obtained
from 12 RA and nine osteoarthritis (OA) patients. Double labelling with cell-specific
antibodies was performed to identify FoxO expression and inactivation in specific
cell populations. In vitro, cultured RA (n = 3) and OA (n = 2) FLS were stimulated
with tumour necrosis factor (TNF) alpha, transforming growth factor (TGF) beta, or
soluble CD154 prior to lysis and detection of FoxO phosphorylation by immunoblot-
ting. FLS proliferative responses to these stimuli were determined in the presence
and absence of the PI3-kinase inhibitor LY294002 by crystal violet staining.
Results Phosphorylated inactive FoxO1, FoxO3a, and FoxO4 were observed in
both RA and OA synovial tissue. Inactivation of FoxO1, FoxO3a, and FoxO4 was
restricted to FLS, T lymphocytes, and synovial macrophages, respectively. Inacti-
vation of FoxO1 and FoxO4 was significantly enhanced (P < 0.05) in RA synovial
tissue compared with OA synovial tissue. No significant differences in the inacti-
vation of T lymphocyte FoxO3a were observed between RA and OA synovial
tissue. In vitro, PI3-kinase-dependent inactivation of FoxO1 was observed in RA
FLS following stimulation with TNF, TGF, and soluble CD154. Inactivation of
FoxO1 was not sufficient to promote FLS proliferation, as only TNF and TGF but
not soluble CD154 stimulated PI3-kinase-dependent FLS proliferation. Our
studies demonstrate that inactivation of FoxO1 and FoxO4 is enhanced in RA
compared with OA, provide the first (patho)physiological evidence of FoxO4 inac-
tivation in vivo, and suggest important roles for FoxO1 and FoxO4 in maintaining,
respectively, FLS and macrophage activation and survival in RA synovial tissue.
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CD4+CD25+ regulatory T cells (Treg) that specialize in the suppression of
immune responses play a critical role in the regulation of peripheral immune toler-
ance and thus might be critically involved in the pathogenesis of autoimmune dis-
eases. As for systemic lupus erythematosus (SLE), however, data concerning
Treg are so far limited. We therefore initiated detailed quantitative and qualitative
analysis of naturally occurring CD4+CD25+ Treg from SLE patients as compared
with healthy controls. FACS analysis revealed increased proportions of
CD4+CD25+ Treg, as well as activated CD4+CD69+ T cells, among peripheral
blood mononuclear cells in SLE patients as compared with healthy controls.
Ongoing experiments aim to analyze the capacity of purified CD4+CD25+ Treg to
suppress the proliferation of autologous or allogeneic T cells. Preliminary results
indicate a tendency towards a reduced suppressive capacity of CD4+CD25+
Treg in SLE patients as compared with healthy controls. Additional experiments
will determine the statistical significance of this observation and will correlate
quantitative and/or qualitative defects of Tregs in SLE patients with clinical data.
Finally, this study will also allow one to experimentally abrogate potential defects
of Treg in SLE patients. This might provide the basis for new therapeutic con-
cepts in the treatment of SLE and other autoimmune diseases.
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Background Polymorphonuclear leucocytes (PMNLs) represent the first line of
defence in innate immunity. PMNLs are the predominant cells accumulating in the
synovial fluid of rheumatoid arthritis (RA) patients and play a crucial role in the
development of tissue damage. Unstimulated PMNLs are postmitotic terminally dif-
ferentiated cells whose default setting is death by apoptosis. Pathogens or inflam-
mation induce a profound transcriptional and translational activity. Aberrant
expression of members of the major chaperone family HSP70 occurs in synovial
tissue of RA [1,2] and in PMNLs subjected to stress in the form of exercise [3] or
polytrauma [4]. Activity and substrate specificity of HSP70s is regulated by the
family of J-proteins. HSP70s and J-proteins together generate important chaper-
one machines, which are not only involved in classical chaperone tasks like proper
protein folding but also in fine tuning of molecules involved in signal transduction
and apoptotic pathways. Hardly any data exist on J-protein expression in PMNLs.
Objectives Establishment of the promyeloid precursor cell line HL60 as a model
for studies on the expression of several members of the HSP70/J-protein families
on the level of mRNA and protein. Investigation of PMNLs from healthy donors
(HD) and RA derived from peripheral blood (PB) and synovial fluid regarding the
presence of members of the HSP70/J-protein chaperone machines.
Methods HL60 cells were cultivated in FCS-supplemented RPMI 1640 medium.
PMNLs were separated by density gradient centrifugation followed by hypotonic
lysis of erythrocytes. Total RNA was isolated and contaminating DNA was elimi-
nated by Dnase digestion when necessary. Gene-specific primers complemen-
tary for various genes of HSP70s and J-proteins were designed and applied in
RT-PCR. The presence and amount of several HSP70s and J-proteins were
analysed by western blots, applying equal amounts of protein per lane.
Results In unstimulated HL60 cells, transcripts of the constitutive member of the
HSP70 family hspa8 (Hsc70) and several inducible HSP70s (hspa1b, hspa5,
hspa6) could be verified. No hspa2 transcript was detected. The same expres-
sion pattern of these five genes was observed in PB-PMNLs from HD. RT-PCR
revealed a clear signal for all J-proteins under analysis (Hdj2, HTid, Hsj1, Mdg1,
Tpr2 and Sec63) in HL60. In contrast, we observed a complete absence of these
J-protein transcripts in PB-PMNLs from HD. Interestingly, in PMNLs from RA
some J-protein transcripts were expressed in PB-PMNLs or synovial fluid PMNLs.
On the protein level, Hsp70, Hsc70 and BiP were detected in HL60, as well as
Hdj2 and HTid. In contrast, Hsc70 and Hdj2 showed a reduced expression, and
moreover BiP and HTid were under the level of detection in HD PB-PMNLs.
Conclusions  We observed a distinct expression of several members of the
HSP70/J-protein chaperone machines in PMNLs from HD or RA, and HL60. We
assume that the observed reduction in protein expression of the HSP70/J-protein
chaperone machines and the complete missing of J-protein transcripts con-
tributes to the pro-apoptotic state of unstimulated PMNLs in the periphery. We
suggest that the reappearance of several J-protein transcripts may be involved in
the altered phenotype and prolonged survival of PMNLs in RA.
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The –786C-variant of the endothelial nitric oxide synthase nos-3 gene has been
shown to be associated with coronary artery disease because of a blunted
inducibility of gene expression [1]. IL-10, a cytokine involved in TH1/TH2-cell differ-
entiation, is a new stimulus for NOS-3 expression [2].
We here address the question whether IL-10-induced NOS-3 expression is
decreased in individuals with the –786C/C genotype and, if so, whether a TH1-
mediated disease like rheumatoid arthritis is associated with this genotype.
Endothelial cells were isolated from an umbilical cord vein of known genotype
and cultured as described [1]. The expression of NOS-3 was analysed by real-
time semi-quantitative RT-PCR [1]. Genotyping was performed as described
elsewhere [1]. Patients met the revised criteria of the ACR for the classification of
rheumatoid arthritis, and donated blood samples after informed consent.
Primary human umbilical vein endothelial cells with the –786C/C genotype did not
respond with an increase in NOS-3 expression to IL-10 incubation (5 ng/ml). This
defect could be repaired after pre-incubation of the cells with a decoy oligonu-
cleotide (10 µmol/l) directed against the C-variant of the promoter. Among 587
patients with rheumatoid arthritis tested, incidences for the –786C/C genotype were
significantly higher than in the general population (17% versus 11.7%; P < 0.01).
NOS-3 is one mediator of anti-inflammatory IL-10 actions. Individuals with the
–786C/C nos-3-genotype have an increased risk for the development of rheumatoid
arthritis. This might be due to the IL-10 insensitivity of the C-variant of the promoter.
Available online http://arthritis-research.com/supplements/7/S1S40
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Background The risk of cardiovascular disease (CVD) in systemic lupus erythe-
matosus (SLE) is exceedingly high. Previously, a lupus pattern of dyslipidemia has
been described (raised triglycerides, and low high-density lipoprotein [HDL]) and
we recently reported that these lipid abnormalities were associated with tumor
necrosis factor (TNF) activity.
Methods Twenty-three women (52 ± 8.2 years) with SLE and a history of CVD
(SLE cases) were compared with 26 age-matched women with SLE and no clini-
cal manifestations of CVD (SLE controls) and 26 age-matched healthy women
(controls). Lipoprotein-related measurements included lipoprotein particle size
determination by use of NMR spectroscopy and affinity of low-density lipoprotein
(LDL) to proteoglycans. Antibodies against apolipoprotein A1 (apoA1) in HDL
and TNF was determined by ELISA. Common carotid intima-media thickness was
measured by B-mode ultrasound as a surrogate measure of atherosclerosis.
Results Anti-apoA1 were raised in SLE cases as compared with SLE controls
(P= 0.03) and controls (P = 0.001), and in SLE controls as compared with controls
(P = 0.01). Among SLE cases, anti-apoA1 was associated with TNF (P= 0.01).
Small dense LDL were more common among SLE controls and controls than in SLE
cases (P = 0.036 and 0.086, respectively). Small HDL was more common among
controls than in SLE cases and SLE controls (P = 0.001). LDL association with pro-
teoglycans did not differ between groups Activity in the TNF system was significantly
associated with triglycerides and negatively with HDL (P< 0.01).
Conclusion SLE-related dyslipidemia showed a surprising pattern with large LDL
and HDL rather than small; that is, not an expected ‘atherogenic’ lipid profile.
Anti-apoA1 antibodies where strongly associated with CVD in SLE. Whether they
may play a pathogenic role (e.g. by inhibiting anti-inflammatory properties of HDL)
is presently under investigation.
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Protein/mRNA expression of cjun, junB, junD, and cfos, levels of the mRNA-desta-
bilizing proteins AUF-1 and tristetraprolin (TTP), and levels of the mRNA-stabilizing
protein HuR were assessed in synovial membranes (SM) from patients with
rheumatoid arthritis (RA), osteoarthritis (OA), joint trauma (JT), or postmortem
normal controls (NC) using ELISA/western blotting and real-time RT-PCR.
Protein expression for Jun/Fos proto-oncogenes was significantly increased
(JunB and JunD) or numerically increased (cJun and cFos) in RA SM compared
with OA, JT, and NC. In contrast, jun/fos mRNA expression was significantly
decreased (cjun and junB) or numerically decreased (junD and cfos) in RA and
OA compared with JT or NC.
Protein expression levels of AUF-1 were comparable among the different groups.
For TTP and HuR, interestingly, significantly increased protein expression was
observed in RA and OA SM compared with either JT or NC.
Discrepancies between the mRNA and protein expression for several jun/fos
genes suggest broad alterations of post-transcriptional processes in the RA SM.
Whereas increased levels of mRNA-destabilizing TTP may contribute to the low
levels of jun/fos mRNA, abundant mRNA-stabilizing HuR may augment translation
of the remaining mRNA into protein. As a consequence, both increased expres-
sion of AP-1-dependent target genes by the activating transcription factors
cJun/cFos and modified binding activity of the resulting AP-1 complexes via the
action of deactivating JunB and JunD may contribute to the pathogenesis of RA.
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Background Mesenchymal stem cells (MSCs) have been isolated from different
tissues/organs, but it is not clear whether they possess distinct biological proper-
ties. We have previously characterized MSCs from the adult human synovial mem-
brane (SM), which can differentiate at the single cell level to cartilage, bone,
adipocytes, and skeletal muscle [1–3]. We have also reported that cells isolated
from the adult human periosteum (P) are chondrogenic in vitro [4]. In the present
work, we show that expanded periosteal cells are multipotential. We then compare
the chondrogenic and osteogenic potentials of P-MSCs with those of SM-MSCs.
Methods MSC populations were enzymatically released from the SM and perios-
teum of four adult human donors. To test multipotency, P-MSCs were subjected
to  in vitro differentiation assays or injected into regenerating tibialis anterior
muscles of nude mice. In vitro chondrogenesis was tested in micromass culture
in the presence of transforming growth factor beta in a chemically defined
medium and assessed by histochemistry for cartilage proteoglycans and by quan-
titative RT-PCR for chondrocyte markers. To investigate bone formation in vivo,
MSCs were seeded into Collagraft scaffolds and implanted under the skin of
nude mice. Bone formation was assessed by histology and the human origin
investigated by in situ hybridization for human ALU genomic repeats and by RT-
PCR for bone markers using primers specific for human cDNA.
Results P-MSCs underwent chondrogenesis, osteogenesis, and adipogenesis in
vitro as well as myogenesis in vivo. Multipotency was inherent at the single cell
level. P-MSCs were compared with SM-MSCs from the same donors in the
capacity to form cartilage in vitro and bone in vivo. Under our experimental condi-
tions, SM-MSCs displayed greater chondrogenic potential than P-MSCs with
higher contents of cartilage-specific proteoglycans and higher expression levels
of mature chondrocyte markers. For bone formation, engraftment of P-MSCs and
SM-MSCs into Collagraft was comparable and either MSC population survived
long term in vivo (20 weeks). Histologically, no bone was evident at 4 weeks. At
later time points (8–20 weeks), abundant bone formation was detected consis-
tently in all periosteal samples. In contrast, bone was rarely observed, and in small
amounts, in the synovial samples, with most human cells contributing to a fibrous-
like tissue. In all cases, bone was mostly of human origin. As evaluated by quanti-
tative RT-PCR, the expression levels of human OC, normalized for human
beta-actin, were significantly higher in the periosteal samples than in the synovial
ones. Bone was neither retrieved in empty Collagraft scaffolds nor in Collagraft
scaffolds seeded with human dermal fibroblasts used for a cell negative control.
Conclusions Expanded P-MSCs can differentiate to cartilage, bone, adipocytes,
and skeletal muscle. Importantly, SM-MSCs displayed a greater chondrogenic
potential in vitro than P-MSCs. By contrast, P-MSCs formed bone in vivo consis-
tently and reproducibly as opposed to SM-MSCs. Our results suggest that MSCs
derived from different tissue have distinct biological properties, thereby pointing to a
need for development of quality controls for MSC preparations in clinical settings.
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Chronic inflammation in rheumatoid arthritis (RA) is mediated by repeatedly acti-
vated proinflammatory Th1 cells. In contrast, Th2 cells that might downmodulate the
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chronic autoimmune response are rarely found in RA. It has been previously docu-
mented that RA T cells are severely impaired in their ability to differentiate into Th2
effectors while exerting enhanced Th1 differentiation. The mechanisms underlying
this functional abnormality, however, have not been delineated. As IL-4 is a most
critical determinant in regulating immune responses by promoting Th2 cell develop-
ment and inhibiting Th1 cell differentiation, we analyzed the role of single nucleotide
polymorphisms (SNPs) in the IL-4 receptor (IL-4R) α-chain, which is critical for
binding of IL-4 and for IL-4 signal transduction, in the differentiation of human T
cells. Three hundred and sixty-one healthy individuals were genotyped by allele-spe-
cific PCR for the two IL-4R α-chain SNPs that are located in functionally important
regions of the IL-4R α-chain — the I50V SNP50 and the Q551R SNP551 in the IL-
4-binding and STAT6-binding domains, respectively. Naive and memory CD4-posi-
tive T cells were isolated from the peripheral blood of individuals who were
homozygous for either allele at SNP50 and SNP551, and were primed for 5 days
with mAbs to CD28 and/or CD3 in the presence or absence of exogenous IL-4.
The phenotype of the resulting differentiated effector cells was then analyzed by
flow cytometric analysis of cytoplasmic cytokines. The SNP551 alleles did not affect
T-cell differentiation. In contrast, the inhibitory effect of IL-4 on Th1 cell differentia-
tion was significantly diminished in CD4 T cells that were homozygous for the
mutated allele at SNP50 (50V) as compared with those with the wild type allele
(I50). Likewise, the augmenting effect of IL-4 on Th2 cell differentiation was
enhanced on T cells that were homozygous for the wild-type allele as compared
with T cells expressing the mutant allele. These data indicate that the mutant allele
of the IL-4R α-chain at SNP50 is associated with a decreased T-cell response to IL-
4. To delineate a potential mechanism of different responses to IL-4 in the cells
expressing different alleles of the IL-4R, T cells form individuals who were homozy-
gous for either the wild-type or the mutant allele at SNP50 were primed with differ-
ent concentrations of IL-4 and analyzed by flow cytometry for STAT6 and
phosphorylated STAT6. Whereas STAT6 concentrations were not different
between T-cell expressing I50 or V50, STAT6 phosphorylation in response to IL-4
stimulation was significantly reduced in T cells expressing the V50 allele compared
with T cells expressing I50. Thus, the V50 SNP50 allele of the IL-4R α-chain might
regulate T-cell differentiation by diminishing T-cell responses to IL-4, resulting in
reduced STAT-6 phosphorylation and subsequently in diminished Th2 cell differenti-
ation. The V50 SNP50 allele might thereby contribute to the development of unbal-
anced Th subset activation, as characteristic for autoimmune diseases, such as RA.
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IL-10 is both an immunoinhibitory (monocytes and T cells) and an immunostimula-
tory (B cells) cytokine that may confer susceptibility and modulate disease
expression in rheumatoid arthritis (RA). The capacity to produce IL-10 (as mea-
sured by production of IL-10 in a lipopolysaccharide-stimulated whole blood
culture) differs about fourfold between individuals. By comparing variance
between monozygotic and dizygotic twins it was estimated that 60% of these dif-
ferences are caused by genetic factors.
To determine relevance for susceptibility to diseases, we determined production
levels of IL-10 in lipopolysaccharide-induced whole blood cultures from 76 new
incident, non-treated RA patients and 63 healthy controls. RA patients had a
50% lower IL-10 production than controls (P < 0.001). In a cohort of women
(≥85 years) with high risk of cardiovascular death [1], we observed that low
innate IL-10 production yielded a threefold increase in risk of dying, which, inter-
estingly, correlates with the presence of the A allele of the IL-10 –2849 promoter
polymorphism (P = 0.021).
To elucidate this genetic basis of IL-10 secretion and the functionality of IL-10
promoter polymorphisms, we used the technique of allele-specific transcript
quantification to characterise the ratio between two alleles of the IL-10 gene in
15 healthy heterozygous individuals. We identified two groups whereby five
healthy donors exhibited a 1:1 ratio whereas seven exhibited a ratio >1
(P < 0.0017) [2]. Donors heterozygous for haplotype IL-10.2 were only prevalent
in the group with higher allelic expression ratios. The G allele of the IL-10 pro-
moter single nucleotide polymorphism –2849 tags this haplotype, providing func-
tional evidence that differential allelic transcription partly explains the constant
associations found with IL-10 production levels.
In conclusion, this study provides evidence that IL-10 haplotypes dictating pro-
duction of IL-10 are involved not only in conferring susceptibility to RA, but also in
risk for cardiovascular death in old age.
References
1. Van Den Biggelaar AH, De Craen AJ, Gussekloo J, Huizinga TW, Heijmans
BT, Frolich M, Kirkwood TB, Westendorp RG: Inflammation underlying
cardiovascular mortality is a late consequence of evolutionary pro-
gramming. FASEB J 2004, 18:1022-1024.
2. Kurreeman FA, Schonkeren JJ, Heijmans BT, Toes RE, Huizinga TW: Tran-
scription of the IL10 gene reveals allele-specific regulation at the
mRNA level. Hum Mol Genet 2004, 13:1755-1762.
P110
Regulation of myeloid cell function and MHC class II
expression by tumor necrosis factor
RB Mueller1,2, A Skapenko1,2, M Grunke2, J Wendler3, B Stuhlmuller4, 
JR Kalden2, H Schulze-Koops1,2
1Nikolaus Fiebiger Center for Molecular Medicine, Clinical Research Group III,
University of Erlangen–Nuremberg, Erlangen, Germany; 2Department of Internal
Medicine III and Institute for Clinical Immunology, University of
Erlangen–Nuremberg, Erlangen, Germany; 3Rheumatologische
Gemeinschaftspraxis, Erlangen, Germany; 4Department of Rheumatology and
Clinical Immunology, Charité University Hospital, Berlin, Germany
Arthritis Res Ther 2005, 7(Suppl 1):P110 (DOI 10.1186/ar1631)
Neutralizing agents to tumor necrosis factor (TNF) are the most successful
means to ameliorate systemic autoimmune inflammation. Neutralization of TNF,
however, is often associated with the development of autoantibodies, in particular
to nuclear antigens, the mechanisms of which are unknown. Here, we analyzed
the effect of TNF and its neutralization on MHC class II expression and function of
antigen-presenting myeloid cells in rheumatoid arthritis (RA). Monocytes were
isolated from the peripheral blood of RA patients before and after anti-TNF mAb
treatment and from controls by negative selection, differentiated in vitro into
macrophages and analyzed by flow cytometry for HLA-DR expression. T-cell
responses to activation by myeloid cells were assessed in proliferation assays,
and mRNA levels of the class II transactivator (CIITA) were determined by semi-
quantitative RT-PCR. HLA-DR expression was significantly reduced on myeloid
cells from RA patients with active disease, but was increased to normal levels
after TNF mAb treatment. Concordantly, in vitro application of TNF to monocytes
from healthy individuals reduced their ability to upregulate HLA-DR during differ-
entiation to macrophages and, importantly, inhibited their ability to stimulate T
cells in mixed lymphocyte reactions. Molecular analysis revealed that the effect of
TNF on HLA-DR expression was mediated via suppression of the transcription
factor CIITA. The data indicate that TNF decreases HLA-DR expression by reduc-
ing CIITA mRNA levels in myeloid cells, functionally resulting in a decreased stim-
ulatory capacity of myeloid cells for T cells. Concordantly, ameliorating disease
activity in chronic inflammatory diseases by neutralizing TNF restores HLA-DR
expression of myeloid cells and their ability to stimulate T cells. Thus, anti-TNF
treatment might lead to augmented T-cell activation by myeloid cells, thereby pro-
moting immune responses to (auto)antigens and the development of anti-nuclear
antibodies that are frequently associated with anti-TNF therapy.
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Background In rheumatoid arthritis (RA), constitutive activation of integrins pro-
motes retention of oxidatively stressed, activated T lymphocytes in synovial tissue
where they perpetuate inflammation through cell–cell contact with synovial
stromal cells, macrophages and plasma cells. We have previously demonstrated
that activation of Ras GTPases, coupled with inactivation of the related GTPase
Rap1, is responsible for oxidative stress in RA synovial fluid (SF) T lymphocytes
[1]. Inactivation of Rap1, however, is incongruous with the observation that Rap1
signaling is absolutely required for integrin function in T lymphocytes. Because T
lymphocytes express multiple Ras homologs (H-Ras, K-Ras, and N-Ras), we
explored the possibility that these proteins may make distinct contributions to
reactive oxygen species (ROS) regulation and integrin function in T lymphocytes.
Objectives To determine which Ras homologs are activated in RA SF T lympho-
cytes, to determine whether Ras homologs selectively regulate ROS production
and integrin-dependent adhesion in T lymphocytes, and to use pharmacological
inhibitors to characterize downstream signaling pathways by which Ras
homologs may mediate these effects.
Available online http://arthritis-research.com/supplements/7/S1S42
Methods Activation of H-Ras, K-Ras, and N-Ras homologs in RA SF T lympho-
cytes were determined by activation-specific GTPase precipitation and
immunoblot analysis. T-lymphocyte intracellular ROS production was measured
by FACS-based analysis of DCFA oxidation. Control, active Ras, and RapGAP
constructs were introduced into human Jurkat T cells and healthy donor periph-
eral blood T lymphocytes by electroporation and nucleofection techniques,
respectively. For ROS analysis, cells were cotransfected with RFP to detect
transfected cells. For static adhesion assays, a luciferase reporter plasmid was
used to detect transfected cells: cells were allowed to adhere to immobilized
fibronectin or recombinant human intracellular adhesion molecule, non-adherant
cells washed off, and adherant cells quantitated by luciferase assays. In some
experiments, cells were preincubated with the pharmacological inhibitors BAPTA-
AM, LY294002, catalase, and DPI prior to ROS or adhesion analysis.
Results All three homologs of Ras were found to be constitutively activated in RA
SF T lymphocytes. Active H-Ras, but not K-Ras or N-Ras, stimulated ROS produc-
tion in both Jurkat and peripheral blood T lymphocytes. H-Ras-induced ROS pro-
duction was sensitive to BAPTA-AM and catalase, but not LY294002 or DPI,
indicating a calcium-sensitive hydrogen peroxide source of ROS that does not
require a functional NADPH oxidase. These results are consistent with our previous
observations in purified RA SF T lymphocytes. In contrast, N-Ras, but not H-Ras or
K-Ras, induced integrin-dependent adhesion in Jurkat T cells and peripheral blood T
lymphocytes. N-Ras-induced adhesion was sensitive to LY294002, indicative of
PI3-kinase signaling. Additionally, inactivation of Rap1 with RapGAP had no effect
on N-Ras-induced adhesion. This represents the first (patho)physiological signaling
pathway by which integrins can be activated independently of Rap1. Our results
suggest that selective targeting of H-Ras and N-Ras may allow specific modulation
of T-cell ROS production and integrin activation in RA T lymphocytes.
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Chronic arthritis is characterized by persistent joint inflammation and concomitant
joint destruction. IL-17 is a novel proinflammatory T-cell cytokine suspected to be
involved in inflammatory and autoimmune diseases such as rheumatoid arthritis.
Here, we report that IL-17 receptor (IL-17R) signaling is required in resident syn-
ovial cells for full progression of chronic synovitis and bone erosion. Repeated
injections of Gram-positive bacterial cell wall fragments (SCW) directly into the
knee joint of naïve IL-17R-deficient (IL-17R–/–) mice had no effect on the acute
phase of arthritis but prevented progression to chronic destructive synovitis as
was noted in wild-type (wt) mice. Micro-array analysis revealed significant down-
regulation of leukocyte-specific chemokines, selectins, collagenase-3, and IL-1 in
the synovium of IL-17R–/– mice. Bone marrow (BM) chimeric mice revealed the
need for IL-17/IL-17R signaling in resident synovial cells for development of full
blown synovitis. Chimeric mice of host wt and donor IL-17R–/– BM cells devel-
oped destructive synovitis in this chronic relapsing SCW arthritis model similar to
wt → wt chimeras. In contrast, chimeric mice of host IL-17R–/– and donor wt BM
cells were protected from full blown destructive arthritis similar to IL-17R–/– →
IL-17R–/– chimeras. These data strongly suggest T-cell IL-17–IL-17R signaling in
resident synovial cells to be a pivotal mechanism through which an acute
macrophage-driven joint inflammation progresses into a chronic destructive syn-
ovitis. Prevention of local synovial IL-17–IL-17R signaling warrants consideration
as a therapeutic target in chronic destructive arthritis.
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Imbalance in cytokine homeostasis is thought to play an important part in the
pathogenesis of chronic inflammatory diseases such as rheumatoid arthritis. We
demonstrated that T cells might exert a pathological effect through direct cellular
contact with monocyte-macrophages, inducing a massive upregulation of IL-1β
and tumour necrosis factor (TNF) [1]. We showed that this mechanism that might
be relevant to chronic inflammation is specifically inhibited by high-density
lipoproteins (HDL) [2]. Like many other stimuli, besides proinflammatory
cytokines, the contact-mediated activation of monocytes induces the production
of cytokine inhibitors such as IL-1Ra. HDL inhibited the production of IL-1β and
TNF but not that of IL-1Ra induced in monocytes activated by membranes iso-
lated from stimulated T cells to mimic cellular contact. This was also the case in
peripheral blood mononuclear cells stimulated by either phytoheamagglutinin or
tetanus toxoid. Similarly, IL-1Ra mRNA expression was not inhibited contrary to
IL-1β and TNF mRNA. This demonstrates that different molecules at the surface
of stimulated HUT-78 cells are involved in the induction of IL-1β, TNF and IL-1Ra
in monocytes, IL-1β and TNF being activated by HDL-specific ligand(s). Separa-
tion of CHAPS-solubilized membrane molecules by liquid isoelectric focusing
showed that two activity peaks were present; one activating IL-1β, TNF and
IL-1Ra production, the other inducing the production of IL-1Ra in the absence of
IL-1β and TNF. Further isolation of these two types of factor by gel filtration
demonstrated that factor(s) inducing IL-1β, TNF and IL-1Ra displayed a Mr
around 40,000 kDa, whereas factors inducing IL-1Ra only displayed Mr around
70,000 kDa and 30,000 kDa. Thus different factors are expressed at the surface
of stimulated T cells that differentially trigger the production of proinflammatory
and anti-inflammatory factors, and are differently affected by HDL.
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Background Apoptosis of peripheral blood T lymphocytes from patients with
Crohn’s disease has been described after in vitro activation followed by incuba-
tion with infliximab. These ex vivo data raised the question of whether in vivo
treatment of rheumatoid arthritis (RA) with the chimeric tumor necrosis factor
alpha antibody, infliximab, causes apoptosis in peripheral blood mononuclear
cells. This study was designed to detect the early effects of infliximab treatment
on apoptosis in the peripheral blood of patients with RA.
Methods Ten patients with active RA (Disease Activity Score [DAS 28] > 3.2)
received 3 mg/kg infliximab intravenously in combination with methotrexate (mean
dose of 25 mg weekly). All 10 patients underwent blood sampling before, 1 hour
after and 24 hours after the administration of infliximab. Apoptosis was deter-
mined using double staining with annexin-V, as an early marker of apoptosis, and
7-amino-actinomycin D (AAD) to exclude necrotic cells from this population.
Peripheral blood erythrocytes were lysed and the mononuclear cells were incu-
bated with the different antibodies. The percentages of annexin-V-positive and 7-
AAD-negative monocytes and lymphocytes were analyzed by flow cytometry. For
statistical analysis, a paired t test was used to compare the percentages of apop-
totic cells 1 hour and 24 hours after treatment with those at baseline.
Results All samples were analyzed for the presence of and change in apoptosis.
At baseline, the median percentage of apoptotic monocytes was 0.90% (range
6.23–0.19); 1 hour after treatment, the median percentage was 0.56% (range
2.90–0.32) and 24 hours after treatment the median percentage was 0.21%
(range 2.90–0.00). In the lymphocyte population, the median percentage of
apoptotic cells was 0.98% (range 2.15–0.00) at baseline as compared with
0.52% (range 6.30–0.00) 1 hour after treatment and 0.39% (range 2.85–0.00)
24 hours after infliximab administration.
Conclusion In this in vivo study we found no statistically significant increase from
baseline in the percentage of apoptotic monocytes or lymphocytes in the periph-
eral blood of RA patients at 1 hour or 24 hours after infliximab treatment.
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Objectives In rheumatoid arthritis (RA), tumor necrosis factor (TNF) alpha is a
major inductor of the proinflammatory/pro-destructive functions of synovial fibro-
blasts (SFB). These effects are predominantly mediated via the TNF receptor-1
(TNFR1). In addition to the NF-κB pathway, the p38 MAP kinase seems to play a
central role for the underlying signal transduction. In the present study, RA-SFB
were compared with osteoarthritis (OA)-SFB concerning the TNF-α/TNFR1/2-
induced secretion of IL-6, IL-8, prostaglandin E2 (PGE2), and matrix metallopro-
teinase-1/tissue inhibitor of matrix metalloproteinase-1 (MMP-1/TIMP-1), as well
as the sensitivity to p38 MAP-kinase inhibition.
Methods Early-passage (second) RA-SFB and OA-SFB were analyzed for TNFR
expression by FACS. The cells were then stimulated with TNF-α (10 ng/ml) or
agonistic anti-TNFR1 (HTR-9) or anti-TNFR2 monoclonal antibodies (UTR-1;
10 µg/ml each) with/without inhibition of the p38 kinase by SB203580 (1 µM).
Secretion of IL-6, IL-8, PGE2, MMP-1, and TIMP-1 was analyzed by ELISA.
Results RA-SFB and OA-SFB both expressed TNFR1 and TNFR2 on their
surface, without significant differences between the two groups. Secretion of
IL-6, IL-8, PGE2, and MMP-1, but not TIMP-1, was significantly augmented by
stimulation of RA-SFB and OA-SFB with TNF-α. Except for PGE2 (induced via
both TNFRs), these effects were exclusively mediated via the TNFR1. Inhibition of
p38 kinase reduced the secretion of IL-6 and PGE2 significantly and equally well
in RA-SFB and OA-SFB. However, the secretion of MMP-1 was significantly sup-
pressed only in OA-SFB, whereas RA-SFB were insensitive to the inhibition of
MMP-1 secretion by p38 inhibition.
Conclusion In early-passage RA-SFB and OA-SFB, TNF-α-induced proinflamma-
tory/pro-destructive functions are predominantly mediated by TNFR1. Strikingly,
RA-SFB are partially resistant to the suppression of pro-destructive MMP-1 by
p38 MAP-kinase inhibition. The underlying structural or functional alterations of
the p38 MAP kinase in RA-SFB may contribute to the pathogenesis and/or thera-
peutic sensitivity of RA.
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Background The synovial membrane is not entirely homogeneous, leading to a
local variability within a joint. Synovial tissue can be retrieved from patients in a
number of ways (e.g. open surgery, blind needle biopsy, and arthroscopy).
Aim To study inter-patient versus intra-patient variability in gene expression in
rheumatoid arthritis (RA) synovial tissue.
Patients and methods Orthopaedic samples Three synovial biopsies were taken
from three RA patients (patients 1–3) at joint replacement surgery. All nine biop-
sies were divided into three, creating nine samples from each joint, and a total of
27 samples.
Arthroscopic samples Two to four synovial biopsies were sampled at arthroscopy
from four RA patients (patients 4–7) with an inflamed knee joint. Multiple samples
were taken from different sites in all patients.
Handling of synovial tissue and microarray analysis All samples were snap frozen
and stored at –80°C. Following RNA extraction (at 4°C), reverse transcription,
cDNA amplification and labelling, each sample was hybridised in duplicate
against a reference, on a cDNA array locally produced, representing 18,139
unique genes. After data filtering, genes were defined as differentially expressed
(DE) if they had a B score > 0 and a fold change > 2. Several hierarchical cluster-
ings were performed to obtain an overview of the data. DE genes in the samples
were used to compare the variation between samples from one biopsy, the varia-
tion between biopsies from one joint and the variation between biopsies from dif-
ferent patients. Clustering also allowed comparisons between the sampling tech-
niques.
Results In the orthopaedic subset, variation between samples within one biopsy
(patients 1–3) was between 1.2% and 6.7% of analysed genes. The amount of
DE genes between biopsies was between 1.2% and 5.9%. Hierarchical cluster-
ing of biopsies showed more similarities within a patient than between patients,
except for one biopsy. One biopsy from patient 1 clustered with biopsies from
patient 2 because the other two biopsies from patient 1 had higher fat cell
content (confirmed microscopically) than any of the other biopsies. This was con-
firmed by gene expression profiles with activity in the fatty acid and lipid metabo-
lism. When these genes were removed from the analysis, the samples clustered
perfectly according to patient. The analysis of the arthroscopic subset (patients
4–7) showed a variation of DE genes between biopsies of 0.3–1.6%, and a
perfect matching in cluster analysis with all biopsies from the same patient clus-
tering together, without any further labouring with data.
Table 1 
Average sample  Total RNA  RNA yield per 
weight (mg) yield (mg) milligram of tissue (mg)
Patients 1–3 32.9 14,808 502
Patients 4–7 19.0 9834 407
Conclusions This study shows that inter-patient variability is greater than intra-
patient variability in gene expression, in RA synovial tissue. We found that one
biopsy is enough to represent one patient as they clustered nicely together, with
one exception, which was related to high content of fat cells in the biopsy. Vari-
ability is in the same order of magnitude in samples close to each other as com-
pared with those further apart within the same patient.
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Background Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are
two inflammatory diseases that are thought to arise from a complex interaction
between multiple genetic factors and environmental triggers. We have previously
demonstrated an association between the Fc gamma receptor (FcγR) genetic
locus on chromosome 1q22-23 and rheumatoid arthritis, and have now extended
our study to include other inflammatory/autoimmune diseases.
Methods  The  FCGR2A-131H/R, FCGR3A-158F/V  and FCGR3B-NA1/NA2
functional polymorphisms and a novel FCGR2B 3′-UTR polymorphism were
examined for association with PMR (n = 69) and GCA (n = 83) in two well-char-
acterised clinical cohorts from Northern Spain. In view of the close molecular
proximity between FCGR2A, FCGR3A, FCGR3B and FCGR2B we have exam-
ined FcγR haplotypes for association with rheumatoid arthritis. Pairwise disequi-
librium coefficients (D′) were initially calculated in 115 matched controls. The
EHPlus program was used to estimate haplotype frequencies for patients and
controls and to determine whether significant linkage disequilibrium was present.
A likelihood ratio test is performed to test for differences between the haplotype
frequencies in cases and controls. A permutation procedure implemented in this
program enabled 1000 permutations to be performed on all haplotype associa-
tions to assess significance.
Results  There was borderline linkage disequilibrium between FCGR2A and
FCGR3A (D′ = –0.313, P = 0.03) with more significant disequilibrium between
FCGR3A and FCGR3B (D′ = –0.646, P = 0.0001). There was a significant dif-
ference in the FCGR2A allele (P = 0.03) and genotype frequencies (P = 0.03)
with GCA compared with controls. Specifically, there was an increase in the
FCGR2A-131RR genotype in both the PMR (odds ratio [OR] = 2.15; 95% confi-
dence interval [CI] = 1.0–4.7, P = 0.05) and GCA (OR = 2.53, 95%
CI = 1.3–5.1, P = 0.01) populations compared with controls.
Increased homozygosity for the FCGR2A-FCGR3A 131R-158F haplotype was
found in 8% controls compared with 25% of PMR (OR = 4.20, 95% CI =
1.3–13.1, P = 0.01) and 24% GCA (OR = 4.46, 95% CI = 1.5–3.3, P = 0.004)
individuals. Logistic regression analyses suggested that both FCGR2A  and
FCGR3A contributed to GCA susceptibility. In addition, homozygosity for the
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FCGR3A-FCGR3B 158F-NA2 haplotype was found in 25% controls compared
with 44% GCA subjects (OR = 2.35, 95% CI = 1.0–5.7, P = 0.06). Logistic
regression analyses suggested that FCGR3A was the most important site con-
tributing to GCA susceptibility.
A subgroup of GCA patients who had experienced visual symptoms was exam-
ined as a marker of disease severity. The most significant findings were increased
homozygosity of a FCGR2A-FCGR3A 131R-158F haplotype (8% controls, 16%
GCA without visual manifestations and 50% GCA with visual manifestations
[OR = 12.86, 95% CI = 1.3–128.2, P = 0.03]). Additionally, the FCGR3A-
FCGR3B haplotype was found in 11/13 individuals who sustained visual mani-
festations. Homozygosity was seen in 25% controls, 27% GCA without eye
involvement and 63% GCA with visual manifestations (OR = 5.83, 95% CI =
0.9–38.9, P = 0.08). For each haplotype logistic regression analyses suggested
FCGR3A was the most important site.
Conclusions We have demonstrated that FCGR2A may contribute to the ‘sus-
ceptibility’ of PMR and GCA in this Spanish population. The increased association
observed with a FCGR2A-FCGR3A haplotype suggests the presence of addi-
tional genetic polymorphisms in linkage disequilibrium with this haplotype that may
contribute to disease susceptibility. In addition, FcγR haplotypes may potentially
define a subpopulation of individuals at greater risk of vascular occlusion. These
findings may ultimately provide new insights into disease pathogenesis.
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Introduction The severity and outcome of chronic arthritis is determined by the
balance between destructive and homeostatic or anabolic molecular signaling
pathways. Increasing evidence suggests a role for embryonic signaling pathways,
essential for development and growth, in the maintenance of tissue homeostasis
and in the induction of repair. Untimely or inappropriate activation of such path-
ways may also have a role in the progression of some diseases. Bone morpho-
genetic proteins (BMPs), originally identified as protein factors that induce a
cascade of endochondral bone formation, have critical functions in cell prolifera-
tion, differentiation, adhesion and death. We have previously identified different
BMPs in patients with chronic arthritis [1]. In this study, we evaluate the effect of
shifting the balance in BMP signaling by reducing endogenous levels of noggin, a
BMP antagonist, in a mouse model of systemic auto-immune arthritis (collagen-
induced arthritis [CIA]), a model of cartilage destruction (methylated BSA
[mBSA]-induced mono-arthritis) and a model of ankylosing enthesitis and
spondyloarthritis (spontaneous arthritis in male DBA/1 mice).
Materials and methods Heterozygous mice with a targeted inactivation of the
noggin gene and insertion of a β-galactosidase reporter (noggin+/LacZ) (a gift from
R Harland, Berkeley, USA), originally in the C57/Bl6 background, were back-
crossed into the DBA/1 background for more than eight generations. mBSA-
induced arthritis was induced by intra-articular mBSA injection on day 1, followed
by injection of subcutaneous IL-1 on three consecutive days. Mice were sacrificed
at day 7. Severity of disease was determined with a histological score based on
exsudate, inflammatory cell infiltration in the synovium, pannus formation, cartilage
and bone destruction. Cartilage destruction and proteoglycan loss was further
quantified using safranin O staining and digital image analysis of the articular sur-
faces from tibia, patella and femur. CIA was induced by allo-immunisation with
chicken type II collagen emulsified in complete Freund adjuvant on day 1, followed
by intraperitoneal booster injection of type II collagen on day 21. Arthritis charac-
terized by ankylosing enthesitis is spontaneously occurring in aging male DBA/1
mice after grouped caging (> 4 males per cage) from the age of 14 weeks
onwards. Incidence and severity of arthritis was assessed clinically and by histol-
ogy in the latter two models. Presence of noggin was determined by immunohisto-
chemistry in wild-type mice and by LacZ staining in noggin+/LacZ mice.
Results Noggin haploinsufficiency did not affect the incidence or clinical severity
of CIA in DBA/1 mice. No differences in histological severity were seen. The his-
tological severity of mBSA-induced monoarthritis in noggin+/LacZ mice was similar
to that of wild-type mice. However, cartilage destruction as determined by digital
image analysis of proteoglycan content was significantly reduced in noggin+/LacZ
mice suggesting a protective role for BMP signaling. Disease incidence and
severity of spontaneous arthritis was similar in noggin+/LacZ and wild-type DBA/1
mice. However, histological analysis of this arthritis showed a slower disease pro-
gression in the haploinsufficient mice. Progression of ankylosing enthesitis, in par-
ticular chondrocyte hypertrophy and new bone formation, was delayed as
compared with wild-type mice. The involvement of noggin in these processes was
confirmed by immunohistochemistry for noggin in wild-type mice and LacZ stain-
ing in noggin+/LacZ mice.
Conclusions Noggin haploinsufficiency has a protective effect on proteoglycan
loss in a mouse model of cartilage destruction. Noggin haploinsufficiency also
slows the progression of ankylosing enthesitis in a mouse model of spondyloarthri-
tis. The role of noggin in ankylosing enthesitis is similar to what is seen during
endochondral bone formation in development. These data provide further evidence
that embryonic molecular signaling pathways, and BMP signaling in particular, are
involved in the balance between tissue destruction, homeostasis and repair.
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Toll-like receptors (TLRs) are pattern recognition receptors of the innate immune
system. TLR2 has been demonstrated to be expressed in synovial tissue of
patients with rheumatoid arthritis (RA) as well as in cultured synovial fibroblasts of
patients with RA and osteoarthritis. However, it is not known whether other
members of the TLR family are expressed in synovial fibroblasts. We have there-
fore examined the expression of TLR1–TLR9 in these cells and performed stimu-
lation experiments using specific TLR ligands. TLR and matrix metalloproteinase
(MMP) mRNA expression was analysed by real-time PCR using 18S-cDNA as an
internal control. A difference of five or more cycles between cDNA of the samples
and non-RT control was considered to be the detection limit. While all fibroblasts
expressed TLR1–TLR6, the expression of TLR2 and TLR3 was significantly
higher in synovial fibroblasts from patients with RA as compared with normal skin
fibroblasts. TLR7, TLR8 and TLR9 mRNA did not reach the detection level. To
assess the function of these TLRs, cultured synovial and skin fibroblasts were
stimulated with the TLR ligands bacterial lipopeptide, poly (I:C), lipopolysaccha-
ride and flagellin. All ligands stimulated the expression of MMP1, MMP3, MMP9
and MMP13 to a certain extent. Whereas the TLR2 ligand bacterial lipopeptide
preferentially induced the expression of MMP1 and MMP3, the TLR3 ligand poly
(I:C) was a more efficient inducer of MMP13 and MMP3 and also induced MMP1
to a lesser extent. Normal skin fibroblasts expressed significantly lower levels of
MMP3 and MMP13 mRNA as compared with synovial fibroblasts of patients with
RA. Our data extend previous reports on the expression of TLRs on synovial
fibroblasts to include TLR1–TLR6 and document that these TLRs are functional.
Depending on the TLR ligand used, MMP expression is differentially induced.
This supports the notion that activation of TLR signalling pathways might con-
tribute to joint inflammation and destruction in RA.
P120
Exploring mechanisms of inflammatory hyperalgesia in
murine collagen-induced arthritis
JJ Inglis1, P Anand2, P Facer2, G Criado1, M Feldmann1, RO Williams1
1Kennedy Institute of Rheumatology, Imperial College London, UK;
2Neuroscience and Psychological Medicine, Imperial College London, UK
Arthritis Res Ther 2005, 7(Suppl 1):P120 (DOI 10.1186/ar1641)
Rheumatoid arthritis (RA) is an autoimmune inflammatory disorder, characterised
by joint swelling and diffuse chronic pain. RA patients display both hyperalgesia
(an exaggerated painful response to a noxious stimulus) and allodynia (a painful
response to a non-noxious stimulus). Collagen-induced arthritis (CIA) in the
mouse is a well-established model of RA that may be useful in the study of inflam-
matory hyperalgesia.
The aim of this study was to establish CIA as a model for studying inflammatory
hyperalgesia, and to assess cellular changes that occur in the nociceptive system
during the course of arthritis.
Arthritis was induced by injection of 2 mg/ml bovine type II collagen in complete
Freund’s adjuvant into the base of the tail of male DBA/1 mice (n = 30). Behav-
ioural analysis was performed for 28 days following arthritis onset. Mechanical
and thermal hyperalgesia was assessed using the Plantar Von-Frey microproces-
sor system and the Hargreaves Plantar test, respectively. Animals were sacrificed
at intervals after arthritis onset, and the lumbar spinal cord was collected and
immunostained for astrocytes using antibodies to glial fibrillary acidic protein.
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Prior to onset of inflammation (post immunisation), little hyperalgesia occurred.
Following arthritis onset there was a rapid decrease in both mechanical (Fig. 1)
and thermal thresholds, reaching a maximum at 7–10 days after onset. Thermal
threshold returned to naïve levels 24 days following arthritis onset, while mechan-
ical hyperalgesia remained throughout the study.
Increased glial fibrillary acidic protein expression was detected in the spinal cord
from the day of arthritis onset, indicating that astrocytic activation occurs in CIA.
This is in agreement with a well-established inflammatory model used for the
study of pain, complete Freund’s adjuvant-induced monoarthritis.
Our results indicate that CIA can be used in the study of pain, and that changes
occur in the nociceptive system during inflammation. As CIA is a well-established
and validated model of RA, it may be of benefit to test analgesics aimed at inflam-
matory pain in this model and to understand the mechanisms involved in inflam-
matory hyperalgesia.
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Background Rheumatoid arthritis (RA) is an autoimmune disease that is thought to
arise from a complex interaction between multiple genetic factors and environmen-
tal triggers. We have previously demonstrated an association between a Fc gamma
receptor (FcγR) haplotype and RA in a cross-sectional cohort of RA patients. We
have sought to confirm this association in an inception cohort of RA patients and
matched controls. We also extended our study to investigate a second autoanti-
body associated rheumatic disease, primary Sjögren’s syndrome (PSS).
Methods  The  FCGR3A-158F/V  and  FCGR3B-NA1/NA2 functional polymor-
phisms were examined for association in an inception cohort of RA patients
(n = 448), and a well-characterised PSS cohort (n = 83) from the United
Kingdom. Pairwise disequilibrium coefficients (D′) were calculated in 267 Blood
Service healthy controls. The EHPlus program was used to estimate haplotype
frequencies for patients and controls and to determine whether significant linkage
disequilibrium was present. A likelihood ratio test is performed to test for differ-
ences between the haplotype frequencies in cases and controls. A permutation
procedure implemented in this program enabled 1000 permutations to be per-
formed on all haplotype associations to assess significance.
Results  There was significant linkage disequilibrium between FCGR3A and
FCGR3B (D′ = –0.445, P = 0.001). There was no significant difference in the
FCGR3A or FCGR3B allele or genotype frequencies in the RA or PSS patients
compared with controls. However, there was a significant difference in the
FCGR3A-FCGR3B haplotype distributions with increased homozygosity for the
FCGR3A-FCGR3B 158V-NA2 haplotype in both our inception RA cohort (odds
ratio = 2.15, 95% confidence interval = 1.1–4.2 P = 0.027) and PSS (odds ratio
= 2.83, 95% confidence interval = 1.0–8.2, P = 0.047) compared with controls.
The reference group for these analyses comprised individuals who did not
possess a copy of the FCGR3A-FCGR3B 158V-NA2 haplotype.
Conclusions We have confirmed our original findings of association between the
FCGR3A-FCGR3B 158V-NA2 haplotype and RA in a new inception cohort of
RA patients. This suggests that there may be an RA-susceptibility gene at this
locus. The significant increased frequency of an identical haplotype in PSS sug-
gests the FcγR genetic locus may contribute to the pathogenesis of diverse
autoantibody-mediated rheumatic diseases.
Acknowledgements SM and JIR are joint first authors. This work was funded by
the Arthritis Research Campaign.
P122
Non-traditional risk and protective factors for
cardiovascular disease in systemic lupus erythematosus
A Cederholm1, E Svenungsson2, D Stengel3, G-Z Fei1, AG Pockley4, 
E Ninio3, J Frostegård1
1Department of Medicine, CIM and CME, Karolinska University Hospital,
Huddinge, Sweden; 2Department of Rheumatology, Karolinska University
Hospital, Solna, Sweden; 3INSERM U 525/IFR14 Cœur Muscle Vaisseaux and
Université PM Curie/Faculté de Médecine Pitié-Salpétrière, Paris, France;
4Division of Clinical Sciences (North), University of Sheffield, UK
Arthritis Res Ther 2005, 7(Suppl 1):P122 (DOI 10.1186/ar1643)
Background There is an important inflammatory and autoimmune component to
atherosclerosis and cardiovascular disease (CVD). It is therefore interesting that
the risk of CVD is so exceedingly high in patients with systemic lupus erythemato-
sus (SLE).
Objective To investigate the role of non-traditional risk and protective factors for
CVD related to inflammation and immune activation in SLE-associated CVD.
Methods Twenty-six women (52 ± 8.2 years) with SLE and a history of CVD
(SLE cases) were compared with 26 age-matched women with SLE and no clini-
cal manifestations of CVD (SLE controls) and 26 age-matched healthy women
(population controls). As a surrogate measure of atherosclerosis, common
carotid intima-media thickness and plaque occurrence were detected by B-mode
ultrasound. Circulating levels of oxidized low-density lipoprotein (LDL) were mea-
sured by a mAb-4E6-based competition ELISA. Several novel non-traditional risk
factors identified by us and others were determined in serum: heat shock protein
(HSP)-related factors (Hsp60, Hsp70 and anti-human Hsp60, anti-human Hsp70
and anti-mycobacterial Hsp65 antibody levels), platelet activating factor-acetylhy-
drolase activity (PAF-AH) and secretory phospholipase A2 GIIA (sPLA2). Anti-
bodies against endothelial cells (aEC) were measured by in-house ELISA.
Results The circulating levels of oxidized LDL and activity levels of PAF-AH, but
not HSP-related measurements, aEC antibodies or sPLA2, were significantly
raised in SLE cases. Oxidized LDL levels and PAF-AH discriminated between
SLE controls and SLE cases (P = 0.0282 or P = 0.008, respectively). PAF-AH
was significantly associated with LDL and cholesterol among SLE/CVD (r = 0.50,
P = 0.009 and r = 0.54, P = 0.004), but not in the other groups tested.
Conclusion The difference in oxidized LDL levels between SLE cases and SLE
controls may indicate that increased LDL modification by oxidation is one the
underlying factors implicated in SLE-related CVD. The association between PAF-
AH and LDL adds support to the notion that PAF-AH, which binds to LDL, might
contribute to atherogenesis in SLE patients. We cannot exclude that PAF-AH is
simply a secondary marker of other as yet unknown processes The role of HSP-
related measurements in CVD in general is complex, since aHSP65 appears to
be atherogenic while HSP70 may be protective. In the present cross-sectional
study, the HSP-related measurements and those of aEC and sPLA2 were not
associated with SLE.
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Objective Dendritic cells (DC) play an important role for initiation and regulation
of immune response. Recent experimental evidence points out the fact that imma-
ture dendritic cells (iDC) can mediate tolerance, presumably by the induction of
regulatory T cells. Therefore, we explored the effects of iDC injection on the
development of collagen-induced arthritis in mice and compared them with
tumour necrosis factor-matured DC, which we were previously shown efficient in
collagen-induced arthritis.
Methods Murine bone marrow-derived DC where cultured in the presence of
GM-CSF and IL-4 for 6 days and were incubated or not for 24 hours with bovine
type II collagen (bCII). The immature phenotype of DC was controlled by flow
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Figure 1
The development of mechanical hyperalgesia in mice with collagen-induced
arthritis.S46
cytometry, IL-12p40 secretion and MLR assays. The iDC were repetitively
injected 7, 5 and 3 days before arthritis induction with bCII. Mice were boosted
on day 21 and the disease course was monitored until day 50. Paw swellings
were measured over time, and radiological and histological analyses of paws
were performed at euthanasia. The antigen-specific T-cell proliferative response
of spleen cells, the Th1/Th2 cytokine production, and the serum levels of
IgG1/IgG2a anti-bCII antibodies were measured.
Results The repetitive injection of tumour necrosis factor alpha-modulated DC
loaded with bCII protects the mice from severe arthritis. This protective effect is
antigen dependent of the DC loading with bCII. The immunosuppressive effect is
associated with a decrease of the anti-bCII antibodies from the IgG2a isotype,
together with the inhibition of interferon gamma synthesis and the decrease prolif-
eration of bCII-specific T cells.
Our data show that repetitive injection of immature unloaded DC protects the
animals significantly as 70% of the mice did not develop clinical signs of the
disease. We quantitated the various regulatory populations in the vaccinated
mice, and observed in the liver and spleen an increase of the T-cell population
expressing the CD49b molecule (DX5 cells). The relevance of this population in
induced protection is under investigation.
Conclusion The use of iDC to modulate the autoimmune response is a rational
approach for cell therapy in diseases such as rheumatoid arthritis.
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In the synovial membrane, early mRNA elevations of IL-1β and IL-6 (6 hours; 450-
fold and 200-fold, respectively) positively correlated with the joint swelling. A sixfold
tumour necrosis factor alpha increase was not significant. Not only IL-2 and inter-
feron gamma (IFN-γ) (104-fold and 200-fold, respectively), but also IL-5 and IL-10
increased acutely (6 hours–day 1; threefold and 35-fold, respectively). In general,
the protein levels for IL-1β, IL-6, tumour necrosis factor alpha, IFN-γ, IL-4, and IL-10
(increase between fourfold and 15-fold) matched the course of mRNA expression.
In the inguinal lymph node there were early mRNA elevations of IL-6 (6 hours;
2.5-fold; positively correlated with the joint swelling) and IL-2 (6 hours; fourfold),
as well as later rises of IL-4 and IL-5 (day 3; 2.5-fold and fourfold, respectively).
At the protein level no significant elevations were observed in comparison with
day 0, except for IL-1β (day 6) and IL-10 (day 1).
In the spleen, there were significant mRNA elevations at 6 hours of IL-1β (1.5-
fold), IL-6 (fourfold; positively correlated with the joint swelling), IFN-γ (threefold),
and IL-2 (sevenfold to 10-fold). IL-5 and IL-10 (twofold and threefold, respec-
tively) peaked from 6 hours to day 3. Increases at the protein level were signifi-
cant compared with day 0 only in the case of IL-2 (day 6).
By day 6 (transition to the chronic phase) the mRNA for cytokines declined to or
below pre-arthritis levels in all organs, except for IL-1β in the synovial membrane
and IL-6 in the spleen. antigen-induced arthritis is thus characterized by: early
synovial activation of macrophages, Th1-like, and Th2-like cells; late, well-segre-
gated Th2-like responses in the inguinal lymph node; late, overlapping Th1-
like/Th2-like peaks in the spleen; and chronic elevation of synovial IL-1β mRNA
and spleen IL-6 mRNA.
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Objectives We performed a detailed analysis of the newly developing immune
system in patients treated with autologous stem-cell transplantation (ASCT) for
severe autoimmune diseases with special respect to the origin and the kinetics of
repopulating B-cell and T-cell subsets in correlation to the clinical response.
Methods Peripheral blood lymphocytes were analyzed using multiparameter flow
cytometry, including monitoring of the TCR-Vbeta repertoire on CD4+ Th cells.
Thymic activity was determined assessing absolute counts of peripheral blood
CD31+ thymic naive Th cells.
Patients and results Thirteen patients with a median follow-up of 54 months
have so far been included in the trial: polychonditis (n = 1), systemic lupus ery-
thematosus (SLE) (n = 6), systemic sclerosis (SSc) (n = 3), panniculitis (n = 1)
and multiple sclerosis (n = 2). Clinical remission has been achieved in all patients
with polychondritis (n = 1), SLE (n = 6) and multiple sclerosis (n = 2) whereas
we observed progression of disease in all patients with SSc (n = 3) and panni-
culits (n = 1). One SLE patient relapsed after being free of any clinical and sero-
logical symptoms for 17 months.
T-lymphocyte compartments reconstituted functionally in all patients, indicated by
the reappearance and persistence of CD45RA+CD31+ thymic naive Th cells in
high numbers with high levels of T-cell receptor excision circles and restored diver-
sity of the Th-cell-receptor repertoire. In terms of Th-cell memory no autoreactive
Th cells could be detected in responding patients. Reconstituted B cells were pri-
marily of naïve phenotype (IgD+CD27–) in the first 12–18 months after ASCT. As
a cellular marker for disease activity, frequencies of CD19+CD27++CD20– plasma
blasts, elevated in SLE patients prior to ASCT, normalized after treatment in all
patients. In case of the non-responding patients with SSc, autoantibody titers were
not affected by treatment. However, no major differences in the pattern of lympho-
cyte reconstitution could be detected as compared with responding patients.
Conclusion The newly developing immune system after immunoablative therapy
could be characterized as ‘juvenile’ in all patients. However, in some patients the
regeneration of a naive immune system alone seems not to be sufficient to regain
self-tolerance. We conclude that both the resetting of central and peripheral tol-
erance and the efficient eradication of autoreactive lymphocytes seem to be a
prerequisite for stable induction of remission.
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Purpose B-cell depletive therapy has been described to have beneficial effects
to patients suffering from rheumatoid arthritis (RA). Nevertheless, the role of B
cells in pathogenesis is not clear. In particular, it is not known whether B-cell
depletion causes changes in the B-cell repertoire after peripheral regeneration.
Therefore we analysed the distribution of the immunoglobulin heavy-chain (Ig-VH)
genes usage of a RA patient before, 7 months and 17 months after anti-CD20
therapy with rituximab.
Methods A patient with active RA has been treated with four weekly doses of
375 mg/m2 rituximab. During the treatment phase, prednisolone was elevated up
to 12.5 mg daily for 4 weeks. After that, the patient remained on a stable dose of
5 mg prednisolone per day without further anti-proliferate treatment. Ig-VH genes
were amplified from genomic DNA of peripheral B cells by nested PCR using
family-specific oligonucleotides. PCR products were subcloned and the
sequences of more than 500 clones were analysed.
Results Following antibody treatment, the patient experienced a good clinical
response lasting over 1 year. Before therapy, the overall VH gene usage of the
RA patient was largely similar to the distributions expected from published data
for normal individuals, except for certain genes (4-34, 1-69, 3-07), which have
already been reported with a biased distribution in autoimmune disorders. In addi-
tion, several clonally related sequences were found in the VH5 family.
B-cell regeneration occurred 7 months after anti-CD20 antibody therapy. Signifi-
cant changes in the distribution of different genes could be observed: 4-34 and
1-69 decreased to a proportion that would be expected in healthy individuals.
Clonally related sequences were not found anymore. A greater overall variety of
the VH gene segments used was observed, in particular in the larger families like
VH3 and VH4. Interestingly, somatic hypermutation was significantly enhanced at
the time point of B-cell regeneration.
Seventeen months after therapy, the general distribution of the VH genes was
comparable with that observed before treatment, except for some genes (4-34
remained at the level found after therapy). No clonally related sequences were
found. Somatic hypermutation was significantly reduced to the frequency deter-
mined before therapy.
Conclusion B-cell depletion by anti-CD20 monoclonal antibody leads to a signifi-
cant modulation of the expressed immunoglobulin-VH gene repertoire after B-cell
regeneration, which is accompanied with a clinical benefit in a single patient.
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Introduction Chronic arthritis usually leads to loss of periarticular bone. Inflam-
matory bone loss results from an imbalance between bone formation and bone
resorption. Recent research has focused on the role of osteoclast formation and
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bone resorption in arthritis. However, bone resorption cannot be seen isolated
since it is closely linked to bone formation and changes in bone formation may
also affect inflammatory bone loss.
Methods To assess bone resorption and bone formation simultaneously, we devel-
oped a histological technique that allowed visualization of osteoblast function by in
situ hybridization for osteocalcin and osteoclast function by histochemistry for tar-
trate-resistant acid phosphatase simultaneously on the same section. Paw sections
from human tumor necrosis factor transgenic mice, which develop erosive arthritis,
were analyzed at three different sites: subchondral bone erosions, adjacent Haver-
sian bone channels and endosteal regions distant from bone erosions.
Results In subchondral bone erosions, resorption sites were far more common
than formation sites. Thus, both the areas covered by osteoclasts as well as
numbers of osteoclasts showed a fivefold increase compared with the area
covered by osteoblasts and osteoblast numbers, respectively. In contrast, adja-
cent Haversian channels showed a completely different bone turnover, with func-
tional osteoblasts significantly more frequent than osteoclasts. Bone turnover in
Haversian channels was even higher (50% bone surface covered by osteoclasts
or osteoblasts) than in subchondral bone erosions (30%). At endosteal sites
distant from bone erosions, bone turnover was far lower (6%) and again bone for-
mation exceeded bone resorption.
Conclusion These data indicate that bone resorption dominates at skeletal sites
close to synovial inflammatory tissue, whereas more distant sites such as the Haver-
sian channels attempt to counterregulate this process by increased bone formation.
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Background and objectives A number of autoantibodies have been described in
individuals with rheumatoid arthritis (RA) leading to interest in their use as diag-
nostic or prognostic markers in RA as well as their pathogenic relevance. By
immunoscreening of a phage-display expression cloning system with RA patient
sera we isolated a cDNA clone encoding the ferritin H chain polypeptide. The
objectives of this study were to establish the frequency and clinical associations
of anti-ferritin antibodies in RA.
Methods We employed an ELISA for the measurement of anti-ferritin antibodies
in RA sera. Briefly, 96-well plates were coated overnight with purified ferritin from
equine spleen. Sera diluted one in 100 were reacted with the plates for 16 hours
at 4°C. After three washes, a goat anti-human IgG/horseradish peroxidase conju-
gate was used to detect bound IgG. The signal for each serum sample was nor-
malised using a reference serum included on each plate. Anti-ferritin antibodies
were measured in 291 subjects with RA, 73 healthy blood donors and 91 sub-
jects with osteoarthritis. Antibody-positive and antibody-negative individuals were
compared with respect to severity of disease as measured by modified Larsen’s
score, demographic variables, rheumatoid factor status and carriage of HLA
DRB1 shared epitope alleles. Correlations were examined between antibody
levels and severity of joint damage assessed by the Modified Larsen’s score.
Results Using a cut-off index of three standard deviations above the mean of the
control group, 49/291 (16.8%) RA patients were positive versus 2/73 (2.7%)
healthy donors and 2/91 subjects with osteoarthritis (P < 0.01). In six positive
and six negative sera these findings were confirmed by western blotting. Anti-fer-
ritin antibodies were more common in males with RA (25.3% males versus
13.7% females, P < 0.02) and levels were positively associated with severity of
joint damage (rs = 0.33, P = 0.02).
Conclusions Anti-ferritin antibodies are present in a subset of individuals with RA
and are associated with more severe joint damage. Ferritin is an abundant protein
in serum and synovial fluid, and therefore ferritin/anti-ferritin immune complexes
could form in these individuals and contribute to joint damage. An alternative pos-
sibility is that anti-ferritin antibodies could modulate the iron-binding properties of
ferritin and so lead to the release of toxic-free iron in the joint. We are currently
examining the frequency of anti-ferritin reactivity in patients with early RA at two
timepoints in order to establish whether or not these antibodies are present in
early disease or are simply a result of longstanding disease, as well as their fre-
quency in other autoimmune diseases. These data will be presented.
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Background and objectives Several recent studies have indicated a second
susceptibility locus for rheumatoid arthritis (RA) in the telomeric MHC close to
the tumour necrosis factor locus, a region containing a number of genes of
unknown function including HLA-B associated transcripts 1 and 2 (BAT1 and
BAT2) and lymphotoxin alpha (LTA). Several single-nucleotide polymorphisms
have been described in this region; however, the influence of each on susceptibil-
ity is not known. In this study we sought to examine the association of individual
single-nucleotide polymorphisms with expression of each mRNA transcript in
response to an inflammatory stimulus.
Methods Peripheral blood mononuclear cells were collected from healthy blood
donors and adherent cells were allowed to differentiate into macrophages by
culture in the presence of 5% serum for 7 days. Cells were then stimulated with
100 ng/ml lipopolysaccharide and harvested at 4-hour and 18-hour timepoints.
Total RNA was prepared using standard methods and reverse transcription per-
formed with ImpromII™ (Promega, Madison, WI, USA). The resulting cDNA was
used as a template for real-time PCR using gene-specific primers for each gene.
Each PCR product was detected with the double-stranded DNA-binding dye
SYBR Green® I (Applied Biosystems, Foster City, CA, USA) and the ABI
7900HT sequence detection system (Applied Biosystems). Quantitation was per-
formed using standard curves generated from plasmid DNA containing each
cloned PCR product and 18S was used as a loading control. Levels of mRNA
transcripts were expressed in relative units (RU). Genotyping was performed for
the BAT1 –991 (1751673), BAT2 (1688185), LTA (1720807) and TNF –308
(1718089) polymorphisms using TaqMan allelic discrimination assays. Expres-
sion levels of each mRNA transcript were compared between individuals of geno-
type 1.1, 1.2 and 2.2 using Kruskal–Wallis tests.
Results Expression of BAT1 mRNA transcripts was significantly less in BAT1 –991
2.2 individuals (n = 6) compared with both 1.1 (n = 6) and 1.2 (n = 5) (median
levels 0.22 RU compared with 0.76 RU and 1.1 RU, respectively) (P = 0.02).
Expression of BAT2 transcripts was lower in 1.1 individuals (n = 9) compared with
both 1.2 (n = 8) and 2.2 (n = 4) genotypes (median levels 0.43 RU compared with
0.77 RU and 0.82 RU, respectively) (P = not significant). For LTA expression, indi-
viduals of genotype 2.2 (n = 4) produced the highest levels, those of genotype 1.1
(n = 6) the lowest, with those of 1.2 genotype (n = 6) intermediate (median levels
6.1 RU compared with 0.81 RU and 2.1 RU, respectively) (P = 0.02). Expression of
all three transcripts had fallen to low levels by the 18-hour timepoint and no differ-
ences were apparent between individuals of different genotype.
Conclusions Polymorphism in the BAT1 –991, BAT2 and LTA genes are associ-
ated with levels of each mRNA transcript produced in response to an inflammatory
stimulus. This suggests the possibility that they may be able to influence suscepti-
bility to RA, and that the protein products they encode may play a role in inflamma-
tory signalling. We are currently extending this genotype–phenotype analysis to
the other members of this gene cluster particularly 1C7, LST1 and AIF1.
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Background Transient production of reactive oxygen species (ROS) plays an
important role in optimizing transcriptional and proliferative responses to T-cell
receptor signaling. Conversely, chronic oxidative stress leads to mitogenic
hyporesponsiveness and enhanced transcription of inflammatory gene products.
It has recently been demonstrated that constitutive activation of the small
GTPase Ras and simultaneous inhibition of Rap1 in synovial fluid (SF) T cells
results in high intracellular ROS production, which is thought to underlie many of
the functional abnormalities observed in these cells in rheumatoid arthritis.
Objectives  To identify the factor(s) responsible for modulation of intracellular
ROS production in synovial T lymphocytes.
Methods Purified rheumatoid arthritis peripheral blood (PB) T cells were incubated
in the presence of different cytokines, in 50% autologous SF, or with autologous SF
monocytes for 72 hours. Activation status of Ras and Rap1 GTPases were deter-
mined using activation-specific probes for these GTPases. Oxidation of the dye
DCF by FACS analysis was used to measure intracellular ROS production.
Results Chronic stimulation of PB T cells for 72 hours with tumor necrosis factro
alpha (TNF-α) or 50% autologous SF resulted in a slight increase in basal ROS
production, but did not increase intracellular ROS production to levels found in
SF T cells. Exposure of PB T cells to SF (but not PB) monocytes for 72 hours,
however, led to a strong increase in ROS production in PB T cells, comparable
with ROS levels in SF T cells. Moreover, similar Rap1 inhibition as found in SF T
cells were observed in PB T cells after exposure to SF monocytes. To demon-
strate that the inhibition of Rap1 is critical in the subsequent increase in ROS
production, PB T cells were nucleofected with the constitutive active isoform of
Rap1 (RapV12). In RapV12 nucleofected PB T cells the SF monocyte-induced
ROS production was prevented. Cell–cell contact is critical, since in PB T cells
separated from SF monocytes by a transwell membrane, the inhibition of Rap1
was relieved, concomitant with an absence in excess ROS production. Addition-
ally, we found that addition of 10 µg/ml recombinant CTLA-4-Ig fusion protein
Available online http://arthritis-research.com/supplements/7/S1S48
also prevented oxidative stress in PB T cells exposed to SF monocytes, which
suggested a central role for CD28. PB T cells were therefore stimulated with
TNF-α, interferon gamma, IL-1β, or transforming growth factor beta, in the pres-
ence or absence of anti-CD28. Here we found that stimulation with anti CD28 by
itself was sufficient to induce Rap1 inhibition and induce a moderate increase in
ROS production. Co-incubation of PB T cells with TNF-α strongly enhanced the
intracellular ROS production.
Conclusion In vitro exposure of PB T cells from rheumatoid arthritis patients to
synovial monocytes leads to a strong increase in intracellular ROS production.
This is mediated by simultaneous Ras activation and inhibition of Rap1. Where
Ras can be activated by a variety of stimuli, Rap1 inhibition is induced by SF
monocytes through CD28 costimulatory signaling.
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Background Post-traumatic osteoarthritis (OA) represents 13% of all OA of the
knee, 9% in the hip, and 73% of all OA of the ankle [1]. The molecular mecha-
nisms that underlie the development of chronic joint surface degeneration follow-
ing a localised, acute joint injury are not known. The aim of this study is to utilise
the cartilage explant model system to identify molecular mechanism of cartilage
damage and repair induced by acute mechanical injury.
Methods  Explants of articular cartilage from preserved areas of the femoral
condyles or the patellar groove of patients undergoing total knee prosthesis were
cultured in vitro under different conditions. After 4 days in culture the samples were
subjected or not to mechanical injury by performing full thickness cuts at a distance
of 1 mm. At different time-points the explants were partly snap-frozen for further his-
tochemical/immunohistochemical evaluation and partly used for RNA extraction and
RT-PCR analysis. The original cartilage was graded using the Mankin score.
Results Gene regulation was detected as early as 4 hours and lasting for at least
6 days after mechanical injury. BAX mRNA, possibly associated with apoptosis of
chondrocytes,  MMP-8, and TIMP-1 mRNA were upregulated in the injured
explants. BMP-2 mRNA was also upregulated by mechanical injury. We could
not detect changes upon damage of cell proliferation as measured by PCNA
mRNA levels at the analysed time points.
Conclusions The explant model system represents a controlled experimental set-
up to study the molecular mechanisms of cartilage degeneration in post-traumatic
OA and to identify potential molecular targets for its prevention.
Reference
1. Buckwalter JA, Saltzman C, Brown T, Schurman DJ: The impact of osteo-
arthritis: implications for research. Clin Orthop 2004, 427(Suppl):S6-S15.
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Background The LE cell phenomenon is a classical test for systemic lupus ery-
thematosus (SLE). Granulocytes engulf bodies, the nature of which has not been
unequivocally demonstrated. Hypotheses range from isolated nuclei to intact
cells undergoing apoptosis. Using the fact that it is autoantibodies to histone H1
that induce this phenomenon, which thus have to bind the material in question,
we investigated histone H1 accessibility to antibodies.
Methods Polymorphonuclear cells (PMNC) were isolated by centrifugation
between Percoll layers, and peripheral blood mononuclear cells over Ficoll
Paque. Cells were either used while vital or after the induction of apoptosis (using
gliotoxin for PMNC and actinomycin D for peripheral blood mononuclear cells
and incubation overnight) or necrosis (heating to 70°C). Apoptosis and necrosis
were verified by both Annexin V/propidium iodide and TUNEL on a flow cytome-
ter. Accessibility of histone H1 was likewise tested by fluocytometry, employing a
monoclonal anti-histone H1 antibody and a matched control antibody together
with a FITC-labelled F(ab′)2 fragment, as well as by SLE sera testing positive for
the LE cell phenomenon and healthy control sera.
Results Apoptosis and necrosis were reliably induced in both PMNC and lym-
phocytes. The monoclonal anti-histone H1 antibody bound necrotic cells, but did
not bind apoptotic or fresh cells. Likewise, LE cell-positive (and thus anti-histone
H1-positive) SLE sera bound to necrotic cells, but not to apoptotic or fresh cells,
while healthy sera bound to neither cell.
Conclusion Since, on cells undergoing apoptosis, histone H1 is not accessible
to specific antibodies, necrotic cells or isolated nuclei must be engulfed in the LE
cell phenomenon.
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Background  Both interferon alpha (IFN-α) and interferon gamma (IFN-γ) are
thought to be involved in systemic lupus erythematosus (SLE) immunopathogene-
sis. In their signal transduction, both cytokines lead to the tyrosine-phosphoryla-
tion and consequent nuclear translocation of the transcription factor Signal
transducer and activator of transcription 1 (Stat1).
Objective To evaluate Stat1 protein and Stat1 phosphorylation in SLE patients
ex vivo and after stimulation with IFN-α as well as IFN-γ.
Methods Peripheral blood mononuclear cells of 25 patients fulfilling ACR criteria
for SLE and of 12 healthy individuals were prepared over Ficoll Paque gradients.
Cells were either stained directly after preparation or after 15 min of incubation in
medium with or without the addition of 100 U/ml IFN-α (Strathmann Biotech) or
IFN-γ (R&D Systems). Intracellular staining was performed using either a mono-
clonal anti-Stat1 antibody and a FITC-labelled rabbit anti mouse antibody (Dako)
with the Fix+Perm kit (An der Grub) or a directly PE-labelled monoclonal anti-
phospho-Stat1 (pStat1) antibody (BD Biosciences Pharmingen) after fixation
with 2% paraformaldehyde and permeabilization with 90% methanol. After stain-
ing, the cells were analyzed on a Becton Dickinson FACScan fluorocytometer.
Gates were set for monocytes and for lymphocytes, and the logarithmic mean flu-
orescence intensity (mfi) was determined.
Results The amount of Stat1 protein, as measured by the mfi, was increased in
lymphocytes of SLE patients as compared with healthy lymphocytes (21.4 ± 14.9
[mean ± standard deviation] versus 7.04 ± 1.54, P < 0.0001, t test), and in mono-
cytes from SLE patients as compared with healthy monocytes (25.1 ± 13.2 versus
10.4 ± 2.54, P < 0.0001). Lymphocytic and monocytic Stat1 mfi correlated both
for SLE patients (Pearson r = 0.57, P < 0.005) and for healthy individuals (r =
0.75, P < 0.005). The amount of phosphorylated Stat1, as measured by pStat1
mfi, was increased in SLE as compared with healthy lymphocytes (1.63 ± 0.40
versus 1.36 ± 0.22, P < 0.02), but not significantly increased in SLE monocytes
as compared with healthy monocytes (4.03 ± 1.64 versus 3.24 ± 1.21, P = not
significant). Nevertheless, the pStat1 mean fluorescence intensities of lympho-
cytes and monocytes were highly correlated, both for SLE patients and healthy
individuals (r = 0.84, P < 0.0001, and r = 0.91, P < 0.0001, respectively).
As compared with incubation in medium alone, incubation with either IFN-α or
IFN-γ increased the amount of pStat1 in SLE lymphocytes (from 1.57 ± 0.29 in
medium alone to 1.82 ± 0.36 [P < 0.01, paired t test] with IFN-α and to 1.85 ±
0.40 [P < 0.002] with IFN-γ). In contrast, IFN-α, but not IFN-γ, increased the
pStat1 mfi in healthy lymphocytes (from 1.41 ± 0.15 in medium alone to 1.83 ±
0.48 [P < 0.002] with IFN-α, but to 1.40 ± 0.18 [P = not significant] with IFN-γ).
Likewise, SLE monocytes increased their pStat1 contents upon incubation with
either IFN-α or IFN-γ (from 3.74 ± 1.18 to 4.66 ± 1.50 [P < 0.05] and 7.28 ±
4.14 [P < 0.001] for IFN-α and IFN-γ, respectively), while healthy monocytes
responded to IFN-α (pStat1 mfi from 3.52 ± 1.11 to 5.23 ± 2.25, P < 0.01), but
not IFN-γ (pStat1 mfi 3.96 ± 5.36, P < 0.001 versus medium).
Conclusions Peripheral lymphocytes and monocytes of patients with SLE
contain more Stat1 protein than those from healthy individuals and show
increased Stat1 phosphorylation. While healthy peripheral bloob mononuclear
cells phosphorylate Stat1 when stimulated by IFN-α only, SLE lymphocytes and
monocytes are primed in a way that enables them to also react to IFN-γ.
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Background Angiogenesis is involved in rheumatoid arthritis since it allows
leukocytes and inflammatory mediators infiltration in the synovium. In turn, inflam-
mation also keeps angiogenesis going as inflammatory mediators stimulate
endothelial cell proliferation.
Objectives We aimed to evaluate the reciprocical relationship between synovium
inflammation and angiogenesis in mice with collagen-induced arthritis (CIA), a
model for rheumatoid arthritis.
Methods: CIA was induced by immunization of DBA/1 mice with collagen II in
adjuvant. Endothelial cells were detected using a GSL-1 lectin-specific immuno-
histochemical staining on knee slides. Angiogenesis, clinical scores and histologi-
cal signs of arthritis were evaluated each week from the induction of CIA to the
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end of the experiment. Angiogenesis was quantified by counting both the isolated
endothelial cells and vessels stained on each slide. To evaluate the effect of an
angiogenesis increase on CIA, vascular endothelial growth factor (VEGF) gene
transfer was performed with adeno-associated virus VEGF (AAV-VEGF) injection
in the muscles of mice with CIA (1010 AAV-VEGF particles intramuscularly
3 weeks before CIA induction). The AAV vectors used in this study contained
either mVEGF164 (AAV-VEGF) or lacZ (AAV-lacZ) cDNA, whose expression
were driven by the cytomegalo virus promoter.
Results As expected, clinical and histological scores of arthritis, evaluated each
week from day 0 to day 55 after induction of CIA, were correlated (P < 0.0001,
r = 0.74, Spearman correlation test). More importantly, angiogenesis increased
as a function of the disease course. A correlation was observed between joint
vascularization and clinical scores of arthritis (P < 0.0001, r = 0.61). A correla-
tion was also shown between vascularization and histological scores
(P = 0.0006, r = 0.51). The overexpression of VEGF induced by gene transfer
was followed by an aggravation of arthritis as compared with the AAV-lacZ
control group (P < 0.0001, analysis of variance test). Histological and quantifica-
tion of angiogenesis are in progress in this experiment.
Conclusion Angiogenesis and inflammation evolved in the same way during the
course of CIA. Stimulation of angiogenesis in mice with CIA led to a worse clini-
cal inflammation. These results suggest an early involvement of angiogenesis in
joint inflammation development, and emphasize the critical role of angiogenesis in
chronic inflammatory arthritis.
Acknowledgement GC was supported by Societe Francaise de Rhumatologie.
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Background Glucocorticoid-induced apoptosis is a phenomenon of consider-
able biological and clinical significance. In particular, lymphoid cells are suscepti-
ble to glucocorticoid-induced apoptosis. In patients with rheumatoid arthritis, one
of the critical hallmarks of synovial T cells is that they suffer from severe oxidative
stress. During the past decade, reduction–oxidation (redox) reactions that gener-
ate reactive oxygen species (ROS) have been identified as important chemical
mediators in the regulation of signal transduction processes. In particular, free
radicals appear to have a central role in the balance between cell growth, survival
and apoptosis.
Objective To investigate the role of free radicals in corticoid-induced apoptosis.
Materials and methods T lymphocytes were isolated from peripheral blood (PB)
and synovial fluid through a negative isolation procedure (Dynal). The cells were
treated with different concentrations of methylprednisolone, in combination with
different inhibitors and substrates of oxidases. Apoptosis was assessed by
annexine V/PI staining, and oxidation of the dye DCF was used to measure ROS
production. Control, active Ras (RasV12) and inhibitory Rap1 constructs
(RapGAP) were introduced in PB T lymphocytes by nucleofection techniques.
Results A time-dependent and concentration-dependent apotosis is induced in T
lymphocytes after treatment with methylprednisolone. But where concentrations
over 200 µM methylprednisolone were required to induce apoptosis in T cells iso-
lated from PB from healthy donors and RA patients, apoptosis in T cells isolated
from the synovial fluid could be readily detected at concentrations of 5–10 µM. To
test whether the disturbed redox balance plays a central role in sensitising T cells
for glucocorticoid-induced apoptosis, PB T cells were first incubated for 12 hours
with subapoptotic concentrations of H2O2 (5–50 µM), and for 48 hours with BSO
(which results in intracellular gluthathione depletion) and NAC (which increases
intracellular gluthathione). Here, both pretreatment of the T cells with H2O2 and
BSO sensitised the T cells for apoptosis, whereas NAC protected T cells from glu-
cocorticoid-induced apoptosis. Moreover, other T cells that are known to suffer
from oxidative stress also showed increased apoptosis following treatment with
methylprednisolone: both HIV-infected CD4 lymphocytes that were isolated from
patients diagnosed with AIDS (n = 3) and T cells that were nucleofected with
RasV12 and Rap1GAP also showed apoptosis at 5–10 µM methylprednisolone.
Concomittant with the apoptosis, a 1.5-fold to 2.5-fold increase in intracellular
ROS production was measured in the pre-apoptotic cells. This increase of intra-
cellular ROS seems to be a critical process in the apoptotic process as incuba-
tion in oxygen-deprived conditions inhibited the apoptosis. Also, addition of
rotenone and catalase inhibited both ROS increase and apoptosis after methyl-
prednisolone treatment, suggestive of a mitochondrial source of the free radicals.
Conclusions Cells suffering from oxidative stress are sensitised to glucocorti-
coid-induced apoptosis.
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Background In murine Th1 cells, interferon gamma (IFN-γ) expression can be
induced by two alternative pathways: a T-cell receptor (TCR)-dependent pathway
and an IL-12/IL-18-dependent pathway. IL-12/IL-18-induced IFN-γ production
might perpetuate inflammatory loops in autoimmunity leading to chronicity of
inflammation. To evaluate a possible role for IL-12/IL-18 induced IFN-γ secretion
in human autoimmune diseases we analyzed here the requirements for TCR-inde-
pendent IFN-γ expression in human resting memory Th cells mimicking the inflam-
matory milieu found at the site of inflammation in rheumatoid arthiritis (RA).
Methods Highly purified CD45RO+ memory/effector Th cells from healthy blood
donors were cultured in the absence of antigen-presenting cells, but in the pres-
ence of different cytokine/chemokine combinations known to be overexpressed in
the joints of RA patients. After different timepoints cells were analyzed on the
single-cell level for the expression of IFN-γ and other cytokines. In addition,
surface molecules such as activation markers and cytokine receptors were ana-
lyzed by FACS. To evaluate intracellular activation pathways, p38 MAP-kinase
inhibitors or cyclosporinA were added in some experiments.
Results IFN-γ production could be induced, starting after 18 hours, peaking at
36 hours, in a subset of 2–10% of human memory/effector Th cells with a cock-
tail of inflammatory cytokines including IL-1β/IL-6/IL-7/IL-8/IL-12/IL-15/IL-
18/MIP1α and tumour necrosis factor alpha. In contrast to mice, IL-12, IL-18 and
an IL-2-receptor common γ-chain signalling cytokine (IL-2 or IL-7 or IL-15) were
determined to be the minimum effective combination. Cytokine-stimulated IFN-γ+
Th cells did not co-produce IL-2/IL-4/IL-5/IL-10 or tumour necrosis factor alpha.
TCR-dependent activation in cytokine-stimulated IFN-γ+ Th cells was excluded as
cyclosporinA did not block IFN-γ production. However, cytokine-induced IFN-γ
production was dependent on the p38 MAP-kinase pathway. In contrast to TCR-
triggered IFN-γ+ Th cells, cytokine-stimulated IFN-γ+ Th cells did not upregulate
4-1BB (CD137).
Conclusions In this study, we have characterized human cytokine-induced IFN-γ+
Th cells. Our results should help to clarify the role of inflammatory cytokine networks
for the perpetuation of human Th-cell-driven autoimmune disorders such as RA.
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Objectives IL-1β is a critical cytokine in inflammation and is involved in the patho-
genesis of rheumatoid arthritis. Blocking IL-1β is efficient in the treatment of
inflammation. Our goal was to inhibit inflammatory arthritis with a new approach
consisting of targeting specific IL-1β peptides in the receptor binding site, and to
prove this concept in an experimental model of arthritis.
Methods Epitopes of IL-1β to be blocked were defined in silico by molecular
modelling. Synthetized peptides (Fmoc strategy) were linked to KLH. Anti-IL-1β
antibodies generated by vaccination of mice against each peptide coupled to
KLH were tested by ELISA and neutralisation assay, determining their ability to
inhibit IL-2 production by EL4/NOB1 cells. Collagen-induced arthritis (CIA) was
induced in DBA/1 mice with type II collagen in complete Freund adjuvant. Mice
were evaluated blindly for clinical arthritis, and joint histology was performed at
sacrifice (60 days post-immunization with type II collagen). Mice were immunized
by peptide conjugated to KLH 11 weeks prior to induction of CIA. Control groups
received KLH alone or saline.
Results Six peptides were obtained and were able to generate anti-IL-1β anti-
bodies in mice (positive ELISA and neutralization assay). Three of them, chosen
on the basis of the ability to generate the highest antibody response, were
studied in CIA. One of them (IL-1β6) yielded a significantly improved resolution of
CIA (P = 0.0003 as compared with KLH control, analysis of variance); the
maximal arthritic score mean was also reduced in the treated group (9.4 ± 1.9
and 14.2 ± 1.7, P < 0.05). Histological analysis showed a clear-cut significant
reduction in inflammation (P < 0.001) and destruction (P < 0.01) scores in the
groups treated with IL-1β6.
Conclusion Active immunization with targeted peptides of IL-1β was able to gen-
erate neutralizing anti-IL-1β auto-antibodies. Vaccination of mice with one of
them, IL-1β6, was efficient in CIA.
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Background Autoantibodies directed against nucleosomal antigens such as
dsDNA and histones are a hallmark of systemic lupus erythematosus (SLE).
Histone H1 constitutes the major antigen in LE cell formation and antibodies to
H1 have been shown to be more specific for SLE than other anti-histone antibod-
ies [1,2]. In order to address the role of histone H1-specific T cells in SLE we
investigated the ex vivo cellular reactivity to histone antigen in SLE patients and
controls, and characterised H1-specific T-cell clones.
Methods Peripheral blood mononuclear cells of 39 SLE patients and 20 healthy
controls (HC) were exposed to purified histones (H1, H2A, H2B, H3, H4), and pro-
liferation as well as cytokine production was measured. In addition, H1-specific T-
cell clones were drawn by limiting-dilution cloning of T-cell lines. T-cell phenotyping
was done by FACS analysis and the cytokines IL-4, interferon gamma (IFN-γ) and
tumour necrosis factor alpha (TNF-α) were measured in the supernatants by ELISA.
Results After stimulation with histone H1, SLE patients showed a significantly
elevated proliferative response as measured by stimulation indices (SI) when
compared with HC (SI mean ± SD, 2.2 ± 1.4 versus 1.5 ± 0.4, P < 0.03) and a
positive response (i.e. SI > 2) in 16 patients compared with only two responders
among HC (Fig. 1). The proliferative response to H2A was also elevated in SLE
patients (SI, 2.9 ± 2.5 versus 1.7 ± 0.8 in HC, P < 0.03), whereas the response
to H2B, H3 and H4 did not differ between patients and HC. Cellular responses
to H1 correlated with the presence of anti-histone antibodies but not with clinical
features or SLE disease activity. H1-specific T-cell clones obtained from one SLE
patient and two HC showed a Th1-like phenotype producing large amounts of
IFN-γ and TNF-α but no IL-4.
Conclusion The increased Th1 autoreactivity to histones H1 and H2A in SLE
patients suggests that these T cells play an important role in the pathogenesis of
SLE not only by driving autoantibody responses but also by virtue of production
of the proinflammatory cytokines IFN-γ and TNF-α.
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Background CCL21 expression in secondary lymphoid organs is instrumental in
mediating L-selectin+ CCR7+ naive T-cell and B-cell recruitment from the blood-
stream via PNAd+ high endothelial venules (HEV). CCL21 is also constitutively
produced by lymphatic vessels functioning as a recruiting factor for CCR7+
mature dendritic cells from peripheral tissues to regional lymphoid organs. The
same factor participates to the inflammatory cascade being associated with lym-
phoid neogenetic events and being upregulated in peripheral lymphatic vessels,
increasing the magnitude of T-cell response by favouring dendritic cell recruit-
ment to draining lymph nodes.
Objectives In this study we analysed CCL21 protein and mRNA expression in
rheumatoid synovium and its relationship with the organizational features of the
inflammatory infiltrate and the vascular system (blood and lymphatic vessels).
Methods  Thirty-one rheumatoid synovial samples characterized by a variable
degree of inflammation and aggregational tendency were analysed by immunohis-
tochemistry and in situ hybridization for CCL21. Molecular features of synovial
vessels were analysed by immunohistochemistry for pan-vascular (CD31), HEV
(PNAd) and lymphatic (LYVE-1) markers.
Results Two distinct patterns were recognized: vascular and non-vascular. Non-
vascular CCL21-producing cells were specifically localized within lymphoid aggre-
gates, frequently surrounding PNAd+ HEV. This pattern was demonstrated to be
similar to human secondary lymphoid organs where, different from the mouse, no
CCL21 mRNA was detected directly in HEV. In contrast, CCL21+ vessels did not
show a specific association with lymphoid organization, lacking PNAd expression
and being recognized inside but also outside perivascular aggregates. Serial
section analysis demonstrated the colocalization of CCL21+ vessels with LYVE-1.
Conclusions This study emphasizes a differential regulation of CCL21 in the
context of synovial lymphoid organization. The anatomical relationship of CCL21-
producing cells with synovial PNAd+ HEV suggests its involvement in cellular
homing although, contrary to the mouse, CCL21 is actually produced perivascu-
larly. Furthermore, CCL21 colocalization with LYVE-1+ lymphatic vessels sug-
gests multiple functions of CCL21 in mediating CCR7+ leucocyte synovial
homing, intratissue clusterization and promoting exit via lymphatics to draining
lymph nodes. These results define CCL21 potential roles in the pathogenetic
cascade of rheumatoid synovitis.
P140
Microparticles from inflammatory cells are strong inducers
of matrix metalloproteinases and inflammatory cytokines in
synovial fibroblasts
JHW Distler1,2, A Jüngel1, LC Huber1, A Seemayer1, RE Gay1, BA Michel1,
JR Kalden2, S Gay1, DS Pisetsky3, O Distler1
1Center of Experimental Rheumatology, University Hospital Zurich, Switzerland;
2Medizinische Klinik III, University Erlangen–Nuremberg, Germany; 3Division of
Rheumatology, Duke University Medical Center, Durham, North Carolina, USA
Arthritis Res Ther 2005, 7(Suppl 1):P140 (DOI 10.1186/ar1661)
Background Microparticles (MPs) are membrane-bound vesicles that are
released from cells during cellular activation and apoptosis. Synovial fluids from
patients with rheumatoid arthritis contain high numbers of MPs. Here we address
the effects of monocyte-derived and T-cell-derived MPs on rheumatoid arthritis
synovial fibroblasts (RASF).
Methods Apoptosis of Jurkat T cells, U937 macrophages and primary cells was
induced by FasL, actinomycin-D, tumour necrosis factor alpha and staurosporine.
Cells were also stimulated with IL-2, concanavalin A, anti-CD3 and lipopolysac-
charide. Isolation of MPs was performed by differential centrifugation. The pres-
ence of MPs was confirmed by FACS analysis for annexin V and CD3 or CD14.
Normal synovial fibroblasts, osteoarthritis synovial fibroblasts and RASF were
incubated with MPs for 6–36 hours. Differentially expressed genes were analyzed
by real-time PCR and confirmed on the protein level.
Results The release of MPs was induced in apoptotic as well as stimulated cells.
Morphological analysis of MPs by electron microscopy showed a population of circu-
lar membrane blebs ranging from 200 to 700 µm. MPs from all cell types induced
strongly the synthesis of mRNA for MMP-1 (72 ± 13-fold), MMP-3 (80 ± 10-fold),
MMP-9 (18 ± 4-fold) and MMP-13 (37 ± 2-fold) in RASF in a dose-dependent
manner. Similar effects were seen on osteoarthritis synovial fibroblasts and normal
synovial fibroblasts. The induction of matrix metalloproteinases (MMPs) was time
dependent, with effects primarily seen after 36 hours. The dose-dependent upregula-
tion of biologically active MMPs was also observed on the protein level. The induc-
tion was specific for the aforementioned MMPs with no induction seen for MMP-2,
MMP-14 or TIMP-1, TIMP-2 and TIMP-3. MPs also increased the synthesis of mRNA
for IL-6 (27 ± 6-fold), IL-8 (35 ± 3-fold), MCP-1 (5 ± 1-fold) and MCP-2 (27 ± 3-
fold) in synovial fibroblasts. No differences in cell viability were observed between
fibroblasts stimulated by MPs and controls. In Iκ-B-transfected RASF, MMPs were
50–75% less inducible by MPs compared with wild-type synovial fibroblasts. The
stimulation of NF-κB-dependent pathways by MPs was confirmed by EMSA.
Perspective By showing induction of various MMPs and key inflammatory
cytokines by MPs, these data provide a novel link between activated and apop-
totic inflammatory cells and the invasive potential of synovial fibroblasts in
rheumatoid arthritis.
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Figure 1
Elevated proliferative responses to histone H1 in patients with systemic lupus
erythematosus (SLE). Proliferation of peripheral blood mononuclear cells from 39
SLE patients and 20 healthy controls (HC) was analysed by measuring [3H]TdR
incorporation, and a stimulation index (SI) > 2 was considered a positive response.S51
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Rheumatoid arthritis is characterized by the presence of autoantibodies. Various
animal models for arthritis have shown a critical role for antibodies in the induc-
tion and progression of the disease, with complement and Fc receptors as the
key effector mechanisms activated by antigen–antibody immune complexes (IC)
in the effector phase of the disease. Although they are required for the perpetua-
tion of the disease, the possible mechanisms by which Fc receptors could con-
tribute to the chronic inflammation in arthritis are still unclear. It is known,
however, that crosslinking FcγR on effector cells induces a variety of cellular
responses, ranging from phagocytosis to secretion of inflammatory mediators and
antibody-dependent cell cytotoxicity. Furthermore, FcγRs on dendritic cells (DC)
are involved in the enhanced MHC class II-restricted presentation of antigen from
IC to CD4+ T cells. Considering that also other antigen-presenting cells (APC)
(like B cells and macrophages) express FcγR, this could be a possible mecha-
nism of exacerbating/maintaining inflammation in arthritis. Therefore, we sought to
explore the role of FcγR and complement in the MHC class II-restricted antigen
presentation in vivo and to identify the APC involved in this process.
To gain more insight into the ability of various types of APC to take up and
present IC to T cells in vivo, we infused ovalbumin (OVA)-IC into naive mice.
Direct ex vivo isolation of the different APC subsets showed that only CD11c+
cells, but not macrophages and B cells, are able to (cross-)present efficiently
antigen from IC to T cells, although both macrophages and DC are able to
capture IC efficiently. Furthermore, depletion of CD11c+ cells, using transgenic
mice, abrogated the enhanced presentation of antigen in IC, confirming that DC
are the predominant APC involved in (cross-)presentation of IC.
To study the contribution of different FcγRs (FcγRI, FcγRII and FcγRIII) in IC-facili-
tated antigen presentation, we injected OVA-IC in wild-type mice and FcγR-knock-
out mice that have received 3 days earlier CFSE-labeled OVA-specific T cells. Our
results indicate that activation of OVA-specific T cells in vivo is 10 times more effi-
cient upon uptake of antibody-complexed OVA than soluble OVA. This effect was
absent in mice lacking FcγRI, FcγRII and FcγRIII, but not in complement factor 3
knockout mice, indicating that the enhanced efficiency was FcγR mediated.
Together, these results indicate that the enhanced presentation of antigen in IC and
the subsequent activation of T cells in vivo is mediated primarily by DC, not by
macrophages or B cells. Therefore, we consider it more likely that the IC-related
contribution of macrophages to rheumatoid arthritis is associated with the release
of proinflammatory cytokines and molecules upon activation induced by FcγR
crosslinking, than to the enhanced activation of autoreactive CD4+ T cells. The
ability to orchestrate and steer the T-cell responses is the responsibility of DC,
further emphasizing the crucial role of DC in controlling (ongoing) T-cell responses.
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Dendritic cells (DC) are professional antigen-presenting cells with the unique
ability to stimulate naïve T cells and to trigger strong immune responses.
However, DC have also shown tolerogenic ability in several systems under
certain conditions, depending on their differentiation/activation status. In particu-
lar, treatment of DC with cAMP-elevating agents promotes impaired dendritic cell
maturation and inhibition of T-cell responses, therefore providing a potential
therapy for autoimmune disorders.
Our objective was to study the effect of cholera toxin (CTx)-treated DC in the
development of mouse collagen-induced arthritis (CIA), a well-established animal
model of rheumatoid arthritis. CTx was chosen because it maintains sustained
high cAMP levels by irreversibly binding to adenylate cyclase.
Arthritis was induced by intradermal injection of 200 µg bovine type II collagen
(bCII) in complete Freund’s adjuvant in the base of the tail of male DBA/1 mice.
Bone marrow-derived DC, loaded with bCII (50 µg) and treated with CTx
(1 µg/ml), were injected at the time of immunization. Arthritis incidence and sever-
ity was assessed for 21 days following arthritis onset. For in vitro analysis of the
effect of DC in T-cell activation, lymph nodes from bCII-immunized mice were col-
lected before arthritis onset and stimulated with CTx-treated DC. Proliferation and
interferon gamma production were determined by thymidine incorporation and
capture ELISA, respectively.
Injection of CTx-treated DC resulted in a decreased arthritis incidence (Fig. 1)
and reduced severity, compared with non-DC treated animals. This effect
required the combination of CTx and antigen specificity, as DC treated with CTx
in the absence of bCII, as well as non-treated DC in the presence of bCII, did not
show a significant reduction in the incidence of arthritis. Furthermore, treatment
with DC alone results in an acceleration of disease progression.
In vitro analysis of T-cell responses revealed that Ctx-treated DC were able to
inhibit both proliferation and interferon gamma production from lymph nodes of
immunized mice. Interestingly, this inhibition was not antigen specific, as it was
also observed in the absence of bCII, suggesting that additional mechanisms are
involved in the reduced arthritis incidence observed in vivo.
In summary, our data indicate that manipulation of dendritic cell activity with
cAMP-elevating agents provides a therapeutic tool for the treatment of antigen-
specific autoimmune disorders.
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Background Patients with systemic lupus erythematosus (SLE) are at high risk of
cardiovascular disease, due to atherothrombosis in particular.The mechanisms
are not clear; however, recently annexin V, an anticoagulant protein, and antiphos-
pholipid antibodies have been implicated.
Methods Twenty-six women (52 ± 8.2 years) with SLE and a history of cardiovas-
cular disease (SLE cases) were compared with two age-matched control groups:
26 women with SLE but no cardiovascular disease (SLE controls) and 26 healthy
women (population controls). Common carotid intima-media thickness was deter-
mined by B-mode ultrasound as a surrogate measure of atherosclerosis. Annexin V
binding to human umbilical vein endothelial cells was assessed by flow cytometry
after 24-hour culture with plasma. The presence of annexin V in carotid atheroscle-
rotic plaques was determined by immunohistochemistry. Annexin V levels in circu-
lation and anti-annexin IgG and IgM antibodies were measured by a commercially
available high-sensitivity ELISA. Pooled sera with high capacity to inhibit annexin V
binding were preabsorbed against different concentrations of antigens such as
cardiolipin and phosphorylcholine and against unrelated antigen tetanus toxoid.
Annexin V-binding assay with flow cytometry was performed.
Results Binding of annexin V was significantly lower when plasma from SLE
cases was used as compared with controls (SLE cases versus population con-
trols P = 0.002, SLE cases versus SLE controls P = 0.02). There was a striking
positive association between annexin V binding and intima-media thickness (R =
0.73, P < 0.001) among SLE cases. The annexin V levels were increased in SLE
cases compared with both SLE controls and PC (P = 0.03 and P = 0.004), but
no differences were detected in anti-annexin V IgG or IgM levels. Depletion of
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Figure 1
Arthitis incidence in bovine type II collagen (CII)–complete Freund’s adjuvant
immunized mice injected with cholera toxin (CTx)-treated dendritic cells (DC).S52
IgG from sera with high capacity to inhibit binding of annexin V induced a 2.7-fold
increase in binding and preincubation of sera with cardiolipin and phosphoryl-
choline resulted in increase of median fluorescence intensity of annexin V binding
to human umbilical vein endothelial cells. Immunohistochemical analysis revealed
the presence of annexin V in all plaques tested.
Conclusions Decreased annexin V binding to endothelium caused by
immunoglobulin may represent a novel mechanism of atherothrombosis. Increas-
ing annexin V binding may thus represent a novel therapeutic possibility.
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Background  Innate immune responses may augment adaptive immune
responses via the adjuvant effect of endogenous apoptotic cell death derived
nucleic acids that activate Toll-like receptors (TLRs). In animal models of lupus,
activation of TLR-9 accelerates renal disease. We studied the expression of TLR-
2, TLR-3, TLR-4 and TLR-9 in the peripheral blood mononuclear cells from
patients with systemic lupus erythematosus (SLE).
Materials and methods Peripheral blood mononuclear cells from 18 SLE
patients, four patients with other rheumatic disorders and three normal controls
were studied for the expression of TLRs by FACS analysis. TLR-2, TLR-3, TLR-4
and TLR-9 expressions was studied in total lymphocytes, CD19+ and CD14+
cells. Disease activity was assessed by the SLEDAI. Patients were divided into
those with active/severe disease and those with inactive/mild disease.
Results Eight out of 18 patients had active disease with mean SLEDAI score
12.3 (± 9.9) while 10 had inactive disease with mean SLEDAI score 2.8 (± 0.9).
Lymphocyte expression of TLR-9 (mean value and standard deviation) was higher
among patients with active/severe disease in comparison with patients with inac-
tive lupus (64 ± 18%, n = 8 versus 19 ± 14%, P < 0.003) (Table 1).
Table 1
Other 
Active Inactive  rheumatic  Healthy 
disease disease  diseases  controls 
(n = 8)  (n = 10)  (n = 4) (n = 3) 
(%) (%) (%) (%)
TLR-9 in lymphocytes 64 ± 18 19 ± 14 22 ± 21 28 ± 3
TLR-9 in CD19+ cells 42 ± 20 25 ± 24 17 ± 14 33 ± 5
TLR-9 in CD14+ cells 31 ± 18 16 ± 13 6 ± 5 24 ± 13
There were no differences between patients and healthy controls regarding the
expression of TLR-2, TLR-3 and TLR-4. The expression of TLR-9 on various B-cell
subpopulations of patients with SLE is currently under investigation.
Conclusions TLR-9, but not TLR-2, TLR-3 and TLR-4, is upregulated in periph-
eral lymphocytes from SLE patients with active/severe disease compared with
patients with inactive/mild disease. There is also a trend for increased expression
of TLR-9 at least on CD19+ and CD14+ cells. Experiments in progress examine
the response of these cells to TLR stimulation.
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Background Previous studies in this laboratory have highlighted the importance
of the proinflammatory cytokine tumour necrosis factor alpha (TNF-α) in the
pathogenesis of rheumatoid arthritis (RA) and suggested a role for bystander-
activated lymphocytes in its chronic production in the RA joint. Normal peripheral
blood (PB) lymphocytes cultured in the presence of a ‘cocktail’ of inflammatory
cytokines (IL-2/IL-6/TNF-α) generated effector cells (TCK) capable of inducing
both immunoglobulin production by B cells [1] and TNF-α production by mono-
cytes in a contact-dependent manner. This was in contrast to lymphocytes acti-
vated antigen dependently, via the T-cell receptor (TTCR), which induced
production of both TNF-α and the anti-inflammatory cytokine IL-10 [2,3]. Lympho-
cytes isolated from the RA synovial membrane exhibited contact-dependent
cytokine induction properties similar to TCK, not TTCR, cells [4].
Objective We have examined the population dynamics and phenotypic changes
induced in PB lymphocytes during culture with IL-2/IL-6/TNF-α to determine how
such cells resemble those found in the RA joint. As the predominant infiltrating
lymphocyte population found to accumulate in the RA synovial membrane is the
CD4+ T cell we have also explored the possibility of generating monocyte TNF-α-
inducing effector cells from purified CD3+CD4+ populations.
Results Lymphocytes cultured with IL-2/IL-6/TNF-α over 8 days demonstrated a
threefold expansion of the natural killer cell population, while the proportion of T
cells remained static. However, both these natural killer and T-lymphocyte popula-
tions were independently able to induce contact-dependent TNF-α production in
monocytes. Interestingly, effector cells generated by culture of the purified
CD3+CD4+ fraction with IL-2/IL-6/TNF-α for 8 days were able to induce at least
threefold more TNF-α production compared with such effectors generated from
the corresponding unfractionated lymphocyte population. We subsequently char-
acterised the different naïve and memory cell populations found within the CD4+
fraction of our bystander-activated lymphocyte cultures (as defined by Lanzavec-
chia and colleagues [5]). Despite an overall net loss in the percentage and
number of total CD4+ T cells, both naïve (CD45RA+CCR7+) and memory popula-
tions (effector:CD45RO+CRR7–; central CD45RO+CCR7+) were still present
after 8 days of culture. However, a preferential retention of effector memory over
central memory lymphocytes has been observed in most donors.
Further phenotypic studies have shown that bystander-activated lymphocytes
also express high levels of components of the adhesion molecules VLA-1, VLA-4,
VLA-5 and LFA-1 (β1, β2 and α4), but lower levels of L-selectin (CD62L). Such
properties are associated with the ability of effector lymphocytes to migrate from
lymph nodes and into tissues.
Conclusions Our results suggest that exposure of PB lymphocytes to a cocktail
of proinflammatory cytokines induces the outgrowth of an activated effector
memory lymphocyte population with the capacity to migrate to inflammatory sites.
Studies currently underway will examine the effector function of different CD4+
subsets in terms of their ability to induce monocyte TNF-α production.
This work will more closely define pivotal cell types responsible for cognate-
dependent cytokine production in diseased joints as well as advancing our under-
standing of the effects and consequences of prolonged cytokine exposure in
chronic inflammation.
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We studied the prevention of a mice model of rheumatoid arthritis, the collagen-
induced arthritis (CIA) model, with DNA-matured dendritic cell injection and then
studied the induction of Treg through this innate immunity stimulation. CIA was
induced as described in DBA/1 mice with bovine type II collagen intradermal
injections. Intermediate DNA-matured dendritic cells were injected at D14
intraperitoneally. The clinical course of arthritis was followed and B-cell and T-cell
responses were assayed. The induction of CD4+CD25+ was tested by flow
cytometry and the induction of Treg markers was quantified by quantitative RT-
PCR. Treatment of CIA with intermediate DNA-matured dendritic cells could
prevent arthritis as well as lipopolysaccharide-matured dendritic cells. Neither B-
cell and T-cell responses were not modified nor was a TH2 response observed.
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The induction of Treg (CD4+CD25+) cells was observed in blood, and lymph
nodes. The induction of foxp3  could be quantified and increased with DNA-
matured dendritic cells in peripheral nodes. In conclusion we could observed a
prevention of CIA with the injection of DNA-matured dendritic cells that did not
modify the specific response against bovine type II collagen. Because of the
absence of T-cell and B-cell response modification as well as TH2 modification,
we do believed that the induction of CD4+CD25+ cells that expressed foxp3 are
involved in the prevention of CIA we observed.
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Background The aetiology of rheumatoid arthritis (RA) has been suggested to be
an interaction between genetic and environmental factors. Genetic susceptibility
to this disease in most of the population is associated with MHC II molecules that
contain an amino acid motif known as the shared epitope (SE). These MHC mole-
cules may bind arthritogenic peptides for presentation to autoreactive T cells.The
nature of the arthritogenic peptide is not known, but recent studies have identified
post-translationally modified proteins containing citrulline as targets of anti-cyclic-
citrullinated peptide (anti-CCP) autoantibodies. It has been shown that in HLA-
DRB1*0401 transgenic mice the conversion of arginine to citrulline at the peptide
side chain position interacting with the SE significantly increases peptide–MHC
affinity and leads to the activation of CD4+ T cells in the transgene mice.
Objective The aim of this work was to investigate the relationship between the
HLADRB1 genotype and the presence of anti-CCP IgG antibodies in sera of
patients with RA.
Methods HLA-DRB1 genotyping was performed using PCR seqence-specific
primers from the DR low resolution kit and DRB1*01, DRB1*04 subtyping kits as
well.
IgG anti-CCP antibody levels were measured by the ImmunoscanRA ELISA kit.
Rheumatoid factor was determined by the nephelometric method (Behring).
Samples of 131 patients with RA were investigated.
Results SE is present in 75 (57.2%) and absent in 56 (42.7%) patients. The
prevalence of anti-CCP autoantibodies is significantly higher in the group of SE-
positive patients (n = 44, 76%) than in the group of non-SE carriers (n = 28)
(P = 0.03; chi-squared test). The average autoantibody level measured in anti-
CCP-positive patients carrying SE is 742.7 U/ml while in the absence of SE
alleles it is 437.5 U/ml, which does not differ statistically.
Conclusion Association of the SE and citrullinated antigens may be one of the
triggers initiating the production of anti-CCP antibodies
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Background Cardiovascular disease (CVD) is common in systemic lupus erythe-
matosus (SLE) patients although it is not clear whether an increased risk of CVD
is a general feature of SLE, or whether this applies only to a subgroup of patients.
Objective To measure early signs of atherosclerosis/vascular dysfunction in
women with SLE with or without CVD and in controls, and to investigate whether
these correlate to circulating markers of endothelial activation.
Methods Twenty-six women with SLE and a history of CVD (defined as a history of
objectively verified angina pectoris, myocardial infarction, cerebral infarction or inter-
mittent claudication; age 52 ± 8.2 years) were compared with age-matched SLE
women without CVD (SLE controls) and population-based age-matched control
women (population controls). Flow-mediated dilatation (FMD) of the Brachial artery
after reactive hyperemia and after sublingual nitroglycerine administration was per-
formed on women who were not already on nitro-related medication. Levels of
thrombomodulin, tumour necrosis factor (TNF) alpha, sTNF receptors, homocys-
teine and fibrinogen have been associated with endothelial activation/inflammation
and were measured in the circulation by use of the ELISA technique.
Results SLE controls and controls did not differ with respect to FMD after reac-
tive hyperemia or after nitroglycerine administration. Only two SLE cases could
be investigated for endothelial function because of nitro-related medication.
However, levels of TNF-α, sTNFR1, sTNFR2, and homocysteine discriminated
between SLE cases, SLE controls and population controls (P < 0.05 for all),
whereas thrombomodulin (P = 0.001) and fibrinogen (P = 0.02) only discrimi-
nated between SLE controls and population controls.
Conclusion Women with SLE who did not have manifest CVD did not differ from
age-matched controls with respect to FMD, a measure of endothelial dysfunction.
Higher levels of circulating markers of endothelial activation/inflammation were
present and discriminated between SLE cases, SLE controls and population con-
trols but these did not correlate to measures of endothelia dysfunction, which
may not be a general feature of SLE.
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Background Rheumatoid arthritis (RA) is characterized by chronic inflammation of
the synovial joints leading to irreversible joint destruction. To prevent and/or slow
down progressive joint destruction, the diagnosis of RA at early stage in the disease
is important. The autoantibodies against citrullinated proteins (aCCP) provide such
ability, representing a marker for early RA. However, a remarkable variety in the
reactivity against different citrulline-containing peptides has been described, which
indicates that not only citrulline but also its flanking amino acid sequences play a
role in the antigenicity and that autoantibodies recognizing such targets are poly-
clonal. Furthermore, B cells isolated from synovial fluid of aCCP-positive RA
patients were shown to produce aCCP antibodies spontaneously, whereas periph-
eral blood B cells require a stimulation to produce these antibodies. The predomi-
nance of IgG production in synovial fluid and synovial tissue was observed in
comparison with serum. These findings altogether provide the evidence for the local
antigen-driven maturation of B cells into aCCP-producing plasma cells within
inflamed RA synovium due to the presence of citrullinated synovial proteins.
Objective The aim of the study was to analyze the occurence of the aCCP-spe-
cific B cells in peripheral blood (PB) and synovial tissue (ST) of RA patients. Three
citrulline-containing peptides derived from human natural proteins were used in
order to test the hypothesis of polyclonal production of aCCP autoantibodies.
Methods PB and ST were collected from nine patients with RA. Biotinylated cit-
rulline-containing peptides derived from human filaggrin (P1), aggrecan (P3) and
fibrin (P0428), and flow cytometry were employed to analyze B-cell populations
specific for citrullinated peptides. The serum levels of aCCP autoantibodies were
evaluated by ELISA kit (Mark2). Statistical analysis was performed by Pearson
and paired t tests using GraphPad software (GraphPad, San Diego, CA, USA).
Results The serum titres of aCCP autoantibodies ranged from 0.0 to 1300.0 U/ml
(median 276.6; 95% confidence interval 34.99–880.4). The CD19+ B cells rec-
ognizing individual synthetic citrullinated peptides were detected in PB and ST of
RA patients, in most cases showing the reaction with at least two of three tested
peptides. The frequencies of these B cells differed for both individual citrullinated
peptides and patients, especially in ST, and the observed maximum was 2.4% for
peptide P1 and P3 in PB and 6.4% for peptide P3 in ST. In some cases, the fre-
quencies of CD19+ B cells specific for citrullinated peptides were increased in ST
as compared with PB of the same patient; for example, 2.07% in ST versus 0.75%
in PB for peptide P0428 or 6.35% in ST versus 0.1% in PB for peptide P3.
However, the frequencies of analyzed citrulline-specific B cells did not correlate to
serum aCCP autoantibodies titers. The data might indicate the presence of several
B-cell subsets specific for different citrullinated substrates within the inflamed joint
and the ongoing autoantigen-driven B-cell activation in the synovium. However, the
clonal relation between B cells specific for the used individual citrullinated pep-
tides remains unclear and will be subsequently analyzed.
Ackowledgements The authors thank Prof. WJ van Venrooij (University of
Nijmegen, Nijmegen, The Netherlands) and Dr JW Drijfhout (Leiden University
Medical Center, Leiden, The Netherlands) for the biotinylated citrullinated pep-
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Rheumatoid arthritis (RA) is a heterogeneous disease, which is also reflected in
the type of cellular infiltrates in the RA synovial tissues. In approximately 25% of
Available online http://arthritis-research.com/supplements/7/S1S54
the patients, the synovial tissue contains cellular infiltrates that have formed orga-
nized structures resembling structures normally observed in lymph nodes, com-
prising follicular dendritic cells (FDCs), with distinct T-cell and B-cell areas,
therefore referred to as ectopic lymphoid structures. In the remainder of the
patients the tissues do not contain FDCs and show either a diffuse lymphocytic
infiltrate or an aggregated T-cell and B-cell infiltrate [1].
The aim of our study is to identify the genes that are expressed in tissues with
these ectopic lymphoid structures by cDNA microarray analysis to gain more
insight into this specific disease process. We previously showed that the gene
expression signatures of synovial tissues from RA patients showed considerable
variability, resulting in the identification of distinct molecular forms of RA [2,3]. To
evaluate whether the genes involved in the formation of ectopic lymphoid struc-
tures could be detected by microarray analysis of whole synovial tissues, we per-
formed an analysis focused on a selection of genes that are known to be involved
in normal lymph node development from murine knockout studies.
Indeed, four out of 13 tissues showed an elevated expression of lymph-node-
associated genes, indicating that microarray analysis of whole synovial tissue
allows the detection of these genes. The expression of the FDC-specific marker
CD21L and immune histochemical staining of synovial tissue sections confirmed
the presence of ectopic lymphoid structures in these tissues. Detailed histochem-
ical analysis further allowed us to subclassify the tissues without lymphoid struc-
tures into tissues containing T-cell and B-cell aggregates and tissues with a
diffuse type of infiltrate.
Comparison of large-scale gene expression profiles between tissues with the
three different types of cellular infiltrates revealed differential expression of genes
involved in several processes such as apoptosis, antigen presentation, angiogen-
esis, chemotaxis and extracellular matrix formation. The results indicate that
tissues with ectopic lymphoid structures comprise a distinct type of gene expres-
sion that includes a spectrum of genes encoding for adhesion molecules,
chemokines, cytokines and their receptors that is required to maintain their highly
organized structure.
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Background Dendritic cells (DC) comprise a heterogeneous network of profes-
sional antigen-presenting cells, directly linking innate and adaptive immunity.
While implicated in the pathogenesis of different chronic inflammatory arthritides,
the analysis of DC subsets has been hampered by a lack of specific DC markers
and reliable quantitation. Previously, we have described the significant reduction
of circulating peripheral blood (PB) myeloid DC (mDC) in rheumatoid arthritis
(RA) patients and the significant reduction of circulating PB plasmacytoid DC
(pDC) in both RA and psoriatic arthritis patients. Furthermore, we have shown
that both of these DC subsets are present in synovial fluid (SF) from RA and pso-
riatic arthritis patients, although mDC significantly exceed pDC.
Objectives This present study characterises the immunophenotype and func-
tional characteristics of RA-derived mDC and pDC in order to assess their poten-
tial pathogenic role in arthritis.
Methods pDC and mDC were sequentially purified by magnetic cell sorting
(MACS) using anti-neuropilin-conjugated magnetic microbeads (pDC) and biotin-
conjugated anti-CD1c followed by positive selection using anti-biotin-conjugated
magnetic microbeads (mDC), from RA PB (n = 3) and SF (n = 3) and compared
with normal healthy controls (mDC, n = 4; pDC, n = 5). Purified cells were phe-
notyped using CD1c-FITC (mDC only), BDCA-2-FITC (pDC only), CD123-PE
(pDC only), CCR5-PE (pDC only), CD11c-PE (mDC only), CD14-PE (mDC only),
CD40-APC, CD62L-FITC, CD80-FITC, CD83-APC, CD86-APC, CCR7-PE pre
and post 24-hour stimulation with TLR2 agonist S. aureus peptiodoglycan (mDC)
or TLR9 agonist CpG oligonucleotide (ODN) 2216 (pDC). Supernatants were
harvested from all cultures and cytokine concentrations analysed using Luminex.
Results Circulating RA PB-derived mDC and pDC display a typical immature DC
phenotype compared with mDC and pDC from healthy control subjects;
however, L-selectin (CD62L) expression was significantly decreased on RA pDC
(P = 0.0369) but not mDC (P = 0.1573). Conversely, while RA SF-derived pDC
displayed an immature phenotype directly comparable with their normal PB-
derived counterparts, RA SF-derived mDC displayed increased CD80 and
CD86, but decreased CD62L, suggesting a less immature phenotype. Moreover,
RA SF-derived mDC had a higher CD14 expression, suggesting that these cells
may be monocyte-derived mDC. FACScan analysis revealed that both SF-derived
DC subsets upregulated maturation markers following Toll-like receptor stimula-
tion. Cytokine analysis revealed that while pDC from both normal PB and RA SF
produced large levels of interferon gamma and tumour necrosis factor alpha in
response to TLR9 stimulation, only RA SF pDC produced low levels of IL-10 and
interferon gamma. Similarly, mDC from both normal PB and RA SF produced
large levels of tumour necrosis factor alpha; however, RA SF mDC produced
more IL-10 than their normal PB counterparts.
Conclusions We report the ex vivo immunophenotype and functional character-
istics of circulating RA PB-derived and SF-derived mDC and pDC.
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Rationale Local bone destruction and osteoporosis in rheumatoid arthritis (RA) is
mediated by the interaction of the receptor activator of nuclear factor kappa B
(RANK) with its ligand (RANKL) and osteoprotegerin (OPG). Effector cells —
osteoclasts — are generated upon the contact between RANK-positive (RANK+)
pre-osteoclasts with RANKL expressed on the surface of osteoblasts or inflamma-
tory cells [1]; a role of the soluble form of RANKL (sRANKL) in synovial fluid (SF)
or serum in the osteoclast maturation has also been discussed. We have previ-
ously reported higher local production of OPG and sRANKL in RA active joints in
comparison with their serum concentration, lower local and systemic concentra-
tions of OPG in RA patients in comparison with those suffering from osteoarthritis
(OA) and no difference in SF-sRANKL levels between RA and OA groups [2].
Method Surface expression of RANKL in T lymphocytes and monocytes was
evaluated by flow cytometry using goat biotinylated polyclonal anti-RANKL and
anti-RANK antisera visualized by streptavidin-phycoerythrin and FITC-conjugated
anti-CD3, anti-CD4 and anti-CD14 monoclonal antibodies. Six paired RA
samples of SF and peripheral blood were analysed. The results were compared
with data from peripheral blood of 18 RA donors, 14 OA donors and 14 healthy
donors, respectively.
Results In SF of RA patients, higher numbers (17%) of CD3+RANKL+ mononu-
clear cells (synovial fluid mononuclear cells) were found than in peripheral blood
mononuclear cell (PBMC) preparations (5%, P = 0.07). In contrast, relatively
more RANKL+CD14+ monocytes (79%) exist in peripheral blood than in SF
(20%) in the same individuals. When PBMCs in different groups were analysed,
significantly higher numbers of CD3+ (8%) and CD4+ (8.9%) PBMCs bearing
RANKL on the surface were found in the RA group than in controls (4.3% and
4.7%, P = 0.03 and 0.02). In addition, RA patients had significantly higher pro-
portions of CD14+RANKL+ PBMC (45.6%) than controls (30.2%, P = 0.013) or
OA patients (29.7%, P = 0.046). On the other hand, RANK expression on
CD14+ PBMC appeared diminished in RA patients (17.3%) when compared with
controls (35.5%, P = 0.013).
Conclusions Our findings suggest that the induction of bone erosions may
depend rather on surface-bound RANKL than on its soluble form. This hypothesis
is supported by our previous findings (see rationale) as well as by differences in
RANKL expression on SF and peripheral blood CD3+ cells and the increased
numbers of RANKL+ lymphocytes in the peripheral blood CD3+ and CD4+ com-
partments in RA patients. The lower ratio of CD14+RANK+ monocytes in periph-
eral blood of RA patients could reflect selective recruitment of RANK+ cells into
the sites with elevated RANKL expression. In such a process, a soluble form of
RANKL would probably play an important role [3].
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Background  Programmed death (PD)-1 is a newly described member of the
immunoglobulin super-family that is expressed on activated T lymphocytes and B
lymphocytes. Engagement of PD-1 with its specific ligands, PD-L1 (B7-H1) and PD-
L2 (B7-DC), inhibits lymphocyte proliferation and cytokine expression, and may play
a role in peripheral tolerance and negative regulation of T-cell and B-cell responses
in vivo. We sought to investigate the expression profiles of PD-1 and PD-1 ligands in
peripheral blood cells of patients with systemic lupus erythematosus (SLE).
Materials and methods Blood was drawn from patients with SLE (n = 16),
rheumatoid arthritis (n = 16), other inflammatory disease (n = 4), and healthy con-
trols (n = 9). Peripheral blood mononuclear cells were separated on a ficoll-
density gradient, and flow cytometry analysis was performed using monoclonal
antibodies against CD3, CD19, CD14, CD25, CD69, PD-1, PD-L1, and PD-L2.
Results See Table 1.
Table 1
Disease group
Systemic 
Healthy lupus  Rheumatoid  Inflammatory 
controls erythematosus arthritis disease
Mean SEM Mean SEM Mean SEM Mean SEM
PD-1+ (%)
in CD3+ 0.6 0.2 0.4 0.1 1.6 0.6 0.5 0.1
in CD19+ 1.7 0.9 1.4 0.3 0.9 0.4 1.1 0.4
in CD25+ 3.0 1.0 2.4 0.7 3.3 1.6 8.5 3.4
PD-L1+ (%)
in CD3+ 2.8 1.2 4.1 0.9 2.3 0.5 2.0 0.6
in CD19+ 3.9 1.3 5.1 0.9 3.7 1.0 11.3 8.0
in CD14+ 5.1 2.0 14.0 5.4 2.9 0.9 5.7 3.2
PD-L2+ (%)
in CD3+ 0.6 0.2 0.5 0.1 0.5 0.2 0.4 0.0
in CD14+ 2.0 0.5 1.4 0.3 1.1 0.5 1.2 0.1
SEM, standard error of the mean. No statistically significant differences were observed.
Conclusions In this preliminary report, SLE patients showed a trend for lower
expression of PD-1 and higher expression of PD-L1 in unstimulated peripheral
blood mononuclear cells compared with other disease controls. These results
corroborate findings linking SLE with polymorphism of the PD-1 gene resulting in
putative altered expression of the PD-L2 [1]. Lower expression of PD-1 in SLE
lymphocytes could be related to ineffective suppression of autoreactive lympho-
cytes and thus to disease evolution. Currently, we investigate expression of PD-1
and its ligands on subpopulations of lymphocytes (CD45RO+, CD27+), as well
as the kinetics of expression upon stimulation.
Reference
1. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnus-
son V, et al.: A regulatory polymorphism in PDCD1 is associated with
susceptibility to systemic lupus erythematosus in humans. Nat Genet
2002, 32:666-669.
P154
Cultured salivary gland epithelial cells from patients with
primary Sjögren’s syndrome and disease controls are
sensitive to signaling via Toll-like receptors 2 and 3:
upregulation of intercellular adhesion molecule-1 expression
MP Spachidou, EK Kapsogeorgou, EA Bourazopoulou, 
HM Moutsopoulos, MN Manoussakis
Department of Pathophysiology, Medical School, University of Athens, Greece
Arthritis Res Ther 2005, 7(Suppl 1):P154 (DOI 10.1186/ar1675)
Background In previous studies, our laboratory has shown that the salivary gland
epithelial cells (SGEC) of patients with primary Sjögren’s syndrome (SS) display
an intrinsically activated phenotype, as characterised by high expression of adhe-
sion, costimulatory and antigen-presenting molecules. Stimulation of Toll-like
receptors (TLRs) expressed by epithelia by native or synthetic ligands of TLR2,
TLR3 and TLR4 may be critically involved in the regulation of immune responses
through the induction of various immunoactive molecules, such as the intercellu-
lar adhesion molecule-1 (ICAM-1/CD54).
Materials and methods Cultured, non-neoplastic SGEC lines derived from minor
salivary gland biopsies of patients with SS (SS-SGEC, n = 4) and controls (n = 4)
were studied. The expression of TLR2, TLR3 and TLR4 mRNA was examined by
PCR. SGEC were stimulated by S. aureus peptidoglycan (100 µg/ml, TLR2-
ligand), the synthetic analogue of dsRNA poly-inosinic:cytidylic acid (polyI:C) (5
µg/ml, TLR3-ligand) and E. coli lipopolysaccharide (100 ng/ml, TLR4-ligand), for 24
and 48 hours. In certain experiments, cells were also primed with interferon alpha
(500 IU/ml) for 24 hours, prior to the stimulation with polyI:C. The induction of
ICAM-1 expression was analysed by flow cytometry on resting and stimulated cells.
Results SGEC lines were found to express TLR2, TLR3, and TLR4 mRNA. In
agreement with their intrinsic activation status and previously published reports,
SS-SGEC lines displayed high constitutive ICAM-1 expression, compared with
control-SGEC lines. Triggering of TLR3 with polyI:C had resulted in significantly
increased ICAM-1 expression (SS-SGEC: sixfold, controls: sevenfold) that
reached maximum expression after 24-hour stimulation. The response to polyI:C
was further enhanced after priming of the cells with interferon alpha. Signaling via
TLR2 by peptidoglycan was found to upregulate moderately ICAM-1 expression
(SS-SGEC: onefold, controls: twofold) after 24-hour stimulation. Despite expres-
sion of TLR4 mRNA (by PCR), as well as of surface CD14 protein (by flow cytom-
etry), lipopolysaccharide stimulation failed to upregulate ICAM-1 expression.
Conclusions Our results indicate the SGEC lines are able to respond to syn-
thetic microbial analogues that stimulate TLR2 and TLR3 by upregulating the
expression of the adhesion molecule ICAM-1/CD54.
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Background Serological markers, especially autoantibodies with high disease
specificity, have their emphasized role in support of the diagnosis of autoimmune
diseases. Detection of anti-cyclic citrulline (anti-CCP) antibodies has gained
increasing interest in clinical practice as they have shown to have strikingly high
(96–89%) specificity for rheumatoid arthritis (RA).
Objective The aim of this study is to summarize our experience in testing anti-
CCP and other autoantibodies on a large number of sera from patients with sus-
pected and definite connective tissue disease.
Methods A total of 2061 sera derived from 1750 patients were requested for
detection of anti-CCP and rheumatoid factor (RF) autoantibodies. Conventional
autoantibodies were also tested according to the requests of clinicians in cases
of 1560 samples. Anti-CCP antibodies were detected with the ImmunoscanRA
Elisa kit, and RF by nephelometry (Behring). Antinuclear antibodies were
detected by IF test on Hep-2 cells (Inova). Anti-Ena antibodies, anti-DNA, anti-
chromatin, anti-cardiolipin were measured using ELISA kits (Inova). Anti-CCP
antibodies exceeding the level of 25 U/ml were considered positive. Samples
expressing antinuclear antibodies at dilution of 1:200 or higher were evaluated.
Results Anti-CCP and RF were present in sera of 331 patients, while 59 patients
were positive only for anti-CCP antibodies.
Autoantibody profile detected in anti-CCP-positive and RF-positive patients (n =
331) — antinuclear antibody positive samples, n = 54 (16.3%): including polimyosi-
tis, scleroderma associated antibodies, n = 7 (2%); systemic lupus erythematosus
associated antibodies (anti-DNA, anti-chromatin, anti-histone, anti-Sm), n=12 (3.6%);
MCTD associated antibodies, n = 5 (1.5%); Sjögren syndrome associated autoan-
tibodies, n = 10 (3%); anti-centromere antibodies, n = 4 (1.3%); and primary biliary
cirrhosis associated antibodies, antimichondrial antibody, n = 4 (1.3%). In four
cases the presence of anti-neutrophyl cytoplasmic antibodies was also seen.
In the group of patients with only anti-CCP positivity (n  = 59) — two (3%)
samples were positive for anti-centromer, one of them for Scl70 as well, one was
positive for PM/Scl like antibodies, one for anti-DNA, one for anti-Rnp/Sm anti-
body, and one sample showed strong antimichondrial antibody positivity.
Conclusion These results show a more complex picture of the occurrence of
anti-CCP antibodies as they may associate with different stages of connective
tissue diseases. We also aimed to initiate further clinical studies to define the role
of this family of autoantibodies in the diagnosis of RA-associated secondary dis-
eases, and also in overlap syndromes.
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Background Pristane-induced arthritis (PIA) in rats is considered an excellent model
for rheumatoid arthritis (RA) since it fulfils the criteria for RA including a chronic
relapsing disease course and is not dependent on immunization with exogenous
antigen. Although the adjuvant pristane is not immunogenic, the disease is MHC
associated and dependent on the activation of (autoreactive) T cells. However, so far
it has not been possible to link the immune response to joint antigens or other
endogenous components. HnRNP A2, the RA33 autoantigen (A2/RA33), is a multi-
functional RNA binding protein involved in splicing and other aspects of post-
transcriptional regulation of gene expression. Autoantibodies as well as autoreactive
T cells against A2/RA33 have been found in patients with RA but the pathogenetic
role of these autoimmune responses is unresolved [1]. It was therefore the aim of this
study to elucidate a potential involvement of A2/RA33 in PIA.
Methods Autoantibodies against A2/RA33 were determined by immunoblotting,
and MHC association of the anti-A2/RA33 immune response was specified by
the presence of autoantibodies, delayed-type hypersensitivity reactions and T-cell
cytokine secretion in DA rats of different haplotypes. Interferon gamma and
tumour necrosis factor secretion by T cells isolated from draining lymph nodes
10 days after pristane injection and restimulation with A2/RA33 in vitro was
determined. Expression of A2/RA33 in joints and organs was analysed by
immunohistochemistry and western blotting. Nasal vaccinations were performed
with A2/RA33 7 days prior to pristane injection.
Results Although anti-A2/RA33 autoantibodies were detected in all four rat strains
investigated, the immune response appeared to be particularly linked to the F and U
MHC haplotypes. Autoantibodies to A2/RA33 were found in 60% of DA1.F sera,
and T cells of all DA1.F rats tested produced intermediate to high levels of inter-
feron gamma upon stimulation with A2/RA33. The reaction seemed to be entirely
produced by CD4+ cells showing a Th1 phenotype. Furthermore, nasal vaccination
with A2/RA33 significantly delayed the onset and decreased severity of arthritis in
DA1.F rats. Finally, immunohistochemical and western blot analyses revealed pro-
nounced overexpression of A2/RA33 in joints of rats suffering from acute PIA, but
not in healthy joints or in joints from animals with chronic PIA.
Conclusion The A2/RA33 autoantigen is targeted by autoantibodies and Th1 cells
in rats with PIA shortly after pristane injection. The presence of autoreactive Th1
cells in conjunction with synovial overexpression of A2/RA33 strongly suggests
involvement of this autoantigen in the pathogenesis of PIA. This is further bolstered
by the observed alleviation and delay of onset of PIA following nasal vaccination
with A2/RA33. Thus, A2/RA33 seems to be one of the primary autoantigens in PIA
that in conjunction with previous observations on the presence of autoreactive
T cells in RA patients may argue for a pathogenetic role also in human RA.
Reference
1. Fritsch R, et al.: Characterization of autoreactive T cells to the autoanti-
gens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin
in patients with rheumatoid arthritis. J Immunol 2002, 169:1068-1076.
Acknowledgements  This work was supported by a grant from the Austrian
Academy of Sciences and by Marie Curie Host Fellowship number HPMT-CT-
2000-00126 of the European Commission Research Directorate.
P157
Influence of methotrexate, leflunomide and tumour
necrosis factor alpha inhibitors on immune competence in
rheumatoid arthritis patients: a long-run monitoring of
Epstein–Barr virus load
N Balandraud1,2, S Guis1,2, JB Meynard3, I Auger1, H Sovran1, J Roudier1,2,
C Roudier1,2
1INSERM UMR 639, Faculté de Médecine, Marseille, France; 2Service de
Rhumatologie Est, Hôpital de la Conception, Marseille, France; 3Institut de
Médecine Tropicale du Service de Santé des Armées, Marseille, France
Arthritis Res Ther 2005, 7(Suppl 1):P157 (DOI 10.1186/ar1678)
Background The risk to develop lymphoma is doubled in patients with rheumatoid
arthritis (RA) in the the absence of immunosuppressive therapy. This risk is slightly
increased by the use of methotrexate or tumour necrosis factor alpha inhibitors
(infliximab and etanercept) [1]. Epstein–Barr virus (EBV) is detected in about one-
third of lymphoma developing in RA patients. The reason why some patients
develop lymphoma is unknown. We have previously shown that RA patients have
an almost 10-fold increase of EBV load in their peripheral blood mononuclear cells
(PBMCs), compared with normal controls [2]. RA patients’ peripheral blood EBV
load is similar to that of healthy transplant recipients (10 copies per 500 ng DNA).
In immunosuppressed transplant recipients, elevation of PBMC EBV load above
500 copies/500 ng DNA predicts the emergence of lymphoma.
Objectives We followed RA patients to evaluate the effects of disease-modifying
anti-rheumatic drugs (DMARDs) (methotrexate and leflunomide) and tumour
necrosis factor alpha inhibitors (infliximab and etanercept) on PBMC EBV load
and to predict lymphoma development.
Methods One hundred and nineteen patients fulfilling the 1987 ACR criteria for
RA were followed for periods of 6 months–4 years. Twenty patients received
methotrexate or leflunomide, eight received only infliximab, 61 received metho-
trexate and infliximab, and 30 received etanercept. A 214 bp fragment from the
conserved long Internal Repeat IR1 was amplified by quantitative PCR to evalu-
ate EBV DNA load. Effect of treatment duration on EBV load was analyzed by the
method of generalized estimation equations.
Results EBV load decreased between the beginning and the end of the study in
patients receiving DMARDs (mean: 20.24 and 3.27) or etanercept (mean: 4.44
and 0.67). This decrease was significant for DMARDs (P = 0.0038). However,
EBV load evolution was not significantly related to treatment duration in patients
under infliximab (mean: 6.36 and 7.82) or infliximab plus methotrexate (mean:
13.49 and 11.92). Of interest, in one patient receiving infliximab plus methotrex-
ate, EBV load reached 540 copies/500 ng over a short period of time.
Conclusion Methotrexate and etanercept decrease EBV load over time. Infliximab
alone or with methotrexate does not influence significantly EBV load. Monitoring
EBV load might help detecting the few patients who are likely to develop lymphoma.
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In 1998 Douek and coleagues described a novel approach to measuring thymic
output using T-cell receptor excision circles (TRECs) measured in CD4+ and
CD8+ T cells. TRECs are byproducts of T-cell receptor gene re-arrangements,
whereby sections of excised DNA re-form as stable episomes that do not replicate
with mitosis. TRECs present in T cells arising from the thymus are thus ‘diluted out’
upon T-cell division and can be used as a surrogate marker of thymic output.
However, the interpretation of TREC number in lymphocyte subsets is confounded
by the influences of T-cell proliferation, intracellular TREC degradation and T-cell
death, and it has been criticised as a measurement of thymic function. Here, we
describe a method for quantifying TRECs in whole blood. This revised assay pro-
vides a representation of ‘total peripheral TRECs’. The effects of T-cell proliferation
and cell death on the determined absolute TREC level are minimised, providing us
with an improved estimation of thymic function over time. In a series of validation
experiments our assay has been shown to have excellent intra-assay and inter-
assay reproducibility and to generate results consistent with previously published
work in healthy controls. We are now using this assay to determine thymic function
in the autoimmune disease systemic lupus erythematosus to test our hypothesis
that a defect in thymic function contributes to lupus pathogenesis.
To measure the absolute TREC number per unit volume of blood (as a representa-
tion of ‘total peripheral TRECs’), the amount of DNA extracted from a volume of
whole blood must be representative of ‘total’ DNA in that volume of blood. We have
compared four methods of DNA extraction from whole blood for consistency of yield
and purity. Figure 1a shows the mean DNA yield from parallel extractions (n = 10)
performed after (a) 1 hour, (b) 6 hours and (c) 24 hours from collection for a single
sample. The overall mean yield was 32.23 µg/ml ± 2.3 standard deviations (SDs).
Two further, separate, samples were similarly prepared in parallel to confirm consis-
tency — (d) 26.8 µg ± 1.97 SD and (e) 26.9 µg ± 2.23 SD (n= 10). To measure
TRECs in samples we have used a quantitative real-time PCR (TAQMAN™) assay to
amplify a known proportion of the extracted DNA. The total TREC number per
sample is determined absolutely from a standard curve (derived from a plasmid con-
taining TREC sequence) and final values are presented as TRECs per millilitre of
whole blood. Figure 1a (top axis) shows that the TREC number is reproducibly calcu-
lated from parallel extractions (n = 5). The intra-assay coefficient of variation is 1.4%
(range 0.8–2.5%) while the inter-assay co-efficient of variation is 2.4% (range
0.6–4.4%). The coefficient of variation is negatively correlated with TREC number (r2
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= 0.83 and 0.66, respectively). Using this assay we have also shown that TRECs are
reliably detectable in healthy controls (Fig. 1b) and show an age-related decline in
keeping with the known reduction in thymic volume over time. TRECs are not
detectable in RAJI (human B-cell lymphoma line) or SW48 (human colonic carci-
noma cell line) (data not shown). We are now using this assay to determine the
TREC number in the autoimmune disease systemic lupus erythematosus to test our
hypothesis that a defect in thymic function contributes to lupus pathogenesis.
While measurement of TRECs in T cells and their subsets provides a representa-
tion of thymic function in the steady state, in the context of autoimmunity, where
abundant auto-antigen provides a constant T-cell-activating stimulus, interpreta-
tion of the TREC number within lymphocyte subsets is confounded. By reliably
and reproducibly estimating total peripheral TRECs we aim to minimise the
impact of T-cell turnover on TREC number in order to gain a better understanding
of thymic function in systemic lupus erythematosus.
Acknowledgement This research is funded by an arc Clinical Research Fellow-
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Introduction In the pathogenesis of rheumatoid arthritis (RA), macrophages (Mφ)
play a pivotal role in synovitis, especially at the cartilage–pannus junction. Both
Mφ and peripheral blood monocytes (MO) are activated and release proinflamma-
tory cytokines (IL-1β, tumour necrosis factor [TNF] alpha). Neutralization of IL1-β
and TNF-α leads to clinical improvement in RA.
Objective To characterize MO expression profiles of patients with active RA
before and after treatment with adalimumab, a fully human, anti-TNF monoclonal
antibody, using microarray analysis. To identify differences in expression of signa-
ture genes between patients with uncontrolled, active RA and those in remission
induced by anti-TNF therapy.
Methods Genome-wide microarray analyses (HG-U133A/B) were performed to
identify signature genes and RA-MO pathways and to establish a customized
cDNA array suitable for monitoring anti-TNF therapy. Untouched MO were nega-
tively selected by magnetic cell sorting from 40 ml peripheral blood samples. Total
RNA was extracted for cRNA synthesis, and was hybridized with whole genome
oligonucleotide and customized cDNA microarrays. The customized cDNA array
consisted of 313 cDNAs derived from gene subtraction analysis and from compar-
ative genome-wide U133A analysis. The array includes RA-relevant signature
genes, and genes triggered or repressed during anti-TNF treatment. To identify
significant gene expressions, bioinformatical MAS 5.0, self-organizing map cluster-
ing and predictive analysis for microrrays (PAM) analyses were performed.
Results Genome-wide analysis of MO mRNA expression in patients with active
RA before and after receiving anti-TNF-α (n = 7) revealed significant differences
in upregulated and downregulated genes. Self-organizing map analysis revealed
six different gene expression clusters. MAS 5.0 and PAM analyses identified 103
differentially expressed genes and permitted the separation of RA patients into
two subgroups of ‘responders’ and ‘non-responders’, correlating with clinical
data (DAS28 and ACR response criteria). Results were confirmed by a cus-
tomized array using most of the PAM-selected genes. Twenty-four genes were
further evaluated by real-time PCR using MO from normal donors and from
patients with RA before and during therapy. Signature genes identified were
characterized as: disease-relevant genes differentially transcribed in activated
RA-MO compared with normal donor MO; genes reversed to ‘normal levels’ by
anti-TNF treatment; or pharmacodynamic marker genes probably indicative of
anti-TNF action. Selected genes, which may be indicative for the response to
therapy, are currently being further evaluated in extended collections of samples.
Conclusions Signatures are important to define MO activation to characterize
disease activity and to support therapeutic stratification. The current gene selec-
tion could contribute to the investigation of the role of MO in a wide range of
rheumatic diseases and therapeutic intervention, improving rheumatologists’
understanding of regulated MO pathways.
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Background Protease-activated receptor-2 (PAR-2) is a G-protein-coupled
receptor recognized to mediate inflammatory responses. Using a PAR-2 ‘knock-
out’ mouse, we previously demonstrated this receptor to play a crucial role in
chronic joint inflammation [1]. Inhibition of PAR-2 activation therefore potentially
represents a novel therapeutic target in treatment of arthritis, but selective antag-
onists are not yet available.
Objective To test the hypothesis that acute joint inflammation could be inhibited
by targeting the ‘tethered ligand’ sequence of PAR-2 using a specific monoclonal
antibody (SAM-11).
Methods The presence of synovial PAR-2 was confirmed in wild-type (PAR-2+/+)
C57BL/6J mice by western blotting using SAM-11 (Santa Cruz, USA). The anti-
inflammatory potential of this antibody, which inhibits PAR-2 activation by prevent-
ing release of its activating ligand, was investigated by intra-articular administration
of SAM-11 to mice prior to induction of acute joint inflammation (under
halothane/O2/N2O anaesthesia) by injection of 20 µl 2% carrageenan and 4%
kaolin (C/K) into the knee joint. Joint swelling was assessed by comparing caliper-
measured knee joint diameter pre and 24 hours post-injection. The swelling
response was compared in untreated, and in two parallel groups of inflamed mice
that had received intra-articular injection of SAM-11 at 5 ng or 10 ng, 5 min prior
to C/K administration. Selectivity of SAM-11 for PAR-2 was confirmed by immuno-
histochemical analysis (in combination with the Animal Research Kit Dako, USA) of
the wild-type mouse brain, which expresses PAR-1, PAR-2, PAR-3 and PAR-4
compared with that of PAR-2 gene-disrupted (PAR-2–/–) mice.
Results Western blotting demonstrated the presence of PAR-2 in normal murine
synovium and substantial upregulation in acutely inflamed joints. Immunohisto-
chemical analysis of the murine brain with SAM-11 revealed staining in PAR-2+/+
mice but not in PAR-2–/– mice, confirming PAR-2 specificity of this monoclonal
antibody. C/K resulted in substantial knee joint swelling, which was significantly
and dose-dependently (P < 0.00001; one-way analysis of variance; n = 4 per
group) inhibited by SAM-11 pretreatment (Fig. 1). These findings are consistent
with a proinflammatory role for PAR-2 in arthritis, and demonstrate that antibody
inhibition of PAR-2 activation ameliorates acute joint inflammation.
Reference
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Figure 1
(a) Lower axis: serial DNA extractions (see text). Bars represent mean of
10 ± standard deviation. Upper axis: T-cell receptor excision circles (TRECs) per
millitre of blood from the same samples (mean ± deviation). (b) TRECs per
millitre of whole blood declines with age over a range of ~2 logs from birth.
Figure 1
Twenty-four hours after intra-articular injection of kaolin, knee joint swelling is
dose-dependently reduced by SAM-11 pre-treatment. ** P < 0.00001, 
* P < 0.01 (n = 4 per group). NS, no significantly.S58
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The objective of this study was to evaluate the use of real-time quantitative PCR
(Q-PCR) using a cellular standard to detect changes in gene expression in syn-
ovial tissue samples that could potentially serve as such biomarkers correlating
with clinical disease activity. Therefore, the effects of treatment with corticos-
teroids, a known effective therapy, were analyzed in patients with active rheuma-
toid arthritis. Patients were randomized to receive either oral prednisolone (n = 10,
60 mg daily for the first and 40 mg daily for the second week) or placebo (n = 11).
All patients underwent an arthroscopic synovial biopsy procedure directly before
and after 14 days of treatment. Real-time Q-PCR was used to quantify gene
expression of tumour necrosis factor alpha, IL-1β, IL-6 and MMP-1 in the synovial
tissue samples. The values were expressed as relative units compared with a cellu-
lar-based standard. Statistical analysis was performed using an analysis of covari-
ance model. The mean DAS28 was 2.0 units lower (95% confidence interval,
1.0–3.0) after prednisolone therapy compared with placebo. The mean DAS28
(± standard deviation) decreased (from 6.27 ± 0.95 to 4.11 ± 1.43) after pred-
nisolone therapy, but not in the placebo group. For gene expression of IL-8 and
MMP-1, the estimated effect of prednisolone compared with placebo was large,
and the confidence intervals excluded the likelihood of no effect. A clear trend
towards reduction was seen in IL-β and tumour necrosis factor alpha mRNA
expression in the prednisolone group, but confidence intervals included the value
for no effect. The results of this study show that mRNA expression of IL-8 and
MMP-1 quantified by Q-PCR may serve as biomarkers in small proof of principle
trials designed to screen for potential efficacy in rheumatoid arthritis patients.
Acknowledgement The clinical part of study was funded by Astra Zeneca, UK.
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Objective To provide a systematic overview on expression profiles, to determine a
ranking score and to give insight in to the heterogeneity of individual patients within
the group of arthritis patients.
Methods Synovial tissue specimens of 10 rheumatoid arthritis (RA), 10 osteoarthritis
and 10 normal donors were subjected to GeneChip HG-U133A expression profiling
according to the standard protocol, starting with 5 µg total RNA and using 15 µg
cRNA for hybridization. Signals were generated with the GeneChip Operating
System and scaled to equal intensities of the whole array. Further analysis included t
test and analysis of variance (ANOVA) statistics as well as functional profile compo-
nent analysis. Classification was performed according to the Prediction Analysis for
Microarrays algorithm. Systematic multiple testing with statistics and classification
tools was programmed in perl using subgroups of patients and subgroups of genes.
Results To characterize the homogeneity of each group, ANOVA and t test statis-
tics were applied using ‘leave one out’ and ‘leave two out’ for candidate selection.
Subsequently, these one or two donors were tested for the predictive value of the
selected candidates. This revealed that one RA donoe, if not participating in the
selection process, grouped to osteoarthritis. Analysis for functional profile compo-
nents showed less infiltration and less inflammation in this donor. However, if this
RA donor contributed to the candidate selection, all RA patients were correctly
classified. Furthermore, donors of other groups were also classified error-free. This
demonstrates that RA with reduced molecular markers of inflammation can still be
separated from osteoarthritis and that incorporation of such RA patients in the
selection process of candidate genes is mandatory for correct classification.
To characterize the importance of each gene for classification, ranking of candi-
dates was performed according to the significance level by t testing. Multiple
subgroups were systematically tested and the ranking of genes was compared.
Using an averaged rank list, gene sets were stepwise expanded and systemati-
cally tested for classification potential. In addition, the contribution of each gene
to the correct classification was assigned to each donor. All together, this infor-
mation can be visualized on a gene and donor specific way including annotation
of significance, classification and proportionate contribution to classification.
Conclusion Systematic multiple testing of gene expression profiles provides a
precise overview on the quality of array data. It allows ranking of gene candidates,
provides insight into patient specific contribution to classification and thus an
individualized interpretation of gene expression data.
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Background While the aetiology of rheumatoid arthritis (RA) is unknown, emerg-
ing data suggest that T cell:macrophage cell–cell interactions are critical in
disease perpetuation. Cytokine/mitogen-activated CD4+ T cells or CD4+ T cells
isolated directly from RA synovial fluid (SF) are known to induce tumour necrosis
factor alpha (TNF-α) production by monocytes via a cell-contact-mediated mecha-
nism. However, little is known about the ability of CD8+ cells to drive such effects.
Objective To investigate the potential role of CD8+ cells in cell-contact-mediated
stimulation of monocytes, via induction of cytokines. To examine whether CD8+
cells isolated from RA SF, like their CD4+ counterparts, have an inherent ability to
drive monocyte activation.
Methods CD8+ or CD4+ cells from healthy volunteer or RA peripheral blood were
isolated by immunomagnetic positive selection and activated by phytohaemagglu-
tinin, IL-15 or a cytokine cocktail (IL-6, IL-15 and TNF-α) for 3/6 days, respec-
tively. SF T cells were purified by immunomagnetic bead separation. T cells were
paraformaldehyde-fixed prior to co-culture with autologous immunomagnetically
purified CD14-positive cells. CD8+/CD4+ cells isolated from RA SF were fixed
without prior stimulation. Secreted cytokine production by monocytes was mea-
sured by ELISA/Luminex after 48 hours. The purity of isolated CD8+/CD4+ popu-
lations was assessed by FACS analysis and was routinely > 95%.
Results Mitogen-activated peripheral blood CD8+ cells induced TNF-α production
by monocytes in a cell-contact-dependent manner. Peripheral blood CD8+ cells
previously activated by IL-15 alone or a cocktail of cytokines similarly stimulated
monocyte TNF-α production. Moreover, CD8+ cells isolated directly from RA SF
induced autologous monocyte TNF-α secretion in the absence of prior in vitro acti-
vation. Levels of monocyte cytokine production stimulated by CD8+ cells were
comparable with levels induced by CD4+ cells in all circumstances investigated.
Conclusion  The ability of CD8+ cells to stimulate monocyte inflammatory
cytokine production via a contact-dependent mechanism provides a novel means
by which T-cell subsets activated within the local cytokine milieu in RA may con-
tribute to the ongoing disease process. Further understanding of the contribution
made by this population to monocyte/macrophage activation is therefore crucial.
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Complement and Fcγ receptor (FcγR) effector pathways are central triggers of
immune inflammation; however, the exact mechanisms for their cooperation with effec-
tor cells and their nature remain elusive. Here we describe a novel regulatory cross-
talk between complement and FcγRs on macrophages as the dominant event in the
Arthus reaction, the classical animal model of immune complex disease. Specifically,
initial contact between immune complexes and macrophages results in cellular regula-
tion: plasma complement-independent C5a production; selective Gi-dependent C5aR
signaling; and C5aR-Gi-mediated FcγR alterations towards FcγRIII, the previously
shown main inducer of tumour necrosis factor alpha and CXCR2 ligand production.
Distinct inhibitors of this refined inflammatory cascade are each effective in disease
prevention, thus indicating cellular components of the C5aR–FcγR axis as potential
new therapeutic targets in the treatment of inflammation and autoimmune diseases.
Acknowledgement Supported by the Deutsche Forschungsgemeinschaft DFG
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Introduction Corticosteroids are the drugs of choice for many rheumatic dis-
eases, including vasculitis. There is controversy concerning the route of adminis-
tration. If there is active vasculitis and the blood vessels of the gastrointestinal
tract are affected, there may be impaired absorption of oral corticosteroids.
Purpose To determine whether patients with active vasculitis, as evidenced by
elevated neopterin, von Willebrand factor antigen (vWFAg), and abnormal nailfold
capillaroscopy (NFC), have equivalent bioavailability of oral prednisolone (OP)
compared with intravenous methylprednisolone (IVMP).
Methods Six patients with rheumatic disease involving vasculitis (juvenile der-
matomyositis, scleroderma, or overlap syndrome), four females, two males (mean
age 17.8 years [range 11–27]; one Hispanic, one Asian, one African American,
three Caucasian) were admitted to an IRB-approved Clinical Research Center
protocol. After fasting overnight, they received 50 mg/m2 OP on day 1, and
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50 mg/m2 IVMP on day 2. Baseline blood samples were drawn 1 min prior to
each corticosteroid dose (neopterin and vWFAg on day 1; prednisolone level on
day 2), at 5, 15, 30, 45, 60, and 90 min and then hourly from the second through
the eighth hour. After extraction, samples were analyzed by reverse-phase HPLC
for the levels of prednisolone (day 1 samples) and methylprednisolone (day 2
samples). The area under the serum OP or IVMP concentration versus time curve
(AUC) was determined using the trapezoid method. NFC images were evaluated
by freeze-frame video microscopy as previously described.
Results  See Table 1. There was a positive correlation coefficient for ∆AUC
(IVMP–OP) with vWFAg, neopterin, and NFC avascularity score of 0.74, 0.68,
and 0.66, respectively; there was a negative correlation coefficient for ∆AUC
(IVMP–OP) with NFC end row capillary/mm of 0.64. Linear regression analysis of
∆AUC (IVMP–OP) and vWFAg approached statistical significance (P = 0.08)
and given that only six patients were evaluated this may be clinically significant.
Table 1
NFC NFC 
end row  avascu-
Neopterin vWFAg  capillary/ larity 
∆AUC (nmol/l),  (U/dl)/ mm, score, 
(IVMP–OP)  normal  blood  normal normal 
Patient Diagnosis (min·ng/µl) < 10 typea = 8–10 = 0
1 JDM +651897 19.5 329/O 4.08 3
2 JDM –21012 5.3 136/A 10.49 0.5
3 JDM +352690 10.7 375/A 4.18 2
4 JDM –268415 6.9 89/B 14.50 1
5 Overlap +924390 14.6 266/O 6.28 2
6 Scleroderma –70879 14.3 179/A 5.16 2
AUC, area under the serum oral prednisolone (OP) or intravenous methyl-
prednisolone (IVMP) concentration versus time curve; vWFAg, von Willebrand factor
antigen; NFC, nailfold capillaroscopy; JDM, juvenile dermatomyositis. aNormal values
per blood type: A = 48–234; B = 57–241; O = 36–157.
Conclusion Patients with elevated vWFAg, neopterin, and/or evidence of abnor-
mal nailfold by capillaroscopy may have decreased absorption of OP. We specu-
late that this observation can provide the rationale for the greater efficacy of IVMP
in the therapy of patients with active vasculitis of rheumatic disease. More patients
will be evaluated to further establish the use of IVMP over OP in active vasculitis.
Acknowledgements  Supported in part by grant M01 RR-00048 from the
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Background Controversy exists in delineating the characteristics and therapeu-
tics involved in late-onset rheumatoid arthritis (LORA) and younger-onset rheuma-
toid arthritis (YORA). Many studies have suggested that the disease process of
the LORA patient is distinctly different, and thus requires different treatment. Our
preliminary work using a rigidly defined, rheumatoid factor (RF)-positive rheuma-
toid arthritis prospective cohort of 263 patients suggests that LORA and YORA
patients are similar after correcting for age-related factors, for example erythro-
cyte sedimentation rate and C-reactive protein. In the same cohort of patients,
Wu and colleagues recently demonstrated that the presence of both shared
epitope-containing DRB1*04 alleles and novel RANKL polymorphisms was asso-
ciated with an 18–20 year earlier onset of rheumatoid arthritis in YORA patients
and did not predict increased severity of disease.
Objective Aim 1 To demonstrate that RF-positive YORA and LORA patients with
the same disease duration have similar baseline disease-related characteristics,
after adjusting for age-related processes. Aim 2 To compare outcomes of RF-
positive LORA and YORA patients with the same disease duration, after account-
ing for age-related processes.
Hypothesis 2A Responses to disease-modifying anti-rheumatic drug treatments will
be similar between LORA and YORA patients with equivalent disease duration.
Hypothesis 2B RF-positive LORA and YORA patients with equivalent disease dura-
tion will have comparable side effects to disease-modifying anti-rheumatic drugs.
Methods This study will use the Consortium of Rheumatology Researchers of
North America and the Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic
Drug Intervention and Utilization Study 1&2 databases, consisting of 15,000
rheumatoid arthritis patients. Patients with known RF positivity will be included in
the cohort, with LORA ≥ 60 and YORA < 60 years of age. We will control for
duration by stratification. We will use two methods to demonstrate similarity
between YORA and LORA subjects: equivalence testing and confidence inter-
vals. Alternate statistical analyses include generalized matching by the propensity
scores method and regression analyses.
Significance LORA patients have been treated inconsistently and with much
apprehension, due to uncertainty about the diagnosis of LORA and concern
about prescribing toxic medications to the elderly. With strictly defined cohorts
showing similar characteristics/outcomes, treatment of the LORA and YORA
patients by physicians should be similar.
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Introduction Ankylosing spondylitis (AS) is a chronic systemic rheumatic disor-
der, which is characterised by sacroiliitis, enthesopathy, and a variety of extra-
articular manifestations. Despite having the strongest association ever described
with a tissue antigen, HLA B27, the pathogenesis of AS remains poorly under-
stood. Immunoregulatory genes and Gram-negative gut bacteria are thought to
be important in disease expression. It is now known that mammalian immune
response to Gram-negative bacteria is mediated by Toll-like receptor 4 (TLR4), a
pattern recognition receptor. Two cosegregating missense mutations have
recently been described in TLR4 that lead to a diminished host response to
Gram-negative bacteria. We hypothesise that TLR4 mutations occur with an
increased frequency in HLA B27-positive individuals who develop AS than in
healthy HLA B27-positive controls, and allow increased survival and the systemic
distribution of Gram-negative gut bacteria to the joints. This study aims to
compare the frequency of two common TLR4 mutations (Asp299Gly, and
Thr399Ile) between AS patients and HLA B27 healthy controls.
Methods The TLR4 genotypes of over 100 patients and 100 HLA B27 healthy
controls were determined using allele-specific PCR and restriction fragment
length polymorphism analysis. The allele frequencies were compared using a chi-
squared test of association.
Results There was no significant difference between the frequency of the
Asp299Gly allele or the Thr399Ile allele in AS and healthy HLA B27 controls.
Conclusion Two common TLR4 polymorphisms, which cause a functional defi-
ciency in host immune response to Gram-negative bacteria, are not significant in AS.
S9
Follow up study of B-lymphocyte depletion in the treatment
of patients with systemic lupus erythematosus
MJ Leandro, JCW Edwards, MR Ehrenstein, G Cambridge, DA Isenberg
Centre for Rheumatology, University College London, London, UK
Arthritis Res Ther 2005, 7(Suppl 1):S9 (DOI 10.1186/ar1712)
Background Systemic lupus erythematosus (SLE) is an autoimmune rheumatic
disease in which B-lymphocytes play an pivotal role. We have induced B cell
depletion utilising a combination of rituximab, cyclophosphamide, and steroids
given intravenously. This regime depletes B-lymphocytes in the peripheral blood.
We now report a long-term follow up study of 24 patients who had failed conven-
tional immunosuppression.
Methods 24 patients (22 female, 2 male, mean age 30 years, range 17–49) were
treated. The mean disease duration was 7.9 years (range 1–18 years). Twelve of
the patients were Caucasian, 8 Afro-Caribbean and 4 of Asian origin. The major-
ity of these patients were treated with two infusions of 1 g rituximab, two infu-
sions of 750 mg cyclophosphamide and two infusions of methylprednisolone
100 mg. Patients were allowed to continue on prednisolone and hydroxychloro-
quine. Only 2 patients continued on azathioprine.
Results The global BILAG score reduced from a median of 13.9 at baseline (SEM =
1.18) to 5 (SD = 1) at three months and 5.0 (SEM = 0.6) at six months. 23/24
patients achieved depletion in the peripheral blood (CD19+ <0.005/l) and there
was improvement in BILAG score in each of the eight systems or organs. The
period of B lymphocyte depletion ranged from three to eleven months except in 1
patient who remains depleted for > 4 years. Whereas the mean total serum
immunoglobulins levels remained within the normal range, analysis of the serum
C3 levels (in 21 patients) showed a statistically significant improvement
(P < 0.0005) at six months as did anti-dsDNA binding (P  < 0.02). 1 patient,
scored the most active (BILAG global score 45) died of sepsis five months after
the infusion having shown a considerable improvement at three months. 1 patient
had a severe infusion reaction. No other serious adverse events were observed. 7
patients have now been retreated, 1 on two further occasions. 1 patient failed to
deplete on retreatment due to a documented specific HACA response.
Conclusion B lymphocyte depletion therapy utilising rituximab has been shown to be
an effective treatment for active refractory lupus. Our data further indicate that both
clinical and serological improvement is seen in the majority of these patients. The effi-
cacy and apparent safety of this treatment in established cases of lupus indicate the
possible use of this treatment in patients earlier in the course of their disease.
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